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Abstract…………………… 
The aim of th is thesis is  to explore the ongoing t ransformat ion in the 
pharmaceut ical  industry and i ts impact  on pharmaceut ical  qual i ty f rom the 
perspect ive of  r isk ident i f icat ion.  This research was bui l t  upon three key pi l lars:  
Theoret ical  Evidence, Operat ional  Evidence, and Opinion-based Evidence. 
 
The regulatory environment is one of  the most important external  factors that  
af fect a company’s organizat ion, processes and technological st rategy. A 
quant i tat ive analys is of  regulatory events s ince 1813 revealed that the focus of 
regulators f rom 1813 to 1970s was centred on cr is is  management and publ ic 
heal th protect ion. Since the 1980s a gradual  move towards a greater focus on 
publ ic  heal th promot ion,  internat ional  harmonizat ion,  innovat ion, and agency 
modernizat ion occurred.  
 
The evolut ion of the pharmaceut ical t ransformat ion was assessed through 
systemat ic rev iew of  the l i terature.  Fourteen factors were ident i f ied that impact 
the pharmaceut ical industry in future years.  These factors,  termed 
“ t ransformat ion t r iggers”,  were considered as the theoret ical  ev idence for the 
ongoing t ransformation. The relat ive importance ranking of  the t r iggers was 
computed based on their  prevalence wi thin the art ic les studied. The four main 
t r iggers with the strongest  theoret ical  ev idence were:  fu l ly integrated pharma 
network, personal ised medic ine, t ranslat ional  research, and pervasive comput ing.  
  
Operat ional  ev idence to ver i fy existence of the t ransformat ion t r iggers was 
compi led through systemat ic col lect ion of  operat ional  data.  Trends in the 
operat ional  ev idence and the associated theoret ical  ev idence were compared. 
Strong correlat ion between theoret ical and operat ional  ev idence was found for 
the four t ransformat ion tr iggers l is ted above. Key areas of  cont rast  inc luded; 
heal thcare management focus, adapt ive t r ials and regulatory enforcement where 
the operat ional  ev idence was stronger than the theoret ical ev idence. 
 
Expert  opinion,  obtained f rom a quest ionnaire-based survey on part ic ipants wi th 
recognised expert ise in pharmaceut ical  regulat ion,  product l i fecycle or 
technology,  val idated the theoret ical and operat ional  ev idence and supported the 
same four main pharmaceut ical t ransformat ion t r iggers.  
 
A qual i ty r isk model der ived from the survey indicated a f i rm relat ionship 
between the pharmaceut ical  qual i ty r isks and regulatory compl iance outcomes 
dur ing the market ing approval  and post -market ing phases of  the product l i fecycle 
and a weaker relat ionship during the pre-market evaluat ion phase.  
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Definitions………………… 
Adapt ive Tr ials:  in adapt ive t r ia ls,  informat ion acquired during a part icular 
c l inical  t r ial  is used to al ter the course of the t r ial  wi thout compromising i ts 
stat ist ical  val id i ty.   
 
Apothecary:  a term often used between the 1600s and 1800s for indiv iduals 
l iv ing in London who had passed the examinat ions of  the Worshipful  Society of 
Apothecaries of  London.  I t  does not refer to the chemist  and druggist .  
 
B ioinformat ics:  appl icat ion of informat ion technology and computer sc ience to 
the f ield of molecular biology.  
 
B iosimi lar  Products:  as def ined in HR 3590 is  a product that  is “highly s imi lar”  to 
the reference product “notwi thstanding minor di f ferences in c l inical ly inact ive 
components,” and for which there are “no cl in ical ly meaningful  di f ferences 
between the biological  product and the reference product in terms of  safety,  
pur i ty and potency of  the product.”  
 
Chemist and Druggist :  a term f i rs t  used to descr ibe both chemical and drug 
merchants and pract i t ioners of  the emerging profession of pharmacy from the 
late 1700s. 
 
Cloud Comput ing: comput ing model  consist ing of  services that  are commodit ised 
and del ivered in a manner s imi lar to t radi t ional  ut i l i t ies such as water,  electr ic i ty,  
gas,  and telephony.  In such a model ,  users access serv ices based on their  
requirements wi thout  regard to where the serv ices are hosted or how they are 
del ivered. 
 
Drug Product:  means a f in ished dosage form, for example,  tablet ,  capsule,  or 
solut ion that contains a drug substance, general ly,  but not necessar i ly,  in 
associat ion wi th one or more other ingredients (source: FDA - 21 CFR Part  314).  
 
Drug Substance: means an act ive ingredient that  is intended to furnish 
pharmacological act iv i ty or other di rect  ef fect in the diagnosis,  cure,  mit igat ion, 
t reatment,  or  prevent ion of  d isease or to af fect  the structure or any funct ion of  
the human body, but  does not include intermediates use in the synthes is of  such 
ingredient (source: FDA - 21 CFR Part  314).  
 
In- l i fe Tria ls:  leveraging emerging computat ion and communicat ion technologies 
to replace Phase I I I  t r ia ls.  
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Live Licensing: implies that  the current Phase I  to IV cl in ical  test ing process may 
eventual ly be select ively or whol ly replaced by a system known as " in- l i fe"  
test ing or " l ive" l icensing 
 
Main Survey: is el ic i t ing expert  opinion on the transformat ion tr iggers and 
inf luence of proposed qual i ty r isks on regulatory compl iance outcomes. 
 
Open Innovat ion: in the pharmaceut ical  context  is def ined as leveraging external  
sources of innovat ion by col laborat ing wi th smal l  b iotechnology companies,  
univers i t ies,  research partnerships,  etc.   
 
Operat ional  Evidence: refers to systemat ic  analys is of  operat ional  data that 
supports the concept of  ongoing pharmaceut ical  t ransformat ion and hence the 
theoret ical  ev idence. I t  is  a lso the consol idated representat ion of  the operat ional  
data in a graphical  or tabular form. 
 
Personal ised Medicine: is concerned wi th the development and administrat ion of 
t reatments (based on a knowledge of genet ic biomarkers or mutat ions) to 
pat ients who might best  respond to an indiv idual ly tai lored treatment.  
 
Pervasive Comput ing:  an environment saturated wi th comput ing and 
communicat ion capabi l i ty 
  
Pharmaceut ical Chemist :  a term that Pharmaceut ical  Society adopted in the 
1840s,  previously referred to mainly French scient ists who promoted the use of 
chemical-based therapeut ics.  
 
Pharmaceut ical Qual i ty:  a branch of  regulatory sc ience that is concerned wi th 
establ ishment  and monitor ing of internal  standards to ensure product qual i ty,  
pat ient  safety and data integri ty f rom the perspect ive of  Good Laboratory /  
Cl inical  /  Manufactur ing /  Dist r ibut ion Pract ices (GxP). 
 
Pharmaceut ical Qual i ty Risk:  is def ined as the potent ial  adverse regulatory 
compl iance outcomes relat ing to product  qual i ty,  pat ient  safety and/or data 
integr i ty dur ing product l i fecycle.    
 
P i lot  Survey: is the methodology used for test ing the rel iabi l i ty  and val id ity of  the 
quest ionnaire used for the main survey. 
 
Product Li fecycle:  is def ined as act iv i t ies pertaining to product development,  
regist rat ion, manufactur ing, distr ibut ion and product use. This f rom a regulatory 
compl iance perspect ive equates to pre-market  evaluat ion,  market ing approval ,  
and post-market survei l lance events.  
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Progressive Licensing: see l ive l icensing.  
 
Regulatory Event:  is  def ined as a legis lat ive act ion or an in it iat ive by regulatory 
authori t ies in response to a publ ic heal th cr is is or to promote a pol icy 
 
Regulatory Science: refers to the sc ience of  developing new tools,  standards, 
and approaches to assess the safety,  ef f icacy,  qual i ty,  and performance of  
regulated medical products. 
 
Systemat ic Review: refers to systemat ic nature of  select ing and assessing 
art ic les against  the acceptance cr i ter ia. 
 
Theoret ical  Evidence:  refers to systemat ic analys is of  l i terature data that  
supports the concept of  the ongoing pharmaceut ical  t ransformation. 
 
Transformat ion: the process by which the pharmaceut ical  industry intends to 
achieve and maintain advantage through changes in operat ional  concepts,  
regulatory sc ience,  and technologies that  wi l l  s ignif icant ly improve i ts capabi l i ty 
to innovate. 
 
Translat ional  Research: a bi-direct ional  shar ing of  knowledge and ideas by the 
sc ient i f ic  and cl in ical  d isc ipl ines to develop diagnost ics that rel iably selects the 
mechanisms leading to breakthrough therapeut ics useful  for  pract ical  
appl icat ions that  enhance human heal th and wel l -being.  
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Structure of This Thesis 
This PhD thesis is  st ructured around seven chapters and a f inal chapter on 
concluding remarks.  The thesis starts wi th character isat ion of the pharmaceut ical  
industry and the regulatory environment (Chapters 1 & 2) wi thin which the 
ongoing t ransformat ion is taking place. Thereafter the three pi l lars of  this 
research are presented, which inc lude: establ ishment of  the theoret ical  ev idence 
through ident i f icat ion and ranking of the t ransformat ion t r iggers (Chapter 3),  
establ ishment  of  the operat ional  ev idence through systemat ic  analys is of exist ing 
product,  regulatory,  and technology related data (Chapter 4),  and establ ishment 
of  the opinion-based evidence through el ic i tat ion of expert  opinion in the f ie ld 
(Chapter 5 & 6).  The thesis concludes wi th a discussion on development of  a 
pharmaceut ical  qual i ty r isk model  (Chapter 7),  impl icat ions f rom pol icy and 
pract ice standpoint ,  and recommendat ions for future research (Chapter 8).  This 
is graphical ly i l lustrated in Figure 0.1.  
 
Figure 0.1 Block diagram depict ing structure of  th is thesis 
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The thesis starts wi th a histor ical  overv iew of  the development of  the 
pharmaceut ical  industry and the associated regulatory environment.  S ince the 
pharmaceut ical  qual i ty is  a branch of  regulatory science, i t  was important to 
understand key aspects of  the regulatory environment wi th in which the ongoing 
t ransformat ion is  tak ing place.  Chapter 2 was wri t ten to achieve this 
understanding. Knowledge gained in Chapter 2 was used to inform regulatory 
discussions, inform l i terature review coverage,  and support  conclusions 
presented in the last  chapter.   
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The scope of this PhD research is l imited to invest igat ion of new and emerging 
qual i ty r isks induced by the on-going pharmaceut ical  t ransformat ion f rom the 
regulatory sc ience perspect ive.  Therefore detai led t reatment of the fol lowing 
topics is out of scope:  
 
  Publ ic pol icy related to f ree movement of  pharmaceut ical  goods, access to 
medic ine, pr ic ing of  medic ine,  provis ion of heal thcare,  immunisat ion,  etc.  
  Business benef i ts/ r isks in the context open innovat ion relat ing to 
product iv i ty ,  compet i t ion,  intel lectual  property r ights,  etc.   
  Drug safety pract ices relat ing to non-cl in ical  laboratory studies  
  Drug safety report ing relat ing to pharmacovigi lance act iv i t ies 
 
Note:  Al though general ly relevant to r isk management  wi thin the pharmaceut ical  
environment,  the r isks associated with drug safety and pharmacovigi lance are 
known and in the context  of  regulatory sc ience do not pose new or emerging 
qual i ty r isks.  For th is reason these two topics were not speci f ical ly t reated as 
new or emerging sources of  qual i ty r isk in th is thesis.  
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Preface………..………… 
After f inishing my MSc in 1991, I  remained at  Liverpool  Univers i ty spending 
couple of  years doing research in the department of  indust r ia l  studies.  During 
this t ime I  col laborated wi th various companies and later jo ined R&D div is ion of  
Mediva (a local  b iotechnology company) as a member of  their  process control  
team. My key responsibi l i ty was to val idate the manufactur ing processes and 
support ing technologies in the Hep-B vaccine pi lot  p lant.  In 1995 I  jo ined Fisons 
Pharmaceut icals ( later became RPR, Avent is ,  and now Sanof i )  support ing 
var ious strategic projects inc luding the development  of  inhalat ion,  sol id dosage,  
and chemical  p i lot  plants and worldwide implementat ion of  data management 
cont rols relat ing to pre-c l in ical ,  c l in ical ,  manufactur ing, and regulatory 
processes. Dur ing my 20 years of  pharmaceut ical exper ience I  have gained 
s igni f icant knowledge of  pharmaceut ical  qual i ty across various stages of  the 
drug product l i fecycle.  Since 2009 I  have assumed the responsibi l i ty  for a team 
of experts,  at  corporate level,  wi th the mission of  helping the process owners in 
ensur ing that systems they use dur ing the product  l i fecycle are f i t  for their  
intended purpose.  A key aspect of  my mission is to predict  regulatory controls for  
new and evolv ing technologies.  This is achieved through internal /external  
benchmarking of  evolv ing trends in pharmaceut ical  technology and regulatory 
sc ience. As part  of  the external  benchmarking, dur ing the per iod 2007 - 2009,  I  
at tended var ious industry conferences designed to explore 21st century 
chal lenges to the pharmaceut ical  industry.  The main focus of  the discourse in 
these conferences was global izat ion and i ts  impact on drug product l i fecycle and 
also rapidly evolv ing technologies /  emerging areas of sc ience that could be 
appl ied to improve safety and ef f icacy of  medical  products.  There were 
discussions around leveraging the knowledge gained from these emerging 
sc ient i f ic  f ields to enhance the tools the industry and regulators use to evaluate 
drugs, b io logics,  and medical devices.  Col laborat ion between al l  the 
stakeholders (federal  agencies,  pat ient groups, academic researchers,  indust ry,  
heal thcare pract i t ioners,  and others) was seen as a key success cr i ter ion.  The 
general  sent iment among the at tendees was that  the pharmaceut ical  industry is 
in the midst of a major t ransformat ion.  
 
Through this  exposure I  learned that  the emerging technologies of fered 
improvement in many stages of  the drug product supply chain. Areas of 
part icular interest to me, f rom a pharmaceut ical  qual i ty perspective, were test ing 
and release of  drug products in the manufacturing f ield and improved pat ient  
compl iance in the c l inical f ield.  I  also learned that the emerging sc ient i f ic  f ie lds 
(e.g.  genomics,  imaging, and informat ics) enabled development  of  targeted 
medic ine – imply ing a shi f t  f rom large-volume block buster paradigm to a smal l -
volume special ised medic ine targeted for a niche pat ient populat ion.  The experts 
in these conferences of ten argued that th is type of t ransformation would mean 
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s igni f icant changes in the way drugs are developed, manufactured, approved, 
distr ibuted and prescr ibed. My chal lenge at  the t ime was to t ranslate th is  
learning into act ionable knowledge support ing pol icy and pract ice f rom a 
pharmaceut ical  qual i ty standpoint.  The prerequis i te for  def in ing this  act ionable 
knowledge was a good understanding of the t ransformat ion- induced r isks and in 
order to ident i fy these r isks one had to discern the factors that inf luenced the 
pharmaceut ical  t ransformat ion. My in i t ial  l i terature search revealed paucity of  
research on pharmaceut ical  qual i ty r isks in the context  of  the ongoing indust ry 
t ransformat ion.  This gap in knowledge was the genesis of my PhD research 
proposal,  which I  presented to Professor James L Ford for considerat ion in ear ly 
2009.   
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CHAPTER 1: Introduction 
 
The or igins of  medic ines probably stemmed f rom observat ion that certain plants 
had effects other than f ight ing hunger and observat ion has always been the most 
important tool  in the development of medic ines (Royal Pharmaceut ical Society,  
2012).  The favourable ef fects of  medic ines are l ikely to be accompanied by some 
adverse s ide ef fects.   Therefore development,  manufacture,  d istr ibut ion,  
prescr ipt ion,  and use of medic ines also require an ethical f ramework to 
safeguard publ ic heal th.  In th is chapter the or ig ins of  the pharmaceut ical  
industry and dr ivers for the need for ethical  f ramework in the form of regulatory 
overs ight are descr ibed. 
 
1.1 DEVELOPMENT OF THE PHARMACEUTICAL INDUSTRY 
This sect ion provides a histor ical  account of  how the pharmacy profession has 
evolved f rom i ts pr imit ive days in Sumerian t imes into the modern 
pharmaceut ical  industry of  today. The intent  of  th is sect ion is to provide the 
reader wi th basic knowledge of  pharmaceut ical  industry and the associated 
regulat ions as the prologue to the rest of  the thes is.   
 
1.1.1 Early days of pharmacy (ancient times to 1100 AD) 
Humans have been exposed to and have needed heal ing f rom disease, s ickness 
and accidents s ince the beginning of t ime. The ear ly pract ice of t reat ing the 
symptoms in var ious civ i l isat ions resul ted in the emergence of special is ts of ten 
rely ing on methods based on pseudoscience and myst ic ism. Over t ime, based on 
tr ia l  and error and through the sc ient i f ic  explorat ion and enl ightenment,  these 
special is ts acquired a body of knowledge that have progressively been 
augmented and ref ined (Anderson, 2005).  
 
The pharmacy profession in i ts pr imit ive form can be traced back to the 
Sumerian civ i l isat ion,  later becoming part  of  the Pers ian Empire and now modern 
day Iraq. From around 4000 BC, Sumerians used medicinal  p lants such as 
l iquor ice, mustard, myrrh,  and opium.  The Sumerians wrote the ear l iest  
surviv ing prescript ions dat ing back to 2700 BC. There were special ists in the 
Sumerian society responsible for prepar ing medic ines,  a separate role f rom 
diagnosis and t reatment,  which was carr ied out by medics.  In ancient Egypt 
Pharmacy was v iewed as an important branch of medic ine and had a high social 
ranking as a profession. Surviv ing papyrus scrol ls,  notably Ebers dat ing from 
1500 BC inc ludes l ist ing of 700 drugs indicat ing that  Egypt ians made and used 
infusions,  o intments,  lozenges, supposi tor ies,  lot ions,  enemas, and pi l ls  in their  
t reatments.  In China (2000 BC), Shen Nung invest igated medicinal  value of 
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several  hundred herbs wrote the f i rst  nat ive herbal  remedies containing 
descr ipt ions of 365 plant -based drugs (Royal  Pharmaceut ical  Society,  2012; 
Anderson, 2005).  Meanwhi le in Pers ia (300 AD) the academic centres l ike 
Jundishapur Univers ity were the scene for the union among great  medical 
sc ient ists from dif ferent c iv i l izat ions. This tradi t ion later produced great 
sc ient ists such as Avicenna and Rhazes who contr ibuted immensely to the f ie ld 
of  medic ine. Notable among their  cont r ibut ion was creat ion of  creat ing the canon 
of medic ine, ident i f icat ion and descr ipt ion of  diseases such as smal lpox and 
measles,  and int roducing the use of mercur ial  o intments (Anderson,  2005; 
Guthr ie,  1945).    
 
The shops sel l ing medic inal goods existed around 1900 BC in the town of  
S ippara on the Euphrates River.  This exempl i f ies f i rst  s igns of organised 
preparat ion and dispensing of  medic inal products for  human use.  People 
pract ic ing this profession over the years have assumed many names inc luding 
apothecar ies,  druggists,  chemists and pharmacists (Anderson,  2005).  
 
1.1.2 Pharmacy in the medieval times (1100 – 1617 AD) 
These were dif f icul t  t imes in cont inental  Europe,  the per iod was l i t tered wi th 
constant wars and f requent  epidemics. Notable among them was Black Death 
that lasted for centur ies.  These existent ia l  condi t ions meant that  new and 
effect ive remedies were needed to improve the heal th of  the ci t izens and during 
this 500 year per iod signi f icant progress was made in the f ield of  medic ine and 
pharmacy (Anderson, 2005; Guthr ie,  1945).  
 
The cont inuing migrat ion of  scholars f rom Pers ia to the west start ing f rom the 8t h  
century t r iggered creat ion of important centres of  learning in I ta ly,  Spain, France 
and England. An example is the medical  school  at  Salerno which was the leading 
school  of  medic ine and pharmacy in Europe (Anderson, 2005; Guthrie,  1945).  
The crusades (1095 to 1291) also had an impact  in that i t  exposed Europeans to 
eastern cul ture and to new ideas on the pract ice of  medic ine and pharmacy. This 
inc luded separat ion of medic ine and pharmacy and compounding of drugs which 
was of ten pract iced in large scale in Egypt.  Other advanced pract ices,  or iginal ly 
establ ished in the Middle East,  relat ing to government inspect ion of shops and 
markets run by pharmacists and herbal ists  were also adopted.   The edict of 
Palermo by Fredrick I I  of  Hohenstaufen (emperor of  Germany and King of Sic i ly) 
in 1231 codi f ied the separat ion of pract ice of medic ine and pharmacy creat ing a 
c lear dist inct ion between responsibi l i t ies of  physic ians and those of  apothecar ies 
laying down regulat ions for their professional  pract ice.  This regulatory f ramework 
was intended to prevent exploi tat ion of s ick and was achieved through c learly 
def ined responsibi l i t ies,  creat ion of a predef ined l is t  of  drugs to be used, l imi t ing 
the number of  premises to cont rol  pr ice and imposit ion of  storage t ime l imits for 
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certain drugs to ensure ef f icacy (Anderson,  2005; Guthr ie,  1945).  Foundat ion of 
society of  apothecar ies in England (1617) is  the key mi lestone towards the end 
of  this era. The term apothecary,  of ten used between the 1600s and 1800s, does 
not  refer to the chemist  and druggist.  I t  was used for indiv iduals l iv ing in London 
who had passed the examinat ions of  the Worshipful  Society of Apothecar ies of  
London.  Al though the apothecary's pract ice inc luded a st rong dispensing 
element,  i t  was more al l -encompassing than the handl ing of drugs and 
chemicals.  Fol lowing a rul ing in the Rose Case (1701-1703/4),  apothecar ies 
became legal ly rat i f ied members of the medical  profession, able to prescr ibe as 
wel l  as dispense medicines (Anderson, 2005; Royal  Pharmaceut ical  Society,  
2012;  Guthrie,  1945).   
 
1.1.3 Pharmacy in early modern times (1617 – 1841 AD) 
From the perspect ive of  pract ic ing medic ine and pharmacy this era was a per iod 
of  t ransi t ion in Europe. Chal lenges to occupat ional  boundaries relat ing to 
dispensing and supply of  medic ines were common place,  wi th regular d isputes 
between phys ic ians and apothecar ies,  and between apothecar ies and chemists 
and druggists (Anderson, 2005).  
 
Chemist  and druggist  was a term f i rst  used to descr ibe both chemical  and drug 
merchants and pract i t ioners of  the emerging profession of pharmacy from the 
late 1700s. Between the 1500s and 1700s, the di f ferences between alchemy and 
medic inal chemistry were not at  al l  c lear but  by 1841 some c lar i ty emerged by 
pure sc ient i f ic  chemists establ ishing their own Chemical  Society (Royal  
Pharmaceut ical Society,  2012).   
 
Pharmaceut ical chemist ,  a term that  Pharmaceut ical  Society adopted in the 
1840s,  previously referred to mainly French scient ists who promoted the use of 
chemical-based therapeut ics.  After 1840s the term was being more widely 
appl ied to those interested in organic chemistry and in the ski l led compounding 
of drugs (Royal  Pharmaceut ical Society, 2010).   
 
During this period the systems of medical t reatment in use included bloodlet t ing, 
leeches, laxat ives and purgat ives (Royal  Pharmaceut ical  Society,  2012).  Many 
drugs were used as laxat ives and diuret ics but  careful  observat ion of  their act ion 
led to ref inement in their  use. The most  recognised appl icat ion is the use of 
d igi ta l is,  by Wil l iam Wither ing – an Engl ish chemist ,  for the rel ief  of  dropsy 
(oedema) in 1785; later recognised as t reat ing the under ly ing heart  fa i lure.  I t  
took much longer to determine isolat ion of  ascorbic acid (v i tamin C) f rom ci t rus 
f rui ts after  James Lind’s observat ion in 1747 that  c i t rus f rui ts  prevented scurvy 
in sai lors on long voyages. These discover ies led to rapid expansion of  surgery 
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f rom the batt lef ie ld into the hospi tal  which inc luded ant isept ics and anaesthet ics 
(Guthrie,  1945;  Royal  Pharmaceut ical  Society,  2012).  
 
Homoeopathic medic ine was also discovered in this per iod.  The founder,  Samuel 
Hahnemann (borne 1755) l ived in Leipzig 1789 -1821 where he became a 
physic ian. In contrast to harsh t reatments such as bloodlet t ing, Hahnemann 
wanted to use more compassionate methods. In addi t ion to homoeopathic 
medic ine he stressed l i festyle changes for the pat ient such as improved 
sanitat ion,  adequate rest ,  proper diet  and regular exerc ise (Royal  
Pharmaceut ical Society,  2012).  
 
1.1.4 Role of bacteriology, physiology and pharmacology  
In the nineteenth century a more logical  approach to drug development was 
establ ished and discover ies in other medical ly related disc ipl ines were in the 
r ise.  The science of bacter iology grew rapid ly and the role of  micro-organisms in 
fermentat ion and disease was suggested.  This l inked to the work of an Engl ish 
physic ian in 1798,  Edward Jenner,  on the prevent ion of smal lpox,  which led to 
establ ishment  of  laborator ies al l  over Europe to search for vaccines with the 
intent  of  both prevent ing epidemics and treat ing establ ished disease. Another 
bacter iologist  Paul Erl ich, work ing on the select ive staining of  bacter ia for 
ident i f icat ion purposes produced the f i rs t  chemotherapeut ic agent,  arsphenamine 
(also known as “Magic Bul let ”)  against syphi l is in 1910 (Anderson, 2005;  Royal  
Pharmaceut ical Society,  2012).   
 
Chemical manufacturers,  especial ly f rom the dye indust ry,  at  th is t ime began to 
test  synthet ic chemicals against  part icular organisms in infected animals.  This 
was a key dr iver for chemical companies to enter the pharmaceut ical arena and 
became pharmaceut ical  companies as a resul t .  Bayer exempl i f ied th is t ransi t ion 
by successful ly developing the dye prontosi l  red,  act ive against  streptococcal  
infect ions.  This was soon shown to be the prodrug of  sulphani lamide which was 
the f i rst  successful t reatment for  pneumonia and saved many l ives.  Alexander 
Fleming’s discovery of  penic i l l in in 1928 is perhaps the most famous instance of 
d iscovery fo l lowing chance observat ions that  also occurred in the f ie ld of  
bacter iology. The development of penici l l in as a commercial  product  as wel l  as 
the search for other act ive substances produced by l iv ing organisms grouped 
together as ant ib iot ics,  were accelerated during the f i rst  wor ld war by 
col laborat ion between the UK and US pharmaceut ical  industry.  In 1944 one of 
the important discoveries der ived f rom soi l -based organisms was streptomycin 
which was act ive against  tuberculosis,  another major k i l ler  d iseases of the 
nineteenth and early twent ieth centur ies.  Unfortunately res istance to these early 
ant ib iot ics soon bui l t  up and the pharmaceut ical industry started to search for 
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synthet ic modif icat ions to combat this and increase stabi l i ty to a l low oral  
administ rat ion (Royal  Pharmaceut ical Society,  2012).   
 
Another start ing point  for drug development was the development of  human 
physiology1,  part icular ly the ident i f icat ion of  glands whose hormone secret ions 
were act ive throughout the body,  and pharmacology, the study of  the act ions and 
uses of  drugs. The isolat ion and analys is of  the secret ions led f i rst  to hormone 
replacement therapy wi th thyroid extracts (1890s) and insul in (1923) and later to 
more rel iable therapy wi th synthet ical ly produced material .  The ident i f icat ion of 
var ious steroid molecules fol lowed wi th cort isone in 1948 and the sex hormones 
in 1955 resul t ing in the f i rst  f ie ld studies of the contracept ive pi l l  in 1960.  In the 
second hal f  of the twent ieth century emphasis was again given to the rel ief  of 
symptoms but  th is t ime wi th the support  of  sc ience. Pharmacology was beginning 
to establ ish the mechanisms by which symptoms were produced even where the 
cause of the malfunct ion was st i l l  unknown.  Oriented to studying impact of  
synthet ic drug on pathological  condi t ions, pharmacology was int imately l inked 
wi th the r ise of  the pharmaceut ical  industry (Royal  Pharmaceut ical  Soc iety,  
2012;  Anderson, 2005).  
 
1.1.5 The emergence of pharmaceutical industry (1860 – 1930)  
The or igin of  the modern pharmaceutical  indust ry t races back to i )  apothecar ies 
that t ransi t ioned into wholesale product ion of  drugs in the middle of  the 19th 
century and i i )  dye and chemical companies that establ ished research labs and 
discovered medical appl icat ions for their  products start ing in the 1880s. For 
example in 1668, Merck began as a smal l  apothecary shop in Darmstadt,  
Germany and in the 1840s i t  began wholesale product ion of  drugs.  Similar ly,  
Scher ing in Germany; Hoffmann-La Roche in Switzer land; Burroughs Wel lcome in 
England; Et ienne Poulenc in France;  and Abbott ,  Smith Kl ine, Parke-Davis,  El i  
L i l ly,  Squibb, and Upjohn in the Uni ted States (US) al l  s tarted as apothecar ies 
and drug suppl iers between the ear ly 1830s and late 1890s.  Other f i rms such as 
Agfa,  Bayer,  and Hoechst in Germany; Ciba, Geigy,  and Sandoz in Switzer land; 
Imperial  Chemical  Industr ies in England; and Pf izer in the US began wi th the 
product ion of organic chemicals (especial ly dyestuf fs) before moving into 
pharmaceut icals (Chemical and engineering News, 2012).  
 
Pharmacy dur ing American civ i l  war  -  Most act ive pharmaceut ical ingredients and 
raw mater ia l  used in the US in the mid-1800s were imported. The heal thcare 
system was very young and st i l l  evolv ing. A mount ing st ruggle of such 
monumental  s ize would cal l  for a medical  department ready to improvise and 
innovate quick ly to meet the needs of a large standing army. Pharmacists were 
                                                 
1 sc ience of  the mechanical ,  physical ,  and biochemical  funct ions of humans, their  
organs, and the cel ls  of  which they are composed 
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engaged in every step of  procurement of  mater ials,  inspect ion and preparat ion of  
f in ished drug products,  d is t r ibut ion to warehouses and hospitals,  and dispensing 
to pat ients.  Dur ing the war,  the Union establ ished a network compris ing as many 
as 30 depots,  wi th key cent res in New York and Phi ladelphia.  The army rel ied 
heavi ly on a handful  of  large domest ic drug companies for stable inventor ies and 
pr ices.  Both the Union and Confederacy establ ished laborator ies to inspect raw 
drug mater ia ls and to prepare f inished medic ines.  Both s ides benef i ted f rom the 
expert ise of  talented and innovat ive chemists and pharmacists to ensure qual i ty 
and ef f ic iency (Hasegawa, 2000).  Ear ly manufacturers to grow their  businesses 
rel ied on innovat ion in manufactur ing rather than the discovery of  new medic ines. 
Leaders of  the period,  such as Edward Robinson Squibb, decided not to patent 
their  innovat ions. This led f i rms to quickly copy the successes of  other f i rms. The 
industry was relat ively smal l ,  wi th most manufacturers providing i tems that 
pharmacists used in their  compounding pract ices.  The dist inct ion between the 
manufacturers was the eponymous name of the owner,  such as Squibb,  Li l ly or 
Abbott ,  guaranteeing qual i ty.  This state of  the industry cont inued through the 
Civi l  War and into the ear ly years of the 20th century (Worthen,  2003).  
 
Emergence of pharmaceut ical  chemistry and pharmacology  -  the integrat ion of  
apothecar ies and dye/chemical  companies into a dist inct  pharmaceut ical  industry 
took place in conjunct ion wi th the emergence of  pharmaceut ical  chemistry and 
pharmacology as sc ient i f ic  f ie lds at  the end of the 19th century.  This meant that 
the ident i f icat ion and preparat ion of  synthet ic drugs were l inked with studying 
their  impacts on pathological  condi t ions.  In 1980s, pharmaceut ical  companies in 
Germany and later in the US and England, establ ished col laborat ive 
relat ionships wi th academic laboratories. These research partnerships and 
resul t ing research f indings focused on dyes, immune ant ibodies, and other 
physiological ly act ive agents that would react wi th disease-causing organisms. 
Synthet ic organic chemistry emerged as an indust r ia l  discipl ine wi th a part icular 
focus in the area of  creat ing dyestuf fs der ived from coal  tar.  Transit ion f rom 
staining cel ls to making them more v is ible under microscopes to dyeing cel ls to 
k i l l  them was a smal l  evolut ionary step. This t ransi t ion enabled chemists to 
modi fy the raw dyestuffs and their  by-products to make them more effect ive as 
medic ines. In 1897,  a chemist at Bayer,  Fel ix Hof fmann, f i rst  synthesized aspir in 
(Chemical  and Engineer ing News, 2012).   
 
Impact  of  Chemical  Indust ry  - the important role of  the chemist  and chemical  
sc ience in pharmaceut icals in the early-20th century is l inked wi th the history of  
the American Chemical  Society 's (ACS) div is ion of medic inal  chemistry.  
Requirements for  accurate analys is of  medic ines contained in the 1906 US Food 
& Drugs Act improved stature of US chemists and hence industr ial  employment.  
But US chemists rarely had the freedom to create new drugs, and relat ively few 
companies manufactured complex therapies.  Those act iv i t ies were largely 
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dominated by German chemists work ing in conjunct ion wi th the major German 
chemical companies. Wor ld War I  sanct ions forced US chemists to copy German 
processes for producing drugs such as aspir in;  Salvarsan for t reatment of  
syphi l is;  and Veronal ,  a powerful  hypnot ic useful in easing the pain of  batt le 
wounds.  In 1920, the focus f rom analys is to synthesis due to wart ime changes,  
was a key dr iver for the ACS div is ion to rename i tsel f  the Div is ion of Medic inal  
Products (Chemical and Engineering News, 2012; Anderson, 2005).  
 
Patent Drug-Makers - whi le largely unregulated by government bodies pr ior to 
the 20th century,  the pharmaceut ical  industry faced chal lenges in di f ferent iat ing 
i ts products f rom patent  drug-makers whose secret  rec ipes were not patented 
and they were peddled on the street  by quacks.  Wrongful  c laims made by the 
patent drug-makers concerning medical ingredients were tested against  the 
nat ional  formular ies and occasional ly exposed by the professional  bodies,  
inc luding nat ional  physic ians '  associat ions, pharmacists '  groups. For example 
the development of  diphtheria ant i toxin in the 1890s and subsequent cases of  
inact ive or contaminated doses led the heal th authori t ies in Germany and France 
to test  and oversee biologicals;  s imi lar ly,  the US Hygienic Laboratory was 
authorised to l icense manufacturers under the 1902 Biologics Control  Act  
(Chemical  and Engineer ing News, 2012; Royal  Pharmaceut ical  Society,  2012).  
However in the US and Europe the author i ty of  the government regulators to 
remove drug products f rom the market or constrain advert is ing claims were 
l imited. Larger companies supported addi t ional legis lat ive intervent ions, 
inc luding the 1906 Food & Drugs Act in the US and s imi lar laws in several  
European countr ies that  prohibi ted adul terat ion and forced manufacturers to 
reveal  ingredients on product labels (Chemical  and Engineer ing News, 2012).  In 
spite of  these regulat ions, in the ear ly  1930s, most medic ines were sold without  
a prescr ipt ion and near ly  hal f  were compounded local ly by pharmacists.  Direct  
d ispensing of medic ine by the physic ians to the pat ients was widespread and 
companies of ten suppl ied physic ians wi th their  favour i te formulat ions.  In the 
1930s in Europe and America whi le the medical profession was wel l -establ ished, 
the pharmaceut ical  industry was only beginning to develop medicines to t reat  
pain,  infect ious diseases, heart condi t ions,  and other ai lments. Direct appl icat ion 
of  chemical  research to medic ine appeared promis ing, but only a few substances 
such as newly isolated v i tamins and insul in,  were more effect ive than treatments 
avai lable at  the turn of  the century.  Nevertheless the industry was at  the 
crossroads of sc ience, medic ine,  and growing heal th care markets set the stage 
for explosive growth (Chemical  and Engineer ing News, 2012).  
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1.1.6 The modern pharmaceutical industry 
Developments stated above led to the formal  st ructur ing of  sc ience, part icular ly  
chemistry,  the r ise of  sc ient i f ic research, and advances in technology and mass-
product ion (Green-Templeton, 2009).  
 
Second World War  – dur ing First  World War in Bri tain,  Burroughs Wel lcome & 
Co. was alone in being able to supply many much needed drugs for mi l i tary use,  
and other companies learned from this example.  Several ,  inc luding May & Baker,  
Nathan & Sons (Glaxo),  and Br it ish Drug Houses developed research 
laboratories in the immediate post -war per iod.  By the Second World War 
pharmaceut ical  companies in the US, Europe and Japan expanded rapidly af ter 
the Second World War by invest ing strongly in research, development and 
market ing (Green-Templeton, 2009; Chemical  and Engineer ing News, 2012).   
 
Post war reconstruct ion -  the demands of the new Nat ional  Heal th Service further 
st imulated the pharmaceut ical  indust ry.  Many new therapies were developed, 
of ten by rat ional design based on increased knowledge of the under ly ing cel lu lar  
mechanisms of drug act ions. During this period the safety regulat ion increased in 
the US and Europe inc luding the int roduct ion of  double bl inded, c l inical ly 
cont rol led tr ials for test ing new medic ines on the pat ients.  This discovery boom 
by the 1970s was decl ining result ing in s igni f icant  drop in the int roduct ion of new 
drugs (Green-Templeton, 2009; Chemical  and Engineer ing News, 2012).   
 
The Genomic age  -  in the f inal decades of  the twent ieth century mergers and 
take-overs created large mult i -nat ional  companies (Big Pharma),  product 
diversi f icat ion meant less rel iance on medicinal  products.  Smal ler biotechnology 
companies were establ ished to accept the chal lenges of  pharmaceut ical 
development in the genomic age (Green-Templeton, 2009).  
 
1.2 PHARMACEUTICAL REGULATORY ENVIRONMENT 
The evolut ion of the pharmacy f rom apothecar ies to the genomic age has 
resul ted in s igni f icant  increase in industr ial isat ion and technological  complexi ty.  
This in turn has introduced ethical  chal lenges impact ing the drug product supply 
chain f rom the perspect ive of product qual i ty,  pat ient safety and related data 
integr i ty.  Management of  these ethical  chal lenges are achieved through 
regulatory legis lat ion and overs ight ,  which col lect ively represents the 
pharmaceut ical  regulatory environment (see Chapter 2 for detai led descript ion).   
 
The pharmaceut ical  industry regulat ions,  part icular ly in Europe Union (EU) and 
the United States (US),  were establ ished wi th the pr imary aim to protect  and 
promote publ ic health but also to respond to unexpected cr is is.  Since the 
pharmaceut ical  industry develops and manufacture products that af fect  pat ients ’  
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qual i ty of  l i fe,  world governments have a keen interest  in the industry and i ts 
products.  
 
The regulatory landscape described in th is  sect ion is l imited mainly to the US 
and the EU wi th a br ief  descript ion of the World Heal th Organizat ion (WHO), see 
Figure 1.1.  The main rat ionale for  th is approach is that  pharmaceut ical  
regulat ions global ly are st rongly inf luenced by US and the EU regulat ions due to 
the colossal  s ize of  the pharmaceut ical markets in these important regions. 
Therefore descr ipt ion of the regulatory landscape for these two regions provides 
a good depict ion of the histor ical  evolut ion of  the modern pharmaceut ical 
regulatory environment.  Another reason for rest r ict ing the scope to these two 
regions was to ensure that  the research undertaken was feasible f rom a work load 
perspect ive.  
 
Figure 1.1 Pharmaceut ical regulatory bodies around the wor ld 
Japanese Ministry of 
Health and Welfare 
(MHW) 
Australia’s Therapeutic 
Goods Administration 
(TGA) 
Food and Drug 
Administration (FDA) 
European Medicines 
Agency (EMA) 
International Conference 
on Harmonization (ICH) 
World Health 
Organization (WHO)
Agência Nacional  
de Vigilância Sanitária 
ANVISA 
 
 
1.2.1 Regulatory environment in the EU 
The regulatory environment in the EU is dr iven by the need to ensure f ree 
movement of goods and protect ion of publ ic heal th (Hartmann, 2005).  Fi f ty years 
ago, each European country had i ts own procedure for market ing author isat ion of  
pharmaceut ical  products.  Products f rom other European countr ies were not 
approved unless they went through the maze of  local  requirements.  Since the 
1960s,  EU pharmaceut icals regulat ion has moved f rom legal  harmonizat ion,  wi th 
the expectat ion of  mutual recogni t ion,  to a complex system that jo ins nat ional 
regulatory procedures and mutual  recogni t ion requirements with di rect EU level 
regulat ion.  The European pharmaceut icals regulatory agency ( i .e.  the EMA – 
formerly EMEA) was establ ished in 1995 and later renamed as European 
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Medic ines Agency (EMA). EMA has become an evaluat ion body with considerable 
authori ty and impact on regulatory decis ions at the European level .   Regulatory 
procedures have been standardised and the EMA has been empowered as a 
c lear ing house to approve medical products for  al l  EU countr ies (Tanser & 
Mosser i ,  2002; Li Bassi  et  al . ,  2003).  The t imel ine of key regulatory events s ince 
1965 is  descr ibed in Table 1.1.  
 
Table 1.1 The t imel ine of  key EU regulatory events s ince 1965 (EURlex, 2012) 
Timeline Regulatory Event 
1965 
Crisis Management, the first pharmaceutical Directive 65/65/EEC was created as a 
reaction to the thalidomide disaster when thousands of babies were born with 
deformities as a result of usage of the drug during pregnancy. The directive aimed at 
harmonizing standards for approval of medicines in the European Economic 
Community (EEC). This was a pivotal event in the history of parmaceutical industry 
with a profound impact on practices relating to clinical trials, manufacturing, and post-
marketing surveilance of drug products (see section  2.3.2 for more detail)  
1975 
After issuance of the first directive the evolution of EU regulatory landscape has been 
less about crisis management and more focused on establishments EU regulatory 
agencies and free movement of medicinal products for human and veterinary use. 
For example in 1975, the regulatory groundwork established ten yeas earlier was 
expanded through Directive 75/319/EEC to establish requirements for i) application 
for authorization to place medicinal products on the market, ii) examination of the 
said application iii) oversight of manufacture and imports coming from third countries, 
iv) safety reporting, and v) establishment of the Committee on Proprietary Medicinal 
Products. 
1987 
Biotechnology Products, complexity and cost of research for new biotechnology 
products that were emerging during the 1980s was the key driver behind Directive 
87/22/EEC. Intent was to create a centralised procedure for authorizing European 
marketing of biotechnology products and making it mandatory for these products to 
be approved in one central location 
1993 
Centralised Procedure, the need for a single pharmaceutical regulatory agency in EU 
triggered the creation of Regulation (EEC) No 2309/93. This regulation established 
the European Medicines Evaluation Agency (EMEA) and laying down the centralised 
community procedures for the authorization and supervision of medicinal products for 
human and veterinary use. 
1993 
Decentralised Procedure, Directive 93/39/EEC laid down a parallel, decentralised 
alternative to the centralised procedure described above. Companies can apply for 
the simultaneous authorisation in more than one EU country of a medicine that has 
not yet been authorised in any EU country and that do not fall within the mandatory 
scope of the centralised procedure.  
1995 
Mutual Recognition Procedure, companies that have a medicine authorised in one 
EU Member State can apply for this authorisation to be recognised in other EU 
countries 
2000 
Orphan Drug Regulation, some conditions occur so infrequently that the cost of 
developing and bringing to the market a medicinal product to diagnose, prevent or 
treat the condition would not be recovered by the expected sales of the medicinal 
product; the pharmaceutical industry would be unwilling to develop the medicinal 
product under normal market conditions; these medicinal products are called 
‘orphan’. Regulation (EC) No 141/2000 lays down a Community procedure for the 
designation of medicinal products as orphan medicinal products and to provide 
incentives for the research, development and placing on the market of designated 
orphan medicinal products. 
 
 
 
 
 
 
	15 
Table 1.1 Continued 
Timeline Regulatory Event 
2006 
Paediatrics Regulation, before a medicinal product for human use is placed on the 
market in one or more Member States, it generally has to have undergone extensive 
studies, including preclinical tests and clinical trials, to ensure that it is safe, of high 
quality and effective for use in the target population. Such studies may not have 
been undertaken for use in the paediatric population and many of the medicinal 
products currently used to treat the paediatric population have not been studied or 
authorised for such use. Market forces alone have proven insufficient to stimulate 
adequate research into, and the development and authorization of, medicinal 
products for the paediatric population. Regulation (EC) No 1901/2006 lays down the 
requirements for providing necessary incentives to enable development and 
commercialisation of medicinal products for paediatrics use. 
2007 
Advanced Therapy Regulation, New scientific progress in cellular and molecular 
biotechnology has led to the development of advanced therapies, such as gene 
therapy, somatic cell therapy, and tissue engineering. This nascent field of 
biomedicine offers new opportunities for the treatment of diseases and dysfunctions 
of the human body. Regulation (EC) No 1394/2007 lays down specific rules 
concerning the authorisation, supervision and pharmaco-vigilance of advanced 
therapy medicinal products.  
2008 
Variation Regulation, in the light of practical experience in the application of 
previous regulations impacting changes to terms of marketing authorization, 
Regulation (EC) No 1234/2008 intends to establish a simpler, clearer and more 
flexible legal framework for these types of changes, while guaranteeing the same 
level of public and animal health protection. 
 
1.2.2 Regulatory environment in the US 
In cont rast to the EU, the regulatory environment in the US has been shaped by 
ser ies of react ive steps of  legis lat ion adaptat ion in response to publ ic heal th 
cr ises leading to creat ion of  US Food and Drug Administrat ion (FDA) (Borchers 
et  a l . ,  2007; S later,  2005).  States wi thin the cont inental  US exerc ised the 
pr inc ipal  control  over domest ical ly produced and dist r ibuted foods and drugs in 
the 19th century,  control  that  was markedly inconsistent f rom state to state. The 
br ief  h istory t imel ine of  key regulatory events s ince 1813 is described in Table 
1.2.  
 
Table 1.2 The t imel ine of  key US regulatory events s ince 1813 (FDA History,  
2012) 
Timeline Regulatory Event 
1813 
The Vaccine Act of 1813, though short-lived, was the first federal law dealing with 
consumer protection and therapeutic substances. Federal authority was limited 
mostly to imported foods and drugs. Adulteration and misbranding of foods and 
drugs had long been a fixture in the American cultural landscape, though the 
egregiousness of the problems seemed to have increased by the late 19th century 
(or at least they became more identifiable). By this time science had advanced 
significantly in its ability to detect this sort of fraud. Also, legitimate manufacturers 
were becoming more concerned that their trade would be undermined by purveyors 
of deceitful goods. Quinine-containing cinchona bark powder could be made less 
therapeutically effective-and much more profitable-by cutting it with just about 
anything, alum and clay masked poor wheat flour and thus netted a heftier return for 
the unethical company, and sufferers of any number of serious or self-limited 
diseases were relieved only of their finances by vendors of worthless nostrums. 
Even the so-called ethical drug firms were guilty of this practice. 
1820 US Pharmacopeia, eleven physicians meet in Washington, D.C., to establish the 
U.S. Pharmacopeia, the first compendium of standard drugs for the United States. 
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Table 1.2 Continued 
Timeline Regulatory Event 
1848 Drug Importation Act, this Act passed by the Congress requiring US Customs Service inspection to stop entry of adulterated drugs from overseas. 
1862 
The Bureau of chemistry was created, President Lincoln appoints a chemist, 
Charles M. Wetherill, to serve in the new Department of Agriculture. This was the 
beginning of the Bureau of Chemistry, the predecessor of the Food and Drug 
Administration. 
1902 
Biologics Control Act, this Act is passed to ensure purity and safety of serums, 
vaccines, and similar products used to prevent or treat diseases in humans. 
Congress appropriates $5,000 to the Bureau of Chemistry to study chemical 
preservatives and colours and their effects on digestion and health. Dr. Wiley's 
studies draw widespread attention to the problem of food adulteration. Public 
support for passage of a federal food and drug law grows. 
1906 
Food and Drugs Act, On 30 June 1906 President Roosevelt signed the Food and 
Drugs Act, known simply was the Wiley Act. This act, which the Bureau of 
Chemistry was charged to administer, prohibited the interstate transport of unlawful 
food and drugs under penalty of seizure of the questionable products and/or 
prosecution of the responsible parties. The basis of the law rested on the regulation 
of product labelling rather than pre-market approval. Drugs, defined in accordance 
with the standards of strength, quality, and purity in the 
1912 
Congress enacts the Sherley Amendment to prohibit labelling medicines with false 
therapeutic claims intended to defraud the purchaser, a standard difficult to prove. 
Mrs. Winslow’s Soothing Syrup for teething and colicky babies, unlabeled yet laced 
with morphine, killed many infants. 
1930 The name of the Food, Drug, and Insecticide Administration is shortened to Food and Drug Administration (FDA) under an agricultural appropriations act. 
1938 
Federal Food and Drug and Cosmetics (FDC) Act of is passed by Congress, 
containing new provisions: 
 Extending control to cosmetics and therapeutic devices.  
 Requiring new drugs to be shown safe before marketing-starting a new 
system of drug regulation.  
 Eliminating the Sherley Amendment requirement to prove intent to defraud in 
drug misbranding cases.  
 Providing that safe tolerances be set for unavoidable poisonous substances.  
 Authorizing standards of identity, quality, and fill-of-container for foods.  
 Authorizing factory inspections.  
 Adding the remedy of court injunctions to the previous penalties of seizures 
and prosecutions. 
1962 
Good Manufacturing Practice is established, thalidomide, a new sleeping pill, is 
found to have caused birth defects in thousands of babies born in western Europe. 
News reports on the role of Dr. Frances Kelsey, FDA medical officer, in keeping the 
drug off the U.S. market, arouse public support for stronger drug regulation. 
Kefauver-Harris Drug Amendments passed to ensure drug efficacy and greater drug 
safety. For the first time, drug manufacturers are required to prove to FDA the 
effectiveness of their products before marketing them.  
1971 
Good Laboratory Practice established, National Centre for Toxicological Research is 
established. Its mission is to examine biological effects of chemicals in the 
environment, extrapolating data from experimental animals to human health. 
1976 
Medical Device Amendments passed to ensure safety and effectiveness of medical 
devices, including diagnostic products. The amendments require manufacturers to 
register with FDA and follow quality control procedures. Some products must have 
pre-market approval by FDA; others must meet performance standards before 
marketing. 
1987 Investigational drug regulations revised to expand access to experimental drugs for patients with serious diseases with no alternative therapies. 
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Table 1.2 Continued 
Timeline Regulatory Event 
1997 Food and Drug Administration Modernization Act reauthorizes the Prescription Drug 
User Fee Act of 1992 and mandates the most wide-ranging reforms in agency 
practices since 1938. Provisions include measures to accelerate review of devices, 
regulate advertising of unapproved uses of approved drugs and devices, and 
regulate health claims for foods. 
1998 
FDA promulgates the Paediatric Rule, a regulation that requires manufacturers of 
selected new and extant drug and biological products to conduct studies to assess 
their safety and efficacy in children. 
2005 
Critical Path Initiative (CPI), FDA's national strategy to drive innovation in the 
scientific processes through which medical products are developed, evaluated, and 
manufactured. Globalization, rapidly evolving technologies, and emerging areas of 
science are having a major impact on FDA-regulated medical products. CPI is 
leveraging the knowledge FDA has gained from these emerging scientific fields to 
enhance the tools it uses to evaluate drugs, biologics, and medical devices. 
 
1.2.3 World Health Organization (WHO) 
According to WHO Nat ional  governments are responsible for establ ishing strong 
nat ional  medic ines regulatory author i t ies wi th c lear mission, sol id legal  basis,  
real ist ic object ives,  appropr iate organizat ional st ructure,  adequate number of  
qual i f ied staf f ,  sustainable f inancing, access to up-to-date evidence based 
technical l i terature,  equipment and informat ion, and capacity to exert ef fect ive 
market control .  The role of  WHO in the area of  medic ines regulatory support  is  
two-fold.  One aspect relates to the development of  internat ional ly recognised 
norms, standards and guidel ines.  The second aspect relates to providing 
guidance,  technical  assistance and tra in ing in order to enable countr ies to 
implement global  guidel ines to meet their speci f ic  medic ines regulatory 
environment and needs (World Heal th Organizat ion, 2006).  
 
1.2.4 The historical events driving the need for regulations  
The history of  the manufacture of  medic ines and heal th products is f i l led wi th 
inc idents relat ing to their  accidental  or del iberate contaminat ion.  Publ ic outcry 
af ter  such occurrences has led to introduct ion or reinforcement of  regulat ion and 
establ ishment  of  regulatory agencies to enforce the laws. Key events responsible 
for int roduct ion or reinforcement of  pharmaceut ical  regulat ions are l is ted in 
Table 1.3.  
 
1.2.5 Pharmaceutical regulations and quality 
Up to 1980s the focus of  regulators was centred on cr is is management and 
publ ic  heal th protect ion -  a basic mission that  has remained consistent over the 
years (US Supreme Court ,  1969).  
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Table 1.3 Key events responsible for  introduct ion or reinforcement of  
pharmaceut ical  regulat ions 
Timeline Reasons for Introduction of Pharmaceutical Regulations 
1813 Control of smallpox 
1848 Control entry of adulterated drugs from to the US 
1902 Major issues with purity and safety of serums, vaccines, and similar products used to prevent or treat diseases in humans 
1906 
Disclosures of insanitary conditions in meat-packing plants, the use of poisonous 
preservatives and dyes in foods, and cure-all claims for worthless and dangerous 
patent medicines. Journalists such as Samuel Hopkins Adams exposed in vivid detail 
the hazards of the marketplace. The nauseating condition of the meat-packing 
industry the final precipitating force behind both a meat inspection law and a 
comprehensive food and drug law. 
1937 
Elixir of sulphanilamide, containing the poisonous solvent diethylene glycol, kills 107 
persons, many of whom were children, dramatizing the need to establish drug safety 
before marketing and to enact the pending food and drug law in the US. 
1962 
Thalidomide, a new sleeping pill, is found to have caused birth defects in thousands 
of babies born in Western Europe. News reports on the role of Dr. Frances Kelsey, 
FDA medical officer, in keeping the drug off the U.S. market, arouse public support 
for stronger drug regulation in the US 
1972 The talcum powder affair in Morhange during 1972, product contaminated by hexachlorophene, a bactericide sufficiently powerful to kill 36 children 
1982 
A "Tylenol scare" began when the first of seven individuals died in metropolitan 
Chicago, after ingesting Extra Strength Tylenol that had been deliberately 
contaminated with cyanide. Within a week, the company pulled 31 million bottles of 
tablets back from retailers, making it one of the first major recalls in American history 
1987 
The Therac-25 was a radiation therapy machine involved in at least six accidents 
between 1985 and 1987, in which patients were given massive overdoses of 
radiation.  These accidents highlighted the dangers of technology validation and 
proving fitness for intended use 
 
A review of  the regulatory events indicates that  s ince 1980s there has been a 
gradual change in regulatory di rect ion towards a greater focus on publ ic heal th 
promot ion, internat ional harmonizat ion, innovat ion, and r isk management (see 
Chapter 2).  
 
The regulatory harmonizat ion is achieved through the Internat ional  Conference 
on Harmonisat ion ( ICH) Launched 20 years ago;  ICH br ings together the drug 
regulatory author i t ies of  Europe, Japan, and the Uni ted States,  a long with the 
pharmaceut ical  t rade associat ions f rom these three regions,  to discuss sc ient i f ic 
and technical  aspects of  product registrat ion.  I t  is  ICH’s mission to achieve 
greater harmonizat ion in the interpretat ion and appl icat ion of technical 
guidel ines and requirements for product registrat ion,  thereby reducing 
dupl icat ion of test ing and report ing carr ied out dur ing the research and 
development of  new medic ines (ICH, 2010).  
 
Innovat ion in th is context re lates to establ ishment of  a robust regulatory sc ience 
program aimed at s t rengthening advances in biomedical  sc iences. Regulatory 
sc ience is cr i t ical  to ef fect ively t ranslate cut t ing edge developments in sc ience 
and technology into promising products and therapies for the pat ients who need 
them. Just  as biomedical  research has evolved over the past few decades;  
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regulatory sc ience must also evolve in important and powerful  ways (FDA 
Strategic Pr ior i t ies,  2010;  EMA Roadmap to 2015, 2010).  
 
Risk management is another key regulatory focus that intends to def ine a 
f ramework to improve regulator ’s abi l i ty to adjust  the level of  regulatory scrut iny 
commensurate wi th publ ic  health r isk,  a major component of  which concerns 
inspect ion of  pharmaceut ical  company’s laboratory,  c l inical ,  manufactur ing, and 
distr ibut ion pract ices.  
 
There is a key di f ference between the pharmaceut ical  and other indust r ies 
regarding product qual i ty,  safety and data-integr i ty.  In the pharmaceut ical  
industry qual i ty pract ices are mandated by law and require establ ishment of  an 
independent internal  Qual i ty Unit  whereas in most other industr ies qual i ty is 
of ten a voluntary act iv i ty.  Within the pharmaceut ical  context ,  the heal th 
authori t ies accomplish their  regulatory scrut iny through review of new product  
appl icat ions and inspect ion of laboratory,  c l in ical,  manufactur ing, and 
distr ibut ion pract ices.  The regulators rely on the industry to do internal 
superv is ion through their  Qual i ty Unit .  The role of  the Pharmaceut ical  Qual i ty 
( through the Qual i ty Uni t ) is  to establ ish and moni tor internal  standards to 
ensure product qual i ty ,  pat ient  safety and data integri ty  f rom the Good 
Laboratory /  Cl inical /  Manufactur ing /  Dist r ibut ion Pract ices (GxP) perspect ive. 
The extent to which each pharmaceut ical  company meets GxP requirements has 
a direct impact on their  abi l i ty to obtain approvals for their  products and maintain 
the market ing author izat ion for those products.   
 
Note:  A pharmaceut ical  drug, also referred to as medicine or medicat ion, is any 
biological ly act ive substance intended for use in the medical diagnosis,  cure, 
t reatment,  or  prevent ion of  d isease.  Vaccinat ion in the other hand, is the 
administ rat ion of  ant igenic mater ia l  (a vaccine) to st imulate an indiv idual 's  
immune system to develop adapt ive immunity to a pathogen.  Detai led discussion 
concerning publ ic pol icy wi th respect  to immunisat ion schemes and related 
safety events are outs ide the scope of  th is thesis.  
 
1.3 CURRENT CHALLANGES IN THE PHARMACEUTICAL 
INDUSTRY 
1.3.1 Ongoing industry transformation  
The pharmaceut ical  industry s ince 1990 has exper ienced a decl ine in Research & 
Development (R&D) product iv i ty,  despite s igni f icant advancements in biomedical 
sc iences and increasing R&D expendi ture.  According to the US FDA, the problem 
exists because the current medical  product development path is becoming 
increasingly chal lenging, inef f ic ient ,  and cost ly.  The FDA, in i ts 2004 landmark 
publ icat ion “Innovat ion/Stagnat ion” (FDA Innovat ion or Stagnat ion,  2004) 
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i l lust rated that  between 1993 and 2003 there was a s igni f icant drop in the 
number of  new chemical  and biologic appl icat ions submit ted for  approval .  The 
FDA claims that th is is because of the r is ing costs of  product development that  
of ten force the innovators to focus their ef for ts on products wi th a potent ia l ly 
high market return.  To address the innovat ion problem and ongoing evolut ions in 
the regulatory landscape, the industry is  making t ransformat ional  changes to the 
pharmaceut ical  business. (See Chapter 3 for  more detai l ) .  This consequent ly 
poses a major publ ic heal th concern s ince fewer resources are deployed on 
products targeted for important publ ic heal th needs such as rare diseases, 
prevent ion indicat ions, or indiv idual ised therapies.  This and other factors such 
as dramat ic increase in number of  overseas R&D and manufacturing faci l i t ies 
and diversi ty and complexi ty of  medical  products also play a key role in 
regulatory bodies to make t ransformat ional  changes in how they work wi th the 
industry to protect  and promote publ ic heal th.  
 
1.3.2 The regulators reaction  
Both the FDA and EMA have strategic in i t iat ives to address the innovat ion 
problem. The FDA’s nat ional  strategy for t ransforming the way FDA-regulated 
medical  products are developed, evaluated, and manufactured involves the 
Cri t ical  Path Ini t iat ive (CPI).   
 
In Europe the EMA ini t ial ly started by establ ishing the Innovat ion Task Force in 
2001.  EMA expanded this ef for t  through the publ icat ion of  i ts  March 2007 report  
“ Innovat ive Drug Development Approaches” wi th the aim of  ident i fy ing sc ient i f ic 
bot t lenecks to the development of  innovat ive medic ines,  both in the industry ’s 
R&D and in the academic environment.   
 
Review of  the out l ined reports and related documents revealed the fo l lowing 
common innovat ion enablers :   
  Better product safety toolk i t  and standards - show that product  is 
adequately safe for each stage of  development 
  Better product ef fect iveness toolk i t  and standards - show that product 
benef i ts people 
  Better product manufactur ing toolk i t  and standards – show product 
manufacturabi l i ty,  that i t  can go f rom laboratory concept to a 
manufacturable product 
  Better product  qual i ty r isk management toolk it  and standards – show that  
the level  of  regulatory scrut iny can be adjusted commensurate wi th publ ic 
heal th r isk  
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1.3.3 The industry reaction 
To address the innovat ion problem the industry has been going through 
s igni f icant t ransformat ional changes af fect ing the business model  (R&D, 
manufacturing,  etc. ),  regulatory compl iance and technology.  Open innovat ion 
(Chesbrough & Crowther,  2006) is a key character ist ic of  the ongoing industry 
t ransformat ion.  In the open innovat ion paradigm central ised and internal ly 
focused approach to innovat ion is becoming obsolete and the pharmaceut ical  
companies are not only t ry ing to create value internal ly  but increasingly 
leveraging external  sources of innovat ion (smal l  biotech, univers i t ies, research 
partnerships,  etc. ) .  Industry t ransformat ion t r iggers are characterised by the 
l i terature review conducted as part  of  this PhD effort .  The important point  to note 
is that the t ransformat ion t r iggers in the context of  the open innovat ion paradigm 
pose chal lenges to Pharmaceut ical  Qual i ty that needs further research, which is 
the main subject  of  this PhD thesis.  
 
The industry is also ful ly engaged with the ICH effort  on establ ishing 
internat ional  qual i ty guidel ines as an enabl ing toolk i t  to help improve innovat ion, 
as detai led above. 
 
1.3.4 The role of the pharmaceutical quality 
Achievement of the goals impl ied in the out l ined common innovat ion enablers 
requires expert ise throughout the drug product l i fecycle,  inc luding contr ibut ion of  
the Pharmaceut ical  Qual i ty (OECD, 1997; ICH E6, 1996; PIC/S, 2009).  To 
harmonise pract ices for this contr ibut ion the regulatory agencies and industry 
started col laborat ion under the auspices of the ICH. This effor t  resulted in the 
fol lowing important qual i ty guidel ines that have been adopted internat ional ly:   
  Pharmaceut ical Qual i ty Risk Management – provides pr inc iples and 
examples of tools for  qual i ty r isk management that can be appl ied to 
di f ferent  aspects of pharmaceut ical  qual i ty ( ICH Q9, 2005) 
  Pharmaceut ical Development  – descr ibes the process for present ing the 
knowledge gained through the appl icat ion of sc ient i f ic approaches and 
qual i ty r isk management  to the development of  a product and i ts 
manufacturing process (ICH Q8, 2005) 
  Pharmaceut ical Qual i ty Systems -  descr ibes model for  a pharmaceut ical  
qual i ty system that can be implemented throughout the di f ferent stages of  a 
product l i fecycle (ICH Q10, 2008) 
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1.3.5 Rationale for the research and importance to the 
Pharmaceutical Industry  
There is academic research in support  of the common innovat ion enablers 
highl ighted in sect ion 1.3.2 above (NIH Research, 2009; EMA Research, 2010).  
The research is mainly concentrated on the safety and ef f icacy aspects.  
A lthough Pharmaceut ical  Qual i ty is playing a key role however there is no 
academic research to support  th is fact.  Furthermore there is  no academic 
research explor ing the qual i ty r isk model needed to cope wi th the new 
environment.  Review of the 38 most c i ted qual i ty management  art ic les publ ished 
between 1989 and 2009 revealed only 2 art ic les that studied pharmaceut ical  
industry (Table 1.4).  Neither of  these art ic les focuses on the industry 
t ransformat ion.  Therefore,  there is a real need for research to character ise the 
regulatory evolut ion and industry t ransformat ion, ident i fy the most  important 
t ransformat ion tr iggers,  determine the impact on Pharmaceut ical  Qual i ty,  and 
develop a qual i ty r isk model for  the new environment.  
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Table 1.4 Prevalence of qual i ty management art ic les by industry 
Total Articles: 38 
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Bou-Llusar et al. (2009) 446 Mixed Mixed Spain 3 
Curkovic et al. (2000) 526 Automotive Manufacturing US 8 
Kaynak  (2003) 214 Mixed Mixed US 177 
Samson & Terziovski (1999) 1024 Mixed Manufacturing Mixed 363 
Ahire & Dreyfus (2000) 418 Mixed Manufacturing US 15 
Ahire & O’Shaughnessy (1998) 449 Automotive Manufacturing Mixed 49 
Ahire et al. (1996) 371 Mixed Manufacturing US 591 
Ahmad et al. (2009) 413 Pharma Distribution Pakistan 1 
Anderson et al. (1995) 41 Mixed Manufacturing US 185 
Antony et al. (2002) 32 Mixed Mixed Hong Kong 50 
Badri et al. (1995) 424 Mixed Mixed UAE 107 
Black & Porter (1996) 61 Mixed Mixed Mixed 408 
Choi & Eboch (1998) 339 Electronics Manufacturing US 150 
Cua et al. (2001) 163 Mixed Manufacturing Mixed 146 
Das et al. (2000) 290 Mixed Mixed US 71 
Douglas & Judge (2001) 193 Healthcare Service US 166 
Dow et al. (1991) 698 Mixed Manufacturing Mixed 175 
Flynn et al. (1994) 42 Mixed Manufacturing US 616 
Forza & Flippini (1998) 43 Mixed Manufacturing Italy 90 
Grandzol & Gershon (1998) 275 Engineering Manufacturing US 94 
Ho et al. (2001) 25 Electronics Mixed Hong Kong 25 
Joseph et al. (1999) 25 Mixed Manufacturing India 30 
Kaye & Anderson (1999) 18 Mixed Mixed UK 60 
Kontoghiorghes (2004)  2 Automotive Manufacturing US 8 
Lai (2003) 304 Mixed Mixed Hong Kong 23 
Lau et al. (2004) 600 Mixed Mixed China 12 
Martinez-Lorente et al. (2000) 223 Mixed Manufacturing Spain 30 
Miyagawa & Yoshida (2005) 52 Mixed Manufacturing China 3 
Powell (1995) 19 Mixed Manufacturing US 903 
Prajogo & Sohal (2003)  194 Mixed Mixed Australia 51 
Rowley & Sneyd (1996) 22 Pharma Manufacturing UK 1 
Rungtusanatham et al. (1998)  43 Mixed Manufacturing Italy 42 
Sanchez- Rodriguez (2004) 306 Mixed Purchasing Spain 10 
Saraph et al. (1989) 20 Mixed Mixed US 740 
Sun (2000) 251 Mixed Manufacturing Mixed 18 
Tamimi (1998) 173 Mixed Mixed US 35 
Tan (2001) 310 Mixed Mixed US 37 
Zu et al. (2008)  226 Mixed Manufacturing US 9 
 
 
 
	24 
1.4 AIMS AND OBJECTIVES OF THIS THESIS  
The aim of th is thesis is  to explore the ongoing t ransformat ion in the 
pharmaceut ical  industry and i ts impact  on pharmaceut ical  qual i ty f rom the 
perspect ive of  r isk ident i f icat ion.  The fol lowing research quest ions and 
associated object ives were def ined to achieve the above aim. The quest ions are 
based on researcher ’s industr ia l  exper ience in pharmaceut ical qual i ty across 
drug product l i fecycle and the prel iminary review of  the l i terature.   
 
  What are the key tr iggers impact ing pharmaceut ical  t ransformat ion? 
  What wi l l  be the impact on regulatory science especial ly  wi th respect to 
qual i ty r isk management?  
  What is a plausible model  for pharmaceut ical  qual i ty r isk suitable for the 
t ransformed environment? 
 
1.4.1 Research Objectives 
The above quest ions were explored by real iz ing the fol lowing object ives:  
 
  Establ ish a good understanding of  the pharmaceut ical  indust ry development 
f rom industr ia l  and regulatory perspect ives 
  Character ise the pharmaceut ical  regulatory environment  wi thin which the 
ongoing t ransformation is tak ing place 
  Ident i fy and rank t r iggers impact ing the pharmaceut ical  t ransformat ion in 
order to establ ish theoret ical ev idence  in support  of the ongoing 
pharmaceut ical  t ransformat ion 
  Establ ish operat ional  ev idence  in support  of the t ransformat ion t r iggers 
  Establ ish opinion-based evidence  in support  of  the t ransformation t r iggers 
  Develop the pharmaceut ical qual i ty r isk model based on the knowledge 
gained from the analys is of  the theoret ical ,  operat ional  and opinion-based 
evidence  
 
Pharmaceut ical qual i ty r isk in the context of  this thesis is def ined as the 
potent ial  adverse regulatory compl iance outcomes relat ing to product qual i ty,  
pat ient  safety and/or re lated data integr i ty during the product l i fecycle.  The term 
l i fecycle inc ludes act iv i t ies pertaining to product  development ,  regist rat ion, 
manufactur ing, dist r ibut ion and product use, which f rom a regulatory compl iance 
perspect ive equates to pre-market evaluat ion,  market ing approval,  and post-
market survei l lance events. The term Regulatory Science refers to the sc ience of 
developing new tools,  standards, and approaches to assess the safety,  ef f icacy,  
qual i ty,  and performance of regulated medical  products.  This is based on the 
FDA def ini t ion provided in i ts sc ience and research website (FDA Def ini t ion,  
2010).  
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1.4.2 Overview of the methods used to accomplish the 
research objectives 
Systemat ic rev iew of  the l i terature was the pr inc ipal  method used for 
character is ing the regulatory environment and ident i fy ing the t ransformat ion 
t r iggers.  This was done by focusing on qual i tat ive content  analys is of the art ic les 
and systemat ic l i terature search (Tranf ie ld et  a l . ,  2003) for select ion of  art ic les.  
I t  is  important  to note that the intent of  the l i terature review was not  to perform a 
“systemat ic  l i terature review”,  which is commonly used method to compare and 
contrast  opposing v iews and opinions. Instead the intent of  this research was to 
perform a systemat ic rev iew of  the l i terature to ident i fy and rank l ikely t r iggers 
inf luencing pharmaceut ical  industry t ransformat ion and the factors that 
character ise the regulatory environment.  
 
The use of the operat ional  ev idence is important as a ver i f icat ion mechanism in 
order to accept  or repudiate the theoret ical ev idence based on the proof f rom the 
real  world scenarios.  The operat ional  evidence was der ived from data col lected 
on pharmaceut ical  companies, products and technologies.  Operat ional  ev idence 
was documented by consol idated representat ion of the operat ional  data in a 
graphical or  tabular form.  
 
The opinion-based evidence in support  of  the theoret ical and operat ional  
ev idence was col lected by surveying opinion of experts in the f ie ld.  The study 
was a quest ionnaire based survey and was conducted in two phases of “pi lot  
survey” and the “main survey”.  
 
Grouping of  the relat ionships between theoret ical ,  operat ional  and opinion-based 
evidence const i tutes the qual i ty r isk model in the context  of  pharmaceut ical  
t ransformat ion.  The relat ionship between theoret ical  and operat ional  ev idence 
was determined by comput ing the simple di f ference between the strength of  the 
theoret ical  ev idence and strength of  the operat ional  ev idence. The fundamental  
backbone of  the qual i ty r isk model is  determining the relat ionship between 
transformat ion- induced qual i ty r isks ( independent var iables) and the 
corresponding regulatory compl iance outcomes (dependent var iables).  This was 
accompl ished by comput ing the covar iance between the respect ive means of  the 
t ransformat ion- induced qual i ty r isks and the regulatory compl iance outcomes. 
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CHAPTER 2: Characterisation of the pharmaceutical 
regulatory environment 
 
2.1 INTRODUCTION 
As discussed in Chapter 1 the regulatory environment is  one of  the most 
important external  factors that affect the organizat ion, processes and 
technological  strategy of a company especial ly in the case of the pharmaceut ical  
industry where i ts products af fect  the qual i ty of l i fe for  i ts consumers.  The 
regulatory environment wi thin the European Union (EU) is dr iven by the need to 
ensure f ree movement of  goods and the protect ion of publ ic heal th (Hartmann, 
2005).  Regulatory procedures have been standardised and the European 
Medic ines Agency (EMA) has been establ ished to approve medical  products for 
al l  EU countr ies (Tancer & Mosser i ,  2002;  Li  Bassi et a l . ,  2003).  In cont rast,  the 
regulatory environment in the Uni ted States (US) has been shaped by a series of  
react ive steps of  legis lat ion adaptat ion in response to publ ic heal th cr ises – 
Examples inc lude the legal ly marketed tox ic el ix i r ,  which resul ted in 107 US 
deaths in the 1930s,  the thal idomide tragedy in Europe in the 1960s and faul ty 
medical  devices causing 10,000 in jur ies and 731 deaths in the mid 1970s in the 
US (Borchers et  a l . ,  2007;  FDA Regulatory Informat ion,  2007).  In order to 
character ise the evolut ion of the regulatory environment,  i t  is  important  to 
explore previous regulatory events, which should al low the ident i f icat ion of the 
key drivers behind legis lat ions and enable the l ikel ihood of  future events to be 
predicted. 
 
The goal  of this chapter is to character ise the pharmaceutical  regulatory 
environment.  Since the requirements for pharmaceut ical  qual i ty are dr iven by 
heal thcare regulat ions,  there is a need to describe the regulatory environment as 
a prerequis i te to fur ther studies.  Therefore th is chapter provides the backdrop to 
the regulatory discussions that wi l l  be covered in the subsequent chapters of  this 
thesis – especial ly regarding the l i terature review coverage for ident i f icat ion of 
the t ransformat ion t r iggers in Chapter 3. 
2.2 LITERATURE SEARCH AND REVIEW 
The methodology used was composed of  two key strands, the Li terature Search 
descr ibed in Steps 1, 2 and 3 and Literature Review descr ibed in Steps 4,  5 and 
6. This approach is i l lustrated in Figure 2.1. 
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2.2.1 Purpose and inclusion criteria (Step1) 
The purpose of  the l i terature review was to character ise the regulatory evolut ion 
and regulatory think ing that  has in the past or  is  current ly shaping the 
pharmaceut ical  regulat ions.  
 
S ince the US and EU are histor ical ly the largest pharmaceut ical  markets,  US 
Food and Drug Administrat ion (FDA) and European EMA were used as the two 
main sources of informat ion for regulatory rulemaking and overs ight  in the 
pharmaceut ical  industry.  In order  to target better the art ic le search, the 1999 to 
2010 t ime-frame was selected. The start ing point  of  1999 as the acceptance 
cr i ter ion for art ic le t imeframe was chosen s ince around this t ime the in i t ial  ideas 
about  pharmaceut ical  t ransformat ion were being discussed within the industry.  
EMA innovat ion taskforce (EMEA/SHMP, 2007) and FDA cr i t ical  path in i t iat ives 
(FDA Cri t ical  Path,  2007;  FDA Innovat ion or Stagnat ion,  2007) are pr ime 
examples for  which the prel iminary del iberat ions started around 1999 but 
became off ic ia l  af ter year 2000. The 2010 endpoint  for  art ic le select ion was 
chosen s ince this was the year when the art ic le search took place.  I t  is  
important to note that af ter  2010 addi t ional  ar t ic les relat ing to regulatory 
environment (Chapter 1) and pharmaceut ical  qual i ty (Chapter 7)  were selected 
as references or for comparison purposes respect ively.  
 
Inc lus ion cr i ter ia incorporated two addi t ional  foc i ,  i )  a regulatory focus - centred 
on regulatory legis lat ion,  history, evolut ion and regulatory innovation and i i )  a 
st rategic focus - centred on the mission and key act iv i t ies of  the regulatory 
agencies wi th some forward looking coverage. Table 2.1 gives a l is t  of  the 
search phrases that were used dur ing database and web searches. 
 
Risks associated with the l i fecycle act iv i t ies such as drug safety and 
pharmacovigi lance are known and in the context of regulatory science do not 
pose new or emerging qual i ty r isks.  For th is reason these two topics were not 
speci f ical ly t reated as new or emerging sources of  qual i ty r isk and therefore not 
l is ted as search phrases in Table 2.1.  
 
2.2.2 Databases and search phrases (Step 2) 
The databases used for th is step were chosen because they contained three 
categories of  art ic le types, namely of  peer-reviewed ar t ic les, those art ic les 
issued by regulatory agencies, and miscel laneous art ic les descr ibed as “Other” .  
Peer-Reviewed Art ic les.  Since the research scope is mult id iscipl inary,  only the 
integrated search engines avai lable through MyAthens or in the publ ic domain 
were considered.  Integrated search engines consol idate l i terature f rom mult iple 
sources making the search process more ef f ic ient.  The two databases that most 
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f i t  the out l ined requirement were Web of Knowledge and Google Scholar and 
these search engines were used to search for the peer reviewed art ic les.  
Regulatory Art ic les.  The US FDA, EMA and Internat ional  Conference on 
Harmonisat ion ( ICH) websi tes were used to search for  ar t ic les issued by the 
regulatory agencies within the t imeframe descr ibed in Step 1 (Sect ion 2.2.1).  
 
Other Art ic les.  The “other”  category mainly inc luded art ic les issued by industry,  
consul t ing,  legal  and research organizat ions.  The general  web search using 
Google was used to look for this category of  art ic les.   
 
Art ic le Search Phrases. These are l isted in Table 2.1, and are indiv idual  or  
combined text  phrases that  were used to look for art ic les in the databases. The 
select ion of  the search phrases was informed by the requirements descr ibed in 
Step 1 (Sect ion 2.2.1).  Execut ion of  the search phrases provided an unf i l tered 
l ist  of  art ic les that potent ia l ly met the acceptance cr i ter ia def ined in Step1. 
Columns 2 and 3 of  Table 2.1 show the number of  art ic les found for each of  the 
art ic le search phrases dur ing the art ic le search process.  Column 4 shows that,  of  
the 358 art ic les found,  14 were selected as the primary  art ic les and addi t ional  16 
were derived  f rom the pr imary art ic les.  
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Figure 2.1 Process for art ic le search, art ic le select ion and trend analys is of  
regulatory events 
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Table 2.1 Databases and art ic le search phrases used in Step 2 and associated results 
Article Search Phrases 
Search year: 2010 
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 Reference 
“European Pharmaceutical Law” 26 3 1 Hartmann, 2005 
“US Pharmaceutical Law” 4 0 0 - 
“Pharmaceutical Regulations” AND Evolution 82 3 1 Tancer and Mosseri, 2002 
“European Regulatory Policies” AND Pharmaceutical 31 3 1 Li Bassi, 2003 
“US Regulatory Policies” AND Pharmaceutical 3 0 0 - 
“The history and contemporary challenges” AND (FDA OR EMEA) 5 1 1 Borchers et al., 2007 
“European Harmonisation” AND Pharmaceutical AND (FDA OR EMEA) 30 0 1 Abraham and Lewis, 1999 
“US Harmonization” AND Pharmaceutical AND (FDA OR EMEA) 8 0 0 - 
“International Collaboration” AND (“Drug regulatory Authorities” (FDA OR EMEA)) 31 0 1 Epstein, 2009 
“Regulatory Modernization” AND Pharmaceutical AND (FDA OR EMEA) 14 0 1 Merrill, 1999 
"FDA Critical Path Initiative" AND “Pharmaceutical Industry”  65 1 1 Woodcock and Woosley, 2008 
"Regulatory Thinking" AND Pharmaceutical AND (FDA OR EMEA) 36 2 1 Abraham and Davis, 2005 
“Regulation and Innovation” AND “Cost benefit Analysis” AND (FDA OR EMEA)  0 0 1* Schwartzman, 1976 
FDA website > Downloads > “FDA Strategic Action Plan 2007” 0 0 1 FDA Strategic Action Plan, 2007 
EMA website > Home > “Roadmap to 2010”  0 0 1** EMA Roadmap to 2010, 2005 
FDA website > Home > Science & Research > “Critical Path Initiative” 0 0 2 FDA Critical Path, 2007; FDA Innovation of Stagnation, 2004 
Total 335 23 30***  
* General web search was conducted which resulted in reference 20 
** As of October 2011 it reads Roadmap to 2015 but the Roadmap to 2010 can also be found in the same webpage 
*** 14 primary and 16 derived articles.  
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2.2.3 Selection of primary articles (Step 3) 
The t i t les of  the unf i l tered art ic les compi led in Step 2 (Sect ion 2.2.2,  Figure 2.1) 
were scanned to el iminate art ic les wi th obvious mismatches to regulatory topics 
in the pharmaceut ical  industry.  For example,  some art ic les deal t  wi th topics 
related to the regulatory agencies but contained a main focus on the provis ion of  
heal thcare services and economic or pol i t ical  issues rather than the regulat ion of 
pharmaceut ical  industry.  Some of the art ic les had t i t les indicat ing that  their 
scope were regulatory in nature but described non pharmaceut ical  industr ies.  
Art ic les wi th these types of t i t les were considered obvious mismatches and were 
el iminated from the l is t .  The remaining art ic les ( i .e.  the c leansed l is t )  were 
considered relevant for addi t ional f i l ter ing as descr ibed below. 
 
For each of the art ic les in the c leansed l ist ,  the abstract,  int roduct ion or the 
equivalent overv iew sect ion of the art ic les were reviewed to determine i f  the 
art ic le met the inclusion cr i ter ia as def ined in Step 1 (Sect ion 2.2.1).  Any forward 
looking or st rategic discussions, opinions or empir ical ev idence that  were 
presented in these art ic les that related to pharmaceut ical  regulat ions f rom 
legis lat ive, histor ical  or innovat ion perspect ives were considered central  to 
meet ing the inc lus ion cr i ter ia def ined in Step 1 (Sect ion 2.2.1).  Those art ic les 
that  met the inc lus ion cr i ter ia were tagged as “pr imary art ic les” and were 
selected for detai led review in Step 4 (Sect ion 2.2.4).  
 
2.2.4 Qualitative reviews of the primary articles (Step 4) 
The content of al l  the pr imary and der ived2 art ic les were reviewed in detai l ,  
meaning that the ent i re art ic le was read in the context  of  the inc lus ion cr i ter ia 
def ined in Step 1 (Sect ion 2.2.1).  Part icular attent ion was paid to texts that 
discussed the mission and key act iv i t ies of  the regulatory agencies that were 
responsible for  and shaped the pharmaceut ical  regulat ions.   Since the purpose 
of  the l i terature review was to determine regulatory th ink ing and behaviour and 
typical ly these are mani fest  in agency mission and demonstrated in their act ions, 
the most  discussed mission and act iv i t ies were c lassi f ied into the s ix categor ies 
l is ted in Table 2.2.  Subsequent ly each category was used i )  as a dr iver of  
pharmaceut ical  regulat ions for  which regulatory events ident i f ied in Step 5 
(Sect ion 2.2.5) were att r ibuted to and i i )  as the scale for  the regulatory t rends 
analys is in Step 6 (Sect ion 2.2.6).  
 
                                                 
2 See sect ion 2.3.1 for  more detai l  
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2.2.5 Identification of important regulatory events (Step 5) 
To ident i fy important regulatory events al l  the pr imary and der ived art ic les were 
reviewed and a descr ipt ion, year and country of  each key regulatory event were 
recorded.  A regulatory event is def ined as a legis lat ive act ion or an in i t iat ive by 
regulatory author i t ies in response to a publ ic heal th cr is is or to promote a pol icy.  
The outcome of th is step is l is ted in Table 2.2.  
 
2.2.6 Identification of regulatory trends with respect to key 
factors driving pharmaceutical regulations (Step 6) 
Each of the regulatory events ident i f ied in Step 5 (Sect ion 2.2.5) were studied in 
the context of the “dr ivers of  pharmaceut ical  regulat ions” establ ished ear l ier  in 
Step 4 (Sect ion 2.2.4).  Dur ing review of  each art ic le every t ime a regulatory 
event was encountered that related to one of  the s ix ident i f ied dr iv ing factors 
(Table 2.2),  i t  was counted as one occurrence together wi th the date of  
occurrence. This process was repeated for each of  the pr imary and der ived 
art ic les and the regulatory t rend analysis was performed using the regulatory 
events l is ted in Table 2.2.  
 
2.3 RESULTS AND DISCUSSION 
The art ic le select ion procedure resul ted in 30 art ic les targeted for l i terature 
review (Table 2.1).  The review of  the l i terature resulted in the ident i f icat ion of 
s ix factors dr iv ing pharmaceut ical  regulat ions, namely: publ ic heal th protect ion,  
publ ic  heal th promot ion, cr is is management ,  harmonizat ion,  innovat ion, and 
modernizat ion.  Important  regulatory events were extracted f rom the selected 
art ic les and tabulated for analys is (Table 2.2).  The number of  art ic les found in 
Google Scholar and Web of Knowledge were 335 and 23 respect ively of  which 14 
pr imary art ic les were selected and addi t ional  16 art ic les were der ived from the 
pr imary art ic les (Table 2.1).  
 
Each Regulatory event was evaluated in detai l  paying part icular at tent ion to 
those texts support ing one or more of the s ix key factors.  The resul ts of the 
evaluat ion are mapped in Table 2.2 to determine the regulatory t rends. The 
explanat ion of  each of the s ix factors fo l lows.  
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Table 2.2 Summary of regulatory events and s ix dr iv ing factors related to 
regulatory miss ion/act iv i t ies 
 Regulatory Event  
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Vaccine Act 1813 US  x x    
Drug Importation Act 1848 US  x     
Biologics Control Act 1902 US x x     
Food and Drugs Act 1906 US  x     
FDA takes it current name 1930 US       
Food, Drug, and Cosmetic Act 1938 US x x     
Factory Inspection Amendment 1953 US  x     
cGMPs Established (21 CFR Part 210/211) 1962 US  x     
EU Directive 65/65/EEC was established 1965 EU x x     
GLPs Established (21 CFR Part 58) 1975 US  x     
EU Directive 75/319/EEC was established 1975 EU  x     
Medical Device Amendments 1976 US x x     
Revision to cGMPs 1978 US  x     
EU Directive 87/22EEC was established 1987 EU    x   
Prescription Drug Marketing Act 1987 US  x     
Safe Medical Devices Act 1990 US  x     
EU Directive 91/356/EEC was established 1991 EU  x  x   
Generic Drug Enforcement Act 1992 US  x     
Prescription Drug User Fee Act (PDUFA) 1992 US   x  x  
EU Regulation 2309/93 was established 1993 EU  x  x   
EU Directive 93/93 was established 1993 EU    x   
ICH E6 GCP Guideline was established 1996 GL  x  x   
FDA Modernization Act 1997 US     x  
21 CFR Part 11 regulation was established 1997 US  x   x x 
ICH Q7 was established 1998 GL    x   
Medical Device User Fee & Modernization Act 2002 US   x  x  
21st Century GMPs – Risk Based Approach 2004 US   x  x x 
Process Analytical Technology 2004 US   x   x 
EU Directive 2004/10/EC 2004 EU  x  x   
FDA Critical Path  2005 US   x  x x 
ICH Q8 was established 2005 GL    x  x 
ICH Q9 was established  2005 GL    x  x 
ICH Q10 was established  2007 GL    x   
FDA Transparency Initiative 2009 US     x  
 
2.3.1 Rationale relating to method selection  
The character izat ion of the rat ionale and behaviour of the regulatory agencies 
required knowledge of  the regulatory legis lat ion, regulatory history,  regulatory 
evolut ion and regulatory innovat ion wi thin the pharmaceut ical  context .  This 
knowledge was gained by review of  relevant art ic les and notable regulatory 
events.  The inc lus ion cr i ter ia were used as a f i l ter ing process for the select ion of  
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art ic les in various steps of  the search methodology (Figure 2.1).  The inc lus ion 
cr i ter ia discussed in Step 1 (Sect ion 2.2.1) were designed to enable the 
select ion of  al l  relevant art ic les that  provided informat ion on the events 
surrounding pharmaceut ical  regulat ion and ini t iat ives.  To focus the scope of the 
art ic le search ef fort ,  i )  regulatory agencies that  s igni f icant ly impact the 
pharmaceut ical  regulat ions global ly and have enforcement presence in the 
largest pharmaceut ical  markets were studied,  and i i )  a blend of  establ ished and 
recent ar i t ic les were selected in order to moderate between art ic les that 
ref lected the evolut inery aspects of the regulat ions and those that bet ter 
mirrored the current  th ink ing of the regulatory agencies.   
 
During the review of  the pr imary art ic les in Step 4 (Sect ion 2.2.4),  papers 
referenced wi th in the text ( i .e.  derived art ic les) that seemed relevant  in scope to 
the pr imary art ic les were searched for wi th in the out l ined databases,  they were 
read and i f  they met the inclusion cr i ter ia they were inc luded in the regulatory 
t rend analys is descr ibed in Step 6 (Sect ion 2.2.6).   Except ions were made in two 
cases where each of  the two art ic les met the inc lus ion cr i ter ia except for the 
t imeframe ( i .e.  issued pr ior  to 1999).  This was only done when the art ic le in 
quest ion was pivotal .  These art ic les were by US Supreme Court  (1969) and 
Schwartzman (1976).   
 
Examples of key regulatory events (Step 5, Sect ion 2.2.5),  tabulated in Table 2.2,  
inc luded passage of  new legis lat ions or amendments to exist ing ones, creat ion 
or dissolut ion of regulatory organizat ions and establ ishment of  global guidance 
for cross agency col laborat ion via ICH. 
 
The regulatory t rend analys is (Step 6, Sect ion 2.2.6) was based on ident i f icat ion 
of  the key regulatory events.  The t imeframe used for ident i f icat ion of  the key 
regulatory events was 1813 to 2010. The 1813 start ing point  was used s ince this 
was the year when the f i rst  regulatory event took place ( i .e. passage of  Vaccines 
Act in the US). The 2010 end point was used s ince this was the year when the 
search was conducted and the latest  regulatory event at  that t ime was 2009 
Transparency Ini t iat ive by the FDA. 
 
2.3.2 Public health protection 
Advances in new drugs, biopharmaceut icals,  medical  devices, and diagnost ic-
tools present s ignif icant  opportuni t ies for improvements in heal th care. Ensur ing 
the safety and ef fect iveness of  medical  products is a key focus of  the regulatory 
authori ty commitment to protect  and promote publ ic heal th.  Approvals of  new 
therapies are only granted i f  their  benef i ts ( l ives saved, extended or enhanced) 
outweigh the r isks they pose (these are blended statements f rom references 
c i ted in previous sect ions).  Publ ic heal th protect ion has been an overr id ing 
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purpose of the pharmaceut ical legis lat ions (US Supreme Court ,  2007) in the past 
and wi l l  remain so in the future s ince the provis ions for  protect ion of  publ ic 
heal th is st ipulated in pharmaceut ical regulat ions as requirements (see t rends in 
Table 2.2).   A pr ime example is the 1962 Kefauver-Harr is amendment (US 
Congress, 2010),  which had a profound impact on drug development process 
especial ly in terms of methods used for design, conduct and analys is of  c l inical  
t r ia ls.  The new author i t ies given to FDA by the Kefauver-Harr is  amendments: 
  Required that manufacturers prove the effect iveness of drug products 
before they go on the market ,  and af terwards report  any ser ious s ide ef fect  
  Required that  ev idence of effect iveness be based on adequate and wel l -
cont rol led c l inical studies conducted by qual i f ied experts.  Study subjects 
would be required to give their  informed consent 
  Gave FDA 180 days to approve a new drug appl icat ion,  and required FDA 
approval  before the drug could be marketed in the Uni ted States 
  Mandated that  FDA conduct  a retrospect ive evaluat ion of the effect iveness 
of  drugs approved for safety - but  not for ef fect iveness -  between 1938 and 
1962 
  A l lowed FDA to set  good manufactur ing pract ices for indust ry and mandated 
regular inspect ions of product ion fac i l i t ies 
  Transferred to FDA control  of  prescr ipt ion drug advert is ing,  which would 
have to include accurate informat ion about s ide effects 
  Control led the market ing of  generic drugs to keep them from being sold as 
expensive medicat ions under new t rade names 
 
Table 2.2 demonstrates the pervasive presence of  publ ic health protect ion in key 
legis lat ions s ince 1813.  
 
2.3.3 Public health promotion and advancement  
A key mission of  the regulatory agencies is commitment to the advancement of  
publ ic  heal th (US Supreme Court ,  2007).  An important aspect of  th is commitment 
is provis ion of an ef fect ive post market ing survei l lance of medical  products (US 
Government Accountabi l i ty Off ice,  2006; FDA Strategic Plan, 2007).  Several  
h igh-prof i le drug safety cases in recent years have heightened the importance of  
th is topic (US Government Accountabi l i ty  Off ice,  2006).  For example at  a 
congressional  hear ings in September 2004,  FDA was cr i t ic ized for tak ing too 
long to te l l  physic ians and pat ients about studies l ink ing the use of 
ant idepressants among chi ldren to an increased r isk of  suic idal  behaviour.  
S imi lar ly,  at  a congressional  hear ing in November 2004, i t  was al leged that FDA 
did not act  quick ly enough on evidence i t  obtained in 2001 about the 
cardiovascular r isks of  Vioxx,  an ant i - inf lammatory drug that was developed and 
marketed by Merck pharmaceut icals.  In the US, this has motivated the 
Government Accountabi l i ty Off ice (GAO) to issue a report  on the effect iveness of  
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FDA in managing post  market ing survei l lance of drug safety decis ion making (US 
Government Accountabi l i ty Off ice,  2006).  As a remediat ion strategy,  the FDA has 
in i t iated cooperat ive programs that seek to br ing safe and ef fect ive medical  
products to pat ients faster and improve communicat ion of  informat ion about  r isks 
of  drugs and devices (US FDA Strategic Plan, 2007).  Concerning the lat ter,  the 
US Congress in the fal l  of  2007 passed the FDA Amendments Act,  mandat ing the 
FDA to establ ish an act ive survei l lance system for monitor ing drugs,  using 
electronic data f rom heal thcare informat ion holders.  The Sent inel  Ini t iat ive is the 
response of the FDA to that mandate, which intends to “…create a new post -
market ing survei l lance system that  wi l l ,  by 2012, be using electronic heal th data 
f rom 100 mi l l ion people to prospect ively monitor the safety of  marketed medical  
products” (P latt  et  al . ,  2009).  
 
Internat ional ly s ince 2007, the FDA and EMA cooperate c losely to faci l i tate the 
shar ing of  documents and informat ion related to assuring the safety,  qual i ty,  and 
ef f icacy of  pharmaceut ical products (FDA Strategic Plan, 2007).  This cooperat ive 
act iv i ty is  intended to further enhance publ ic heal th promot ion and protect ion in 
the EU and the US (FDA Strategic Plan, 2007).  
 
The future t rends in publ ic  heal th advancement wi l l  l ikely involve evolut ionary 
changes in pat ient  communicat ion,  new enforcement tools,  use of new label l ing 
concepts,  and post  market ing survei l lance (Plat t  et  al . ,  2009; Psaty & Burke,  
2006).  
 
2.3.4 Crisis management 
Histor ical ly governmental react ion to serious publ ic heal th events has been the 
key driver for ear ly landmark pharmaceut ical  legis lat ions.  
The congressional  mi lestones (Table 2.2) inc lude: 
  The Federal  Food, Drug,  and Cosmetic Act (FD&C) of 1938, which was 
passed af ter  a legal ly marketed toxic el ix i r ,  k i l led 107 people,  inc luding 
many chi ldren.   
  The Kefauver-Harr is  Amendments of  1962, which were st imulated by the 
thal idomide t ragedy in Europe, st rengthened the rules for drug safety and 
required manufacturers to prove the effect iveness of their  drugs.  
  The Medical  Device Amendments of 1976,  which fol lowed a U.S. Senate 
f inding that faul ty medical devices had caused 10,000 in jur ies, including 
731 deaths.  The law appl ied safety and effect iveness safeguards to new 
devices 
 
Another landmark US legis lat ion, The Pat ient  Protect ion and Affordable Care Act 
(HR 3590),  was s igned into law on March 23, 2010.  This t ime the mot ivat ion 
behind the legis lat ion was a response to a di f ferent k ind of cris is,  which was the 
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expansion of heal thcare coverage to over 30 mi l l ion uninsured Americans.  
A lthough the legis lat ion has largely received favourable response f rom the 
Pharmaceut ical industry,  provis ions relat ing to an approval  pathway for  
b ios imi lars have drawn a mixed response from the innovator-drug and gener ic-
drug part  of  the industry (PhRMA, 2009).  A “bios imi lar”  product as def ined in HR 
3590 is  a product that  is “highly s imi lar” to the reference product  
“notwi thstanding minor di f ferences in c l in ical ly inact ive components, ” and for 
which there are “no c l in ical ly meaningful  d i f ferences between the biological  
product and the reference product in terms of  safety, pur i ty and potency of the 
product. ” 
 
The t rend in cr ises management, which was prevalent at early stages of  
regulatory evolut ion,  is now changing.  Since 1976, regulatory agency rule-
making in the pharmaceut ical industry is increasingly dr iven by internat ional  
harmonizat ion,  foster ing innovat ion and regulatory modernizat ion (Table 2.2).   
According to the Inst i tute of Cr ises Management ( Inst i tute of Cr ises Management, 
2009),  the Pharmaceut ical industry hi t  the top-ten in the l is t  of  cr is is-prone 
industr ies in 1999 and has remained there ever s ince. Examples of  other cr is is-
prone industr ies inc lude food, petroleum, automobi le,  and aircraf t  industr ies.   
The most recent report  issued in 2009 ranks the indust ry at  number seven 
( Inst i tute of  Crises Management,  2009).  Based on the t rends observed in Table 
2.2 wi thin the next decade the indust ry is l ikely to cont inue exper iencing 
chal langes largely due to int roduct ion of new technologies and pract ices in an 
open innovat ion context  that  are advancing in a faster rate than the associated 
regulatory environment (discussed in Chapter 3).  I t  is  also important  to note that 
the regulatory controls relat ing to these new and emerging technologies and 
pract ices are less mature than the exist i t ing regulatory controls governing 
product safety and eff iacy.   However unl ike some of the ear l ier  events, the 
outcome may not involve landmark legis lat ions that created the current  
regulatory environment.  This is largely due to the existence of  a mature 
regulatory f ramework in developed countr ies.   
 
2.3.5 Harmonization 
Col laborat ion between regulators and the industry wi l l  increasingly encourage 
further global  harmonizat ion with an ult imate goal  of having one appl icat ion per 
t r ia l  to al l  authori t ies (Funning et al . ,  2009).  For example the FDA and the EMA 
cooperate c losely wi th internat ional  partners,  reinforcing the US and EU 
contr ibut ion to global  harmonizat ion (EMA Roadmap to 2010, 2005).   In 2009, the 
FDA announced a col laborat ive agreement with the EMA for a Good Cl in ical  
Pract ices Ini t iat ive (Bass & Klasmeier,  2009).  Under th is new ini t iat ive, the two 
agencies wi l l  increase col laborat ion on inspect ion act iv i t ies to ensure that 
c l inical  t r ials are conducted in a consistent ,  appropriate and ethical  fashion 
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(Bass & Klasmeier,  2009).  The agreement ,  s igned in 2005, faci l i tates among the 
agencies the exchange of  informat ion relat ing to legal  and regulatory issues, 
sc ient i f ic  advice,  orphan-drug designat ion,  inspect ion reports,  market ing-
authorizat ion procedures and post -market ing survei l lance (Bass and Klasmeier,  
2009).  The FDA and EMA also work c losely wi th ICH on matters of  harmonizat ion.  
These agencies have already publ ished numerous guidance documents on topics 
such as qual i ty (Table 2.2) and various aspects of  pharmacogenomics (Sudhop 
et  al . ,  2008).  
 
The major i ty of the interv iewed scient ists,  regulatory managers and regulators in 
an empir ical  study of the pharmaceut ical industry, bel ieved that “European 
harmonizat ion would ei ther raise safety standards or at  least  maintain them as 
high as previous nat ional  standards” (Abraham & Lewis,  1999).   
 
The FDA is t ry ing to increase number of  non-US pre-approval  inspect ions for 
drug products manufactured wi th in the developing countr ies.  This is exempl i f ied 
by establ ishing a c lose col laborat ion wi th China and India (Epstein et  al . ,  2009).  
The FDA also works wi th internat ional  and inter-governmental  bodies on the 
harmonizat ion of  internat ional  standards,  guidance, recommendat ions,  and r isk 
analys is pr inc iples.  Regional  drug regulatory agencies have also embarked on 
harmonizat ion schemes for pharmaceutical regulat ions (FDA strategic Act ion 
Plan, 2007; Epstein et  a l . ,  2009).  
 
2.3.6 Fostering innovation 
Empir ical  studies have shown that  regulat ion is one of  many external  dr ivers that 
af fect  the technological  strategy of  a company (Schwartzman, 1976).  Examples 
of  other external  dr ivers include the business environment (shaped by customers,  
compet i tors,  and suppl iers),  new and emerging technologies,  avai labi l i ty of  
sk i l led human resources, etc.  Prof i tabi l i ty may decrease as a resul t  of  
regulat ion- induced costs.  Several  studies have been ci ted, which indicate an 
increase of  100 to 1000% in R&D costs per new chemical ent i ty as a resul t  of  
pharmaceut ical  regulat ion (Schwartzman, 1976).  The regulators dur ing the Seoul 
ICDRA conference suggested that  technological  innovat ion is  essent ial  for  
regulat ion to succeed and that focused attent ion by regulators is needed to 
encourage speci f ic  k inds of  technological  change (World Heal th Organizat ion,  
2006).  They also recommended that  nat ional  regulatory agencies should 
cont r ibute to ensur ing the r ight balance between the need for innovat ion and 
equi table access, and between commercial  and publ ic heal th interests (World 
Heal th Organizat ion,  2006).  
 
Within the pharmaceut ical industry, regulatory agencies are responsible for 
advancing the publ ic  heal th by helping to speed innovat ions that  make medic ines 
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more effect ive,  safer,  and affordable.  To this end they need to cont inual ly 
examine whether current  regulat ions are st i l l  val id today and for future needs 
(US FDA strategic Act ion Plan, 2007;  Carney, 2005).  There is some evidence 
that th is is happening in recent years.  The ICH qual i ty guidel ines (Q8, Q9, Q10) 
and FDA’s Cr i t ical  Path ini t iat ive (Woodcock, 2007; Woodcock and Woosley,  
2008) are some examples. Both FDA and EMA have issued reports on how they 
intend to foster innovat ion (FDA Cri t ical  Path,  2007; EMEA/SHMP, 2007; US FDA 
Innovat ion or Stagnat ion,  2004).  Table 2.3 provides an overv iew of  the key 
points.  
 
The strategic investment by regulators in scient i f ic areas such as those l isted in 
Table 2.3 wi l l  contr ibute to medical product innovat ion.  The investment is l ikely 
to produce some advanced scient i f ic  regulatory standards wi th the intent  of  
providing predictabi l i ty and enhancing eff ic iencies for product  development 
(EMEA/SHMP, 2007; FDA Innovat ion or Stagnat ion,  2004).  The ul t imate goal  of  
the st rategic investment by the regulators is to increase publ ic access to new 
medical  products by helping the industry to shorten the medical product 
development t ime, ident i fy doubtful  products ear l ier  in development,  and get 
more promis ing products into the development pipel ine (Table 2.3).  
 
2.3.7 Modernization 
The concept  of  modernizat ion within regulatory authori t ies took root  in mid 1990s.  
The aim is to expedi te regulatory approval  process so new pharmaceut ical  
products could reach the market  more quickly.  Science- led modernizat ion of  
regulatory processes wi l l  require modernised faci l i t ies to support  more ef f ic ient  
operat ions with state of  the art  technologies.  I t  wi l l  also require innovat ive 
approaches to expand access to sc ient i f ic  expert ise to integrate emerging 
sc ience into regulatory processes.  Provis ion of modern information inf rast ructure 
and informat ion management to enable improvements in data-driven regulatory 
decis ion processes is another key enabler (FDA Strategic Act ion Plan, 2007).   
 
Within the US, the FDA Modernizat ion Act of 1997 is enacted to extend ear l ier  
legis lat ion designed to expedi te the FDA approval  process. The law also 
encouraged the harmonizat ion of the regulatory process between the U.S.,  
Europe, and Japan to avoid dupl icat ion,  so pat ients would have greater access 
to new drugs worldwide (Tancer & Mosser i,  2002).   
 
Modernizat ion in the EU shares some s imi lar i ty with the US approach but there 
are also major di f ferences. A summary of  key points for  the US and the EU 
modernizat ion act iv i t ies are tabulated in Table 2.4 (Bass and Klasmeier,  2009; 
FDA Innovat ion or Stagnat ion,  2004; Merr i l l ,  1999).  
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2.3.8 Discussion  
In this chapter the regulatory environment was descr ibed in relat ion to key 
dr ivers behind the pharmaceut ical  regulat ions.  Table 2.2 summarises the 
important regulatory events that have taken place since 1813 (Tancer & Mosser i ,  
2002,  Borchers et  al . ,  2007, Worthen, 2006).   I t  is  ev ident that  f rom 1813 to 
1970s the focus of regulators was centred on Cris is Management  and Publ ic 
Heal th Protect ion - a basic mission that has remained consistent  over the years 
(US Supreme Court ,  1964).  Since the 1980s a gradual  move in the regulatory 
environment towards a greater focus on Publ ic Heal th Promot ion, Internat ional  
Harmonizat ion, Innovat ion, and agency Modernizat ion may be seen.  The change 
in focus is  an important development s ince regulators consider the col laborat ive 
sc ience-dr iven regulatory environment central  to foster ing innovat ion and 
enabl ing cont inuous improvements.    
 
A lthough there is a posit ive t rend in regulatory harmonizat ion global ly,  there 
have been histor ical  di f ferences between var ious regulatory regions (e.g.  US, EU, 
Japan,  etc.)  especial ly wi th regards to the pre-market rev iew of the new drug 
appl icat ions. These di f ferences have had publ ic heal th impl icat ions - for instance 
according to a quant i tat ive survey, over twice as many new prescript ion drugs 
were wi thdrawn from the market on grounds of safety between 1971 and 1992 in 
the UK as there were in the US. This was at t r ibuted to a more str ingent US pre-
market rev iew standards, causing the FDA to release fewer unsafe drugs onto 
the market in the f i rst  place (Abraham & Davis,  2005).   
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Table 2.3 Key aspects of US and EU regulatory approaches to foster ing innovat ion 
FDA approach to fostering innovation 
(FDA Innovation or Stagnation, 2004) 
EMA approach for fostering innovation 
(EMEA/SHMP, 2007) 
 Developing better evaluation tools with a particular focus on biomarkers 
 Streamlining clinical trials  
 Harnessing bioinformatics  
 Moving manufacturing into the 21st century 
 Developing products to address urgent public health needs 
 At-risk populations – paediatrics 
 Focus on biomarkers  
 Statistical methods and clinical study designs  
 Faster access tools – conditional approvals  
 Risk management plans  
 Clinical trials  
 Global harmonization  
 Interaction between industry and academia  
 Advanced therapies and emerging treatments 
 
Table 2.4 Key aspects of  US and EU approach to regulatory modernizat ion   
Key aspects of US FDA modernisation 
(FDA Innovation or Stagnation, 2004; Merrill, 1999) 
Key aspects of EU EMA modernisation 
(EMA Roadmap to 2010, 2005) 
 Renewal of the prescription drug user-fee program 
 Reforms of the FDA’s drug approval process by integrating emerging science 
into regulatory processes  
 Changes in drug promotion and labelling rules 
 Expediting study and approval of fast-track drugs  
 Reforms in device regulation 
 Harmonization of regulation with international standards  
 Modernise FDA’s Information Technology platform 
Modernise EMEA by: 
 Efficient and transparent procedures  
 Top quality scientific assessment  
 Timely access to safe and effective innovative medicines  
 Continuous monitoring of medicinal products  
 Access to information  
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2.3.9 Summary of the salient points  
As discussed in Sect ion 2.2,  purpose of the l i terature review and review of the 
regulatory events was to character ise the regulatory environment. The regulatory 
environment has two key elements;  one that deals wi th publ ic heal th pol icy and 
another is concerned with sc ient i f ic  methods. The f i rst  element is pr imari ly 
concerned with pol i t ical  and socioeconomic issues part icular ly those relat ing to 
f ree movement of  goods, access to medic ine,  drug product  pr ic ing,  etc.  The 
latter is  pr imari ly concerned wi th provis ion of sc ience-based regulatory controls 
to ensure the safety and ef f icacy of pharmaceut ical products for human use.  
Both elements have a profound impact on innovat ion and product iv i ty of  drug 
discovery and development processes.  
  
Due to uncertaint ies and var iat ions in the pol i t ical  landscape at the indiv idual  
country level ,  a uni f ied predict ion of where the publ ic heath pol icy wi l l  be in the 
future cannot be accurately est imated and also is  outside the scope of th is 
research. For example access to medic ine in UK is based on the guidance of  the 
Nat ional  Inst i tute for  Heal th and Care Excel lence (NICE) whose mission is to 
provide independent guidance to heal thcare professionals and others to ensure 
qual i ty and value for money. Whereas s imi lar  guidance and decis ion making in 
the US is largely performed by the heal thcare insurance providers.  However wi th 
respect to the second element,  the regulatory act ions to date indicate a move 
towards publ ic health promot ion,  modernizat ion and foster ing innovat ion.  
A lthough this t rend in regulatory thinking is l ikely to cont inue in the future i t  is  
a lso reasonable to posit  that the industry t ransformat ion and dispers ion of  
d isrupt ive technologies (discussed in Chapter 3) wi l l  provide new regulatory 
chal lenges that  wi l l  perhaps require cr is is management responses to regulatory 
ru le making f rom t ime to t ime. 
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CHAPTER 3: Identification and ranking of triggers 
impacting the industry transformation: a systematic 
review of the literature…………………..…. 
 
3.1 INTRODUCTION 
As descr ibed in Chapter 1 (Sect ion 1.3) the product iv i ty in the pharmaceut ical  
industry has exper ienced a decl ine since 1990 despite increasing expenditure 
and investments in R&D (Cockburn,  2006; Cohen et  al . ,  2004; Ahlborn et  al . ,  
2005;  Peck wt al . ,  2007; Deloi te whi te paper,  2009; Grabowski  & Kyle,  2008).  
Chal lenging,  inef f ic ient,  and increasingly cost ly product development is a key 
reason for the decl ine in product iv i ty (FDA Innovat ion or Stagnat ion,  2004).  
According to the FDA the r ise in costs of  product development is  forc ing the 
innovators to focus their  ef forts on products wi th a potent ia l ly high market return 
(FDA Innovat ion or Stagnat ion,  2004).   
 
To address the innovat ion problem stated above and the ongoing changes in the 
regulatory environment descr ibed in Chapter 2 (EMA Road Map to 2010,  2005 ;  
EMA Road Map to 2015, 2009; FDA Strategic Act ion Plan, 2004;  Woodcock & 
Woosley,  2008;  Mi lne, 2006),  the industry is  making t ransformat ional  changes to 
the pharmaceut ical  bus iness. In Chapter 1 t ransformat ion was def ined as the 
process by which the pharmaceut ical  industry intends to achieve and maintain 
advantage through changes in operat ional  concepts, regulatory sc ience,  and 
technologies that  wi l l  s igni f icant ly improve i ts  capabi l i ty to innovate.   
  
A key feature of  the ongoing industry t ransformat ion is open innovat ion.  This 
means that  pharmaceut ical  companies no longer rely solely on their central ised 
and internal ly focused R&D and are increasingly looking towards external  
sources of  innovat ion such as research partnerships wi th smal l  b iotechnology 
companies,  univers i t ies,  governmental  organizat ions, etc.  (Enkel et  a l . ,  2009; 
Chesbrough ,  2003; Talaga, 2009; Crommel in et  a l. ,  2010).  Since 2001, some of 
the large pharmaceut ical  companies such as Glaxo,  Pf izer and Li l ly  have 
exper imented wi th the open innovat ion approach (Hunter & Stephens, 2010).  
Hunter and Stephens (2010) see open innovat ion as “a valuable model  for  large 
pharmaceut ical  companies” and argue that adopt ing an open innovat ion cul ture 
wi l l  require a change in operat ional concepts,  deployment of  new technologies 
and appl icat ion of resources to nurture external  col laborat ions and moni tor their  
progress to ensure success.  
 
Systemat ic review of the l i terature is a plausible method to character ise potent ia l  
t ransformat ion t r iggers.  The systemat ic discernment of  pat terns f rom a widely 
diverse set  of  studies and/or body-of-research requires analyt ical  rev iew 
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(Ginsberg & Venkatraman, 1985).  In this study a l i terature review focusing on 
qual i tat ive content analys is of the pr imary art ic les wi th systemat ic l i terature 
search (Tranf ield et  al . ,  2003) for  select ion of  ar t ic les was used. I t  is  important 
to note that  the intent of  the l i terature review was not to perform a “systemat ic 
l i terature review”,  which is commonly used method to compare and contrast 
opposing views and opinions. Instead the intent  of  th is research was to perform 
a systemat ic review of  the l i terature to ident i fy and rank l ikely t r iggers 
inf luencing pharmaceut ical  industry t ransformat ion. The term “systemat ic rev iew” 
refers to systemat ic nature of select ing and assessing art ic les against the 
acceptance cr i ter ia.  The outcome of the l i terature review descr ibed in th is 
Chapter is termed “theoret ical  ev idence” and used throughout th is thesis.  
 
The aim of th is Chapter is to ident i fy and categor ise pharmaceut ical  industry 
t ransformat ion t r iggers and associated theoret ical  qual i ty r isks by tak ing a 
systemic approach to reviewing the relevant l i terature.  
 
In establ ishing the theoret ical  ev idence in this chapter,  the coverage of  the 
art ic le select ion/ review was inf luenced by the changes in the regulatory 
environment described in Chapter 2.  As a reminder these changes inc luded a 
greater focus on publ ic heal th promot ion,  internat ional  harmonizat ion,  and 
innovat ion.  
 
3.2 METHOD 
A six step process was fol lowed that was organised into three phases; art ic le 
select ion,  art ic le review and art ic le c lassi f icat ion.   
 
Step 1:  Select ion of pr imary art ic les 
Step 2:  Review of  the primary art ic les  
Step 3: Select ion of der ived art ic les 
Step 4: Test ing for art ic le divers i ty  
Step 5: Searching for t ransformat ion t r iggers in al l  art ic les  
Step 6: Ranking of t ransformat ion t r iggers  
 
The select ion phase involved development of  a select ion procedure, which 
ident i f ied art ic les that were considered relevant  (Step 1 – Sect ion 3.2.1, Step 3 – 
Sect ion 3.2.3).  The review phase involved the detai led review of the primary 
art ic les to discern l ikely t r iggers for pharmaceut ical t ransformat ion (Step 2 – 
Sect ion 3.2.2, Step 5 – Sect ion 3.2.5) and test ing of  art ic le divers i ty (Step 4 – 
Sect ion 3.2.4) and the c lassi f icat ion phase was performed to determine relat ive 
importance ranking of  the t ransformat ion t r iggers wi th respect to their prevalence 
wi th in the art ic les studied (Step 6 – Sect ion 3.2.6).  
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3.2.1 Selection of primary articles (Step 1) 
As ment ioned previously t ransformat ional  change in a given industry is 
inf luenced by regulatory pol icy, industry environment and technological evolut ion 
(Meyer et  a l . ,  1990).  I t  is  therefore important  that the select ion procedure for the 
pr imary art ic les taps into the diverse body of  l i terature that  inc ludes academic,  
industr ia l  and government issued art ic les.  The inc lus ion cr i ter ia and search 
phrases l is ted in Table 3.1 was used in the search procedure to ident i fy the 
pr imary art ic les.  The pr imary art ic le select ion procedure is conceptual ly 
i l lust rated in Figure 3.1.  
 
Table 3.1 Inc lusion cr i ter ia and search phrases used for select ion of  pr imary 
art ic les 
Inclusion criteria Search phrases 
 Publication year  
(quantitative measure, >= 2000) 
 Citations 
(quantitative measure, targeted most cited)  
 Pharmaceutical transformation relevance 
(qualitative measure) 
 Strategic regulatory focus 
(qualitative measure) 
 
 pharmaceutical “industry transformation” 
 “pharma 2020” 
 “future biopharma”  
 “open innovation”  
 ”regulatory evolution” 
 “Pharmaceutical Sciences by 2020”  
 FDA "Critical Path" 
 “EMEA Roadmap”  
 
F igure 3.1 Conceptual i l lustrat ion of  the process for select ing pr imary art ic les 
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Database and Search Phrases -  Since th is PhD research involves topics that 
span mult ip le disc ipl ines such as pharmaceut ical  t ransformat ion,  pharmaceut ical  
innovat ion,  pharmaceut ical  technology, and pharmaceut ical  regulatory sc iences, 
the search tools used had to be diverse.  For peer-reviewed academic art ic les,  
Web of  Knowledge, Science Direct ,  Wi ley Onl ine Library and JSTOR were used. 
Regulatory agency websi tes US FDA, European Medic ines Agency (EMA),  Heal th 
Canada and Internat ional  Conference on Harmonizat ion (ICH) were the main 
source of  regulatory art ic les.  Art ic les publ ished by the consult ing f i rms and other 
research organizat ions were col lected through general  Google Web Search or 
Google Scholar.   The Google Scholar search was l imited to art ic les in business, 
medic ine, pharmacology and social  sciences subject  areas. The inc lus ion cr i ter ia 
and search phrases l is ted in Table 3.1 was used in the search procedure wi thout 
t runcat ion and in quotes when shown. Google Search is a web engine owned by 
Google Inc.   The main purpose of Google Search is to look for speci f ied text in 
publ ic ly accessible documents of fered by web servers and one of  i ts key features 
is the abi l i ty to rank web pages that  match a given search phrase. 
 
Publ icat ion Year -  the art ic les for  each t ransformat ion t r igger were selected f rom 
a per iod of  t ime that was as recent as possible.  This approach was based on the 
assumption that more recent  art ic les ref lect  bet ter the current th ink ing of the 
academic,  consult ing,  governmental,  industry and research organizat ions.  The 
art ic le search was performed in 2010 and inc luded art ic les publ ished from 2000 
to 2010.  Year 2000 was selected s ince the in it ial  exploratory work on art ic le 
select ion revealed that forward looking opinions wi thin the art ic les typical ly 
considered a 5 to 10 year t ime-horizon. 
 
Number of  Ci tat ions - this select ion cr i ter ion represents the total  number of 
c i tat ions per art ic le.  Frequency of c i tat ion of  an art ic le is a s ign of i ts 
pervasiveness and hence i ts abi l i ty to inf luence current and future think ing. I ts  
value is impacted by the year of  publ icat ion. Therefore a balance between 
recentness (publ icat ion date) and pervasiveness (number of  c i tat ions) was 
needed and was designed into the ranking procedure (Step 6 – Sect ion 3.2.6).  I f  
avai lable,  the citat ion informat ion was gathered f rom the publ isher of the source 
journal ,  otherwise Google Scholar was used to determine the number of  c i tat ions. 
 
Pharmaceut ical Transformat ion Relevance - the l i terature search was focused on 
art ic les that  had relevance to the heal thcare sector in general  and the 
pharmaceut ical  industry in part icular.  This search was performed by review of  
the abstract and/or the int roduct ion sect ion of  the art ic les which had met the 
in i t ia l  cr i ter ia (publ icat ion date,  containing the word “pharmaceut ical”  or  
“healthcare” in the t i t le or abstract) and therefore considered an interest ing 
art ic le for  fur ther evaluat ion.  
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Strategic Regulatory Focus - the in i t ial  exploratory art ic le search revealed that,  
wi th in the US and the EU, the current and future th inking of the regulators is 
of ten art iculated in their  long term strategic plans.  These plans deal t  with the 
topics that are important f rom the perspect ive of  publ ic heal th protect ion and 
promot ion. One such topic is the creat ion of  a regulatory environment that 
enables the development of  innovat ive l i fe saving drugs, which regulators v iew 
as important to promot ion of publ ic health. The regulators use their  long term 
st rategic p lans to communicate their  current  achievements and future act ions 
relat ing to protect ion and promot ion of  publ ic heal th.  For these reasons the last  
two search phrases l isted in Table 3.1 ( i .e.  FDA "Cr i t ical  Path",  “EMEA 
Roadmap”)  were designed to discern art ic les that  speci f ical ly deal t  wi th forward-
looking regulatory ini t iat ives. 
 
3.2.2 Review of the primary articles (Step 2) 
Each primary art ic le was reviewed in detai l ,  meaning that  the ent i re art ic le was 
read focusing on v iews, opinions, act ions and evidence that provided topics on 
pharmaceut ical  industry evolut ion f rom innovat ion and regulatory sc ience 
perspect ive.  Mult iple occurrence of a part icular topic relat ing to innovat ion or 
regulatory sc ience was deemed important and was tagged as a t ransformat ion 
dimension.  Af ter review of  a l l  the pr imary art ic les ( i .e.  ar t ic les selected dur ing 
the ini t ia l  search) the ident i f ied t ransformat ion dimensions were c lassi f ied into 
s imi lar groups, which are termed “Transformat ion Tr iggers”.  
 
3.2.3 Selection of derived articles (Step 3) 
During review of  the primary art ic les any referenced art ic les that were deemed 
relevant ( i .e.  covering s imi lar topics as the pr imary art ic le) were noted. After a 
review of  the ident i f ied art ic le’s abstract  and/or introduct ion sect ion,  a 
determinat ion was made whether the relevant art ic les were compliant  wi th the 
same inc lusion cr i ter ia as for the pr imary art ic les and i f  so they were considered 
as der ived art ic les.  The content of  these art ic les were then searched for 
t ransformat ion t r iggers as descr ibed in Sect ion 3.2.5 below. 
 
3.2.4 Testing for article diversity (Step 4) 
I t  was necessary to enhance general izat ion of  resul ts der ived f rom the l i terature 
review to demonstrate that art ic les support ing each of the t ransformat ion t r iggers 
came f rom diverse sources but wi th s imi lar  sourc ing character ist ics,  i .e.  art ic le 
type, age and pervasiveness. This goal  was achieved through the design of the 
procedure for select ing art ic les and was tested through descr ipt ive stat ist ics and 
appl icat ion of the Kruskal-Wal l is H-test (Sect ion 3.3.1; Chan & Walmsley, 1997).    
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3.2.5 Search for transformation triggers in all articles (Step 5) 
The content of each art ic le was searched using the search phrases l isted in 
Table 3.2.  Two or more search phrases were used for  each t ransformat ion t r igger.  
An art ic le was deemed relevant to a t ransformat ion t r igger i f  i t  covered at  least  
one of  the Related Search Phrases l is ted in Table 3.2.  The intent was to focus 
the search effor t  on new and emerging pharmaceut ical  r isk areas and not on the 
wel l -character ised r isk topics relat ing to drug safety and pharmacovigi lance.  
  
Table 3.2 Search phrases related to the t ransformation t r iggers used in Step 5 
Transformation Trigger Corresponding search phrases 
T1 - Healthcare Management Focused  Healthcare Management 
 Health care Management 
 Biomarkers/Diagnostic-s 
 Drug/Device Combo 
T2 – Fully Integrated Pharma Network  FIPNet 
 Research Collaborations 
 Research Partnerships 
 External Partnerships 
 Externalization 
 In Licensing 
T3 - Personalised Medicine  Personalised medicine 
 Individualised medicine 
 Targeted Medicine 
 Open Innovation 
T4 - Virtual R&D  Virtual R&D 
 Virtual Discovery 
 Virtual Pharma 
T5 - Translational Research  Translational Research 
 Biomarkers 
 Predictive Medicine 
T6 - Adaptive Trials  Adaptive Trials 
 In-Life Trials 
T7 - Global Harmonization  FDA EMEA Partnerships 
 Global Harmonization 
T8 – Science and Risk Based Regulations  Risk Based Approach 
 Science-based regulations 
 Science-driven regulations 
T9 – Live Licensing  Live Licensing 
 Progressive Licensing 
T10 – Enforcement  Enforcement 
 Compliance 
T11 – Biotechnology  Biotechnology 
 Future of biotechnology 
T12 – Nanomedicine  Nanotechnology 
 Nanomedicine 
 Nanomaterials 
 Nanoscience 
T13 - Bioinformatics  Bioinformatics 
 Biocomputing 
 Virtual Lab 
T14 – Pervasive/Cloud Computing  Pervasive Computing 
 Cloud Computing 
 Ubiquitous computing 
 Biomedical Sensors 
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3.2.6 Ranking of transformation triggers (Step 6) 
In order to highl ight  the relat ive ranking of each t ransformat ion t r igger a 
weighted scor ing approach was employed, s imi lar to that  described by Chan and 
Walmsley (1997).  To achieve this,  an importance weight score was appl ied to 
each att r ibute character iz ing the art ic le.  These at t r ibutes inc lude publ icat ion 
source, publ icat ion year,  and number of  c i tat ions per art ic le,  which are described 
below. The weighted score for each art ic le wi th respect to each of  the 
t ransformat ion t r iggers was computed based on the weight ing scheme l is ted in 
Table 3.3.   
 
Table 3.3 Weight ing scheme used in Step 6 for  relat ive importance ranking of  the 
art ic les 
Article Attribute Importance Weight  
Publication Year Year Score (YS) 
>2005 3 
2000-2005 2 
<2000 1 
Article Source Source Score (SS) 
Gov  5 
Acd  4 
Con 3 
Ind 2 
Org 1 
Citations Citation Score (CS) 
> 10 3 
5 to 10 2 
<5 1 
 
i )  Publ icat ion Source. Regulatory pol icy,  the current th ink ing of the regulators,  
and their  future plans are tangible examples of future regulatory direct ion and 
therefore were given the largest weight.  Academic peer rev iewed art ic les by 
def in i t ion are thoroughly vet ted and therefore were given the second largest 
weight .  Art ic les wr i t ten by renowned consult ing organizat ions typical ly ref lect  
and inf luence the key stakeholders in the industry and therefore receive next 
pr ior i ty weight .  Art ic les wr i t ten by industry pract i t ioners not publ ished in peer 
rev iew journals and non-Pharma research organizat ions receive the lowest 
weight respect ively.   
 
i i )  Publ icat ion Year.  Art ic les publ ished  before 2000 (Pre) or on/af ter 2000 (Post).  
Pre was used to account  for one derived art ic le publ ished in 1998 (Love, 1998) 
that  was inc luded as an except ion s ince i t  met the acceptance cr i ter ia except for  
the publ icat ion date, which was c lose enough to 2000 and therefore was inc luded.   
 
i i i )  Number of  Citat ions .  This select ion cr i ter ion represents the total  number of  
c i tat ions per art ic le.  Frequency of c i tat ion of  an art ic le is a s ign of i ts 
pervasiveness and hence i ts abi l i ty to inf luence current and future think ing. I ts 
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value is impacted by the year of  publ icat ion. Therefore a balance between 
recentness (publ icat ion date) and pervasiveness (number of  c i tat ions) was 
needed and was designed into the ranking procedure (Table 3.3).  I f  avai lable the 
c i tat ion informat ion was gathered f rom the publ isher of  the source journal ,  
otherwise the Google Scholar was used to determine the number of  c i tat ions.  
 
The prevalence of  the t ransformat ion t r iggers in the pr imary and der ived art ic les 
was determined as descr ibed in Step 5 (Sect ion 3.2.5) and their  re lat ive ranking 
was performed in accordance wi th the fo l lowing computat ional  procedure (Table 
3.4).  
 
In Table 3.4 Equat ion 3.1 was used to determine the geometr ic mean (central  
tendency) of  the weighted scores for each art ic le.  In Equat ion 3.2 the weighted 
scores were mult ipl ied by the geometr ic  mean to determine a s ingle Consol idated 
Weighted Score (CWS) for each art ic le.  Equat ion 3.3 was used to compute 
relat ive importance ranking of each of the CWS relat ive to the ent i re populat ion 
of CWSs. Equat ion 3.4 was used to f ind the ordinal posi t ion of  the CWSs. Some 
ordinal  posi t ions had the same value, which were termed “Ties”.  Equat ion 3.5 
and Equat ion 3.6 were used to compute the ordinal  posi t ion of the CWS taking 
into account the Ties. Equation 3.7 was used to perform the ranking in reverse 
order.  Equat ion 3.8 was used to calculate a s ingle consol idated ranked score for 
each transformat ion t r igger (by adding columns of the rank matr ix) .  Larger the 
consol idated ranked score the higher the relat ive ranking of the t ransformat ion 
t r igger.  
 
Table 3.4 Procedure used in Step 6 for comput ing relat ive importance ranking of  
al l  art ic les 
 Equation 3.1: Geometric Mean  
 Equation 3.2: Consolidated weighted score 
 Equation 3.3: Rank including Ties 
 
Equation 3.4: Ordinal Position 
 Equation 3.5: Tie Count (R10 is an empty cell) 
 Equation 3.6: Rank correction to account for Ties 
 Equation 3.7: Rank in Reverse order 
 Equation 3.8: Cj =  RRij  where i=1..n and j=1..k 
 
The structure of the ranking matr ix  is i l lustrated in Table 3.5. In this matr ix the 
rows represent the primary and derived art ic les and the columns represent the 
t ransformat ion t r iggers.  Scores per art ic le and a given transformat ion t r igger is 
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captured in the matr ix,  the corresponding weighted scores are calculated and 
f inal ly the relat ive importance ranking is computed based on the procedure 
descr ibed above. 
 
Table 3.5 Structure of  the ranking matr ix used in Step 6 for relat ive importance 
ranking of  al l  art ic les 
 C1 C2 Cj 
 scores 
A1  F11 F12 F1j 
A2 F21 F22 F2j 
Ai Fi1 Fi2 Fij 
 weighted scores 
A1 Fw11 Fw12 Fw1j 
A2 Fw21 Fw22 Fw2j 
Ai Fwi1 Fwi2 Fwij 
 ranked scores 
A1 RR11 RR12 RR1j 
A2 RR21 RR22 RR2j 
Ai RRi1 RRi2 RRij 
RankCj  C1=Ri1 C2=Ri2 Ck=Rij 
i  = 1 . . .  n    and     j  = 1 . . .  k 
A - art ic le; n -  sample s ize; k -  number of  t ransformation t r iggers; F -  t r igger 
f requency (1 - present,  0 -  absent);  Fw -  weighted tr igger f requency;  RR - 
reverse rank of  each data point  
 
3.3 RESULTS AND DISCUSSION  
3.3.1 Results for article search and article diversity testing 
The art ic le select ion procedure resul ted in 22 pr imary art ic les targeted for  
l i terature review; and 60 derived art ic les f rom review of  the primary art ic les 
(Table 3.6).   
 
Test ing of art ic le source divers i ty (Sect ion 3.2.4) was achieved using descr ipt ive 
stat ist ics provided in Table 3.7 and Kruskal-Wal l is  H-test  for  Transformat ion 
Tr iggers (HT T) .  The nul l  hypothesis was def ined to mean that most art ic les have 
s imi lar sourc ing character ist ics and the al ternat ive hypothesis was def ined to 
mean that  most art ic les have diverse sourc ing characterist ics.   
 
 
     )1(3
)1(
12
1
2
 







 Nn
SumR
NN
H Kj
j
j
…Equat ion 3.9 
Rj  (Rank of each transformat ion t r igger in Table 3.8;  where j  = 1 . . .  K) 
nj  =  (number of  data points per t ransformat ion t r igger in Table 3.8;  where  j  = 
1 . . .  K) 
N = 146  ( total number of data points for al l  t ransformat ion t r iggers) 
K = 14   (number of  t ransformat ion t r iggers)  
df  = (K-1) =13  (degrees of  f reedom)     
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HT T = 13.02  (resul t  of  solv ing Equat ion 3.9)   
 
S ince HT T =13.02 is less than the chi-squared H-test  table value of 19.812 (Chan 
& Wamsley,  1997) the probabi l i ty of  occurrence i .e.  the p-value is greater than 
0.10. Hence the nul l  hypothesis is accepted and i t  can be concluded that most 
art ic les have s imi lar sourc ing characterist ics – meaning most art ic les are 
academic in nature,  publ ished af ter 2005 wi th less than 5 c itat ions.    
 
The qual i tat ive assessment of v iews,  opinions and ev idence presented in the 
pr imary art ic les resulted in 14 t ransformat ion t r iggers. The relat ive importance 
ranking resul ts for each of  the t ransformat ion t r iggers are provided in Table 3.8.  
 
3.3.2 Results of the literature review  
Among the 14 t ransformat ion t r iggers, 4 t r iggers namely Ful ly Integrated Pharma 
Network (Trigger 2) ,  Personal ised Medicine (Trigger 3 ) ,  Translat ional Research 
(Trigger 5)  and Pervasive Comput ing (Trigger 14)  were found to be the most  
prevalent wi th in the art ic les studied.  Note that  the ordinal  posit ioning of  the 
t ransformat ion t r iggers in Table 3.8 (1 to 14) is di f ferent  f rom their  importance 
ranking provided at  the end of  the table.  The 14 tr iggers are s imply l is ted in the 
order of  t ransformation topics that were addressed dur ing the l i terature search 
and review process i .e.  organizat ion,  product,  regulatory and technology related 
topics respect ively.  
 
Information wi th in the art ic les relat ing to t ransformat ion t r iggers were 
synthesised into statements that  are presented below for each of the t r iggers.   
The proposed open innovat ion t rends and the theoret ical qual i ty r isks for each of 
the four main t ransformat ion t r iggers are also discussed below.   
 
Trigger 1:  Heal thcare Management  Focused -  the main thrust of  the discussions 
in the referenced art ic les seem to suggest  that  pharmaceut ical  industry is 
t ransforming from a mainly product-based industry to a heal thcare management 
concept wi th more emphasis on preventat ive and l i fe-sty le medic ine and 
associated serv ices.  I t  is  ant ic ipated that the industry wi l l  integrate a larger 
heal th of fer ing wi th sustainable pr ic ing models for  a wider array of  products and 
services, inc luding gener ics,  diagnost ics,  d isease management, prevent ion and 
knowledge management (Peck et a l . ,  2007; Shah et  al . ,  2009; Foster,  2008).  
 
Tr igger 2:  Ful ly Integrated Pharma Network -  a major theme wi th in the l i terature 
pointed to a pharmaceut ical business model that is based on a ful ly integrated 
global  network that  inc ludes other pharmaceut ical or  b iotechnology companies,  
univers i t ies, organizat ions, and even indiv iduals in some cases (Woodcock & 
Woosley,  2008;  Br i t ish Telecommunicat ions, 2007; Deloi t te Consult ing,  2002;  
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Hohman el  al . ,  2009; Lundberg & Rei l ly,  2009; EMRC, 2005; Woosley & Cossman, 
2007).  
 
Tr igger 3:  Personal ised Medic ine - the l i terature (Humer,  2004;  Jain,  2005; Phan 
et  al . ,  2009; Aspinal l  & Hamermesh, 2007; Guidi & Lippi ,  2009; Adams et al . ,  
2006) points to the l ikely t rends that  specif ic t reatments and therapeut ics best  
sui ted for an indiv idual  are increasing in prevalence. There is no s ingle def in i t ion 
for personal ised medicine but one general  theme among the art ic les suggested 
that  personal ised medicine is concerned wi th the development and administ rat ion 
of t reatments (based on a knowledge of  genet ic biomarkers or mutat ions) to 
pat ients who might best respond to an indiv idual ly tai lored t reatment (Humer, 
2004;  Jain, 2005; Phan et al . ,  2009;  Aspinal l  & Hamermesh, 2007; Guidi  & Lippi ,  
2009;  Adams et al . ,  2006).  This is exempl i f ied by a quote f rom Adams et al .  
(Adams et al . ,  2006) “By 2015, a 21-year-old could undertake a whole genome 
test to ident i fy r isk factors for  chronic condi t ions, such as a specif ic cancer or 
heart  d isease. I t  would also reveal  the potent ial  for adverse drug react ions to 
drugs. This knowledge wi l l  enable a new level  of  consumer responsibi l i ty. ”   
 
Trigger 4:  V irtual  R&D  -  the main argument in the referenced art ic les (Talaga, 
2009;  Hohman et a l. ,  2009; Ginsburg & McCarthy,  2001; Shuchman, 2007; 
PricewaterhouseCoopers,  2008; Love, 1998) is that large pharmaceut ical  
companies are shif t ing investment away f rom tradi t ional  in-house research 
act iv i t ies and focusing more on developing super ior deal-making and al l iance 
capabi l i t ies to enable v ir tual R&D, which is  also l inked to the concept of open 
innovat ion.  
 
Tr igger 5:  Translat ional  Research - the referenced art ic les (Ahlborn et al . ,  2005; 
EMR, 20005; Phan et a l . ,  2009; Mulder at  al . ,  2008; Ginsburg & McCarthy,  2001; 
O’Connel l  & Robl in,  2006;  Marrer & Dieter le, 2007;  Michelson wt al . ,  2006;  
Zerhouni ,  2007; Wehl ing, 2006) descr ibe l ikely t rends in t ranslat ional  research 
and def ine i t  as a bi -direct ional  shar ing of  knowledge and ideas by the scient i f ic  
and c l inical  discipl ines to develop diagnost ics that rel iably select  the 
mechanisms leading to breakthrough therapeut ics.  Some of  the benef i ts argued 
by the art ic les inc lude matching pat ients wi th therapy, improved compl iance wi th 
therapy, reduced drug development costs,  and reduced heal thcare costs.  
Advances in computat ional  tools such as predict ive bio-s imulat ion systems, in-
s i l ico  model ing techniques and bioinformat ics are also highl ighted in some of  the 
art ic les as playing a key role in enabl ing the real izat ion of  the t ranslat ional  
research (Ahlborn et a l . ,  2005; EMR, 20005).  
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Table 3.6 Art ic le search phrases used dur ing the select ion procedure and the associated art ic le select ion results 
Article search phrases 
S
o
u
r
c
e
 
R
e
s
u
l
t
s
*
 
S
e
l
e
c
t
e
d
*
*
 
R
e
f
e
r
e
n
c
e
 
i) pharmaceutical “industry transformation” Academic 77 1 (Cockburn, 2006) 
ii)  “pharma 2020” Academic 31 0 – 
iii) “future biopharma” Academic 2 1 (Cooke, 2001) 
iv) “Pharmaceutical Sciences by 2020” Academic 2 2 (Crommelin et al., 2010; Shah et al., 2009) 
v) FDA "Critical Path" Academic 384 7 (Woodcock & Woosley, 2008; Woosley & Cossman, 2007; Jain, 2005; Aspinall 
& Hamermesh, 2007; Wehling, 2006; Miller et al., 2005; Calfee, 2006) 
vi) “EMEA Roadmap” Academic 6 2 (Milne, 2006; Heemstra, 2008) 
Used the same search phrases above (i to vi) Industry 174 5 (Peck et al, 2007; Deloitte, 2009; British Telecommunications, 2007; Mulder et 
al., 2008; PriceWaterhousecoopers, 2008) 
Used the same search phrases above (i to vi) Regulatory 106 4 (FDA innovation or Stagnation, 2004; EMA Road Map to 2010, 2005; EMA 
Road Map to 2015, 2009; FDA Strategic Action Plan, 2007) 
Primary Articles: 22 ; Derived Articles: 60 ; Total Articles: 82 
*  Number of  art ic les meet ing the ini t ia l  search cr i ter ia 
**  Number of  pr imary art ic les selected after  rev iew of  abstract  and/or introduct ion sect ion  
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Table 3.7 Descr ipt ive stat ist ics support ing the test ing of  the art ic le diversi ty 
Article Type No. of articles % Article Age 
No. of 
articles % Citations 
No. of 
articles % 
Government 6 7% Before 2000 1 1% 5 to 10 10 12% 
Industry 12 15% 2000 to 2005 24 29% > than10 26 32% 
Other 12 15% After 2005 57 70% < than 5 46 56% 
Consulting 15 18% - - - - - - 
Academic 37 45% - - - - - - 
This table provides informat ion on number of  art ic les relat ing to type,  age and ci tat ions. The corresponding percentage is  calculated 
against the overal l  sample s ize (sample s ize = number of ar t ic les studied = 82)  
 
 
Table 3.8 The pervasiveness and relat ive ranking of the t ransformat ion t r iggers in the pr imary and der ived art ic les……….  
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n 11 16 22 6 15 8 7 8 7 5 7 6 11 17 
Rank 7 3 1 12 4 13 9 6 11 14 8 10 5 2 
n = pervasiveness of  the t r igger in al l  art ic les; sample s ize (total  number of  ar t ic les) = 82 
See Appendix A for more detai led analys is  
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Trigger 6:  Adapt ive and In- l i fe Tria ls  -  in adapt ive t r ials,  information acquired 
dur ing a part icular c l inical  t r ia l  is used to al ter the course of  the t r ia l  wi thout 
compromising i ts stat ist ical  val idi ty.  In- l i fe test ing wi l l  leverage emerging 
computat ion and communicat ion technologies and could replace Phase I I I  t r ia ls.  
Such measures could shorten the developmental  p ipel ine f rom the current  10 to 
12 years to between 3 and 5 years (Boswel l ,  2002).  Closer relat ionship wi th 
regulatory author i t ies is a key factor to ensure success (Ahlborn et al . ,  2005; 
Heemstra et  al . ,  2008;  Fraser,  2006;  Mi l ler  et a l . ,  2005;  Boswel l ,  2002; 
Prendergast et  a l. ,  2004).  
 
Tr igger 7:  Global  Harmonizat ion - harmonizat ion discussions focus mainly on 
col laborat ion between regulators and the indust ry,  especial ly in the ICH zone 
(North America, Europe and Japan). Referenced art ic les inc lude predict ive 
statements hoping for  a level  of  global  harmonizat ion that  may ul t imately result  
in the seemingly unattainable goal  of  having one appl icat ion per t r ia l  to al l  
authori t ies (EMA Road Map to 2010, 2005; FDA Strategic Act ion Plan, 2007; 
Funning et  a l . ,  2009; Pharmaceut ical  Science and Cl inical  Pharmacology 
Advisory Committee Meet ing, 2009;   Bass et al . ,  2009).  
 
Tr igger 8:  Science and Risk Based Regulat ions -  the art ic les examined argued 
that  wi th the fates of  the regulators and the industry more intertwined than ever,  
publ ic  heal th depends on regulatory innovat ion as much as on sc ient i f ic  progress. 
From the perspect ive of  regulatory innovat ion an important  step towards 
achieving the out l ined goal  involves internat ional  col laborat ion between 
regulators and industry (Calfee, 2006),  which has been exempl i f ied through ICH 
efforts manifested in issuance of  a wide range of  standards,  part icular ly those 
related to Qual i ty Risk Management,  Pharmaceut ical  Development and 
Pharmaceut ical Qual i ty System (EMA Road Map to 2010, 2005;  FDA Strategic 
Act ion Plan, 2007; Sneha & Varshney, 2009; Cal fee,  2006; FDA Cri t ical  Path,  
2006;  Yu, 2008; Garcia et  a l . ,  2008).  
 
Tr igger 9:  L ive Licensing -  discussions on this topic mainly have a conceptual  
tone due to uncertain commitment f rom the regulatory bodies.  According to the 
l i terature l ive l icensing impl ies that  the current  Phase I  to IV c l in ical  test ing 
process may eventual ly be select ively or whol ly replaced by a system known as 
" in- l i fe"  test ing or " l ive" l icensing (Heal th Canada, 2007;  Vis iongain,  2008).  
Those proposals involve cumulat ive test ing of  the drug throughout i ts l i fecycle.  
In this paradigm the industry would cont inual ly test  drugs wi th smal ler ,  more 
focused c l inical  t r ials.  I f  a t r ia l  shows eff icacy and safety,  a l ive l icense would be 
given, al lowing the company to market the drug in a l imi ted manner (V is iongain,  
2008;  Heal th Canada,  2007; Wright,  2007; Herbert ,  2007; Lexchin,  2008).   
 
Tr igger 10:  Enforcement – the art ic les studied ant ic ipate a substant ia l  increase 
in regulator ’s compliance and enforcement act ions, part icular ly in the overs ight  
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of inspect ions, product promot ion and unapproved drugs (Boswel l ,  2002; 
Hamburg, 2009; Basi le,  2009).   
 
Tr igger 11:  Biotechnology - the recent  appl icat ions of biotechnology wi l l  dr ive 
medical breakthroughs that  wi l l  enable the people to improve their  heal th and 
increase their  longevity dramatical ly .  To exploi t  potent ia l  of  biotechnology and 
emulate successes of  the biotech companies,  large Pharma wi l l  l ikely structure 
themselves as a col lect ion of biotechnology s i tes,  which compete wi th each other 
and external  b iotechnology companies to supply compounds into a cent ral ised 
development organizat ion (Sager,  2001; US Nat ional  Intel l igence Counci l ,  2000; 
Schmid & Smith,  2004; Cooke, 2001).  
 
Tr igger 12: Nanomedic ine -  general ly the referenced art ic les (Wagner et  a l . ,  
2006;  European Science Foundat ion,  2006; Sahoo et al . ,  2007; Wiek et  al . ,  2009) 
pointed to increasing use of nanobiotechnology by the pharmaceut ical  and 
biotechnology indust r ies.  Technical  achievements in nanotechnology were 
appl ied to improve drug discovery and pharmaceut ical  manufactur ing.  Some 
argued that in the near future,  i t  might be possible to model accurately the 
st ructure of  an indiv idual  cel l  and to predict i ts funct ion using computers 
connected to nanobiotechnology systems (Kewal,  2005).  These futur ist ic  
statements imply that the detai led v i r tual  representat ion of how a cel l  funct ions 
might enable sc ient ists to develop novel  drugs wi th unprecedented speed and 
precis ion, wi thout doing any exper iments in l iv ing animals.  
 
Tr igger 13:  Bioinformat ics - the referenced art ic les (FDA strategic Plan, 2007; 
Phan et al . ,  2009; Sneha & Varshney,  2009; Inst i tute for  A l ternat ive Futures and 
the Draper Laboratory,  2005; Rauwerda,  2006;  Ananthaswamy, 2003) largely 
focused on appl icat ion of informat ion technology and computer sc ience to the 
f ie ld of  molecular biology. Some also focused on bioinformat ics f rom regulator ’s 
perspect ive implying that i t  involves use of  modern computer systems to 
ef fect ively manage the regulatory product- informat ion supply chain.  
 
Trigger 14: Pervasive Comput ing -  the referenced art ic les (Saha & Mukher jee, 
2003;  Satyanarayanan,  2001; Clemensen at  a l. ,  2004; Scheff ler  & Hirt ,  2005; 
Osmani et  al . ,  2008; Floerkemeier & Siegemund, 2003; Pandian,  2008; Engin et  
a l . ,  2005; Sr i ram at al . ,  2009) character ise pervasive computing as an 
environment saturated with comput ing and communicat ion capabi l i ty.  Smart  
medicat ion packaging, t iny wireless sensors implanted on the pat ient body to 
moni tor var ious v i ta l  s igns,  and remote monitor ing devices to determine how 
pat ients respond dur ing cl in ical  t r ia ls are just  some examples. Another pervasive 
aspect of comput ing is provis ion of external ly hosted services for management of 
data (e.g.  c l inical ,  manufactur ing,  product survei l lance, etc.)  and associated 
technical infrastructure.  The concept is of ten t imes referred to as c loud 
comput ing (Orwat   et  a l . ,  2008; Buyya et  a l. ,  2009; Sloan, 2009; Sneha & 
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Varshney, 2009),  which  is  a comput ing model  consist ing of services that  are 
commodit ised and del ivered in a manner s imi lar to t radi t ional ut i l i t ies such as 
water,  electr ic i ty,  gas, and telephony.  In such a model,  users access serv ices 
based on their  requirements wi thout regard to where the serv ices are hosted or 
how they are del ivered.  
 
3.4 CONCLUSIONS  
This systemat ic rev iew of  the l i terature has enabled ident i f icat ion of  14 t r iggers 
impact ing the ongoing t ransformat ion in the pharmaceut ical industry.  Their 
importance-ranking reveal that of  the 14 t ransformation t r iggers 4, namely Ful ly 
Integrated Pharma Network (Trigger 2 ) ,  Personal ised Medic ine (Trigger 3 ) ,  
Translat ional  Research (Trigger 5 )  and Pervasive Comput ing (Trigger 14)  are 
considered as the most impactful .   
 
The theoret ical  ev idence presented in this Chapter against  each of  the 
t ransformat ion t r iggers was veri f ied through operat ional  ev idence that  is  
presented in Chapter 4.   
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CHAPTER 4: Establishment of operational evidence 
in support of the transformation triggers: a systematic 
analysis of the operational evidence 
 
4.1 INTRODUCTION 
This Chapter explores ongoing t ransformat ion in the pharmaceut ical3 industry 
and i ts impact on pharmaceut ical  qual i ty f rom the perspect ive of  r isk 
ident i f icat ion.  The 14 transformat ion t r iggers presented in th is Chapter are 
f indings of the systemat ic rev iew of the l i terature performed in Chapter 3, which 
provided the theoret ical  ev idence  in support  of  these tr iggers and ranked their  
re lat ive importance wi th respect to pharmaceut ical  t ransformat ion. Having 
establ ished the theoret ical  ev idence for the t ransformat ional t r iggers the aim of 
th is Chapter is to determine the corresponding operat ional  ev idence .  The 
operat ional  ev idence was derived from data col lected on pharmaceut ical  
companies,  products and technologies.  This approach is predicated upon the 
hypothesis that  such data has the potent ial  to provide valuable operat ional  
informat ion about the t ransformat ion within the industry. Operat ional  ev idence is 
def ined here as the consol idated representat ion of  the operat ional  data in a 
graphical or  tabular form. The use of  the operat ional  ev idence is important as a 
ver i f icat ion mechanism in order to accept  or repudiate the theoret ical  ev idence 
based on the proof  f rom the real wor ld scenar ios.  The key elements of  this 
Chapter are descript ion of  the methods used for data col lect ion, graphical  
presentat ion of  the resul ts and commentary on meaning of  the resul ts.   
 
4.2 METHOD 
The operat ional  data on pharmaceut ical  products were col lected from 
Datamoni tor,  Cl inicalTria ls .gov,  FDA Orphan Drug database and from Table 2 of  
the paper by Wagner et  al .  (2006).  Other types of operat ional  data,  not  related to 
pharmaceut ical  products, were col lected f rom databases l isted in Sect ion 4.2.2. 
These databases were selected because they were the leading and 
comprehensive source of data that  was needed for this study.  
 
4.2.1 Description of the product related databases  
Datamoni tor -  is owned by the Datamoni tor group,  which is a wor ld- leading 
provider of  premium global  business informat ion, del iver ing independent  data,  
analys is and opinion across many indust r ies inc luding pharmaceut ical  and 
                                                 
3 The word pharmaceut ical col lect ively refers to pharmaceut ical  and 
biopharmaceutical companies 
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heal thcare industry.  The PharmaViate Explorer search tool  wi th in the 
Datamoni tor  database was used to col lect  operat ional data.   
 
Cl inicalTr ia ls .gov - is  a registry and resul ts database of  federal ly and pr ivately 
supported c l in ical t r ia ls conducted in the US and around the world.  
Cl inicalTr ia ls .gov gives informat ion about  a t r ia l 's  purpose, who may part ic ipate,  
locat ions,  and phone numbers for more detai ls.  The advanced search tool within 
the Cl in ical t r ials.gov database was used to col lect  operat ional  data.   
 
Orphan Drug database – is owned by the FDA, which provides for grant ing 
special  status to a product to t reat  a rare disease or condi t ion. The combinat ion 
of  the product to t reat the rare disease or condi t ion must meet certain cr i ter ia.  
This status is referred to as orphan designat ion and drugs designated by the 
FDA as orphan are searchable in the Orphan Drug database. The search tool  
wi th in the orphan drug database was used to col lect  operat ional  data.  
 
The paper by Wagner et  a l .  (2006) is a global  survey of companies pursuing 
nanomedic ine appl icat ion in the pharmaceut ical and medical device industry. At 
the t ime of data col lect ion th is paper was the only comprehensive source of  
nanomedic ine appl icat ions in the pharmaceut ical  industry. Informat ion f rom 
Table 2 of  th is paper was used for  compi l ing the operat ional  ev idence. 
 
4.2.2 Operational data collection and analysis  
The operat ional  data were col lected based on the search cr i ter ia descr ibed 
below for each of the 14 t ransformat ion t r iggers.  The databases were searched 
according to the method and search att r ibutes def ined for each t r igger in the 
fo l lowing sect ions.   
 
Data col lect ion was performed between July and November of  2010 and 
therefore i t  excludes some months in second hal f  of  2010 (detai ls  in the 
fo l lowing Sect ions).  In order to al ign the search t imelines between the theoret ical  
and operat ional  ev idence, the operat ional  data search t imeframe was set at  year 
2000 to 2010.  For t ransformation t r iggers where a clear t rend could not be 
establ ished f rom the col lected data the start ing t imeframe for the search was set  
at  a t imel ine earl ier  than year 2000.  For product related searches involv ing 
Datamoni tor  database the scope of  data col lect ion also inc luded the 
developmental  drug products with a future launch date. In order to accommodate 
launch dates beyond 2010 the search t imeframe for this  type of search was 
extended to 2015. 
 
Operat ional  data related to pharmaceut ical companies,  products and 
technologies were exported into an excel spreadsheet  for fur ther c lassi f icat ion 
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and analys is.  The data were plot ted and the resul t ing t rends are presented in 
Sect ion 4.3. 
 
4.2.2.1 Trigger 1 - Healthcare Management Focused 
The operat ional  data for  th is Tr igger was col lected f rom the Datamonitor 
database*.  The object ive was to veri fy theoret ical  evidence relat ing to 
diversi f icat ion of  the pharmaceut ical industry (Chapter 3) f rom a diversi f ied 
revenue perspect ive.  Divers i f ied revenues for 37 top pharmaceut ical  companies 
(Table 4.1 – based on s ize of annual  revenue and the R&D port fol io)  were 
col lected.  Timel ine of 2000 to 2010 for actual  diversi f ied revenues and 2011 to 
2015 for  projected revenues were used. The researcher col lected the operat ional  
data on 24 July 2010.  
 
*  Datamonitor websi te: ht tp:/ /www.datamonitor.com/kc/pharma/ 
4.2.2.2 Trigger 2 -  Fully Integrated Pharma Network 
The operat ional  data for  th is Tr igger was col lected f rom the Datamonitor 
database. The object ive was to veri fy theoret ical ev idence relat ing to 
diversi f icat ion of  the pharmaceut ical  industry (Chapter 3) f rom a product port fol io 
perspect ive.  The product port fol io ( i .e.  R&D pipel ine and product l is t ing) of  the 
top pharmaceut ical  companies was searched. Timel ine of 2002 to 2010 for the 
marketed products and 2011 to 2015 for projected product  pipel ine was used. 
2704 drug products were found, of  which 1489 met “product sourc ing” and 
“product age” search cr i ter ia l is ted in Table 4.2.  The researcher col lected the 
operat ional  data on 24 July 2010. 
 
Table 4.1 The top pharmaceut ical  companies used in Datamoni tor database 
search 
Company name Company name 
Abbott  
Actelion 
Alcon 
Allergen 
Astra Zenica  
Boehringer Ingelheim 
Bayer  
Biogen Idec 
Bristol Myers Squibb 
Celgene  
Cephalon 
Daiichi Sankyo 
Eli Lilly  
Forest  
Genzyme 
Gilead  
Glaxo 
Johnson & Johnson  
King Pharmaceuticals 
Lundbeck  
Menarini 
Merck 
Merck KGaA  
Novartis  
Mylan 
Novo Nordisk  
Nycomed  
Otsuka  
Pfizer  
Roche 
Sanofi-aventis  
Servier 
Shionogi  
Shire  
Teva 
UCB 
Watson 
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Table 4.2 Datamonitor database search cr i ter ia for col lect ion of product related 
operat ional  data 
Category Criteria 
Molecule type Small molecule, therapeutic proteins, monoclonal antibody, vaccine 
Therapeutic area 
Cardiovascular, central nervous system, endocrine, metabolic & genetic, 
gastroenterology, genitourinary, haematology, immunology and 
inflammation, infectious diseases, musculoskeletal, oncology, respiratory 
Product sourcing Internal External (acquired, co-developed, in-licensed, merger & acquisition, other) 
Company type 
The following terms were derived from the Datamonitor database: 
Big Pharma: Pharmaceutical companies with revenue in excess of $10 
billion 
Mid Pharma: Companies with ethical product revenues between $1 and 
$10 billion, excluding Japanese and biotechnology companies  
Japan Pharma: Pharmaceutical companies legally registered in Japan  
Generics: Pharmaceutical companies that manufacture off patent drug 
products  
Biotech: Biotechnology companies specialised in research, development 
and manufacturing of  biological drug products 
Product age (very old >15y, old 11-15y, recent 5-10y, new <5y 
Product launch/expiry Global, US, 5EU, Japan, Rest Of the World (ROW) 
 
4.2.2.3 Trigger 3 – Personalised Medicine 
The operat ional  evidence for th is t r igger was col lected f rom FDA Orphan Drug 
database*.  The object ive was to veri fy theoret ical  evidence that the 
pharmaceut ical  industry is increasingly focusing on research, development and 
commercial izat ion of  products and serv ices targeted for indiv idual  pat ient  needs 
(Chapter 3).  Timel ine of 1994 to 2010 was used. 2200 products wi th orphan drug 
designat ion status were selected for analys is.  The FDA assigns an orphan drug 
designat ion status to a product when orphan drug designat ion request f rom a 
pharmaceut ical  company is deemed a good candidate for t reat ing a rare disease. 
Upon sat isfact ion of regulatory requirements the FDA approves the designated 
orphan drug for  commercial  use.  The researcher col lected the operat ional  data 
on 30 August and 20 October,  2010.  
 
*  Link to the US FDA Orphan Drug database: 
ht tp:/ /www.accessdata.fda.gov/scr ipts/opdl ist ing/oopd/ index.cfm 
4.2.2.4 Trigger 4 – Vir tual R&D 
The operat ional  data for  th is Tr igger was col lected f rom the Datamonitor 
database. The object ive was to veri fy theoret ical ev idence that pharmaceut ical  
industry is external iz ing the discovery and development of  products (Chapter 3).  
The product port fo l io of  the top pharmaceut ical  companies was searched. 
Timel ine of 2002 to 2010 for the marketed products and 2011 to 2015 for 
projected product pipel ine was used.  2704 products met the “therapeut ic area”,  
“product sourc ing” and “company type” search cr i ter ia l is ted in Table 4.2.  The 
researcher col lected the operat ional  data on 24 July 2010.  
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4.2.2.5 Trigger 5 – Translational Research 
The operat ional  evidence for th is Tr igger was col lected from the FDA database 
on Biomarkers*.  The object ive was to use the prevalence of  b iomarkers as a 
surrogate indicator to veri fy the theoret ical  ev idence relat ing to t ranslat ional  
research in pharmaceut ical industry (Chapter 3).  Biomarker approval t imel ine of 
1991 (ear l iest  approved biomarker) to 2010 (year when the search was 
performed) was used to select  71 biomarkers that met the “FDA approved” 
search cr i ter ia.  The researcher col lected the operat ional  data on 30 August 2010. 
 
*  Link to the FDA biomarker webpage: 
ht tp:/ /www. fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenet ics/  
ucm083378.htm. The webpage was replaced s ince the f i rst  v is i t  and as of  
October 2011 the new l ink is:  
ht tp:/ /www. fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenet ics/uc
m083378.htm 
 
4.2.2.6 Trigger 6 – Adaptive Trials 
The US Cl inical  Tria ls database* was used to col lect  the operat ional  evidence to 
ver i fy theoret ical  ev idence and demonstrate i f  the use of  the adapt ive c l in ical 
t r ia ls is in the r ise within the pharmaceut ical  industry (Chapter 3).  Adapt ive t r ia ls 
submission t imel ine of  2000 to 2010 was used to select 38 studies that  met the 
“Adapt ive design” search cr i ter ia in the database.  The researcher col lected the 
operat ional  data on 30 August 2010.  
 
*  Link to the US Cl inical  Tr ia ls database website: 
ht tp: / /c l in ical t r ials.gov/ct2/search/advanced 
 
4.2.2.7 Trigger 7 – Regulatory Harmonisat ion 
The Internat ional  Conference on Harmonisat ion (ICH) websi te* was used to 
col lect operat ional  ev idence to ver i fy theoret ical  ev idence and demonstrate i f  
regulatory harmonizat ion exists at  the global  level  (Chapter 3).   The ICH 
Guidance approval  t imel ine of 1993 to 2010 was used to select  73 guidel ines 
that met the “qual i ty”,  “safety”,  “ef f icacy” and “mult id isc ipl inary” search cr i ter ia.  
The researcher col lected the operat ional  data on 30 August  2010. 
 
*  Link to the ICH guidel ine webpage: 
ht tp: / /www. ich.org/products/guidel ines/qual i ty/art ic le/qual i ty-guidel ines.html.  
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4.2.2.8 Trigger 8 – Science and Risk Based Regulat ions 
The FDA Cooperat ive Research and Development Agreements (CRDA) database* 
was used to col lect  the operat ional  ev idence to ver i fy theoret ical  ev idence and 
determine whether pharmaceut ical  regulat ions are increasingly being based on 
sc ience and r isk based approaches (Chapter 3).  The content of  92 CRDA 
documents were examined for common themes relat ing to research topics that  
were designed to use sc ience and r isk based approaches to improve the 
regulatory overs ight  act iv i t ies.  The researcher col lected the operat ional  data on 
2 September 2010.  
 
*  Link to the FDA CRDA webpage: 
ht tp: / /www. fda.gov/ScienceResearch/Col laborat iveOpportuni t ies/Cooperat iveRes
earchandDevelopmentA greementsCRADAs/ucm122820.htm 
 
4.2.2.9 Trigger 9 – Progressive/Live Licensing 
The FDA, EMA, and Health Canada websites were used to col lect operat ional  
evidence to ver i fy theoret ical  ev idence that regulators intent to al low commercial  
use of medicinal  products in a progressive fashion (Chapter 3).  Extensive search 
of  the websi tes resources such as pos it ion papers,  strategic plans, guidel ines,  
press releases, news, etc.  was performed to indent i fy any off ic ia l informat ion 
relat ing to the intent of  actual implementat ion of  “Progressive Licensing” or “Live 
Licensing”.  The search was performed on 2 September 2010. 
 
FDA websi te:     ht tp: / /www.fda.gov/ 
EMA websi te:    ht tp:/ /www.ema.europa.eu/ema/ 
Heal th Canada website:  ht tp:/ /www.hc-sc.gc.ca/ index-eng.php 
 
4.2.2.10 Trigger 10 – Regulatory Enforcement 
The FDA Warning Let ter database* was used to col lect operat ional  ev idence to 
ver i fy theoret ical  ev idence relat ing to regulatory enforcement in pharmaceut ical  
industry (Chapter 3).  The FDA warning letter  issuance t imel ine of 2000 to 2010 
was used to select 664 warning let ters that  met the “CGMP”, “Cl in ical” .  “Act ive 
Pharmaceut ical Ingredients” and “Devices” search cr i ter ia.  The researcher 
col lected the operat ional  data on 10 November 2010.  
 
*  FDA Warning Letter database webpage- 
ht tp:/ /www.accessdata.fda.gov/scr ipts/warninglet ters/wlSearchExcel .cfm 
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4.2.2.11 Trigger 11 – Biotechnology 
The Datamonitor database was used to col lect  the operat ional  ev idence to ver i fy 
theoret ical  ev idence and demonstrate i f  drug products based on large molecules 
are in the r ise (Chapter 3).  The drug product port fo l io wi th a launch t imel ine of  
2002 to 2015 was searched and 2704 developmental  and commercial ised 
products that met the “molecule type”,  “ therapeut ic area”,  and “product 
launch/expiry”  search cr i ter ia (Table 4.2) were selected for analys is.  The 
researcher col lected the operat ional  data on 24 July 2010.  
 
4.2.2.12 Trigger 12 – Nanomedicine 
The paper by Wagner et  a l .  (2006) was used to col lect  the operat ional  evidence 
to ver i fy the theoret ical  ev idence and determine i f  nanotechnology based drug 
products prevalence on the market are r is ing (Chapter 3).  List  of  nanomedic ine 
products on the market  f rom Table 2 of the paper was used to select 36 
nanomedic ine based drug products.  The researcher col lected the operat ional  
data on 24 July 2010. 
 
4.2.2.13 Trigger 13 – Bioinformatics 
The US and EU Patent Off ice websi tes* were used to col lect  the operat ional  
ev idence to ver i fy the theoret ical  ev idence and determine i f  B ioinformat ics 
related technologies are prevalent in the pharmaceut ical industry (Chapter 3).  
The approved patents for t imel ine of 2000 to 2010 was used to select 55 US 
patents that met the [ (((SPEC/Bioinformat ics AND SPEC/Therapy)  AND 
ACLM/computer)  AND ISD/20000101->20100101)]  search cr i ter ion, 72 EU 
patents that met the [ “Bioinformat ics” in Ti t le f ie ld]  search cr i ter ion,  and 20 EU 
patents that met the [ “Bioinformat ics” AND “Computer”  in Tit le/Abst ract f ield and 
“2000:2010” in the Appl icat ion Date f ie ld]  search cr i ter ion.  The researcher 
col lected the operat ional  data for  US patents on 24 July 2010 and EU patents on 
20 October 2010.  
 
*US PO - ht tp: / /patf t .uspto.gov/netahtml/PTO/search-adv.htm 
*EU PO – ht tp: / /worldwide.espacenet.com/quickSearch 
 
4.2.2.14 Trigger 14 – Pervasive/Cloud Computing 
The US and EU Patent Off ice websi tes* were used to col lect  the operat ional  
ev idence to ver i fy the theoret ical  ev idence and determine i f  pervasive and c loud 
comput ing technologies are prevalent in the medical f ield (Chapter 3).  The 
approved patents for t imel ine of  2000 to 2010 was used to select 323 patents 
that met the search cr i ter ia stated in Table 4.3. The researcher col lected the 
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operat ional  data for US patents on 1 September 2010 and EU patents on 20 
October 2010.  
 
*US PO - ht tp: / /patf t .uspto.gov/netahtml/PTO/search-adv.htm 
*EU PO – ht tp: / /worldwide.espacenet .com/advancedSearch?locale=en_EP 
 
Table 4.3  Search cr i ter ia used to col lect  operat ional data f rom the US and EU 
Patent Off ices on Pervasive/Cloud comput ing 
Database Search Criteria Patents 
US Patent Office:  
(TTL/telemedicine AND ISD/20000101->20100901) 11 
 
(((TTL/(implantable AND device) AND SPEC/(computer AND sensor)) AND 
ACLM/(Drug AND Delivery)) AND ISD/20000101->20100901) 
14 
 
(TTL/(implantable AND biosensor) AND ISD/20000101->20100901) 6 
 
(SPEC/(((intelligent AND embedded) AND Medication) AND Package) AND 
ISD/20000101->20100901) 
41 
 
(ABST/(((Remote AND patient) AND monitoring) AND Clinical) AND ISD/20000101-
>20100901) 9 
European Patent Office:  
“Telemedicine” in the title AND 2000:2010 as the publication date 90 
 
“Implantable drug delivery device” AND “sensor” in the title or abstract AND 
2000:2010 in the publication date field 
13 
 
“Remote patient monitoring” AND “Clinical” in the title or abstract AND 2000:2010 in 
the publication date field 
18 
 
“Implantable biosensor” in the title AND 2000:2010 in the publication date field 90 
 
“Electronic” AND “medication” AND “patient” in the title or abstract AND 2000:2010 in 
the publication date field 31 
 
4.3 RESULTS AND DISCUSSION 
The theoret ical ev idence for the 14 t r iggers l isted below was establ ished in 
Chapter 3.  The corresponding operat ional  ev idence is establ ished in th is  Chapter 
and the resul ts presented below. The discussion for each tr igger ref lects the 
interpretat ion of  the operat ional  ev idence as i l lust rated in Figures 4.1 to 4.12.  
Raw data upon which the Figures 4.1 to 4.12 were constructed are presented in 
Appendix A 
 
Trigger 1:  Heal thcare Management  Focused - an increase in pharmaceut ical  
revenues from products or serv ices other than from the t radi t ional ly strong 
prescr ipt ion drug sales would mean that the pharmaceut ical  indust ry is 
diversi fy ing and that Trigger 1  is  tak ing root.  Revenue information relat ing to 
non-prescr ipt ion drug products (drug products that  do not  require wri t ten 
instruct ions f rom a physic ian or dent ist  to a pharmacist) of  37 pharmaceut ical  
companies was used as the primary indicator of  divers if icat ion in the 
pharmaceut ical  industry.  Since divers i f icat ion is divergence from establ ished 
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core products/serv ices,  of  the 37 pharmaceut ical  companies l is ted,  only those 
that had “non-prescr ipt ion drug” and “other”  revenue informat ion were selected 
for t rend observat ion. This l imited the f inal l is t  to 16 pharmaceut ical  companies. 
The actual and projected revenue informat ion was col lected for f inancial  years 
2002 to 2015.  Operat ional  t rends observed in Figure 4.1 for  non-prescript ion 
drug products and serv ices show a substant ia l  increase in divers i f ied revenue. 
 
Figure 4.1 Pharmaceut ical divers i f icat ion - increase in pharmaceut ical  revenues 
from non-tradi t ional  products or serv ices (Trigger 1) 
 
 
Trigger 2:  Ful ly Integrated Pharma Network - the rat io of  internal ly developed 
versus external ly  developed drug products is an indicat ion of the degree to which 
the pharmaceut ical  industry is leveraging external sources of innovat ion. To 
determine this t rend the Datamoni tor database was searched for products that 
were launched or to be launched between 2002 and 2015.  Sources of launched 
or to be launched products in the database were c learly tagged in the excel 
spreadsheet and categor ised as “ internal” ,  “acquired product”,  “co-developed”,  
“M&A”,  “other external”,  “ in- l icensed” and for products in development phase 
“n/a”.  The word Internal  means that  the products were developed in house. 
Acquired product  means that  the product  was purchased f rom another 
organizat ion. Co-developed  means the product was co-developed wi th another 
pharmaceut ical  company under specif ic agreement.  M&A  means the product was 
inheri ted through merger and acquis i t ion.  In- l icensed  product refers to t ransfer of  
a l icense by agreement f rom another organizat ion in order to develop or market 
the part icular product.  Other external  refers to acquis i t ion of  products external ly 
by other means than explained above.  The term “n/a” means not appl icable and 
is used for products in the development phase. The acquired product ,  co-
developed, M&A, in- l icensed and other external  were col lect ively consol idated 
into a s ingle category cal led “external” .  For the purposes of th is analys is “n/a” 
was excluded. The age of  the drug product was categor ised into very old >15 
years,  old = 11-15 years,  recent  = 5-10 years,  new<5 years.  The prevalence of 
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external  sources of products for the newer products would be a posi t ive 
indicat ion that  Tr igger 2 is tak ing root.  The trends observed in Figure 4.2 show a 
substant ial  increase in external  sourc ing for  newer products.  
 
Figure 4.2 Product sourc ing - rat io of  internal ly developed versus external ly 
developed drug products (Trigger 2) 
 
Trigger 3:  Personal ised Medic ine - since personal ised medic ine,  by def ini t ion,  is 
concerned with the development of  drugs for niche  pat ient  populat ions (Chapter 
3),  designat ion of  orphan drugs by the FDA is a good indicator of  t rends in 
personal ised medicine. In except ional  cases some personal ized medic ines may 
target larger segments of  the populat ion;  for  instance oncology products such as 
Hercept in exempl i fy th is for t reatment of  breast cancer.  Data col lect ion focused 
on drugs that  had received orphan drug designat ion between 1993 and 2010. 
Trends observed in shows a substant ia l  increase in FDA orphan drug 
designat ions (Figure 4.3),  gradual  increase in FDA approved Biomarkers (see 
Tr igger 5),  and gradual  increase in Launch of b iological ( large-molecule) drugs 
(see Tr igger 11).   
 
Figure 4.3 FDA orphan drug designat ion for drug products wi th niche pat ient 
populat ions (Trigger 3) 
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Trigger 4:  V irtual  R&D - a key feature of  v i r tual R&D involves outsourc ing 
research act iv i t ies to th ird part ies or in some cases co-development wi th other 
pharmaceut ical  companies (Chapter 3).  In order to invest igate the l ikely t rends in 
Virtual R&D the col lected data were c lassi f ied into three categor ies of  i )  drug 
products developed through Internal  R&D or i i )  drug products developed 
external ly through thi rd party agreements or i i i )  drug products developed through 
partnerships wi th other pharmaceut ical  companies. The external izat ion and 
col laborat ion t rends for Big Pharma, Mid Pharma, Japan Pharma, Biotech, and 
Generics (Pharma industry c lassi f icat ions as def ined by Datamoni tor)  were 
der ived by calculat ing the rat io of  external ly developed drug products to internal  
drug products and co-developed drug products to internal  drug products.   The 
trends observed in Figure 4.4 show that  Mid Pharma and Generics play leading 
roles in external izat ion of research and that col laborat ion among pharmaceut ical  
companies is low in general  but s l ight ly more pronounced in Big Pharma.  
 
Figure 4.4 Research outsourc ing and col laborat ive R&D (Trigger 4) 
 
 
Tr igger 5:  Translat ional  Research - the goal  of  t ranslat ional  research is to 
fac i l i tate exchange of  informat ion between precl in ical  sc ient ists and c l in ical  
pract i t ioners to implement in-v ivo measurements that  more accurately predict  
drug ef fects in humans (Chapter 3).  Prevalence in regulatory approval of  
b iomarkers is a good indicat ion that  t ranslat ional research is increasing. In order 
to prove this point ,  a l is t  of  approved biomarkers by the FDA ( i .e.  in-vivo 
measurements) was analyzed to determine the number of  products associated 
wi th approved biomarkers and date of  biomarker approval  for  t rending purposes. 
S ince the FDA does not  publ ish expl ic i t  approval date for biomarkers, the date of 
the ear l iest  publ ished research related to the prototypic drugs (drug associated 
wi th the label  informat ion def ining the biomarker context) was used as a 
surrogate indicator – see the web l ink in Sect ion 4.2.2.5 for a l is t  of  val id 
approved biomarkers publ ished by the FDA. The word “val id” is descr ibed by the 
FDA as a biomarker that  is measured in an analyt ical  test  system with wel l  
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establ ished performance character ist ics and for which there is an establ ished 
scient i f ic  f ramework or body of  ev idence that eluc idates the physiological,  
toxicological ,  pharmacological ,  or  c l in ical  s igni f icance of  the test  resul ts.  
A lthough sporadic at  t imes,  Figure 4.5 shows a general upward trend in the 
number of  val id biomarkers over the last  two decades.   
 
Figure 4.5 Approved biomarkers as an indicator for prevalence of t ranslat ional  
research (Tr igger 5) 
 
 
Tr igger 6:  Adapt ive Tr ia ls - informat ion about c l inical  t r ials is of ten maintained in 
regist ry and resul ts databases f requent ly managed by governmental  
organizat ions. One such database that is publ ical ly avai lable and also contains 
informat ion on adapt ive t r ia ls  is Cl in ical t r ia ls.gov. This database was searched 
for studies containing the phrase “adapt ive design” in Phase I ,  Phase I I  and 
Phase I I I  c l in ical  t r ia ls that  were f i rst  submit ted to the FDA between 2000 and 
2010.  Figure 4.6 shows a steady increase in the number of  adapt ive c l inical  
t r ia ls s ince 2005 and a sharp decl ine in 2010 is apparent.  From a publ ic pol icy 
perspect ive emerging approaches such as UK’s pat ient  access scheme is 
boost ing ear ly access to medic ine, which is l ikely to impact the design and 
conduct of  c l in ical  t r ia ls.  I t  is noteworthy to ment ion that  current ly this approach 
is local ized to UK and not adopted global ly.  
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Figure 4.6 Prevalence of adapt ive c l in ical  t r ia ls  (Trigger 6) 
 
 
Tr igger 7:  Global  Harmonizat ion - creat ion and deployment of  internat ional  
guidel ines is the direct indicat ion of regulatory and industry commitment to 
global  harmonizat ion.  To val idate th is assert ion the ICH guidance database was 
searched for ev idence of  harmonizat ion relat ing to safety,  ef f icacy and qual i ty of 
drug products.  Trends observed in Figure 4.7 shows that  the act iv i t ies on global  
regulatory harmonizat ion have remained more or less constant  dur ing the last  2 
decades except for a large spike in 2009 and 2010.   
 
F igure 4.7 Trends in regulatory harmonizat ion based on ICH publ icat ions 
(Tr igger 7) 
 
 
Tr igger 8:  Science and Risk Based Regulat ions -  research conducted by 
regulators in cooperat ion wi th the industry and other research organizat ions was 
used as a surrogate indicator that  regulatory rule making is l ikely to benef i t  f rom 
resul ts of  such cooperat ion.  The FDA database containing a l is t  of  cooperat ive 
research and development agreements was searched. The review of FDA’s 
CRADA agreements resulted in a c lassi f icat ion of  research focus into one of  the 
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fol lowing categor ies: B ioinformat ics,  Personal ised Medic ine,  Cr i t ical  Path 
In i t iat ive,  Process Analyt ical Technology, B iotechnology, Pervasive Comput ing, 
Nanomedic ine,  Qual i ty by Design and Other categor ies.  The trends observed in 
Figure 4.8 shows that the agreements are largely focused on bioinformat ics,  
personal ised medicine and in support  of  FDA’s cr i t ical  path ini t iat ive.  
 
Figure 4.8 FDA’s cooperat ive research and development  agreements (Tr igger 8) 
 
Trigger 9:  Progressive/Live Licensing - the FDA, European Medic ines Agency 
(EMA) and Health Canada websi tes were extensively searched for ev idence of  
procedures for drug product l icensing that al lowed progressive use of  medicinal  
products,  i .e.  start ing the commercial  use in Phase I I I  c l in ical  development under 
certain condit ions. A l though there were some forward looking statements in the 
Heal th Canada websi te,  there was no indicat ion in any of  these regulatory 
websi tes that  medic inal  products intended for human use are awarded 
progressive market ing author izat ion whi le in the c l inical  development phase. 
There was no operat ional evidence in support of this transformat ion t r igger.   
 
Tr igger 10:  Regulatory Enforcement -  the Issuance of  observat ions by the 
regulators to pharmaceut ical  companies is an indicat ion of  their enforcement of  
appl icable regulat ions (Hamburg, 2009).  Al though this takes place in the US, EU 
and other regulated markets,  due to f reedom of  informat ion act  in the US only 
FDA warning let ters are avai lable publ ic ly.  Trends observed in Figure 4.9 shows 
that the issuance of  FDA warning let ters seemed cycl ical  s ince 2000 wi th a sharp 
increase in 2009.  
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Figure 4.9 FDA enforcement pharmaceutical regulat ions (Trigger 10)  
 
 
Tr igger 11:  Biotechnology - t rends in commercial izat ion of smal l  molecule drug 
products (chemical basis) compared with large molecule drug products 
(biological  basis)  in the pharmaceut ical market can be used as an indicator to 
determine the posit ion of  biotechnology in the pharmaceut ical  industry.  To 
substant iate this,  launch informat ion for  smal l  and large molecule drug products 
for Global ,  US, 5EU, Japan, and Rest of  the World markets was extracted form 
the Datamonitor  database and analyzed. Trends observed in Figure 4.10 shows 
that the number of  drug products containing smal l  molecules has r isen since 
2002 with a sharp decl ine in 2011.  At the same t ime number of  drug products 
containing large molecules increased gradual ly and the projected convergence 
wi th smal l  molecule drug products can be seen by 2014.  
 
Figure 4.10 Smal l  versus large molecule drug product launches (Tr igger 11) 
 
 
Tr igger 12:   Nanomedic ine - each nanomedic ine product l is ted in the work of 
Wagner et  a l  (2006) was c lassi f ied into 9 therapeut ic categories (Cardiology, 
Central  Nervous System, Genitour inary,  Immunology & Inf lammation, Infect ious 
Diseases, Metabol ic Disorders,  Musculoskeletal ,  Oncology, Ophthalmology).  The 
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number of  nanotechnology based drug products for each therapeut ic category 
was determined. The trends observed in Figure 4.11 show uneven peaks and 
troughs in market ing of  nanotechnology based drug products s ince 1993 with an 
isolated r ise in 2005.  
 
Figure 4.11 Prevalence of  Nanotechnology based drug products and 
Bioinformat ics in the pharmaceut ical  industry (Tr igger12 and 13)  
 
 
Tr igger 13: Bioinformat ics - examining patent  informat ion on a part icular 
technology can provide evidence of i ts  prevalence and l ikely future t rends. To 
test this assert ion the bioinformat ics search keywords below were searched in 
the US and EU patent  databases.  Trends observed in Figure 4.11 show a r ise in 
bioinformat ics patents s ince 2000 with peaks at 2004 and 2008.  The 2010 data 
do not represent  the ful l  year.  
 
Tr igger 14: Pervasive/Cloud Comput ing - examining patent informat ion on a 
part icular technology can provide evidence of i ts  prevalence and l ikely future 
t rends. To test this assert ion the pervasive comput ing search phrases were 
grouped into f ive themes of  Telemedic ine, Implantable Drug Del ivery,  
Implantable Biosensors,  Intel l igent Medicat ion Package and Remote Pat ient  
Moni tor ing.  These themes were der ived f rom Chapter 3 as the possible areas of  
pharmaceut ical  appl icat ions.  The US and EU patent  databases were searched 
according to the search cr i ter ia stated in Sect ion 3. The trends observed in 
Figures 4.12 and Table 4.4 shows a substant ial  r ise in number of pervasive 
comput ing patents s ince 2000 wi th key areas of focus on intel l igent medicat ion 
package and telemedicine. Note that  2010 data does not  represent  the ful l  year. 
 
	75 
Figure 4.12 Pervasive comput ing t rends in pharmaceut ical  indust ry (Tr igger 14) 
 
 
Table 4.4 Appl icat ion of pervasive comput ing technology in the pharmaceut ical 
Industry 
Pervasive Computing Pharmaceutical Application Number of Patents 
Implantable Biosensors 24 
Implantable Drug Delivery 27 
Remote Patient Monitoring 40 
Telemedicine 101 
Intelligent Medication Package 131 
 
4.3.1 Discussion  
The operat ional  evidence presented in Sect ion 3 provides substant ive evidence 
in support  of  pharmaceut ical  industry t ransforming from a prescr ipt ion drug-
centr ic industry to a diversi f ied heal thcare industry (Figure 4.1).  Changes in the 
pharmaceut ical  business model are also evident in that there is more focus on 
external  sources for supplement ing the product port fol io (Figure 4.2).  The newer 
drug products are three t imes as l ikely to be sourced external ly as developed 
internal ly.  The pharmaceut ical  industry move towards indiv idual ised medicine is 
supported by orphan drug designat ion (Figure 4.3),  development and avai labi l i ty 
of  val id genomic biomarkers (Figure 4.5) as wel l  as industry shif t  f rom a smal l -
molecule blockbuster drug strategy to a large molecule based targeted drug 
st rategy (Figure 4.10).  For v i r tual  R&D the operat ional  ev idence can be 
interpreted in two ways: a) heal thy increase in external izat ion in that the 
pharmaceut ical  companies are increasingly exploi t ing external  sources of  
innovat ion (Figure 4.4) and b) comparat ively less enthusiasm on col laborat ive 
drug discovery and development among pharmaceut ical  companies (Figure 4.4).  
The modest but steady increase in the number of  approved c l inical  biomarkers 
(Figure 4.5) is apparent and is a surrogate indicator that  c l inic ians and scient ists 
are work ing c losely in the context of  t ranslat ional  medic ine to develop products 
ta i lored for speci f ic  populat ions.  The operat ional  data in support  of  t ranslat ional  
research exclude addi t ional  ev idence,  which was not known during the ini t ia l  
data col lect ion (August 2010) i .e.  14 biomarkers that current ly are in the review 
and consul tat ion stage wi thin the FDA (Woodcock et al . ,  2011).  There is enough 
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operat ional  ev idence to support  the concept of  adapt ive c l inical design (Figure 
4.6) however i t  is  a smal l4 proport ion of al l  the c l inical studies that are conducted 
wi th in the same t ime per iod.  Al though regulatory harmonizat ion relat ing to 
common safety,  ef f icacy and qual i ty guidance (Chapter 3) is f i rmly supported by 
the operat ional  ev idence (Figure 4.7) however the current data col lect ion found 
no evidence to suggest that  the di f ferent regulatory authori t ies wi l l  eventual ly  
fu l ly harmonise the pre-market evaluat ion and post  market  survei l lance of drug 
products.  Operat ional  ev idence for sc ience and r isk based regulat ions is mainly 
l imited to efforts of  US FDA’s corporat ive research agreements and EMA’s 
innovat ion taskforce, which are largely focused on personal ised medic ine, 
t ranslat ional  research and bioinformat ics topics (Figure 4.8).  Progressive product 
l icensing al though a revolut ionary concept has not been implemented in pract ice;  
th is was conf i rmed s ince at the t ime of  data col lect ion no operat ional  data was 
found to substant iate this act iv i ty.  I t  is  l ikely that  th is topic wi l l  remain in the 
conceptual  phase unt i l  there are robust methods to f i rmly assure product safety 
at  ear ly stages of product development,  which may be possible in the arena of  
the personal ised medicine. Regulatory enforcement data are only based on the 
US FDA due to f reedom of informat ion act  in the US; enforcement data for EMA 
were not  publ ic ly avai lable dur ing the data col lect ion per iod.  The operat ional  
data point to cycl ical  enforcement prof i le except a sharp increase in 2009 
(Figure 4.9);  th is is widely at t r ibuted to FDA commissioner ’s  tough stance on 
ef fect ive regulatory enforcement (Woodcock et a l . ,  2011).  Appl icat ion of  
biotechnology is supported by st rong evidence that the projected pharmaceut ical 
product port fo l io wi th in the next f ive years wi l l  have equal  number of  large and 
smal l  molecule drug products (Figure 4.10).  This supports the l i terature assert ion 
that pharmaceut ical industry is  focusing more and more on biologics (Chapter 3),  
which is also consistent  wi th industry move towards personal ised medic ine 
(Chapter 3).   The operat ional  data in support of nanotechnology are somewhat  
errat ic (Figure 4.13).  Clear ly there is ev idence that  nanotechnology plays a role 
in drug development however the amount and consistency of  operat ional  data 
does not indicate a steady r ise.  Bioinformat ics as an enabl ing technology 
(Chapter 3) support ing t ranslat ional  research and personal ised medic ine is 
tak ing root and i ts prevalence in the heal thcare industry can be not iced in 
analys is of  the worldwide patent data s ince 2000 (Figure 4.11).  The operat ional  
ev idence supports the l i terature assert ion that  pervasive comput ing wi l l  
increasingly play a key enabl ing role in pharmaceut ical  indust ry with a part icular 
focus on pat ient support act iv i t ies such as intel l igent medicat ion, te lemedicine 
and remote pat ient moni tor ing (Table 4.4, Figure 4.12).   
                                                 
4 As of 17 September 2012 there are 132,526 c l inical  t r ials wi th locat ions in 179 
countr ies c l in icalst r ia ls .gov  
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4.3.1.1 Proposed theoret ical quali ty r isks:  
The assessment of the theoret ical  ev idence presented in Chapter 3 f rom an open 
innovat ion and qual i ty r isk management perspect ives have resulted in the 
fol lowing proposals that were val idated and the outcomes are presented in 
Chapter 6.   
 
Tr igger 2:  Ful ly Integrated Pharma Network -  the open innovat ion t rends for th is 
t ransformat ion t r igger wi l l  l ikely impact select ion and employment of  external  
research and commercial  partnerships and in- l icensing of  products.  These 
changes wi l l  result  in qual i ty r isks that wi l l  require establ ishment of effect ive due 
di l igence and product t ransfer processes to mit igate the potent ia l  r isks.  
 
Tr igger 3:  Personal ised Medic ine -  the open innovat ion t rends for  th is 
t ransformat ion t r igger wi l l  l ikely impact research, development,  manufactur ing,  
distr ibut ion,  market ing and survei l lance of novel  and complex products such as 
combinat ion, biological  and biotechnology products.  From the perspect ive of  
qual i ty r isk management  these novel  and complex products,  which require 
convergence of  mult iple scient i f ic  and technological  discipl ines,  wi l l  chal lenge 
the regulators, industry,  and heal thcare professionals in their  safe and effect ive 
use.  The resul tant  theoret ical qual i ty r isks wi l l  require provis ion of 
mult id isc ipl inary regulatory knowledge and ski l ls  to mit igate the potent ial  r isks.  
 
Trigger 5:  Translat ional  Research -  the open innovat ion t rends for  th is  
t ransformat ion t r igger wi l l  l ikely impact research partnerships and research 
informat ion shar ing.  The resul tant  theoret ical  qual i ty r isks wi l l  require 
establ ishment  of  ef fect ive due di l igence for research partnerships and provis ion 
of  robust data management pol ic ies and procedures to mit igate the potent ial  
r isks.    
 
Trigger 14: Pervasive Comput ing - the open innovat ion t rends for  th is 
t ransformat ion t r igger wi l l  l ikely resul t  in prevalence of  smart  implantable 
devices for product t racking, pat ient monitor ing and drug del ivery and 
outsourcing of informat ion systems for management of  c l in ical  and product data 
(e.g.  for c l in ical  t r ia ls,  drug safety survei l lance, customer complaints,  etc. ) .  The 
resul tant  theoret ical qual i ty r isks wi l l  require establ ishment of  ef fect ive 
val idat ion procedures to ensure rel iabi l i ty of  smart  devices and provis ion of  data 
management procedures to ensure securi ty and integr i ty of  outsourced data to 
mit igate the potent ia l  r isks. 
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4.4 CONCLUSION 
In this Chapter the operat ional  ev idence has been provided for al l  the 14 
t ransformat ion t r iggers except for  Trigger 9 “Progressive Licensing” for which no 
operat ional  data was found.  The quant i tat ive comparison of  theoret ical  versus 
operat ional  ev idence wi l l  be provided in Chapter 8.  A l though this Chapter 
ver i f ies the theoret ical  ev idence, i t  does not val idate the proposed qual i ty r isks 
der ived from the theoret ical  evidence. In addi t ion,  given that  the l i terature 
resul ts take t ime to publ ish,  there is a di f ference in knowledge wi thin the 
l i terature and those of experts in the f ield.  Therefore there was a need to 
augment the theoret ical and operat ional  ev idence by creat ing a view of  the 
current  s i tuat ion in the f ield. This was done by el ic i t ing opinion of experts wi th 
operat ional  knowledge of the indust ry t ransformat ion and the associated qual i ty 
r isks.  The val idat ion of the proposed qual i ty r isks,  f rom the perspect ive of  
opinion-based evidence, is  the subject  of  Chapter 5 and 6,  which wi l l  be 
descr ibed next.  
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CHAPTER 5: Development of the Survey for the 
Study of the Expert Opinion 
 
5.1 INTRODUCTION 
The theoret ical  ev idence for factors inf luencing the ongoing t ransformat ion in the 
pharmaceut ical  industry was establ ished in Chapter 3 and corresponding 
operat ional  ev idence was provided in Chapter 4.  A set  of  pharmaceut ical qual i ty 
r isks proposed in Chapter 3,  were considered l ikely to have been induced by the 
four main t ransformat ion t r iggers. The opinion-based evidence in support  of the 
theoret ical  and operat ional  ev idence was col lected by surveying the opinion of  
experts in the f ield ( i .e.  recognised experts in the f ie ld of  pharmaceut ical  
regulat ion,  product l i fecycle,  or  pharmaceut ical technology – see sect ion 6.2.2).  
The aim of th is Chapter is to descr ibe the development of  the method that was 
used for el ic i tat ion of  expert  opinion presented in Chapter 6.  The study was a 
quest ionnaire based survey and was conducted in two phases, namely:  “pi lot  
survey” and the “main survey”.  This Chapter descr ibes detai ls of  the pi lot  survey 
that was performed to ensure rel iabi l i ty and val idi ty of  the study design (Robson,  
2002;  Carmines & Zel ler ,  1979).The intent  of  the pi lot  survey was to test  the 
study design and processes and make the necessary improvements to enable the 
commencement of  the main survey.  The outcome was to create the main survey 
quest ionnaire (Chapter 6) by improving the pi lot  quest ionnaire.  
 
5.2 METHOD  
Methods descr ibed in th is sect ion are appl icable to the expert  opinion study. 
A lthough the remainder of  this sect ion wi l l  focus on the methods for the pi lot  
survey, however there are aspects of  the methods that also apply to the main 
survey – namely:  quest ionnaire anonymisat ion and ethical  considerat ions. 
 
5.2.1 Pilot survey design overview 
The design approach for the pi lot  survey was based on cogni t ive interv iewing 
using verbal  probing technique.  Data were col lected using the interv iew notebook. 
Col lected data were analyzed using qual i tat ive descr ipt ion of the emerging 
themes, quant i tat ive descript ion of  the c lassi f ied observat ions, and quant i tat ive 
analys is of  the responses to the pi lot  survey quest ionnaire (Appendix B2). 
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5.2.2 Pilot survey participants 
Part ic ipants for the pi lot  survey were selected from the researcher ’s employer 
(Sanof i ,  a global  pharmaceut ical  company).  The cr i ter ia for  select ion of  pi lot  
survey part ic ipants inc luded: 
  The number of part ic ipants should be in the range of 6 to 10 
  There should be at least  one representat ive f rom each of  key phases of  the 
product l i fecycle ( i .e.  pre-c l in ical  development,  c l in ical  development and 
manufacturing)  
  The part ic ipants should have at  least  10 years of  experience in the 
pharmaceut ical  industry  
  The part ic ipants should have operat ional  exper ience with products based 
on chemical  synthesis or biological  process 
  The part ic ipants should have good understanding of  the drug products 
l i fecycle and the regulatory environment  
  The part ic ipants should have operat ional  knowledge of  qual i ty act iv i t ies 
wi th in the product l i fecycle  
 
5.2.3 Pilot Survey questionnaire design 
The pi lot  survey quest ionnaire (Appendix B2 - improved vers ion of  the pi lot  
quest ionnaire was also used in the main survey, see Sect ion 6.2.5) contained a 
number of  c losed-ended quest ions based on the Likert  Scale wi th four opt ions 
(Leal et al . ,  2007):  1.  Very Unl ikely 2. Unl ikely 3. L ikely 4. Very Likely including 
an opt ion for Don’ t  Know. The rat ionale behind choosing a four- interval  
measurement scale was to avoid gravitat ion towards the centre and encourage 
the part ic ipants who were recognised experts to take a c lear stance. The 
quest ions were categor ised into the fo l lowing four sect ions wi th an addi t ional  
sect ion focusing on part ic ipant instruct ions and def in i t ion of terms (Appendix B2). 
The quest ions presented in each of  the sect ions were based on the informat ion 
der ived from: Chapter 3 for  t ransformat ion t r iggers and open innovat ion,  Chapter 
4 for  proposed t ransformat ion- induced qual i ty r isks and associated compl iance 
outcomes, and this Chapter for  the part ic ipant detai ls and the overal l  
methodology for  the survey. 
 
  Part ic ipant Detai ls  
  Pharma Transformat ion Tr iggers and Risks  
  Open Innovat ion and Regulatory Compl iance  
  Assessment of  Transformat ion-Induced Qual i ty Risks 
 
Pilot ing the Quest ionnaire  -  The quest ionnaire was pi loted using the cognit ive 
interviewing method (Wal l is,  1999) by interv iewing part ic ipants.  Dur ing pi lot ing 
the quest ionnaire,  the cognit ive interv iewing method was appl ied using the 
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verbal probing technique (Wal l is,  1999).  The focus of the verbal probing was the 
survey quest ions.  A one-hour interv iew wi th each part ic ipant was performed 
dur ing which the part ic ipant answered the survey quest ion,  the interv iewer then 
asked for other speci f ic informat ion relevant to the quest ions, or to the speci f ic 
answer given.  In general ,  the interv iewer "probes" further into the rat ionale and 
basis for  the response. The key benef i t  was to improve the pi lot  quest ions and 
hence the main survey quest ionnaire by explor ing issues relat ing to part ic ipant  
comprehension and ident i fy st ructural  problems such as erroneous skip patterns 
(procedures that  di rect  respondents to answer only those i tems relevant to them) 
and unclear layout dur ing the interv iew process. The pi lot  interview notebook 
was used to col lect the observat ions.  The notebook contained the quest ions, 
part ic ipant ’s response to the quest ions,  and c lassi f icat ion of  any comments 
(Table 5.1) that  the part ic ipant made related to the quest ion or the survey 
procedure.  This interv iew captured two types of  data,  namely part ic ipant 
responses to the survey quest ions and part ic ipant comments to the assessment 
of  survey rel iabi l i ty and val idi ty.  
 
Table 5.1 Classi f icat ion of  the Cognit ive Interv iew Comments for the pi lot  
quest ionnaire 
Comment Category Comment Classification 
Reliability related Survey procedure 
Logical layout and flow of the questions 
Clarification for better understanding 
Spelling or grammatical errors/suggestions 
Validity related Appropriateness of the measurement scale 
Challenges to the usefulness/validity of the question 
 
5.2.3.1 Rel iabil i ty and Validi ty Assessment  
Reliabi l i ty and val idi ty were performed in three areas relat ing to:   
i )  Rel iabi l i ty of  the data col lect ion method 
i i )  Val idi ty of  the data col lect ion method 
i i i )  Qual i tat ive descr ipt ion of  the emerging themes 
 
i )  Rel iabi l i ty of the data col lect ion method  -  pi lot  data relat ing to part ic ipant 
comments were analyzed wi th the aim of  improving the reproducibi l i ty of  the 
survey quest ionnaire. 
 
i i )  Val id i ty of  the data col lect ion method  -  the aim of the val id ity assessment was 
to improve f i tness of the quest ionnaire for  i ts intended use.  This involved 
assessment of  val id i ty wi th respect to quest ionnaire content,  structure and 
part ic ipant sampl ing - col lect ively termed as external val idi ty.   
 
Construct val idi ty is ev idence that  the measurement scale wi thin the 
quest ionnaire is appropr iate for  the study (Robson,  2002).  Construct val idi ty was 
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assessed and improved during pi lot  survey based on the information col lected 
f rom the cogni t ive interv iewing.  
Content val id i ty is  the extent to which the content of  a survey quest ionnaire is 
representat ive of the research domain i t  is  intended to cover (Robson, 2002).  
Content val id i ty was der ived from the l i terature review (Chapter 3).  
 
i i i )  Qual i tat ive descript ion of the emerging themes  -  the data f rom the cogni t ive 
interviewing was categor ised into themes, which in turn informed the act ions 
needed to improve the quest ionnaire and the associated survey procedures. 
 
5.2.3.2 Questionnaire Anonymisat ion 
The pi lot  quest ionnaires were anonymised according to the fol lowing pseudo-
code procedure (designed by the researcher)  and a l ink f i le containing the 
part ic ipant detai ls and the corresponding anonymised code.  The pseudo-code 
was composed of  f ive elements each wi th two characters represented in EE-SS-
CC-RR-NN format.  Detai ls of  each of  the f ive elements are:  
  EE: Expert ’s  second let ter of  f i rst  name and second let ter of  last  name 
  SS: BP for Big Pharma /  SP for Smal l  Pharma /  CO for  Contract  
Organizat ion /  CN for Consult ing organizat ion /  OT for Other 
  CC: First  two let ters of part ic ipant ’s organizat ion name 
  RR: Regulatory Domain of Expert ise; US for  FDA /  EU for EMA /  UE for both 
  NN: Part ic ipant ID. A sequent ia l number assigned based on the order in 
which the quest ionnaires were sent to the part ic ipants 
 
The anonymisat ion procedure was also appl ied to the main survey. 
5.2.4 Ethical considerations 
The expert  opinion study protocol  (Appendix B4) for the survey was submit ted to 
Liverpool  John Moores Universi ty (LJMU) Research Ethics Commit tee (REC) for 
rev iew. The pi lot  survey did not commence recrui tment unt i l  uncondi t ional  
approval  was received.  
 
Informed Consent  -  informed consent for pi lot  survey part ic ipants was performed 
in compl iance wi th the LJMU procedure on “Obtaining Informed Consent for  
Research Part ic ipat ion”.  Ini t ia l ly  verbal  consent of the part ic ipant  was secured 
dur ing the awareness discussions (v ia telephone).  Subsequent ly an e-mai l  
containing a br ief  statement referencing the summary of  the te lephone 
conversat ion and that the candidate had verbal ly consented to take part  in the 
survey was sent  to the part ic ipant.  In addit ion a statement was inc luded in 
Part ic ipant Informat ion Leaf let  (PIL - Appendix B1) and the quest ionnaire to 
c lear ly indicate i ts voluntary nature and the fact  that  returned completed 
quest ionnaire impl ies part ic ipant ’s consent.  
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5.3 RESULTS FOR THE PILOT SURVEY 
The results for the pi lot  survey were c lassi f ied into three categor ies that 
character ise part ic ipant  prof i les,  descr ibe part ic ipant interv iew outcomes, and 
enhance rel iabi l i ty  of  the quest ionnaire.  The remainder of  this Sect ion provides 
an overview of  the results relevant to each c lassi f icat ion and introduces the 
respect ive tables that contain the raw data.  
 
5.3.1 Participant profiles 
The pi lot  interv iews inc luded total  of  s ix part ic ipants whose prof i les are based on 
the data f rom Sect ion B of  the pi lot  quest ionnaire and summarised in Table 5.2.  
 
Table 5.2 Part ic ipant detai ls for  the pi lot  survey 
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US FDA 6     6 100 
EU EMA 4     4 67 
Other 4     4 67 
Big Pharma  6    6 100 
Pharmaceutical   4   4 67 
Biopharmaceutical   3   3 50 
15+ years    6  6 100 
Good Laboratory Practice     2 2 33 
Good Manufacturing Practice     5 5 83 
Good Clinical Practice     1 1 17 
GxP5     1 1 17 
 
5.3.2 Pilot interviews 
The pi lot  interv iews composed of responses from six part ic ipants.  Each interview 
lasted approximately 1 hour.   During pi lot  interv iews interact ion wi th the 
part ic ipant was performed in accordance wi th the cogni t ive interv iew process 
descr ibed in Sect ion 5.2.3.  Al l  remarks made by the part ic ipants dur ing the 
interview were captured as embedded comments wi th in the excel  vers ion of  the 
quest ionnaire in Appendix B3 and summarised in a table in Appendix B5. Due to 
part ic ipant preference scripted verbal  probing was not used. Instead, the 
object ive of  the verbal  probing, the role of  the interv iewer and the role of  
part ic ipant were expla ined at the beginning of each interv iew. The part ic ipants 
were encouraged to f reely chal lenge the quest ionnaire content,  sty le ( layout and 
                                                 
5 GxP – Good Laboratory, Cl in ical ,  Manufactur ing, Research Pract ices 
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format of the quest ions) and the measurement scale dur ing the interv iew. Al l  the 
comments made by al l  the part ic ipants during the cogni t ive interview process 
were att r ibuted to a sect ion or a quest ion wi thin the pi lot  survey quest ionnaire.  
There were 59 comments of  which 90% were related to content  of the quest ions, 
7% to sty le of  the quest ions and 2% to the measurement scale.  Cogni t ive 
interview comments guided improvements of  the quest ionnaire,  which resul ted in 
reducing the number of  quest ions f rom 36 to 30. 
 
The impact  of  these comments on the quest ionnaire design is  discussed in 
Sect ion 5.4.1 and 5.4.2. 
 
5.3.3 Category and frequency of cognitive interview comments  
All  the comments made by al l  the part ic ipants during the cogni t ive interview 
process were att r ibuted to a sect ion or a quest ion within the pi lot survey 
quest ionnaire and l is ted in Appendix B5. The f requency of part ic ipant comments 
by category (Content, Style,  and Measurement)  is  a lso provided in Table 5.3.  
During pi lot  interv iews interact ion wi th the part ic ipant was performed in 
accordance with the cogni t ive interv iew process descr ibed in Sect ion 5.2.3. Al l  
remarks made by the part ic ipant dur ing the interv iew were captured as 
embedded comments wi thin the excel vers ion of the quest ionnaire. 
 
5.4 DISCUSSIONS AND CONCLUSIONS OF PILOT SURVEY 
5.4.1 Pilot interviews 
Part ic ipant  Prof i les  -  analys is of  the part ic ipant  prof i les indicates that  they al l  
have extensive professional  exper ience (15+ years) in the pharmaceut ical  
industry. They have strong expert ise in the US and EU regulat ions with some 
knowledge of  other regulatory environments such as France, Germany, Japan, 
Brazi l ,  and Canada regulatory env ironment.  They have gained most of  their  
operat ional  experience in the context  of  big Pharma indust ry,  which is evenly 
distr ibuted between pharmaceut ical (67%) and biopharmaceut ical  (50%) business. 
The regulatory expert ise for the majori ty of  the part ic ipants is focused on the 
manufactur ing qual i ty,  fol lowed by laboratory qual i ty;  c l inical  qual i ty and 
research qual i ty (Table 5.2).   
 
Cogni t ive Interv iew Comments  – a great major i ty of  the part ic ipant  comments 
f rom the cogni t ive interv iew relate to the content of  the quest ions with few 
remarks relat ing to sty le and composit ion of  the quest ions and only one comment 
concerning the measurement scale as i l lust rated in Table 5.3. 
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5.4.2 Improving the pilot questionnaire 
To ident i fy quest ions that  needed the most improvement the quest ions were 
c lassi f ied into t iers of pr ior i ty.  This was done by sort ing the quest ions in 
descending order of  pr ior i ty us ing the respect ive f requency of  the cogni t ive 
interview comments provided in Table 5.3. Quest ions wi th the most comments 
required the most  attent ion and hence placed in Tier 1: 
 
Table 5.3 Frequency of  part ic ipant cogni t ive interv iew comments by category for 
the pi lot  survey 
Quest ion 
# of  
Part ic ipant 
Comments 
Comment Category 
  Quest ions Content Quest ion Style 
Measurement 
Scale 
Sect ion A 1 1 0 0 
Sect ion B 1 0 1 0 
Sect ion C 0 0 0 0 
Sect ion D 0 0 0 0 
Sect ion E 13 7 6 0 
Count 15 8 (53%) 7 (47%) 0 (0%) 
Q6 1 1 0 0 
Q7 4 4 0 0 
Q8 8 6 2 0 
Q9 11 11 0 0 
Count 24 22 (92%) 2 (8%) 0 (0%) 
Q10 1 1 0 0 
Q11 3 3 0 0 
Q12 1 1 0 0 
Q13 0 0 0 0 
Q14 2 1 1 0 
Q15 5 5 0 0 
Q16 2 2 0 0 
Q17 4 4 0 0 
Q18 2 2 0 0 
Q19 6 5 1 0 
Q20 2 2 0 0 
Q21 2 2 0 0 
Q22 1 1 0 0 
Q23 3 2 1 0 
Q24 0 0 0 0 
Q25 2 2 0 0 
Q26 3 2 1 0 
Q27 1 1 0 0 
Q28 1 1 0 0 
Q29 0 0 0 0 
Q30 1 1 0 0 
Q31 4 4 0 0 
Q32 4 3 0 1 
Q33 3 3 0 0 
Q34 0 0 0 0 
Q35 1 1 0 1 
Q36 4 4 0 0 
Count 59 53 (90%) 4 (7%) 2 (3%) 
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Tire 1 – Q19,Q15,Q17,Q36,Q32,Q31,Q33,Q23,Q11,Q26 (Order:  lef t  to r ight) 
Ti re 2 – Q20, Q35, Q16, Q25, Q14, Q18, Q21 
Tire 3 – Q22, Q27, Q10, Q12, Q30 
Tire 4 – Q24, Q34, Q13, Q29 
 
The improvements to the quest ionnaire are most  ef fect ive by studying the 
cogni t ive interv iew comments and apply ing the potent ial  enhancements to the 
survey.  This approach for improving the pi lot  quest ionnaire was appl ied wi th a 
part icular focus on Tier 1 & 2 quest ions.  The summary of changes made to the 
pi lot  quest ionnaire is l is ted in Table 5.4. 
 
Table 5.4 Improvements made to the quest ionnaire due to pi lot  survey 
Quest ion Changes made to pi lot  quest ionnaire 
Quest ion 6 Added Good Research Pract ice (GRP) to the l ist  
Quest ion 8 Replaced “External izat ion of  S/W Appl icat ions” with 
“Outsourcing of Data Management” 
Quest ion 9 Added help comments 
Quest ions 11, 15, 17 None of  the comments suggest rephras ing of  the 
quest ions 
Quest ion 16 Removed the word “Smarter”  
Quest ions 18 to Q36 Reduced number of  quest ions f rom 18 to 12. The 
composit ion of the quest ions was changed to achieve an 
open-ended style.  The measurements scale was revised to 
measure the l ikel ihood of adverse compl iance outcomes 
for i )  each of the t ransformat ion- induced r isks and i i )  
areas wi thin the product l i fecycle that are most impacted. 
 
5.4.3 Conclusion 
The resul ts  presented in th is Chapter conf i rm the rel iabi l i ty of  the survey 
quest ionnaire subject  to improvements in some areas (Sect ion 5.4.2).  The 
quest ionnaire for  the main survey was bui l t  to ref lect  these improvements and is 
presented in Chapter 6.   
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CHAPTER 6: Establishment of opinion-based 
evidence in support of the transformation triggers 
 
6.1 INTRODUCTION 
The aim of th is Chapter is to present  the results of the expert  opinion survey 
developed in Chapter 5.  The survey was performed to el ic i t  expert  opinion on the 
i )  proposed t ransformat ion t r iggers and associated qual i ty r isks ident i f ied in 
Chapter 3,  and i i )  relat ionship between the proposed qual i ty r isks and the 
regulatory compl iance outcomes present dur ing drug product l i fecycle.  Expert  
opinion was sampled using the main survey quest ionnaire wi th part ic ipants who 
were experts in the f ields of  pharmaceut ical regulat ion, pharmaceut ical product  
l i fecycle or pharmaceut ical technology.   
 
6.2 METHOD 
The quest ionnaire design, anonymisat ion,  and ethical  considerat ions of  the main 
survey are based on the methods described in Chapter 5.  Addi t ional  methods 
specif ic to the main survey are provided in th is sect ion. 
 
6.2.1 Main survey design overview 
The survey design was based on the relat ional  non-exper imental  f ixed method 
(Robson,  2002).  The word “relat ional”  means that the survey was set up to 
speci f ical ly explore relat ionships between part icular variables ( i .e.  the 
relat ionship between t ransformat ion- induced qual i ty r isks and the regulatory 
compl iance outcomes). The survey was non-exper imental  in that the researcher 
did not  del iberately change or manipulate the var iables dur ing the conduct of  the 
main survey. I t  was a f ixed method since the survey design was ful ly def ined 
before the data col lect ion took place. Data were col lected using the main survey 
quest ionnaire.   
 
6.2.2 Main survey participants 
The part ic ipants of  the main survey were recognised experts in the f ield of  
pharmaceut ical  regulat ion,  product l i fecycle,  or pharmaceut ical  technology. They 
had strategic v iew of  the pharmaceut ical  qual i ty in their  respect ive organizat ion,  
were typical ly the “go-to” person on matters of  qual i ty and regulatory compl iance 
and of ten represent their  companies in external  academic or indust r ia l 
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organizat ions. They had mult idisc ipl inary qual i ty expert ise with exposure6 to 
qual i ty issues affect ing the drug product l i fecycle7,  and exper ience in the 
pharmaceut ical  or biopharmaceut ical industry as an employee or as a serv ice 
provider.  They represented their respect ive organisat ion in external  departments 
l is ted in the sampl ing f rame (Sect ion 6.2.3).  Assignments of  members was based 
on expert  knowledge of  the members on the subject  matter that the department 
was commissioned to undertake. Therefore the survey part ic ipants selected f rom 
these departments are considered experts.  
 
A combinat ion of  purposive (the pr imary sampl ing method) and snowbal l  
sampl ing (Mack et al . ,  2005; Robson, 2002) was used for part ic ipant  select ion.  
Purposive sampl ing groups part ic ipants according to preselected cr i ter ia relevant 
to a part icular research quest ion.  The sample was taken from the organizat ions 
that  make up the sampl ing f rame (Sect ion 6.2.3).  Snowbal l  sampl ing was used as 
an aid to the purposive sampl ing, which requires the part ic ipants to ident i fy other 
potent ial  candidates f rom the sampl ing f rame.  
 
6.2.3 Sampling frame 
The sampl ing f rame is the source of the el igib le populat ion f rom which the 
survey sample was drawn. Potent ial  candidates for th is study were recruited f rom 
the organizat ions l is ted in Table 6.1.  These organizat ions were representat ive of  
pharmaceut ical  experts who gather and formulate solut ions to chal lenging 
regulatory problems and publ ish their  work. The key cr i ter ia for select ing the four 
organizat ions l isted in Table 6.1 were i )  focus on pharmaceut ical  sc ience,  
technology and regulat ions in the context  of  drug development,  approval ,  and 
manufacturing i i )  diverse membership that  inc luded industry professionals,  
industry serv ice providers,  regulatory agencies and academia i i i )  act ive 
involvement in regulatory sc ience topics and iv) a spec if ic focus on 
pharmaceut ical  qual i ty f rom the perspect ive of  Good laboratory,  manufacturing,  
c l inical  or pharmaco-v igi lance Pract ice and r isk management.  Inc lus ion of  
consult ing professionals f rom serv ice providers to the pharmaceut ical industry 
was important  for enhancing sample divers i ty  s ince these professionals 
exper ience a wide range of  industry pract ices dur ing their  service of fer ings. 
None of the consult ing professionals had any work ing relat ionship with the 
researcher or were of fered consul t ing engagements wi th the col laborat ing 
organisat ion as part of  their  survey part ic ipat ion.   
 
                                                 
6 Exposure to qual i ty issues affect ing two or more elements of  the drug product 
l i fecycle 
7 Li fecycle:   laboratory studies > c l in ical  s tudies > product approval  > product 
manufactur ing > product dist r ibut ion > product  survei l lance 
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Table 6.1 Target  part ic ipant organizat ions f rom which the main survey 
part ic ipants were selected 
Organization Department 
International Society for Pharmaceutical 
Engineers (ISPE) 
Board of directors 
Good Automated Manufacturing Practice 
forum 
Parenteral Drug Association (PDA) Science Advisory Board 
Biotech Advisory Board 
Regulatory and Compliance Advisory Board 
Quality Risk Management Interest Group 
Research Quality Association, formerly BARQA GMP, GLP, GCP, PV Committee Leaders 
American Association of Pharmaceutical 
Scientists (AAPS) 
Quality By Design (QBD) Working Group 
 
6.2.4 Main survey participant inclusion criteria 
The candidates meet ing the fol lowing cr i ter ia were selected for the survey.  
  Those who had qual i ty and compl iance knowledge in good laboratory,  
c l inical ,  and/or manufactur ing pract ice AND 
  Those who had exper ience wi th US (FDA) regulat ions and/or EU (EMA) 
regulat ion AND 
  Those who had current  work ing knowledge of qual i ty relevant  to medic inal 
products based on pharmaceut icals and/or biologics 
 
Part ic ipants were al lowed to wi thdraw from the study at any t ime.  
 
6.2.5 Main survey questionnaire 
The main survey quest ionnaire (Table 6.3) is the revised and enhanced vers ion 
of the pi lot  survey quest ionnaire (Appendix B2) discussed in Chapter 5.  
 
6.2.6 Ethical consideration 
The REC approval was obtained for the revised vers ion of the quest ionnaire,  
which was based on the improvements ident i f ied dur ing the pi lot  study.  The 
ethical  approval  for the main survey fol lowed the process descr ibed in Chapter 5 
except for the informed consent for the part ic ipants f rom the PDA. The informed 
consent for  th is  populat ion was secured via col laborat ion wi th the PDA in order 
to comply wi th PDA’s pr ivacy pol icy for  their  members.  There was no 
fundamental  change to process approved by the REC. The only adjustment 
involved the PDA assigning a coordinator to interact  wi th the part ic ipants in 
place of the researcher.  The researcher t rained the PDA coordinator on 
requirements of the approved study protocol  ( inc luding informed consent)  pr ior  to 
commencement of the survey.   
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6.2.7 Procedure for performing the main survey 
The survey procedure had two key steps: i )  part ic ipant awareness and informed 
consent i i )  quest ionnaire complet ion.  Potent ia l  candidates were contacted by 
te lephone to secure their  verbal  consent to part ic ipate in the survey. The 
te lephone conversat ion was intended to last  up to 30 minutes and focused on 
explaining the informat ion leaf let ,  instruct ions on how to complete the main 
quest ionnaire and addressing any process related quest ions that  candidates may 
have had. During the te lephone conversat ion i t  was expl ic i t ly stated that 
part ic ipat ion in the survey was voluntary and there was no obl igat ion to 
cont r ibute to research study. The telephone conversat ion stopped at  th is point  
and i f  the candidate consented he/she was considered as a “part ic ipant” in the 
study. Prior  to the teleconference meet ing,  an e-mai l  containing electronic copy 
of the informat ion leaf let and the quest ionnaire was sent  to the candidates. After 
the phone conversat ion,  an e-mail  containing a br ief  statement referencing the 
summary of the phone conversat ion and that  the candidate had verbal ly 
consented to take part  in the survey was sent to the part ic ipant .  The part ic ipants 
were asked to complete the quest ionnaire of f l ine and return the completed 
electronic or scanned copy to the pr inc ipal  invest igator.  The quest ionnaires were 
checked for completeness upon receipt  and the part ic ipant  contacted to address 
any gaps.  The main survey conduct was deemed closed once al l  the completed 
quest ionnaires and subsequent  communicat ion to address issues were received 
wi thin a s ix month per iod f rom start  (March 2012) of  the main survey study.  The 
main survey study was c losed on September 2012. 
 
For part ic ipants f rom the Parenteral  Drug Associat ion (PDA) the survey conduct 
was somewhat di f ferent.  For th is populat ion Survey Monkey (an onl ine survey 
appl icat ion) was used to inform, seek consent and col lect  part ic ipant  responses 
to the main survey quest ionnaire onl ine. This approach was taken to conform to 
the pr ivacy pol icy of the PDA and to ensure equivalence to the paper process the 
Survey Monkey quest ionnaire and associated communicat ion procedure were 
al igned to the study protocol approved by the LJMU REC. The al ignment was 
achieved by comparing the quest ions, instruct ions and layout  of  the onl ine 
survey wi th that  of  the approved paper quest ionnaire.   
 
6.2.8 Definition of key terms  
The fol lowing are def ini t ion of key terms used to describe the main survey data.  
 
  The interval  scale (Table 6.2) was used to capture part ic ipant scores to 
mult ip le choice (Likert)  quest ions in the quest ionnaire  
  The binary  scale (Table 6.2) was used to capture part ic ipant scores to 
s imple Yes or No quest ions in the quest ionnaire  
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  The mean  is  the ari thmet ic average of part ic ipant scores for each quest ion 
in the quest ionnaire  
  The dataset  refers to part ic ipant scores for quest ions in the quest ionnaire 
that  use interval  (Likert)  scale for  measurement ( i .e. Q10 to Q30 except  
Q24 of  the main quest ionnaire)  
  The dataset mean  is  the average part ic ipant scores for the ent ire dataset  
 
Table 6.2 Measurement range for interval  and binary scales 
Scale Measurement Range 
Interval Very Unlikely  0 to 25 
Unlikely    25 to 50 
Likely    50 to 75 
Very likely    75 to 100 
Don’t Know   0 to 100 (the participant does not know  
    enough to respond but the potential   
    answer could be within the full range of  
    the scale) 
Binary Yes / No   100 / 0 
 
6.3 RESULTS FOR THE MAIN SURVEY 
The results for the main survey were c lassi f ied into three categor ies that 
character ise part ic ipant  prof i les,  supply descr ipt ive stat ist ics for survey 
quest ions,  and summarise part ic ipant comments to survey quest ions. The 
remainder of  this sect ion provides an overview of  the resul ts relevant to each 
c lassi f icat ion and introduces the respect ive tables that contain the raw data.  
 
6.3.1 Participant profiles  
The main survey inc luded 80 par t ic ipants of  which 33 (41%) responded to the 
quest ionnaire.  Respondent prof i les - based on their answers to quest ions in 
Sect ion B in the quest ionnaire -  are summarised in Table 6.4.  
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Table 6.3 Main Survey quest ionnaire def in i t ions, part ic ipant detai ls and t ransformat ion related quest ions 
SECTION A – Def in i t ions   
GxP – Good Laboratory, Cl inical ,  Manufactur ing,  Research Pract ices  
ICH – Internat ional  Conference on Harmonizat ion  
Innovat ion – the int roduct ion of new technologies or methodologies  
Open Innovat ion - the pract ice of  leveraging the discovery of  others and not rely exclusively on own R&D for innovation  
Pervasive Technologies – smart  implantable devices used for product t racking, remote pat ient monitor ing or drug del ivery  
Pharma Transformat ion - is concerned wi th ongoing disrupt ive changes current ly shaping the operat ional  concepts,  
organizat ion, and technologies impact ing pharmaceut ical innovat ion and the abi l i ty to meet the demands of a changing 
heal thcare environment 
 
Post-market Survei l lance – Regulatory agency r isk assessment act iv i t ies that  take place after  approval of  the drug product  
Pre-market Assessment – Regulatory agency r isk assessment act iv i t ies that take place pr ior  to approval  of the drug 
product 
 
Product Lifecycle - a l l  phases in the l i fe of  the product f rom the in i t ial  development through market ing unt i l  the product ’s 
discont inuat ion 
 
Qual i ty – the degree to which a set of  inherent  propert ies of  a product,  system or process ful f i ls  requirements  
Qual i ty Risk – a GxP act iv i ty that i f  not performed properly may have the potent ia l  to resul t  in adverse events impact ing 
product qual i ty,  data integr i ty or pat ient  safety 
 
SECTION B - Part ic ipant  Detai ls  
Likert  
scale 
used? 
1. Expert  ident i f icat ion code: No 
2. Organizat ion name: No 
3.  Regulatory domain of expert ise: No 
4. Organizat ion type: No 
     5a. Experience in:  No 
     5b. Years of  Experience: No 
6.  Qual i ty domain of expert ise:  No 
SECTION C – Pharmaceut ical Transformat ion Triggers and Risks  
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Table 6.3 Cont inued  
7. Which of the fo l lowing is a key driver for the current Pharmaceut ical  Transformat ion? 
  Business Environment 
  Regulatory Environment 
  Open Innovat ion 
  Other (please specify):  
No 
8.  Which of the fo l lowing Open Innovat ion t rends do you think is current ly pract iced in the pharmaceut ical  industry? *  
e.g.  Cl in ical  Studies,  Safety Report ing, IT Data Centres, etc.  
  Commercial  Partnerships 
  Increased In Licensing  
  Research Partnerships  
  Research Informat ion Sharing  
  Focus on Combinat ion Products 
  Focus on Biological  Products 
  Focus on Pervasive Technologies   
  Outsourc ing of  Data Management 
  Other (please Specify):  
No 
9. Lack of which of the fol lowing wi l l  pose a GxP Risk in an Open Innovat ion environment?  
  Ef fect ive Due Di l igence 
  Ef fect ive Product  Transfer  
  Mult id isc ipl inary Regulatory Knowledge (e.g.  for combinat ion products) 
  Ef fect ive Product  Character izat ion  
  Data Securi ty and Integr i ty  
  Technology Val idat ion (means obtaining proof  of f i tness for intended use) 
  Other (please Specify):  
No 
SECTION D – Open Innovat ion and Regulatory Compliance  
10.  Open Innovat ion wi l l  have s igni f icant impact on external  partner/al l iance select ion and overs ight? Yes 
11. Open Innovat ion wi l l  have s igni f icant impact on legal  f ramework for exchange of  research informat ion? Yes 
12. Open Innovat ion wi l l  have s igni f icant impact on data management in the context  of  data securi ty,  integr i ty and 
pr ivacy? 
Yes 
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Table 6.3 Cont inued  
13. Biological /Biotech products wi l l  become major part  of  the project  and product port fol io? Yes 
14.  Prevalence of  pervasive technologies wi l l  require mul t idiscipl inary knowledge and ski l ls to deal  wi th convergent  
sc ient i f ic discipl ines (e.g.  smart implantable drug del ivery devices)? 
Yes 
15. Exist ing regulatory approaches are adversely impact ing the innovat ion dr ive in the industry? Yes 
16.  Regulatory approach that  is responsive to new discover ies whi le maintaining safety and eff icacy standards wi l l  
improve innovat ion dr ive? 
Yes 
17.  Regulatory in it iat ives such as FDA's Cr i t ical  Path and EMA's Innovat ion Task force (ITF) wi l l  have a signi f icant  
impact in industry 's innovat ion drive? 
Yes 
SECTION E – Assessment of  Transformat ion-Induced Qual i ty Risks  
a) GxP Due Di l igence of External Partners and Al l iances  
18.  What  is the l ikel ihood that  problems wi th due di l igence process wi l l  resul t  in adverse GxP compl iance outcomes when 
select ing external  a l l iances /  partners? 
Yes 
19.  What  part (s) of  the product  l i fecycle is most at r isk of adverse compl iance outcomes? No 
b) Product Transfer  
20.  What  is the l ikel ihood that  problems wi th product t ransfer* process wi l l  resul t  in adverse GxP compl iance outcomes? 
*Internal ly wi th in a company or between the company and external  partners.  
Yes 
21.  What  part (s) of  the product  l i fecycle is most at r isk of adverse compl iance outcomes? No 
c) Mult id isc ipl inary Regulatory Approach  
22.  What  is the l ikel ihood that  insuff ic ient mult id isc ip l inary qual i ty knowledge/expert ise across a range regulatory 
s ituat ions* wi l l  resul t  in adverse GxP compl iance outcomes? *e.g.  combinat ion products that  may require regulatory 
knowledge of  diagnost ics,  drugs and devices 
Yes 
23.  What  part (s) of  the product  l i fecycle is most at r isk of adverse compl iance outcomes? No 
d) B iological /B iotech Products  
24.  Are Biological /Biotech products more complex and di f f icul t  to character ise than chemical ly synthesised products? 
  Yes /  No 
No 
25.  What  is the l ikel ihood that  poor process understanding and product integr i ty* controls wi l l  resul t  in adverse GxP 
compl iance outcomes? * contaminat ion controls,  stabi l i ty controls,  ster i l i ty assurance   
Yes 
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Table 6.3 Cont inued  
26.  What  part (s) of  the product  l i fecycle is most at r isk of adverse compl iance outcomes? No 
e) Data Secur i ty and Integr i ty  
27.  What  is the l ikel ihood that  external izat ion of  GxP data creat ion,  storage and maintenance wi l l  resul t  in adverse GxP 
compl iance outcomes? 
Yes 
28.  What  part (s) of  the product  l i fecycle is most at r isk of adverse compl iance outcomes? No 
f)  Technology Val idat ion  
29.  What  is the l ikel ihood that  technology* val idat ion support ing product l i fecycle wi l l  result  in adverse GxP compliance 
outcomes? * relat ing to manufactur ing and laboratory automat ion and informat ion management systems 
Yes 
30.  What  part (s) of  the product  l i fecycle is most at r isk of adverse compl iance outcomes? No 
Likert  measurement scale was used for quest ions in Table 1 that  are tagged as “Yes”.  For quest ions 19, 21,  23,  26,  28,  30 the fol lowing 
response opt ions were used:  
  Pre-market Evaluat ion /  Market ing Approval /  Post-market  Survei l lance /  Don’ t  Know 
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Table 6.4 Part ic ipant detai ls for  the main survey  
Participants: 80 
Respondents: 33 
Response rate: 41%  
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US FDA 31     44.3 
EU EMA 24     34.3 
Other 15     21.4 
       
Big Pharma  10    26.3 
Small Pharma  5    13.2 
Consulting  16    42.1 
Contract Research/Manufacturing Org.  5    13.2 
Other  2    5.2 
       
Pharmaceutical   31   55.4 
Biopharmaceutical   20   35.7 
Other   5   8.9 
       
10-5 years    1  3.0 
10-15 years    2  6.1 
15+ years    30  90.9 
       
Good Laboratory Practice     11 19.7 
Good Manufacturing Practice     31 55.4 
Good Clinical Practice     5 8.9 
Good Research Practice     4 7.1 
Other     5 8.9 
Response rate varies by question since each respondent was allowed to choose multiple options 
for Section B questions with the exception of the question relating to “Years of Experience” where 
participants were only allowed to choose one option. 
 
6.3.2 Descriptive statistics for the main survey 
The f requency of the part ic ipant responses to Sect ion C quest ions - cover ing 
quest ions relat ing to transformat ion t r iggers, open innovat ion,  and 
transformat ion- induced qual i ty r isks - is  tabulated in Table 6.5.  Some 
part ic ipants provided mult ip le suggest ions (discussed in Sect ion 6.4) for  the 
open ended element of  these quest ions,  which are counted separately and 
ref lected in the response frequency calculat ions.  
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Table 6.5 Response count for t ransformat ion related quest ions for  the main 
survey 
Section C Q
ue
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n 
Trigger / Risk R
es
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e 
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ou
nt
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e 
R
at
e 
%
 
Pharma 
Transformation 
Triggers 
Q7 
 
Business Environment 27 47 
Regulatory Environment 20 35 
Open Innovation 8 14 
Other (please specify): 2 4 
Total 57 100% 
Open 
Innovation Q8 
Commercial Partnerships 20 19 
Increased In-licensing  17 16 
Research Partnerships  13 12.5 
Research Information Sharing  2 2 
Focus on Combination Products 13 12.5 
Focus on Biological Products 16 15 
Focus on Pervasive Technologies   3 3 
Outsourcing of Data Management 18 17 
Other (please Specify): 3 3 
  Total 105 100% 
Pharma 
Transformation 
Risks 
Q9 
Effective Due Diligence 18 19.5 
Effective Product Transfer  19 20 
Multidisciplinary Regulatory Knowledge 13 14 
Effective Product Characterization  16 17 
Data Security and Integrity  9 10 
Technology Validation 14 15 
Other (please Specify) 4 4.5 
  Total 93 100% 
Response rate varies by question since each respondent was allowed to choose multiple options 
for questions listed in column 2. 
 
The responses to quest ions in Sect ions C, D and E were standardised (see Table 
6.2) for a l l  part ic ipants and mean of  the standardised scores and respondent 
comments per quest ion is inc luded in Table 6.6.   
 
The f requency of part ic ipant responses for t ransformat ion-induced qual i ty r isks 
( independent variables) and compl iance outcomes (dependent var iables) is 
captured in Table 6.7 and Table 6.8 respect ively.  
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Table 6.6 Part ic ipant response stat ist ics for the main survey 
Transformat ion  
Triggers and Risks 
Mean of   
standardised scores 
No. of  Part ic ipant 
comments 
Q7 55.56 2 
Q8 38.64 3 
Q9 44.95 4 
Q24 30.30 2 
Compl iance Outcomes 
(dependent variables) 
Mean of   
standardised scores 
No. of  Part ic ipant 
comments 
Q19 32.58 2 
Q21 28.79 2 
Q23 30.30 2 
Q26 32.58 2 
Q28 32.58 2 
Q30 30.30 3 
Qual i ty Risks ( independent 
var iables) 
Mean of   
standardised scores* 
No. of  Part ic ipant 
comments 
Q10 65.91 2 
Q11 64.39 2 
Q12 65.23 0 
Q13 70.83 2 
Q14 73.11 1 
Q15 62.50 3 
Q16 66.67 2 
Q17 59.85 3 
Q18 69.32 0 
Q20 67.42 3 
Q22 68.94 4 
Q25 75.00 2 
Q27 56.82 2 
Q29 57.20 2 
*analysis dataset  for Likert  
scale quest ions   
Mean: 65.94 
SD:  17.75 
 
 
Table 6.7 Part ic ipant response count for quest ions relat ing to qual i ty r isks for 
the main survey 
Quest ion 
Very 
Unl ikely Unl ikely Likely 
Very 
Likely 
Don’t  
Know Skipped 
Q10 0 2 17 9 1 4 
Q11 1 2 13 10 3 4 
Q12 1 2 14 10 1 4 
Q13 0 1 11 15 2 4 
Q14 0 0 10 17 2 4 
Q15 0 6 12 9 2 4 
Q16 1 4 9 14 1 4 
Q17 2 6 11 9 1 4 
Q18 0 1 13 13 1 5 
Q20 0 2 15 11 0 5 
Q22 0 1 18 11 3 3 
Q25 0 1 7 20 0 5 
Q27 0 7 13 4 4 5 
Q29 0 9 13 5 1 5 
Total  5 44 176 157 22 60 
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Table 6.8 Part ic ipant response count  relat ing to compl iance outcomes for the 
main survey 
Question 
Pre-market 
Evaluation 
Marketing 
Approval 
Post-market 
Surveillance 
Don’t 
Know  Skipped 
Q19 5 11 16 6 5 
Q21 2 10 18 3 5 
Q23 2 12 16 4 6 
Q26 6 11 15 3 8 
Q28 6 10 16 5 6 
Q30 4 11 14 5 6 
Total 25 65 95 26 36 
 11.85% 30.81% 45.02% 12.32% 17.06% 
Response rate varies by question since each respondent was allowed to choose multiple options 
for questions listed in column 1. 
 
6.3.3 Respondent comments on the main survey questions 
The fol lowing is commentary on remarks that  the respondents made on the 
var ious quest ions wi thin the quest ionnaire.  The exact text  provided by 
respondents is enclosed in quotat ion marks.  
 
Respondent comments on quest ions 7 - 9:  
Qual i ty r isk on the one hand and over ly prescr ipt ive standard promulgat ion and 
an exaggerat ion of  r isk on the other were ident i f ied as opposing opinions and 
addi t ional  dr ivers of  industry t ransformat ion.  One part ic ipant stated that “open 
innovat ion trends current ly pract iced in the indust ry include vir tual  organizat ions,  
cont ract  manufacturing and professional  consort iums”.  Other areas of  r isk 
ident i f ied by part ic ipants inc lude i )  durat ion of  research partnerships versus 
durat ion of  the product development l i fecycle i i )  supply chain management in i ts 
broadest context  i i i )  management understanding of  qual i ty rather than just  
compl iance and iv) product  adulterat ion and drug counterfei t ing.   
 
Respondent comments on quest ions 10 - 17: 
Concerning the impact of  open innovat ion on external partner/al l iance select ion, 
two part ic ipants suggested that  companies were al ready downsizing and 
outsourcing var ious act iv i t ies and that more scrut iny in partner select ion was 
needed.  One part ic ipant thought that  “ legal  f ramework for open innovat ion should 
probably be establ ished,  but was not sure i f  i t  would happen” and another 
part ic ipant had an opposing view stat ing that “ legal  f ramework is pret ty wel l  
developed already”.  Regarding the prevalence of  biological/b iotechnology 
products one part ic ipant  bel ieved that th is was already part  of project and 
product port fo l ios of  pharmaceut ical  companies and this is a t rend that wi l l  
accelerate.  In contrast  another part ic ipant suggested that 
b iological /b iotechnology products tended to be highly expensive targeted drugs 
and current t rends in heal thcare management may not embrace these products 
as a f i rst  l ine of  therapy. On mult idiscipl inary knowledge/ski l ls  one part ic ipant 
stated that “what  is required from a compl iance point  of  v iew are more 
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indiv iduals with medical  exper ience making judgments regarding pat ient  care and 
less involvement of  bureaucrats to encourage peer rev iew and ensure at tent ion 
to fundamental  sc ient i f ic  pr inc ipals”.  On regulatory approach to compl iance and 
innovat ion one part ic ipant  suggested that “compl iance is al l  too of ten a self -
fu l f i l l ing prophecy in which a perceived problem is blown out  of proport ion to r isk.  
Overbearing regulat ion for years has been used to cont rol  respect ive markets 
leading to di f f icul ty in int roducing newer technologies part icular ly those that  rely 
on unique drug del ivery systems, are customised to a specif ic  pat ient,  or  are 
mult i faceted in one way or another.  Overbear ing regulat ion would resul t  in a loss 
of  innovat ion,  the swal lowing up of  smal ler ,  entrepreneuria l  organizat ions,  drug 
shortages of  some medic ines, and perhaps even the curtai lment of  gener ics”.  
Another part ic ipant focused more on the legal  aspect s tat ing that “concern about 
adverse publ ic i ty and legal  issues (potent ia l  c lass act ion lawsui ts)  are leading to 
conservat ive decis ion making in port fo l io management  and regulatory review”.  
Another part ic ipant summarised the regulatory approach as “the bar for  safe and 
ef fect ive is increasing”.  One part ic ipant stated that “ regulators have no incent ive 
in making anything easier for anyone and was not opt imist ic that the regulatory 
apparatus,  which has evolved in Europe and the USA in part icular,  can support  
an innovat ive environment”.  Concerning regulatory in it iat ives one part ic ipant 
opined that  “ these ini t iat ives may work i f  regulators provide f lexibi l i ty in 
regulatory f i l ings”.  A couple of  the part ic ipants expressed a more scept ical  tone 
opining that regulat ion never leads to innovat ion or innovat ion dr ive,  regulat ion 
should focus on one thing and one thing only, making sure that there is a supply 
of  safe medic ine for everyone and that new ideas gain market access at  the 
appropriate pace. Such ini t iat ives to date have tended to be largely pol i t ical  and 
seem to lack the strategic partnership needed wi th al l  sectors of  the 
Pharmaceut ical Industry ( i .e.  Big Pharma as wel l  as Gener ics).  
 
Respondent comments on quest ions 18 - 30: 
On GxP due-di l igence for external  partners/al l iances one part ic ipant commented 
that  “al l  the phases of the product l i fecycle were at  r isk as long as the focus 
remains on regulatory compl iance rather than real  compl iance”.  The part ic ipant 
def ined real  compl iance as “developing and manufacturing safe and ef fect ive 
medic ines from a strong ethical  base focusing on combat ing unethical  and 
cr iminal elements of  the heal thcare product supply chain”.  With respect o 
product t ransfer one part ic ipant stated that  “potent ia l GxP compl iance r isks wi l l  
depend a lot  on qual i ty of  product t ransfer planning and execut ion”.  Another 
part ic ipant stated that “ the GxP compl iance was a moving target ,  which of ten has 
absolutely nothing to do with product  safety”.  One part ic ipant proposed 
“ inadequate knowledge management and process characterizat ion cont inue to be 
major roadblocks in ear ly commercial izat ion”.  One comment focused on 
contractual  process expressing a great deal  of concern dur ing the technology 
t ransfer process f rom one organizat ion to another and that  the “cont ract giver 
discovers i t  takes much more t ime and resource than they had imagined”.   
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Another comment at t r ibuted inadequate knowledge of  dosage form processes to 
“poor inspect ions outcomes stat ing that there is a di rect relat ionship between 
industry implementat ion of innovat ive technology and more regulatory scrut iny”.  
Concerning mult id isc ipl inary regulatory knowledge/ski l ls  one part ic ipant stated 
that “ the compl iance r isks are high af ter the ini t ia l  product approval  s ince f i rms’  
compl iance and qual i ty systems trend to deter iorate dur ing the commercial  
manufactur ing”.  Regarding complexi ty of  the biological /biotechnology product 
character izat ion, couple of  the part ic ipants opined that  the process is the 
product and in some cases they are more di f f icul t  to character ise chemical ly or 
biochemical ly,  but  in some cases they aren' t .   Further explaining that “complex 
biologics have been used safely for decades; there is no reason to be hung up 
on complexi ty”.   One comment focused on regulators understanding of  
contaminat ion cont rol  and stat ing that  the “recent dr ive to manufacture even non-
ster i le drugs in c lassi f ied c lean rooms as a complete waste of  money and 
regulatory ef for t ” .   Another comment at t r ibuted majori ty of  regulatory product  
recal ls to “poor understanding of  product performance long term, especial ly with 
product component interact ions”.  
 
With respect to external izat ion of  GxP data management one comment stated 
that “some aspects of data col lect ion, and storage has been in place for decades 
and compl iance problems have been comparat ively rare” and another comment 
focused more on use of social  media in the industry imply ing that “ i t  may present 
a larger qual i ty and compl iance r isk than internal  data management systems”.  
Concerning technology val idat ion one comment discussed the new technology 
adopt ion in the industry saying that  the “pharmaceut ical  and biopharmaceut ical  
industr ies have lagged behind other technological industr ies in the adaptat ion of 
modern informat ion and process management technologies”.   The commenter 
at t r ibuted this lag largely to “misplaced regulatory concerns and unfortunate 
regulatory requirements”.  Another comment focused on computer val idat ion 
approaches not ing that  they “have not changed s igni f icant ly in 20 years and 
therefore the current methodologies are unprepared for use of new "c loud based" 
comput ing”.  
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6.4 DISCUSSIONS AND CONCLUSIONS 
The results  of  the main survey relat ing to each sect ion of the quest ionnaire are 
discussed. The support ing data for the fol lowing discussion is provided in Tables 
6.4 to 6.8.   
 
6.4.1 Participant details (questions 2 to 6 of main survey 
questionnaire)  
Analysis of  the part ic ipant  prof i les indicated that  they al l  had extensive 
exper ience (15+ years) in the pharmaceut ical  industry (Q5a, Q5b in Table 6.3).  
They had expert ise in the US and EU regulat ions wi th some knowledge of  other 
regulatory environments such as Aust ral ia,  Braz i l ,  Canada,  Japan, New Zealand, 
Switzer land,  the Pharmaceutical  Inspect ion Co-operat ion Scheme and the World 
Heal th Organizat ion (Q3 in Table 6.3).  Most of the respondents l inked their  
operat ional  experience wi th Big Pharma and Consult ing companies serv ing 
mainly the pharmaceut ical  and biopharmaceut ical  business (Q4 in Table 6.3).  
The regulatory expert ise for major i ty of  the part ic ipants focused on the 
manufactur ing qual i ty,  fol lowed by laboratory qual i ty;  c l inical  qual i ty and 
research qual i ty (Q6 in Table 6.3).  
 
The 41% response rate (Table 6.4) is appropriate s ince the respondent prof i les 
character ise the part ic ipant populat ion ( i .e.  the 80 part ic ipants).  The fol lowing 
key character ist ics of  the part ic ipant populat ion are st rongly represented in the 
respondent prof i les as demonstrated in Table 6.4:   
  Part ic ipants wi th operat ional  experience in pharmaceut ical industry and as 
service providers 
  Part ic ipants wi th operat ional  knowledge of  the US and EU regulatory 
environment  
  Part ic ipants wi th operat ional  knowledge of  good laboratory and 
manufacturing pract ice.  In pract ice the drug product qual i ty and associated 
pat ient safety concerns are more prominent dur ing product approval and 
rout ine use of the drug product  than dur ing the research and development 
phase. Therefore i t  is  appropr iate that  most  respondents have experience in 
good laboratory and manufacturing pract ice 
 
The part ic ipants were selected - by the researcher or the PDA coordinator in the 
case of  PDA part ic ipants - f rom speci f ic  departments within the organisat ions 
l isted in Table 6.1.  The word “department” is used to col lect ively refer  to terms 
such as advisory board, commit tee,  work ing group and interest  group.   The 
departments l is ted in Table 6.1 have a speci f ic  mission and their  members were 
assigned by their respect ive organisat ions. Assignments of  members was based 
on expert  knowledge of  the members on the subject  matter that the department 
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was commissioned to undertake. Therefore the survey part ic ipants selected f rom 
these departments are considered experts.  
 
One potent ia l  area of improvement is addit ional  expert ise in the c l inical  qual i ty 
arena.  More part ic ipants wi th this expert ise would have provided a sharper 
image of qual i ty r isk and compl iance outcomes associated wi th the pre-market 
evaluat ion phase of  the product l i fecycle.  
 
6.4.2 Transformation triggers and risks (questions 7 to 9 of 
main survey questionnaire)  
In addressing quest ions relat ing to pharmaceut ical  t ransformat ion most 
part ic ipants agreed that  the Business  and Regulatory  environment play the 
leading role in the ongoing transformat ion within the industry wi th open 
innovat ion playing somewhat of  a lesser role (Q7 in Table 6.5).  Among the open 
innovat ion t rends commercial  partnerships,  outsourcing of  data management 
act iv i t ies, focus on biological products and in- l icensing received the most 
at tent ion. Part ic ipants also suggested increase in other open innovation t rends 
that inc lude v i r tual  organizat ions,  cont ract  manufacturing and professional  
consort iums (Q8 in Table 6.5).  From the perspect ive of  qual i ty r isks,  the 
part ic ipants gave the highest importance to ef fect ive due di l igence, product 
t ransfer and product character izat ion act iv i t ies fo l lowed by technology val idat ion 
and mult id isc ipl inary regulatory knowledge (Q9 Table 6.5).  Provis ions for data 
secur i ty and integr i ty received the lowest score (Q9 Table 6.5).   
 
6.4.3 Open innovation and regulatory compliance (questions 
10 to 17 of main survey questionnaire) 
There was support  amongst part ic ipants that open innovat ion would have a 
s igni f icant inf luence on select ion and overs ight  of  external  partners (Q10 in 
Table 6.7) and management of  data f rom the perspect ive of  data secur i ty,  
integr i ty and pr ivacy (Q12 in Table 6.7).  The prevalence of  biological and 
biotechnology products in pharmaceut ical  companies’  project  and product 
port fo l ios (Q13 in Table 6.7) and prevalence of pervasive technologies requir ing 
mult id isc ipl inary knowledge/sk i l ls (Q14 in Table 6.7) received the most l ikel ihood 
of  occurrence from the part ic ipants.  Part ic ipants did not agree that exist ing 
regulatory approaches adversely impact pharmaceut ical innovat ion (Q15 in Table 
6.7) and there was modest support  for  the assert ion that  the current regulatory 
in i t iat ives such as “Cr i t ical  Path” of  the US FDA and “Innovat ion Task Force” of  
EMA had s igni f icant posi t ive impact on pharmaceut ical  innovat ion (Q17 in Table 
6.7).  
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6.4.4 Assessment of transformation quality risks (questions 
18 to 30 of main survey questionnaire) 
Poor process understanding for biological  /  b iotechnology products and problems 
wi th due di l igence process for  external  partners/al l iances was seen as posing 
the most  qual i ty r isks fol lowed by lack of  mult idiscipl inary qual i ty knowledge and 
expert ise across a range of  regulatory s ituat ions (Q18, Q22, Q25 in Table 6.7).  
External iz ing management of GxP related data and lack of ef fect ive technology 
val idat ion processes were deemed important but  comparat ively less important as 
sources of  qual i ty r isks (Q27, Q29 in Table 6.7).  According to the experts (Table 
6.8) the out l ined qual i ty r isks f rom a GxP compl iance perspect ive are most 
not iceable dur ing the post  market ing survei l lance and market ing approval  phases 
of  the product l i fecycle.  In comparison, the part ic ipant responses suggest that  
qual i ty r isks are less impactful  dur ing pre-market evaluat ion phase and that most 
of  the impact is focused on due di l igence of  external  partners/al l iances, 
biological /b iotechnology product character izat ion and external izat ion of GxP data 
management. 
 
6.4.5 Conclusion 
Given that l i terature results take t ime to publ ish,  there is a di f ference in 
knowledge wi th in the l i terature ( i .e.  wi th respect  to the theoret ical  ev idence 
presented in Chapter 3) and those of experts in the f ield.  Therefore there was a 
need to have a v iew of  the current s i tuat ion by el ic i t ing opinion of  experts wi th 
operat ional  knowledge relat ing to industry t ransformat ion and associated qual i ty 
r isks.  The main survey has closed this gap by providing valuable f ie ld 
informat ion that is used to determine the pharmaceut ical qual i ty r isk model  
presented in Chapter 7.  
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CHAPTER 7: General Discussions & Development of 
a Pharmaceutical Quality Risk Model 
 
7.1 INTRODUCTION 
The pharmaceut ical industry, s ince 1990, has exper ienced a decl ine in research 
and development product iv i ty,  despite s igni f icant advancements in biomedical  
sc iences and increasing R&D expendi ture (Sect ion 1.3.1).  The product iv i ty 
decl ine consequent ly poses a major concern s ince fewer resources are deployed 
on products targeted for important publ ic health needs such as rare diseases,  
prevent ion indicat ions, or indiv idual ised therapies. This prospect  has mot ivated 
both the indust ry and the regulators to make transformat ional  changes to the way 
drug products are discovered,  developed,  approved, and used – with the ult imate 
aim of producing innovat ive products to protect  and promote publ ic heal th 
(Sect ions 2.3.2 and 2.3.3).   
 
During the design and implementat ion of  these transformat ional  changes, a key 
considerat ion for the pharmaceut ical  industry and regulators is to ensure that 
r isks associated wi th qual i ty of  products,  safety of  pat ients and integr i ty of  
related data (col lect ively termed “pharmaceut ical  qual i ty r isks”) are ef fect ively 
addressed.  In the pharmaceut ical  industry the qual i ty uni t  – mandated by law – 
plays a key role in addressing these r isks (Sect ion 1.2.5).  Therefore an important 
goal  for the qual i ty uni t  should be to determine potent ia l  r isks int roduced by the 
ongoing pharmaceut ical  t ransformat ion and devise a plausible qual i ty r isk model 
to ident i fy areas wi th in the product l i fecycle that require the most at tent ion. 
 
This or iginal  research (see Sect ion  7.4.3) set  out to study the ongoing 
pharmaceut ical  t ransformat ion wi th the aim of  i )  establ ishing theoret ical  
ev idence for key t r iggers inf luenc ing the pharmaceut ical  t ransformat ion, i i )  
ident i fy ing t ransformat ion- induced qual i ty r isks,  i i i )  accumulat ing operat ional  
ev idence so as to conf i rm or deny the theoret ical  ev idence, iv) e l ic i t ing opinion 
of  expert  pract i t ioners to acquire f ie ld knowledge of the t ransformat ion- induced 
qual i ty r isks and their  relat ionship to regulatory compl iance outcomes, and v) 
us ing this information to propose a pharmaceut ical  qual i ty r isk model for  the 
drug product l i fecycle.  To accompl ish the above aim this PhD research was bui l t  
upon the fol lowing three key pi l lars:  
  Theoret ical  Evidence - represented by t ransformat ion tr iggers der ived f rom 
the systemat ic rev iew of the l i terature 
  Operat ional  Evidence -  represented by Figures 4.1 to 4.12 der ived f rom the 
systemat ic analys is of  operat ional  data 
  Opinion-based Evidence - represented by resul ts of  the expert  opinion 
survey 
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The ident i f icat ion and ranking of importance of  the t r iggers impact ing 
pharmaceut ical  t ransformat ion, termed “ theoret ical  ev idence”,  were performed in 
Chapter 3.  The importance ranking of the fourteen t ransformat ion t r iggers ( l is ted 
below) resul ted in select ion of  four t r iggers (Trigger 2,  3,  5,  and 14) as the basis 
for proposing potent ial  qual i ty r isks impact ing the pharmaceut ical  qual i ty.   
 
Tr igger 1:  Heal thcare Management  Focused 
Tr igger 2:  Ful ly Integrated Pharma Network 
Tr igger 3:  Personal ised Medicine 
Tr igger 4:  V irtual R&D  
Tr igger 5:  Translat ional  Research 
Tr igger 6:  Adapt ive Cl inical  Tr ia ls 
Tr igger 7:  Regulatory Harmonisat ion 
Tr igger 8:  Science and Risk Based Approach 
Tr igger 9:  Progressive/Live Licensing  
Tr igger 10:  Regulatory Enforcement 
Tr igger 11: B iotechnology  
Tr igger 12:  Nanomedic ine 
Tr igger 13:  B ioinformat ics 
Tr igger 14: Pervasive/Cloud Comput ing 
 
The corresponding “operat ional  ev idence” - backing the theoret ical  ev idence 
f rom the perspect ive of  industr ial  pract ice - was provided in Chapter 4.  The next 
step was to propose a plausible model  for  pharmaceut ical qual i ty r isk.  To do this 
i t  was necessary to el ic i t  expert  opinion in the f ie ld (Chapter 6) regarding the 
theoret ical  ev idence and use experts ’  knowledge to determine the relat ionship 
between the proposed qual i ty r isks and the compl iance outcomes. 
 
The aim of th is Chapter is to discuss the f indings of the previous chapters, 
compare them with f indings in the l i terature and use the survey data f rom the 
expert  opinion study to determine the relat ionship between the proposed qual i ty 
r isks and the compliance outcomes. 
 
7.2 METHOD 
The methods descr ibed in this sect ion are used to:  i )  determine the strength of  
the operat ional  ev idence, i i )  determine the t r ipart i te relat ionship between expert  
opinion, theoret ical  ev idence and operat ional  ev idence, i i i )  construct  a 
pharmaceut ical  qual i ty r isk model us ing data f rom the main survey, and iv) 
ident i fy other research s imi lar to th is PhD research for the purposes of 
comparison.  
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This sect ion is rel iant on Chapter 6 s ince the descr ipt ive stat ist ics for the main 
survey data referenced here are descr ibed in Chapter 6.  
 
7.2.1 Determining strength of theoretical evidence and 
operational evidence  
The method for measur ing strength of  the theoret ical ev idence was based on the 
ranking of  the t ransformat ion t r iggers ( i.e. the higher the ranking, the higher the 
st rength of  the theoret ical  ev idence).  However in order to ensure a s imple 
comparison between the theoret ical  and operat ional  ev idence, the measurement 
scale for  st rength of  the theoret ical ev idence was converted into an interval  
scale (Flynn et  al .  1994) with ten equal  intervals wi th values between 0 and 100 
(Table 7.1).  Since the theoret ical  ev idence rankings are in descending order the 
highest  st rength values are assigned to the lowest ranking numbers (Table 7.2,  
7.3) 
 
Table 7.1  Measurement  scale to show the strength of  the theoret ical  ev idence 
Theoretical Evidence Rank Interval Theoretical Evidence Strength Interval 
1.0 – 1.4 90 – 100 
1.4 – 2.8 80 – 90 
2.8 – 4.2 70 – 80 
4.2 – 5.6 60 – 70 
5.6 – 7.0 50 – 60 
7.0 – 8.4  40 – 50 
8.4 – 9.8 30 – 40 
9.8 – 11.2 20 – 30 
11.2 – 12.6 10 – 20 
12.6 – 14.0 0 –10 
 
The strength of  the operat ional  ev idence was determined through v isual 
examinat ion of  the Figures 4.1 to 4.12 and the observed trends were converted 
into a s imple st rength scale to enable di rect comparison wi th the st rength of  the 
theoret ical  evidence. In order to faci l i tate th is s imple l ike- for- l ike comparison, 
the measurement scale for  the operat ional  ev idence and theoret ical  ev idence 
were al igned.  
 
The method for measur ing strength of  the operat ional  ev idence was based on the 
interval  scale (Flynn et  a l .  1994) wi th values from 0 to 100. The scale was 
div ided into seven equal  intervals with “None” at the lowest  end and “Very 
Strong” at  the highest end of the interval (Table 7.2).  Seven intervals were 
chosen to provide maximum precis ion in al locat ing the strength values for the 
operat ional  ev idence. Each interval  qual i tat ively def ines the amount of  
operat ional  ev idence present  for t ransformat ion t r iggers. The “Very Strong” 
interval  was subdiv ided into two t iers to dif ferent iate between evidence from 
mult ip le versus s ingle operat ional  indicator.  The word “ indicator” refers to the 
category of  operat ional  data that was used to bui ld the operat ional  ev idence (see 
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Sect ion 4.3).  Three indicators were used to bui ld the operat ional  ev idence for 
t ransformat ion Trigger 3 (personal ised medic ine) and hence the operat ional  
ev idence for th is t r igger was assigned the highest st rength value (Table 7.3).   
 
Table 7.2 Measurement scale to show the strength of the operat ional ev idence 
Strength of Operational Evidence  Interval Scale 
Very Strong (tier 1): significant amount of operational evidence from multiple 
indicators exist 
86 – 100 
Very Strong (tier 2): significant amount of operational evidence from a single 
indicator exists 
71 – 86 
Strong: reasonable amount of operational evidence exists 57 – 71 
Medium: some operational evidence exists 43 – 57 
Weak: little operational evidence exists 29 – 43 
Very Weak: very little operational evidence exists 14 – 29 
None: no operational evidence exists 0 – 14 
 
7.2.2 Relationship between theoretical evidence and 
operational evidence 
The relat ionship between theoret ical and operat ional  ev idence was determined 
by comput ing the s imple di f ference between the st rength of  the theoret ical  
ev idence and strength of  the operat ional  ev idence. 
 
The s imi lar i ty between the theoret ical  and operat ional  ev idence was deemed 
excel lent  i f  computed di f ference was 0 to 10; Good  i f  10 to 20; Acceptable  i f  20 
to 30;  and Weak  i f  > 30. The “computed di f ference” was based on the argument 
that  numerical distance between strength of  the theoret ical  and operat ional  
ev idence is a s imple indicator of  their s imi lar i ty or  contrast .  The lower values of  
“computed di f ference” mean high s imi lar i ty in st rength between the theoret ical  
and operat ional  ev idence and conversely the higher values of the “computed 
di f ference” indicate low s imi lar i ty in strength between the theoret ical  and 
operat ional  ev idence. 
 
7.2.3 Relationship between theoretical evidence, operational 
evidence, and expert opinion 
The sum of respondent comments on the quest ions mapped against  each 
transformat ion tr igger was considered as the pr imary indicator of  respondents ’  
level of interest on a t ransformat ion r igger and hence i t ’s  perceived importance. 
This is based on this researcher ’s observat ion during cogni t ive interv iew 
sessions of the pi lot  study where respondents focused more on topics that  were 
di rect ly related to their  respect ive area of  expert ise or topics that they had a 
part icular interest and hence tended to provide more commentary on those topics.   
This survey var iable was therefore used in determining st rength of  correlat ion 
between the expert  opinion and the corresponding theoret ical and operat ional  
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evidence. The correlat ion between the t ransformat ion t r iggers and the main 
survey quest ions was determined as fol lows:  
 
The main survey quest ions that  addressed topics related to a t ransformation 
t r igger was mapped to that  t r igger (Table 7.4).  For each transformat ion t r igger 
the strength of  the expert  opinion was determined by comput ing the sum of the 
respondent comments to mapped quest ions. For each transformat ion t r igger the 
ranking and strength of  the theoret ical  evidence, the st rength of  the operat ional  
ev idence, and the strength of the expert  opinion were tabulated in Table 7.3 and 
7.4.  The correlat ion between the expert  opinion strength and each of the other 
columns wi thin Table 7.4 was computed using Equat ion 7.1.  In this case, 
correlat ion (Table 7.3) rather than covar iance was used because the 
measurement scale for  the variables is in di f ferent units.  Correlat ion between 
theoret ical  ev idence (Transformat ion Tr iggers) and the expert  opinion was  
computed using CORREL (Equat ion 7.1),  which is Microsoft  Excel  funct ional i ty 
(Microsoft  Corporat ion,  2012).  
 
CORREL ([expert  opinion strength]  1  t o  T ,  [X] 1  t o  T )  . . .Equat ion 7.1 
 
Where T is the number of t ransformat ion t r iggers = 14 and X = Column 3 or 4 in 
Table 7.4,  represent ing “theoret ical  ev idence strength” and “operat ional  ev idence 
st rength” respect ively.   
 
7.2.4 Relationship between quality risks and regulatory 
compliance 
The relat ionship between the t ransformat ion- induced qual i ty r isks and the 
regulatory compl iance outcomes for the main survey was determined by 
comput ing their  covar iance. Indiv idual  mean of  main survey quest ions for the 
t ransformat ion- induced qual i ty r isks ( independent var iables) were calculated 
(Table 7.6).  Indiv idual  mean of survey quest ions for the regulatory compl iance 
outcomes (dependent var iables:  i .e.  pre-market evaluat ion,  market ing approval ,  
and post-market survei l lance) were calculated (Table 7.6).  Covariance between 
the independent and dependent var iables was computed using Equat ion 7.2.  
Covar iance between independent and dependent var iables was  computed using 
COVAR (Equat ion 7.2),  which is Microsoft  Excel funct ional i ty (Microsoft  
Corporat ion,  2012).  
 
COVAR (( [Qual i ty Risks]  1  t o  I ,  [Y]  1  t o  D )  …Equat ion 7.2 
 
Where I  and D are the number of  main survey quest ions relat ing to independent 
and dependent  var iables = 4 and Y = Column 4 or 5 or 6 in Table 7.6,  
represent ing “pre-market evaluat ion” or “market ing approval”  or “post-market 
survei l lance” respect ively.   
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7.2.5 Method for identifying other research similar to this PhD 
research 
This sect ion descr ibes the method used to ident i fy other research s imi lar to the 
work presented in th is thesis.  The search method focused on ident i fy ing art ic les 
that dealt  wi th topics related to “ Industry Transformat ion” and “Qual i ty Risk 
Management/Model”  in the context of the pharmaceut ical industry. These topics 
were used to perform the art ic le search wi th in the search t imeframe of 2000 to 
2013.  The art ic le search databases used inc luded JSTOR, Cambridge Journals,  
Emerald,  IngentaConnect ,  Nature,  Science Direct ,  Taylor & Francis,  Oxford 
Journals,  and Google Scholar.  The “Industry Transformat ion” and “Qual i ty Risk 
Management/Model”  were used as search phrases in the t i t le of  the art ic les. The 
search was performed in February 2013. Art ic le relat ing to serv ice industry and 
non-prof i t  or  governmental  organisat ions were excluded. The intent was to f ind 
research art ic les target ing industr ies that have some simi lar i ty to the 
pharmaceut ical  industry,  especial ly those wi th substant ive R&D operat ion. 
Art ic les that general ly covered topics of  interest f rom a theory or pract ice point  
of  v iew were considered as “relevant” and were considered.  Art ic les that  were 
wri t ten in the context  of  the pharmaceut ical industry were considered as “direct ly 
re levant”.   
 
The art ic le search method for the “Qual i ty Management” topic is descr ibed in 
Sect ion 1.3.5. 
 
7.3 RESULTS 
The resul ts  presented in th is sect ion are intended to provide ins ight  into the 
relat ionships between the theoret ical ,  operat ional  and opinion based evidence 
presented in previous chapters.  This covers two key aspects,  i )  Relat ionship 
between the Theoret ical ,  Operat ional  and Survey  ev idence, and i i )  Relat ionship 
between Independent  and Dependant  var iables - the grouping of  these 
relat ionships const i tutes the qual i ty r isk model in the context  of  pharmaceut ical  
t ransformat ion,  which is presented in Sect ion 7.3.3.  
 
7.3.1 Relationship between theoretical and operational 
evidence 
The relat ionship between the theoret ical and operat ional ev idence was 
establ ished by a s imple comparison of  the strength of  the theoret ical  ev idence 
and strength of  the operat ional  ev idence. The resul ts of  th is comparison are 
tabulated in Table 7.3.   The importance ranking of  theoret ical  evidence is 
captured in Column 2 and the corresponding strength values are captured in 
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Column 3. The observed strength of  the operat ional  ev idence is captured in 
Column 4. The outcome of the “computed di f ference” between strengths of  the 
theoret ical  and operat ional  ev idence indicat ing degree of  their  s imi lar i ty is 
captured in Column 5. 
 
Table 7.3 Relat ionship between theoret ical and operat ional  ev idence relat ing to 
ver i f icat ion of t ransformat ion t r iggers 
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1 Healthcare Management Focused 7 55 90 35 
2 Fully Integrated Pharma Network* 3 80 80 0 
3 Personalised Medicine* 1 100 100 0 
4 Virtual R&D 12 20 45 25 
5 Translational Research* 4 70 60 10 
6 Adaptive Trials 13 10 50 40 
7 Regulatory Harmonization 9 45 50 5 
8 Science & Risk Based Regulations 6 60 55 5 
9 Progressive/Live Licensing 11 30 0 30 
10 Regulatory Enforcement 14 0 55 55 
11 Biotechnology 8 50 60 10 
12 Nanomedicine 10 35 50 15 
13 Bioinformatics 5 65 65 0 
14 Pervasive/Could Computing* 2 90 70 20 
*Transformation triggers 2, 3, 5, and 14 with strong theoretical and operational evidence 
**Strength scale: Very Strong1 = 86-100; Very Strong2 = 71-86; Strong = 57-71; Medium = 43-57; 
Weak = 29-43; Very Weak = 14-29, 30, None = 0-14 (see Section 7.2.1) 
***Strength of theoretical evidence minus the operation evidence: Excellent 0 to 10; Good 10 to 20; 
Acceptable 20 to 30; Weak > 30 (see Section 7.2.2) 
 
7.3.2 Relational data for the quality risk model 
The relat ionship between the t ransformat ion t r iggers and the expert  opinion were 
establ ished by determining the correlat ion between the sum of  respondent 
comments for the mapped survey quest ions and each of i )  the t ransformat ion 
t r igger ranks and i i )  the st rength of  operat ional  ev idence. The results are l isted 
in Table 7.4 and Table 7.5.  Column 2 ident i f ies the main survey quest ions that  
are mapped into a given transformat ion t r igger.  Columns 3, 4,  and 5 contain the 
st rength of  theoret ical ev idence, operat ional  ev idence and expert  opinion 
respect ively.  The strength of  expert  opinion is represented by the sum of 
respondent comments to mapped quest ions.  Note that  the st rength values are in 
di f ferent uni ts and hence Correlat ion and not Covar iance was used to determine 
their  re lat ionship.   
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Table 7.4 Correlat ion between transformat ion t r igger ranking,  operat ional  
ev idence and the main survey 
Pharmaceutical Transformation Triggers 
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* 
1 - Healthcare Management Focused 8,22 6 90 7 
2 - Fully Integrated Pharma Network 8, 9,10,18 3 80 9 
3 - Personalised Medicine 8,9,10,11,13, 22,24 1 100 19 
4 - Virtual R&D 8 11 45 3 
5 - Translational Research 8,17 4 60 6 
6 - Adaptive/In-life Trials   12 50 0 
7 - Global Harmonization 7,17 9 50 5 
8 - Science & Risk Based Regs. 15,16,17 7 55 8 
9 - Live Licensing  13 0 0 
10 - Enforcement  17 14 55 3 
11 - Biotechnology  8,13,24 8 60 7 
12 - Nanomedicine  10 50 0 
13 - Bioinformatics   5 65 0 
14 - Pervasive/Cloud Computing 8,9,12,14, 29 2 70 10 
* Results from Chapters 3, 4 and 6 
 
The result  of  the Correlat ion computat ion between the expert  opinion and the 
theoret ical  and operat ional  ev idence is  provided in Table 7.5.    
 
Table 7.5 Correlat ion between theoret ical and operat ional  t ransformat ion 
evidence and the main survey var iables 
 
Expert Opinion 
(sum of respondent comments for mapped 
questions) 
Theoretical Evidence 
transformation trigger ranks (Table 7.4) α = 0.7584 
Operational Evidence 
operational evidence strength (Table 7.4) α = 0.7182 
 
The fundamental backbone of  the qual i ty r isk model is determining the 
relat ionship between t ransformat ion- induced qual i ty r isks ( independent  var iables) 
and the corresponding regulatory compl iance outcomes (dependent variables).  
This was accompl ished by comput ing the covar iance between the respect ive 
means of  the t ransformat ion- induced qual i ty r isks and the regulatory compl iance 
outcomes (Table 7.6).  This was performed by f inding the covariance between the 
mean of  the main survey quest ions that  const i tute the independent var iables and 
mean of  the main survey quest ions that  comprise the dependent var iables.  Three 
correlat ion coeff ic ients one for each of the dependent  var iables were computed 
and the results captured in Table 7.6.   
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Table 7.6 Qual i ty Risk Model -  covar iance between transformat ion- induced 
qual i ty r isks and compl iance outcomes of the main survey 
Independent Variables Dependent Variables 
Quality Risk Questions Quality Risk mean  C
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Q18 69.32 Q19 15.15 33.33 48.48 
Q20 67.42 Q21 6.06 30.30 54.55 
Q22 68.94 Q23 6.06 36.36 48.48 
Q25 75.00 Q26 18.18 33.33 45.45 
Q27 56.82 Q28 18.18 30.30 48.48 
Q29 57.20 Q30 12.12 33.33 42.42 
Covariance between independent & dependent variables -2.8058 5.2928 5.6754 
 
7.3.3 Development of the pharmaceutical quality risk model 
Figure 7.1 is the conceptual depict ion of the qual i ty r isk model showing the 
relat ionship between qual i ty Risks  and regulatory compl iance Outcomes  in terms 
of  their  covariance. The r isk assessment was focused on assessing the 
l ikel ihood of adverse compl iance outcomes dur ing product l i fecycle due to the 
t ransformat ion induced r isks i f  they are not proper ly integrated wi th and 
managed as part  of  the qual i ty management system. 
 
Figure 7.1 Conceptual depict ion of the pharmaceutical  t ransformat ion qual i ty r isk 
model 
 
The covar iance between t ransformat ion- induced qual i ty r isks and the 
corresponding regulatory compl iance outcomes was computed and found to be 
negat ive for the pre-market evaluat ion and posit ive for the market ing approval  
and post-market survei l lance phases of  the product l i fecycle (Table 7.6).  The 
qual i ty r isk model indicates a f i rm relat ionship between the pharmaceut ical  
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qual i ty r isks ( independent var iables) and regulatory compl iance outcomes 
(dependent var iables) during the market ing approval  and post-market ing phases 
of the product l i fecycle and a weaker relat ionship dur ing the pre-market 
evaluat ion phase. This model can be used by the industry pract i t ioners to 
develop appropriate r isk mit igat ion strategies in product l i fecycle act iv i t ies that  
are impacted by the four main t ransformat ion t r iggers and the associated 
transformat ion- induced qual i ty r isks.  
 
7.4 GENERAL DISCUSSION 
The intent of  the general  discussion is to address the research quest ions that 
were asked in Chapter 1 and to provide a commentary on simi lar  work that exists 
wi th in and outside the pharmaceut ical  industry.  The strength of  relat ionship 
between the theoret ical  and operat ional  ev idence is also discussed. 
 
7.4.1 Relationship between theoretical and operational 
evidence 
The computed di f ference between strengths of theoret ical and operat ional  
ev idence, presented in Table 7.3,  suggest an “excel lent” correlat ion with respect 
to Tr igger 2 (Ful ly Integrated Pharma Network),  Tr igger 3 (Personal ised 
Medic ine),  Tr igger 5 (Translat ional  Research),  Tr igger 7 (Regulatory 
Harmonisat ion),  Tr igger 8 (Science and Risk Based Regulat ion),  Tr igger 11 
(Biotechnology),  and Tr igger 13 (Bioinformat ics).  This means that  there is a 
st rong agreement between the theoret ical  and operat ional  ev idence for these 
tr iggers.  However the areas of  strong contrast where the computed di f ference is 
“weak” are Tr igger 1 (Heal thcare Management Focused),  Tr igger 6 (Adapt ive 
Cl inical  Tr ia ls),  Tr igger 9 (Progressive/Live Licensing),  and Tr igger 10 
(Regulatory Enforcement) .  The areas of moderate simi lar i ty between the 
theoret ical  and operat ion evidence, where the computed di f ference is 
“good/acceptable” inc lude Tr igger 12 (Nanomedic ine),  14 (Pervasive/Cloud 
Comput ing),  and Trigger 4 (Virtual  R&D). See Sect ion 8.1 for fur ther commentary 
and conclusion. 
 
The results  of  the “computed di f ference” provided in Table 7.3 are dependant on 
researcher’s interpretat ion of t rends in Figures 4.1 to 4.12. Although these 
trends are based on sol id operat ional  data,  however assignment of  st rength 
values to those t rends is based on researcher’s  v isual  observat ions. An area of  
improvement would be to improve the accuracy of the st rength values assigned 
to the operat ional  ev idence. This can be done by requir ing mult iple researchers 
to perform the same visual observat ions and averaging resul ts of  strength values 
they assign to each observat ion.  
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7.4.2 Addressing research questions  
The specif ic f indings of this research study are discussed in detai l  in each 
Chapter.  This sect ion wi l l  synthesise these f indings into uni f ied form in order to 
answer the research study’s three main quest ions:   
 
Quest ion 1 :  What are the key tr iggers impact ing pharmaceut ical  t ransformat ion? 
The theoret ical  ev idence establ ished in Chapter 3 ident i f ied fourteen t r iggers 
inf luencing the ongoing pharmaceut ical  t ransformat ion.  Four of  these tr iggers:  
fu l ly integrated Pharma network,  personal ised medic ine,  t ranslat ional  research, 
and pervasive comput ing were considered the most impactful  on drug product 
l i fecycle.  The importance of  the four t r iggers was fur ther supported by the 
operat ional  ev idence establ ished in Chapter 4.   
  
Quest ion 2 :  What wi l l  be the impact on regulatory science especial ly  wi th respect 
to qual i ty r isk management? The impact on regulatory sc ience was determined 
from the perspect ive of  pharmaceut ical  qual i ty.  The opinion of  expert  
pract i t ioners in the f ie ld (Chapfer 6) conf i rmed the theoret ical proposal  that  GxP 
due di l igence, drug product t ransfer,  product character isat ion,  mult idisc ipl inary 
regulatory sk i l ls /knowledge, and data secur i ty/ integr i ty -  re lated to products and 
pat ients - are the main areas of qual i ty r isk that should be managed in pract ice 
wi thin the framework of  the pharmaceut ical  qual i ty.        
 
Quest ion 3 :  What is a plausible model for  pharmaceut ical  qual i ty r isk sui table for 
the t ransformed environment? The qual i ty r isk model  (Sect ion 7.3.3) was def ined 
based on the data col lected from the expert  opinion study.  The analys is of  th is 
data indicates that there is  f i rm relat ionship between the proposed 
pharmaceut ical  qual i ty r isks and the compl iance outcomes that take place dur ing 
the market ing approval  and post -market survei l lance phases of the product 
l i fecycle.  The qual i ty r isk model indicates that  the relat ionship between 
pharmaceut ical  qual i ty r isks and the compl iance outcomes dur ing pre-market 
evaluat ion ( i .e.  research and development)  phase of the product l i fecycle is 
s ignif icant ly weaker. Al though in pract ice the regulatory compliance issues are 
prominent  in the market ing approval and post-market ing phases of the drug 
product l i fecycle than the pre-market evaluat ion phase, based on Author ’s 
industr ia l  exper ience,  the compl iance outcomes in the pre-market ing phase also 
exist .  One explanat ion for the mismatch between this research f inding and the 
operat ional  experience is that  the prof i le of the respondents in the main survey 
(Sect ion 6.3.1) f rom a product l i fecycle expert ise standpoint  inc luded fewer 
experts wi th c l inical  and medical  background, which would be necessary to 
accurately est imate the impact  of  the qual i ty r isks in the pre-market evaluat ion 
phase of the product  l i fecycle. From a product  l i fecycle expert ise standpoint  
most of the respondents (55.4%) had a commercial  manufacturing background 
and lesser percentage (8.9%) had c l in ical  and medical  background. 
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7.4.3 Comparison of this PhD research with similar work in the 
literature 
In order to compare this PhD research with s imi lar work in a wider context ,  the 
fo l lowing three perspect ives are discussed wi th respect to their  t reatment ins ide 
and outside the pharmaceut ical  indust ry.   
i )  General  approaches to qual i ty management  
i i )  Industry t ransformat ion  
i i i )  Management of  qual i ty r isks induced by industry t ransformat ion  
The intent is  to enr ich the discourse by explor ing main features/ themes of other 
s imi lar research and discuss how they relate to what  has been presented in this 
thesis.  Since the work in this thesis is essent ia l ly centred on the three key 
concepts of  qual i ty management ,  industry t ransformat ion and r isk management,  
the comparat ive discussion below is  al igned accordingly.   
 
The examinat ion of  the l i terature presented below conf i rms that th is PhD 
research is an or iginal body of work that  has not  been performed before. 
A lthough there are areas of s imi lar i ty between the l i terature and this research, 
however nei ther of  the art ic les selected for comparison focused on qual i ty r isks 
induced by pharmaceut ical  industry t ransformat ion.  
 
7.4.3.1 General approaches to qual ity management 
In int roducing this PhD research in Chapter 1 the study of qual i ty management 
topic was explored in the l i terature and i t  was found that  of the 38 most  c i ted 
qual i ty management  art ic les (Sect ion 1.3.5) publ ished between 1989 and 2009 
only two art ic les studied pharmaceut ical  industry (Rowley & Sneyd,  1996; Ahmad 
et  a l . ,  2009).   The main themes in the 38 art ic les relate to theory and pract ice of  
Qual i ty Management (Badr i  et  al .  1995; Das et al .  2000; Dow et al .  1991; Flynn 
et  a l .  1994; Saraph et  a l .  1989; Zu et  al .  2008),  theory and pract ice of  Total  
Qual i ty Management (Bou-Llusar et  a l .  2009; Kaynak  2003;  Samson & 
Terz iovski  1999;  Ahire et  a l .  1996;  Antony et al .  2002; B lack & Porter 1996; Choi  
& Eboch 1998;  Cua et a l .  2001; Douglas & Judge 2001; Forza & Fl ippini  1998; 
Grandzol  & Gershon 1998; Ho et  a l .  2001; Joseph et  a l .  1999; Mart inez-Lorente 
et  a l .  2000; Powel l  1995;  Tamimi 1998),  and their  study in some special ised 
s i tuat ions such as qual i ty awards,  Deming method, role of  top management,  
qual i ty performance, cont inuous improvement,  service qual i ty,  etc.  (Curkovic et  
a l .  2000;  Ahire & Dreyfus 2000;  Ahire & O’Shaughnessy 1998; Ahmad et al.  2009; 
Anderson et al .  1995; Kaye & Anderson 1999; Kontoghiorghes 2004; Lai 2003; 
Lau et  a l .  2004; Miyagawa & Yoshida 2005; Prajogo & Sohal 2003; Rowley & 
Sneyd 1996; Rungtusanatham et al .  1998; Sanchez- Rodr iguez 2004;  Sun 2000;  
Tan 2001).   
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Two of  the special ised studies were set in the pharmaceut ical  industry, The f i rst  
(Ahmad et al .  2009) conducted a narrow research studying serv ice qual i ty in 
pharmaceut ical  supply chain wi thin Pakistan. They focused on measur ing 
rel iabi l i ty of  serv ice qual i ty wi th in the pharmaceut ical supply chain and did not  
address any new or emerging r isks relat ing to regulatory sc ience.  Therefore no 
meaningful  comparisons can be made between their study and this PhD research. 
The second study (Rowley & Sneyd 1996) on the other hand descr ibes a 
quest ionnaire-based survey of  the UK pharmaceut ical industry,  which 
invest igated the implementat ion of total  qual i ty in research-based environments.  
They concluded that  two central  issues that  may meri t  further invest igat ion are 
the relat ionship between total qual i ty and the research culture and the 
measurement of qual i ty in R&D. This conclusion is compat ible wi th the proposal 
in Sect ion 8.3 of  th is thesis that  addi t ional  research is  needed to better 
character ise the t ransformat ion- induced qual i ty r isks wi thin the pre-market  
evaluat ion ( i .e.  R&D) phase of  the product l i fecycle.   
 
7.4.3.2 Industry transformation 
The l i terature search for “ Industry Transformat ion” revealed 180 art ic les of  which 
12 were deemed relevant  and four were di rect ly relevant to the pharmaceut ical 
or  heal thcare industry.  Of the four art ic les Ramaprasad & Johnson (2000) 
focused on use of  e-technologies to fundamental ly t ransform physic ian off ice 
v is i t  impact ing the operat ions wi thin the off ice  ( the way appointments,  pat ient 
records,  and bi l l ing is handled),  the nature of  the vis i t  (preparat ion for,  
interact ion, and fol low-up wi th the pat ient) ,  and the physician  ( the concept of  
v i r tual  physic ian – reducing barr iers to gett ing second or mult ip le opinions via 
physic ian col laborat ion using onl ine communicat ion technology).  The f inding of 
th is art ic le is compat ible wi th the f indings of th is PhD research in relat ion to 
pervasive comput ing and i ts importance to pat ient  heal thcare f rom the 
perspect ive of  drug del ivery and prescr ipt ion compl iance in an invest igat ional  or 
commercial-use sett ing. See Sect ion 8.3 for recommendat ion for future research 
that could further enr ich this f ie ld.   
 
Arora et  a l .  (2009) on the other hand focused on industry t ransformat ion in the 
context  of  Indian patent reform and i ts impact on R&D investment and innovat ion 
wi th in the pharmaceut ical  industry.  They observed that  the pat terns in data 
col lected f rom 315 Indian drug procedures are consistent  wi th the idea that at  
least  some Indian f i rms have shi f ted to a more R&D-intensive business models in 
the wake of patent reform. They did not address industry t ransformat ion relat ing 
to regulatory sc ience and hence there is no tangible s imi lar i ty between work 
done by Arora et  al .  and this PhD research.  Therefore no meaningful 
comparisons can be made between the two bodies of  work.  
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Ugalde et  al .  (2009) analyzed the case of  Merck pharmaceut icals and shows that 
th is f i rm, considered during many decades to be the most innovat ive,  highly 
sc ient i f ic  and prof i table,  has in the last  years t ransformed i tself  into a 
commercial  enterpr ise.  The authors argue that  f i rm’s main object ive is to 
increase the sales of  drugs regardless of their therapeut ic value. They point  out 
that  d iscovery of  t rue innovat ive drugs that  add new therapeut ic value has 
decreased notably in recent years.  The Authors present data indicat ing that 
Merck's case is not unique and that  innovat ive pharmaceut ical  industry, known 
as "Big Pharma", has fol lowed the same trend.  There is no substant ive s imi lar i ty 
between work of  Ugalde et  a l.  and this  PhD research except for Big Pharma 
diversi f icat ion – which is due to an increase in pharmaceut ical revenues from 
products or serv ices other than f rom the t radi t ional ly st rong prescr ipt ion drug 
sales.  
 
The research conducted by Lee (2012) in agricul tural  biotechnology, al though 
not  in a pharmaceut ical  set t ing,  is relevant  and c lose enough in approach to 
explore.  The study used Delphi  method to integrate v iews of  experts f rom 
industry and academia regarding future di rect ion of agricultural  biotechnology in 
Taiwan in order to ext ract the cr i t ical success factors inf luencing industry 
t ransformat ion.  The author t reats t ransformat ion as two types i )  non-cross-
domain  type in which “enterprises concentrate on the development of  their 
exist ing product,  but change the act iv i t ies of  product ion technology,  market ing 
direct ion, market t ransformat ion,  and the hor izontal  or vert ical  integrat ion” and i i )  
cross-domain  type in which “enterpr ises give up their  or ig inal  products and 
operate in the exist ing or new business areas; at  the same t ime, they invest in or 
operate products of  the new business area to decrease the operat ional  r isk”.  The 
study div ides the cr i t ical parameters inf luencing the industry t ransformat ion into 
“pr imary act iv i t ies” (product  l i fecycle act iv i t ies) and “support  act iv i t ies” (enabl ing 
processes) and uses Fuzzy Delphi  to assign importance level to each of  the 
cr i t ical  parameters. 
 
Areas of  s imi lar i ty between the study conducted by Lee and this PhD research 
inc lude: 
 
  Use of  l i terature review to determine factors inf luencing industry 
t ransformat ion 
  Use of  quest ionnaire based survey to el ic i t  expert  opinion 
  Ranking of  cr i t ical  factors inf luencing the indust ry t ransformat ion  
  Industry diversi f icat ion – Author ’s descr ipt ion of cross-domain 
t ransformat ion approach is consistent wi th the concept of  pharmaceut ical 
industry diversi f icat ion exempl i f ied by Trigger 1 (Healthcare Management  
Focused) in Chapter 3 and 4.  
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Areas of  contrast  inc lude: 
  Agriculture biotechnology industry versus pharmaceut ical industry 
  Transformat ion from a supply chain perspect ive versus transformat ion f rom 
a sc ience and qual i ty r isk management  perspect ive  
  Use of  operat ional  data as an intermediate control  to back-up l i terature 
f indings versus moving di rect ly from l i terature f indings to expert  opinion 
el ic i tat ion 
 
The main themes of the other relevant art ic les on indust ry t ransformat ion were 
management sc ience centr ic wi th the fol lowing focus:  
 
  The role of  informat ion technology in enabl ing or impeding industry 
t ransformat ion (Howard et  a l .  2001;  Hanley 2003; Mortehan 2004; King and 
Lyyt inen 2004,  Pussep et  al .  2012) 
  The role of  technological  change in t r igger ing industry t ransformat ion in 
automot ive industry (Struben 2008;  Bouza et  a l .  2009) 
  The role of  al l iances, st rategic partnerships and v i r tual organisat ions in 
industry t ransformat ion (El l iot  2006;  Gersch et  al .  2006;  Karvonen 2008;  
Goeke et  al .  2010) 
  Industry t ransformat ion to lean enterpr ise model  (Hal lam 2003) 
 
7.4.3.3 Quali ty Risk Management 
The search resul ted in 138 art ic les of  which nine were direct ly re levant to qual i ty 
r isk management.  None of  the other art ic les was compat ible wi th scope of  th is 
PhD research and they mainly focused on the operat ional  process for how to 
conduct r isk management ,  special ised tools used to perform r isk assessment,  
and the theory and pract ice of  qual i ty by design.  
 
The general  theme of qual i ty r isk management topics that  these art ic les covered 
were as fo l lows: 
 
  Appl icat ion of  Qual i ty Risk Management in pharmaceut ical industry.  Mainly 
focusing on r isk management pract ices and appl icat ion of ICH Q9. 
(Claycamp, 2007;  Ahmed et  al. ,  2008;  Hajela and Al i ,  2011;  Charoo and Al i ,  
2012; Vartak,  2012).  
  The procedural  aspect of  how to implement a qual i ty management  system 
focusing on the key aspects such as r isk ident i f icat ion,  r isk assessment,  
r isk control  and r isk communicat ion (BR, 2007;  Claycamp, 2007; Charoo 
and Al i ,  2012).  
  Various tools used to conduct r isk assessment (Dimeny and Popescu, 2006; 
Claycamp, 2007; Dahiya et  al . ,  2009;  Xu et  a l . ,  2010) 
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  Qual i ty by design - focusing on ful l  understanding of  how product  at t r ibutes 
and associated process relate to product  performance ( too numerous to l ist  
– 180 art ic les and books) 
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CHAPTER 8: Conclusions and Recommendations for 
Future Research………………… 
 
The aim of th is Chapter is to synthesise the conclusions discussed in ear l ier  
chapters into a unif ied whole highl ight ing new knowledge that  inform pol icy, 
pract ice and future research. 
 
8.1 CONCLUSIONS 
The regulatory environment descr ibed in Chapter 2 conf i rmed that regulatory 
sc ience (of  which pharmaceut ical  qual i ty is a branch) has a substant ia l  impact on 
drug product l i fecycle with respect to innovat ion and product iv i ty.  Publ ic heal th 
protect ion, publ ic heal th promotion,  cr is is management, harmonisat ion, foster ing 
innovat ion,  and modernisat ion were ident i f ied as key topics def ining mission of 
the regulatory author i t ies.  Provis ion of  science-based regulatory controls to 
ensure the safety and ef f icacy of  pharmaceut ical products were considered an 
important instrument in managing r isk.  From the perspect ive of  sc ience-based 
regulatory controls the regulatory act ions to date indicate a move towards publ ic 
heal th promot ion, modernizat ion and foster ing innovat ion.  A lthough this t rend in 
regulatory th ink ing is l ikely to cont inue in the future i t  is  also reasonable to posit  
that the industry t ransformat ion ( those discussed in Chapter 3)  wi l l  pose new 
regulatory chal lenges that  require mit igat ion strategies to manage r isks.  Some of 
these chal lenges are ident i f ied as future research in Sect ion 8.3.  
 
In Chapter 3 pharmaceut ical  t ransformat ion was def ined as the process by which 
the pharmaceut ical industry intends to achieve and maintain advantage through 
changes in operat ional  concepts,  regulatory science, and technologies that wi l l  
s igni f icant ly improve i ts capabi l i ty  to innovate.  Open innovat ion was ident i f ied as 
an important  element of  the t ransformat ion and was def ined as leveraging 
external  sources of innovat ion by col laborat ing wi th smal l  b iotechnology 
companies,  univers i t ies,  research partnerships,  etc.  The outcome of the 
systemat ic rev iew of  the l i terature,  which is also referred to in thesis as 
“ theoret ical  ev idence” ident i f ied fourteen tr iggers impact ing the ongoing 
t ransformat ion in the pharmaceut ical industry. The importance-ranking of these 
tr iggers revealed that of  the fourteen transformat ion t r iggers four,  namely Ful ly 
Integrated Pharma Network,  Personal ised Medic ine,  Translat ional  Research and 
Pervasive Comput ing are considered as the most impactful .   
 
The assessment of the ident i f ied pharmaceut ical  t r iggers f rom an open 
innovat ion perspect ive suggested that  the t rends l is ted below wi l l  l ikely increase 
in the pharmaceut ical  industry and wi l l  have an impact on pharmaceut ical  qual i ty 
f rom a r isk management perspect ive.  
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  External  research, commercial  partnerships and in- l icensing of products  
  Research and Development on combinat ion,  biological  and biotechnology 
products  
  Smart  implantable devices for product t racking,  pat ient  moni tor ing,  drug 
del ivery  
  Outsourc ing of  informat ion systems for management of  c l in ical  and product 
data (e.g.  for  c l inical  t r ials,  drug safety survei l lance, customer complaints,  
etc. )   
 
The impact on pharmaceut ical  qual i ty was further explored from a r isk 
perspect ive and the fol lowing qual i ty r isk areas were proposed.    
  GxP due di l igence of external  research/commercial  partners 
  Product  t ransfer processes  
  Mult idisc ipl inary regulatory knowledge and ski l ls  
  Product  character isat ion 
  Data secur i ty and integr i ty 
  Technology val idat ion to ensure f i tness for  intended use 
 
The theoret ical ev idence relat ing to the t ransformation t r iggers were supported 
by the operat ional  ev idence and the proposed qual i ty r isks were examined during 
the expert  opinion survey.   
 
In order to conf i rm the existence or absence of  theoret ical ev idence, operat ional  
ev idence in Chapter 4 was establ ished based on pract ical appl icat ion of the 
t ransformat ion t r iggers.  The trends in operat ional  evidence and the associated 
theoret ical  ev idence were compared to ident i fy areas of s imi lar i ty and contrast .  
In general  there is  a good correlat ion between the theoret ical ev idence der ived 
from the l i terature review and the corresponding operat ional  ev idence. The 
st rength of  the operat ional  evidence supports the l i terature f indings that  Triggers  
2 (fu l ly  integrated Pharma network),  3 (personal ised medic ine),  5 ( t ranslat ional  
research)  and 14 (pervasive comput ing) are important dr ivers of  pharmaceut ical  
industry t ransformat ion (Table 7.3) and hence were used to determine their  
impact on pharmaceut ical qual i ty.  Key areas of contrast  however are Trigger 1 
(heal thcare management focused),  Tr igger 6  (adapt ive/ in- l i fe t r ia ls),  and Trigger 
10  (enforcement)  for which the operat ional  ev idence is stronger than the 
theoret ical  ev idence (Table 7.3).  A general  explanat ion for  th is contrast  could be 
at t r ibuted to the fact  that  there is a pauci ty of  academic research in the f ie ld of  
pharmaceut ical  qual i ty (see Sect ion 7.4).  This is part icular ly t rue for Trigger 10 
and to a lesser extent to Trigger 1.  The explanat ion for  Tr igger 6 is more 
nuanced and could be l inked to the or ig inator of  the adapt ive t r ial  concept ( i .e.  
led by industry hence lag in academic work).  
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Having establ ished the theoret ical  ev idence and the support ing operat ional  
ev idence for  the t ransformat ion t r iggers i t  was necessary to examine them from a 
real i ty-on-the-f ield perspect ive using an expert  opinion survey descr ibed in 
Chapter 6.  The survey resul ts support  the theoret ical  and operat ional  ev idence 
on the four main pharmaceut ical  t ransformat ion t r iggers.  The correlat ion between 
st rength of  the opinion-based var iable ( i .e.  survey respondent comments for the 
mapped quest ions) and strength of  the evidence-based variables ( i .e.  theoret ical  
and operat ional  ev idence) were computed and found to be wi th in the acceptable 
range (Table 7.4, 7.5).  This indicates that the expert  opinion survey val idate 
importance ranking of  the t ransformat ion t r iggers. 
 
As demonstrated in this thesis the pharmaceut ical  industry t ransformat ion is 
changing the way the drug products are developed,  approved,  manufactured and 
used. The tradi t ional  approaches to regulatory sc ience wi l l  face chal lenges.  The 
pharmaceut ical  industry should ensure that  the pharmaceut ical  qual i ty 
evolves/t ransforms in paral lel  wi th other aspects of  the ongoing t ransformat ion 
focusing their  at tent ion more on sc ience and r isk based approaches to qual i ty.  
 
8.1.1 Policy and practice implications 
As discussed in Chapter 1 and 2, in the pharmaceut ical  industry qual i ty r isks are 
expected to be managed wi thin a qual i ty r isk management f ramework as 
recommended by ICH Q9 (2005) guidance. This global  regulatory guidance 
def ines the f ramework as “an ef fect ive qual i ty r isk management approach that 
can further ensure the high qual i ty of  the medic inal products to the pat ient by 
providing a proact ive means to ident i fy and control  potent ial  qual i ty issues 
dur ing development,  manufacturing and post market ing use”.  Another ICH 
guidance discussed in Chapter 1 and 2 was ICH Q10 (2007),  which def ines a 
model for  a pharmaceut ical  qual i ty system that  can be used throughout  the 
di f ferent stages of a product l i fecycle and can provide an effect ive f ramework to 
implement qual i ty r isk management .  This guidance descr ibes pharmaceut ical  
processes that govern management responsibi l i ty (organizat ion) ,  cont inual  
improvement of the pharmaceut ical  qual i ty systems (support) ,  and cont inual  
improvement of process performance and product  qual i ty  (product l i fecycle).   
 
The f indings of  th is research study would be a valuable input to implementat ion 
of  the ICH qual i ty r isk management  f ramework stated above. From a pract ical  
standpoint  the mit igat ion st rategies for the management of  the qual i ty r isks 
should be bui l t  into the pharmaceut ical processes that govern organizat ion ,  
support ,  and product l i fecycle  act iv i t ies (conceptual ly i l lustrated in Figure 8.1 
based on ICH Q10). The important organisat ion  re lated processes that  should be 
considered are the qual i ty systems management,  qual i ty audi t ,  and qual i ty r isk 
management processes. These processes are overarching in scope and wi l l  
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cover al l  the proposed areas of qual i ty r isk.  The support  processes typical ly deal  
wi th t ransverse topics that  apply across the product l i fecycle.  Act iv i t ies that 
should be considered for th is  category inc lude product and process improvement,  
personnel  qual i f icat ion and t raining,  management of  suppl iers and 
subcontractors,  and val idat ion of  systems/equipment to ensure f i tness for 
intended use. The product l i fecycle  processes that  govern post -market ing 
act iv i t ies ( i .e.  manufacturing,  dist r ibut ion,  and survei l lance of commercial  drug 
products),  market ing approval  act iv i t ies ( i .e.  regulatory submission and 
maintenance), and pre-market ing act iv i t ies ( i .e.  non-cl in ical laboratory studies 
and c l inical  development) should be considered. Appl icat ion of  the qual i ty r isk 
model descr ibed here would mean that the pr ior i ty for  implementat ion of  r isk 
mit igat ion controls should be given to the post-market ing and product  approval 
act iv i t ies that are signi f icant ly impacted by the proposed qual i ty r isks related to i )  
external  partner due di l igence and overs ight,  i i )  product t ransfer,  i i i )  
character izat ion of b iological /b iotechnology products,  and iv) outsourc ing of  GxP 
data management. 
 
Figure 8.1  Pharmaceut ical qual i ty processes where qual i ty r isk controls should 
be bui l t  
 
8.2 RESEARCH LIMITATIONS 
A key l imitat ion of this research was lack of  s imi lar peer reviewed research for 
comparison purposes. This is a unique study and the researcher at  the t ime of  
conduct ing this research did not f ind any publ ished research wi th s imi lar 
coverage. Another l imitat ion was pauci ty of  regulatory data in publ ic domain.  To 
the extent possible both US FDA and EMA databases were consul ted for 
regulatory evidence. However in some cases (e.g.  regulatory enforcement) due 
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to f reedom of informat ion act  the only publ ic ly avai lable data was found in the 
US FDA databases. Regardless of  country of  or ig in s ince the US FDA has an 
extensive regulatory network and global  overs ight on drug products marketed in 
the US this l imitat ion did not negat ively impact the val idi ty of  the resul ts. 
 
8.3 RECOMMENDATIONS FOR FUTURE RESEARCH 
The scale of  th is research study is large and there are many interest ing areas for 
future research, some examples inc lude: 
 
A dedicated expert  opinion survey focusing on pre-market evaluat ion phase is 
needed in order to more accurately character ise the relat ionship between the 
proposed qual i ty r isks and the regulatory compl iance outcomes for this phase of  
the product l i fecycle.   
 
Sect ion 8.1.1 discussed some areas within the product  l i fecycle that requires 
most at tent ion from a sc ience and r isk based approaches to qual i ty management.  
Assessment of  how c losely the proposed model (Figure 8.1) is appl ied across the 
pharmaceut ical  industry would be a good indicator i f  sc ience and r isk based 
approaches are being bui l t  into the qual i ty r isk management f ramework.   
 
The pharmaceut ical qual i ty as a subset  of regulatory sc ience has a potent ia l  to 
s igni f icant ly impact product iv i ty in industry and as such science and r isk based 
approaches to pharmaceut ical qual i ty should be encouraged through more 
academic research. As demonstrated in Chapter 1 the paucity of  the academic 
research and peer rev iewed papers on this topic is palpable.  
 
Future research in the special ised branch of  pharmaceut ical  qual i ty is also 
needed,  some examples inc lude:   
  Chal lenges posed by progressive/ l ive l icensing model of  product approval  to 
pharmaceut ical  qual i ty.  
  Impact of  sc ience and r isk based approach to pharmaceut ical qual i ty on 
depth and frequency of regulatory inspect ions. 
  Regulatory compl iance in pat ients ’  home - use of  smart  drug del ivery and 
moni tor ing systems – impl icat ions for the regulators and the pharmaceut ical  
industry.  
  Real  t ime product release – move from t radi t ional  analyt ical  chemistry 
(Qual i ty Control  concept) to real  t ime product release using onl ine smart  
analyt ical  devices. 
  Impact of  embedding smart  devices in pr imary product packaging on 
improving pat ient  compl iance.  In c l inical t r ials or dur ing rout ine use eff icacy 
of certain drug products is di rect ly related to st r ict  adherence to prescribed 
f requency of  drug intake. Ensur ing pat ient  compl iance is di f f icul t  and 
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bui ld ing intel l igence in pr imary packaging of the drug product may help.  The 
aim of th is proposed research is to invest igate the ef fect iveness of  such 
solut ions 
  Impact of  embedding smart  devices in pr imary product packaging on 
managing r isks associated wi th counterfei t ing.  
  Regulatory compl iance and intel lectual  property impl icat ion of c loud 
comput ing when appl ied to pre-cl in ical ,  c l inical ,  safety report ing,  and 
manufacturing data.  
  Impact of  the appl icat ion of  pervasive comput ing in GxP environments and 
character is t ics of  val idat ion methodology needed to ensure f i tness for 
intended use.  
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Postscript………………… 
When I started this research,  I  was confronted wi th a subject that was vast in 
scope and mult id isc ipl inary in nature.  At  t imes, i t  seemed impossible to imagine 
bui lding a path through the maze of topics connect ing the beginning to the end.  
From today’s vantage point  I  c lear ly see a shortcut ,  a st raight  l ine connect ing 
then and now. But I  guess this is the purpose of the PhD journey, during which 
my knowledge and learning behaviour has evolved in the fol lowing two key areas.  
 
The f i rst  area was the appl icat ion of  the sc ient i f ic  method. As an industry 
pract i t ioner one tends to be minimal ist ic when i t  comes to wr i t ten communicat ion 
and tend to rely on exper ience,  inst inct,  some data, and often assumpt ions to 
formulate and test  hypothesis. This PhD research has undone my 20 years of  
industr ia l  approach to problem solv ing and enabled me to learn how to 
ef fect ively apply r igorous methods to a sc ient i f ic  inquiry.   
 
The second area was the progression of  my think ing overt ime on the ongoing 
pharmaceut ical  t ransformat ion and i ts impact on pharmaceut ical  qual i ty.  There 
were topics for which I  had f i rm opinions and the research ei ther conf i rmed or 
disproved my think ing (e.g.  indust ry divers i f icat ion,  v i rtual R&D, personal ised 
medic ine, regulatory harmonisat ion,  and regulatory enforcement).  For some 
topics my think ing was not ful ly developed and the research f indings improved 
my knowledge base (e.g.  nanotechnology, bioinformat ics and pervasive 
computing).  Other topics such as t ranslat ional  research, l ive l icensing and 
adapt ive c l in ical  t r ials were new knowledge for which I  did not have any pr ior  
point  of  reference. 
 
So how has this new knowledge been implemented in pract ice? The fol lowing are 
some of the programs that I  have in i t iated or contr ibuted to in the context of 
Sanof i .  In some cases this involved establ ishment of  working groups to explore 
the topics and propose pract ical solut ions.  
 
  Direct ives and guidel ines on qual i ty r isk management 
  Due-di l igence pract ices relat ing to external  partners 
  Risk rat ing methodology for compl iance ranking of manufactur ing s i tes  
  Risk rat ing methodology for compl iance ranking of  GxP data management 
systems 
  Control  measures for qual i ty r isks associated wi th pervasive and c loud 
comput ing 
  Recrui tment of  qual i ty experts wi th mult id iscipl inary regulatory knowledge 
(drugs,  biologics,  devices, etc. ) 
  Presentat ions to var ious R&D and manufactur ing teams 
	128 
References………………… 
Abraham J, Davis C. Comparat ive analys is of drug safety wi thdrawals in the UK 
and the US (1971–1992):  Impl icat ions for current  regulatory think ing and pol icy.  
Social Science and Medic ine .  2005; 61:881-892. 
 
Abraham J,  Lewis G. Harmonis ing and compet ing for  medic ines regulat ion:  how 
heal thy are the European Union's systems of  drug approval?  Social  Science and 
Medic ine .  1999; 48:1655-1667.  
 
Adams J,  Mounib E, Pai  A, Stuart  N, Thomas R, Tomaszewicz P.  Healthcare 
2015:  Win-win or lose-lose?.  Somers, NY: IBM Global  Business Serv ices;  2006.  
 
Ahire SL, Dreyfus P. The impact of  design management and process 
management on qual i ty:  an empir ical  examinat ion.  Journal  of  Operat ions 
Management .  2000; 18:549–575. 
 
Ahire SL, Golhar DY, Wal ler MA. Development and val idat ion of  TQM 
implementat ion constructs.  Decis ion Sciences .  1996;  27:23–56.  
 
Ahire SL, O’Shaughnessy KC. The role of  top management commitment in qual i ty 
management: an empir ical  analys is of the auto parts industry. Internat ional  
Journal  of  Qual i ty Science .  1998; 3:5–37. 
 
Ahlborn H, Henderson S, Davies N. No immediate pain rel ief  for  the 
pharmaceut ical  industry.  Current Opinion in Drug Discovery & Development .  
2005;  8:384-391.  
 
Ahmad N, Awan MU, Raouf A, Sparks L. Development of  a serv ice qual i ty scale 
for pharmaceut ical  supply chains,  Internat ional  Journal  of  Pharmaceut ical  and 
Heal thcare Market ing .  2009;  3:26-45.  
 
Ahmed R, Baseman H, Ferrei ra J,  Genova T, Harc lerode W, Hartman J,  Kim S, 
Londeree N, Long M, Miele W, Ramji t  T,  Raschiatore M, Tomonto C. PDA Survey 
of  Qual i ty Risk Management  Pract ices in the Pharmaceut ical ,  Devices,  & 
Biotechnology Industr ies.  PDA Journal of Pharmaceut ical Sciences and 
Technology .  2008; 62:1-21 
 
Ananthaswamy A. March of  the motes. New Scient ist .  2003;  179:26. 
 
Anderson JC, Rungtusanatham M, Schroeder RG, Devaraj  S. A path analyt ic 
model of a theory of qual i ty management under ly ing the Deming Management 
Method:  prel iminary empir ical  f indings.  Decis ion Sciences .  1995; 26:637-658. 
 
Anderson S. Making Medic ine: A br ief  h istory of  Pharmacy and Pharmaceut icals .  
Wi l tshire,  England: Pharmaceut ical  Press; 2005. 
 
	129 
Antony J,  Leung K, Knowless G. Cr i t ical success factors of TQM implementat ion 
in Hong Kong indust r ies.  Internat ional  Journal  of  Qual i ty and Reliabi l i ty  
Management .  2002; 19:551–566. 
 
Arora A, Branstetter L, Chatter jee C, Saggi  K. Strong medic ine? Patent reform 
and the transformat ion of  the Indian pharmaceut ical  indust ry .  Pi t tsburgh, PA: 
Carnegie Mel lon Univers ity;  2009.  
 
Aspinal l  MG, Hamermesh RG. Real iz ing the promise of  personal ized medic ine .  
Tampa, FL: Harvard Business Review; October 2007. 
 
Badri  M, Davis D.  A study of measur ing the cr i t ical  factors of  qual i ty 
management. Internat ional  Journal  of  Qual i ty & Rel iabi l i ty  Management .  1995;  
12:36–53. 
 
Basi le EM, Furman Forrest  P,  Lee M.  FDA’s Out look under the New 
Administ rat ion .  Washington, DC: King & Spalding Cl ient  Alert ;  2009.  
 
Bass S, Klasmeier C, Lugard MJF, Si lv is LR, Simon C-M. US  Food and Drug 
Administrat ion and European Medic ines Agency Enter into New Good Cl inical 
Pract ices Col laborat ion .  Chicago, IL:  Sidley Aust in LLP; 2009. 
 
B lack SA, Porter LJ. Ident i f icat ion of the cr i t ical  factors of  TQM. Decis ion 
Sciences .  1996; 27:1-22.  
 
Borchers AT, Hagie F, Keen CL, Gershwin ME. The History and contemporary 
chal lenges of  the US Food and Drug Administrat ion.   Clinical Therapeut ics .  2007;  
29:1-16. 
 
Boswel l  C. The Future of  Pharmaceut icals is in Targeted Treatment.  Chemical  
Market Reporter .  2002; 262(22):12-12. 
 
Bou-Llusar JC, Escr ig-Tena AB, Roca-Puig V, Belt rán-Mart ín I .  An empir ical  
assessment of the EFQM Excel lence Model:  Evaluat ion as a TQM f ramework 
relat ive to the MBNQA Model.  Journal  of  Operat ions Management .  2009; 27:1–22. 
 
Bouza M, Ul l i -Beer S, Dietr ich P, Wokaun A. Comparison of  Possible 
Transformat ion Processes in the Automobi le Industry Proceedings of  the 9th 
Swiss Transportat ion Research Conference .  2009. 
 
Bri t ish Telecommunicat ions. Pharma Futurology: Joined-up Heal thcare-2016 and 
beyond .  London,  England:  Touch Br ief ings;  2007.  
 
Buyya R, Shin Yeo C, Venugopal S, Broberg J,  Brandic I .  Cloud comput ing and 
emerging IT plat forms: Vis ion,  hype, and real i ty for del iver ing comput ing as the 
5th ut i l i ty.  Future Generat ion Computer Systems .  2009; 25:599-616.  
 
	130 
Calfee J E. Playing catch-up - The FDA, science, and drug regulat ion. American 
Enterpr ise Inst i tute for  Publ ic Pol icy Research .  2006; 5:1-9.  
ht tp: / /www.aei .org/out look/24130. Accessed July 2010. 
 
Carmines EG. and Zel ler  RA. Rel iabi l i ty  and val id i ty Assessment .  London, 
England: SAGE Publ icat ions; 1979. 
 
Carney S. Interv iew: Vincent Lee on the Pharma industry,  the FDA and publ ic  
educat ion wi th respect to drugs and their  development.  Drug Discovery Today .  
2005;  10:1411-1414.  
 
Chan Y, Walmsley R.  Learning and Understanding the Kruskal-Wal l is  One-Way 
Analys is-of-  Var iance-by-Ranks Test  for  Dif ferences Among Three or More 
Independent Groups. Physical Therapy .  1997;  77:1755-1761.  
 
Charoo NA and Al i  AA. Qual i ty r isk management in pharmaceut ical  development. 
Drug Development and Indust r ia l Pharmacy .  2012; 00:1-14.  
 
Chemical and Engineer ing News (Anon).  Emergence of  Science and Industry:  
1870-1930. Chemical  and Engineer ing News .  2005; 83:3 
ht tp: / /pubs.acs.org/cen/coverstory/83/8325/8325emergence.html .  Accessed 
November 2012.   
 
Chesbrough H and Crowther AK. Beyond high tech: ear ly adopters of  open 
innovat ion in other industr ies. R&D Management .  2006; 36:229-236. 
 
Chesbrough HW. The Era of  Open Innovat ion.  MIT Sloan Management review .  
2003;  44:35-41. 
 
Choi  TY, Eboch K. The TQM paradox: relat ions among TQM pract ices,  plant 
performance, and customer sat isfact ion. Journal of Operat ions Management .  
1998;  17:59-75. 
 
Claycamp HG. Perspect ive on qual i ty r isk management of pharmaceut ical qual i ty.  
Drug Informat ion Journal .  2007; 41:353-367. 
 
Clemensen J,  Larsen SB, Bardram JE. Developing Pervasive e-heal th for moving 
experts f rom hospital  to home. IADIS Internat ional  Journal  on WWW/Internet .  
2004;  2:57-68.   
 
Cockburn IM. Is the Pharmaceut ical Industry in a Product iv i ty Cr is is? Innovat ion 
Pol icy and the Economy. 2006;  7:1-32.  
 
Cohen J,  Gangi  Q, Lineen J,  Manard A. Strategic al ternat ives in the 
pharmaceut ical  industry.  Manager ia l  chal lenges in the Pharmaceut ical ,  Biotech, 
and Medical  Device Industr ies .  Evanston, IL:  Kel logg School of  Management;  
2004.  
	131 
 
Cooke P.  Biotechnology Clusters in the UK: Lessons f rom Local izat ion in the 
Commerc ial izat ion of Science. Smal l  business economics .  2001; 17:43-59. 
 
Crommel in D, Stolk P, Besancon L,  Shah V, Midha K, Leufkens H. 
Pharmaceut ical sciences in 2020. Nature Reviews Drug Discovery .  2010;  9:99-
100. 
 
Cua KO, McKone KE, Schroeder RG. Relat ionships between implementat ion of 
TQM, JIT,  and TPM and manufactur ing performance. Journal  of  Operat ions 
Management .  2001; 19:675-694.  
 
Curkovic S, Melnyk S, Calantone R, Handf ield R. Val idat ing the Malcolm Baldr ige 
Nat ional  Qual i ty Award Framework through Structural  equat ions model l ing.  
Internat ional  Journal  of  Product ion Research .  2000;  38:765–791. 
 
Dahiya S, Khar RK, Chhikara A. Opportuni t ies,  chal lenges and benef i ts of  using 
HACCP as a qual i ty r isk management tool  in the pharmaceut ical industry.  The 
Qual i ty Assurance Journal .  2009; 12:95-104.   
 
Das A, Handf ie ld RB, Calantone RJ, Ghosh S. A cont ingent v iew of  qual i ty 
management -  the impact  of internat ional  compet i t ion on qual i ty.  Decis ion 
Sciences .  2000;  31:649-690.  
 
Deloi t te Consult ing. Strategic f lex ibi l i ty  in l i fe sc iences – f rom discovering the 
unknown to exploi t ing the uncertain .  New York, NY: Deloi t te Research;  2002. 
 
Deloi t te whi te paper.  The future of  the l i fe sc iences industr ies:  Transformat ion 
amid r is ing r isk .  Deloi t te Touche Tohmatsu; 2009.  
 
Dimeny G and Popescu S. Qual i ty r isk Management in the Pharmaceut ical  
Industry .  Internat ional  Conference on Business Excel lence. Brasov,  Romania; 
2006;  Oct:129-134. 
 
Douglas TJ,  Judge Jr.  WQ. Total qual i ty management implementat ion and 
compet i t ive advantage: the role of  st ructural  control  and explorat ion.  Academy of 
Management Journal .  2001; 44:158-169.  
 
Dow D, Samson D, Ford S. Exploding the myth:  do al l  qual i ty management 
pract ices cont r ibute to super ior qual i ty performance? Product ion and Operat ions 
Management .  1999; 8:1-27. 
 
E l l iot  S.  Technology Enabled Innovat ion,  Industry Transformat ion and the 
Emergence of  Ambient Organizat ions.  Industry and Innovation .  2006; 13:209-225.  
 
EMA. European Medic ines Agency and Massachusetts Inst i tute of  Technology 
launch jo int  project  on regulatory science .  EMA Research;  2010. 
ht tp: / /www.ema.europa.eu/ema/ index. jsp?cur l=pages/news_and_events/news/201
	132 
0/11/news_detai l_001143. jsp&murl=menus/news_and_events/news_and_events. j
sp&mid=WC0b01ac058004d5c1 .Accessed June 8,  2011. 
 
EMA. Road Map to 2010: Prepar ing the Ground for the Future .  London, England: 
2005.  ht tp: / /www.ema.europa.eu/ema/ index. jsp?cur l=pages/regulat ion/  
general /general_content_000164. jsp&mid=WC0b01ac05800293fc.  Accessed 
October 30,  2011. 
 
EMA. Road Map to 2015 :  The Agency’s Contr ibut ion to Science, Medic ines, 
Heal th.  London, England: (draf t  for publ ic consul tat ion),  2010. 
ht tp: / /www.ema.europa.eu/ema/ index. jsp?cur l=pages/about_us/general /general_c
ontent_000292. jsp&mid=WC0b01ac05800293a4&murl=menus/about_us/about_us.
jsp&jsenabled=true .Accessed June 8,  2011. 
 
EMEA/SHMP Think-Tank Group.  Final  Report  – Innovat ive Drug Development 
Approaches .   Medicines Control  Agency;  2007.  
ht tp: / /www.ema.europa.eu/docs/en_GB/document_l ibrary 
/Other/2009/10/WC500004913.pdf.  Accessed October 30, 2011.  
 
EMRC. Nanomedic ine: An ESF - European Medical  Research Counci ls (EMRC) 
Forward Look report .  Strasbourg,  France: European Science Foundat ion;  2005. 
 
Engin M, Demirel  A,  Engin EZ, Fedakar M. Recent  developments and trends in 
biomedical sensors.  Measurement .  2005; 37:173-188. 
 
Enkel E,  Gassmann O, Chesbrough H. Open R&D innovat ion:  explor ing the 
phenomenon. R&D Management .  2009; 39:311-316.  
 
Epstein J,  Sei tz R, Dhingra N, Ganz PR, Gharehbaghian A, Spindel  R, Teo D, 
Reddy R. Role of  regulatory agencies.  Biologicals .  2009;  37:94-102.  
 
EURLex – Access to European law. ht tp: / /eur lex.europa.eu/RECH_naturel .do.  
Accessed 26, Nov 2012.  
 
European Science Foundat ion.  Nanoscience and the Long-Term Future of 
Informat ion Technology (NSIT) .  Strasbourg,  France: European Science 
Foundat ion;  2006. 
 
FDA Def in i t ion. Advancing Regulatory Science. 
(ht tp: / /www.fda.gov/sc ienceresearch/specialtopics/regulatoryscience/default .htm, 
Accessed July 2010. 
 
FDA History.  
ht tp: / /www. fda.gov/AboutFDA/WhatWeDo/History/Mi lestones/ucm128305.htm. 
Accessed 26, Nov 2012 
 
	133 
FDA. Crit ical  Path Opportuni t ies In i t iat ive ;  2007.  
ht tp:/ /www. fda.gov/ScienceResearch/SpecialTopics/Cri t icalPathIni t iat ive/Cri t ical
PathOpportuni t iesReports/ucm077248.htm. Accessed October 30, 2011. 
 
FDA. Crit ical  Path Opportuni t ies Report .  Department of Health and Human 
Serv ices. Rockvi l le,  MD: 2006. 
 
FDA.  FDA Strategic Act ion Plan:  Chart ing Our Course for  the Future .  Department 
of  Heal th and Human Serv ices. Rockvi l le,  MD: 2007.  
ht tp: / /www. fda.gov/downloads/AboutFDA/ReportsManualsForms/Reports/Strategi
cAct ionPlan/UCM061415.pdf .    Accessed on October 30,  2011. 
 
FDA. FDA Strategic Act ion Plan:  Chart ing Our Course for  the Future .  US 
Department of  Heal th and Human Serv ices; 2007.  
 
FDA. Innovat ion or Stagnat ion:  Chal lenge and Opportuni ty on the Cr i t ical  Path to 
New Medical  Products;  2004. ht tp: / /www.fda.gov/ScienceResearch/ 
SpecialTopics/Cr i t icalPathIni t iat ive/Cr i t icalPathOpportuni t iesReports/ucm077262.
htm. Accessed October 30, 2011.  
 
FDA. Innovat ion/Stagnat ion: Chal lenge and Opportuni ty  on the Cri t ical  Path to 
New Medical  Products .  US Department of  Heal th and Human Serv ices;  2004. 
 
FDA.  Regulatory Informat ion:  Legis lat ion.  Department of  Heal th and Human 
Serv ices. Rockvi l le,  MD: 2007.  
ht tp: / /www. fda.gov/RegulatoryInformat ion/Legis lat ion/defaul t .htm. Accessed on 
October 30, 201. 
 
FDA. Strategic Pr ior i t ies 2011-2015 -  Responding to the Publ ic Heal th 
Chal lenges of the 21st Century .  2010.   
ht tp:/ /www. fda.gov/AboutFDA/ReportsManualsForms/Reports/ucm227527.htm. 
Accessed June 8,  2011. 
 
Floerkemeier C, Siegemund F. Improving the Effect iveness of  Medical  Treatment 
wi th Pervasive Comput ing Technologies .  Seat t le,  WA: Second Internat ional  
Workshop on Ubiqui tous Comput ing for Pervasive Heal thcare Appl icat ions; 2003.  
 
Flynn BB, Schroeder RG, Sakakibara S. A f ramework for qual i ty management 
research and an associated measurement inst rument.  Journal  of  Operat ions 
Management .  1994;  11:339-366.  
 
Forza C, Fl ippini  R. TQM impact on qual i ty conformance and customer 
sat isfact ion: a causal model .  Internat ional  Journal  of  Product ion Economics .  
1998;  55:1-20. 
 
Foster BC. Foresight Scanning: Future Direct ions of  Cl in ical  and Pharmaceut ical  
Research. Journal of Pharmaceut ical  Sciences .  2008;  11:108-122. 
	134 
Fraser H. Pharma 2010: A bi t ter  sweet  pi l l .  Specra Onl ine .  2006; Issue 2. 
ht tp: / /newsweaver.co.uk/spectrajournal /e_000118357000063547.cfm?x=b11,0,w. 
Accessed July 2010. 
 
Funning S, Grahnen A, Er iksson K, Kett is-Linbald A. Qual i ty Assurance within 
the Scope of  Good Cl in ical  Pract ice (GCP) – What is the Cost of  GCP-related 
Act iv i t ies? A Survey within the Swedish Associat ion of the Pharmaceut ical  
Industry (LIF) ’s Members.  Qual i ty Assurance Journal .  2009;  12:3-7.  
 
Garc ia T, Cook G, Nosal R.  PQLI Key Topics – Cr i t ical i ty,  Design Space, and 
Control  Strategy. Journal of  Pharmaceut ical  Innovat ion .  2008; 3:60-68. 
 
Gersch M, C Goeke C. Industry t ransformat ion–Conceptual considerat ions f rom 
an evolut ionary perspect ive. Journal  of  Business Market  Management .  2007; 
192:151-182. 
 
Ginsberg A, Venkatraman N. Cont ingency perspect ive of  organizat ional  strategy:  
a cr i t ical  rev iew of the empir ical  research. Academy of Management Review .  
1985;  10:421-34. 
 
Goeke C, Gersch M, Frei l ing J.  The co-evolut ion of  a l l iances and industr ies:  How 
industry t ransformat ion inf luences al l iance format ion and v ice versa.  Research in 
Competence-Based Management .  2010; 5:79-109. 
 
Ginsburg GS, McCarthy JJ.  Personal ized medic ine: revolut ioniz ing drug 
discovery and pat ient  care.  TRENDS in Biotechnology .  2001; 19:491-496.  
 
Grabowski H, Kyle M. Mergers and al l iances in pharmaceut icals:  effects on 
innovat ion and R&D product iv i ty .  The economics of corporate governance and 
mergers.  Northampton, MA: Edward Elgar Publ ishing; 2008.  
 
Grandzol  J,  Gershon M. A survey instrument for  standardiz ing TQM model l ing 
research. Internat ional  Journal  of  Qual i ty Science .  1998; 3:80-105. 
 
Green-Templeton lectures,  2009. ht tp: / /www.gtc.ox.ac.uk/academic/ lectures-
seminars/gt lectures/green-templeton-lectures-2009/t i l l i - tansey/the-or igin-and-
evolut ion-of-the-pharmaceut ical- industry.html.  Accessed 26, Nov 2012. 
 
Guidi  GC, Lippi  G. Wil l  “personal ized medic ine” need personal ized laboratory 
approach? Clinica Chimica Acta .  2009; 400:25-29. 
 
Guthr ie D. A history of  Medic ine .  London, England: Thomas nelson and Sons Ltd,  
1945.  
 
Hajela R and Al i  H. Risk assessment & management  in pharmaceut ical 
industr ies:  Vi ta l  requirement to ensure product qual i ty.  Journal  of  Pharmacy 
Research .  2011; 4:1909.  
	135 
Hal lam CRA. Lean enterpr ise self -assessment as a leading indicator for  
accelerat ing t ransformat ion in the aerospace industry .  Massachuset ts Inst i tute of 
Technology.  2003. 
 
Hamburg M. Effect ive Enforcement and Benef i ts to Publ ic Health.  Food and Drug 
Administrat ion.  2009. ht tp: / /www.fda.gov/NewsEvents/Speeches/ucm175983.htm. 
Accessed June 2010. 
 
Hanley,  S.  The col laborat ive power of  IT leads industry t ransformat ion.  Leading 
Edge.  2003; 22:62-64. 
 
Hartmann M and Hartmann-Varei l les F.  Recent Developments in European 
Pharmaceut ical Law 2004: A Legal  Point  of  View. Drug Informat ion Journal .  
2005;  39:193-207.  
 
Hasegawa GR. Pharmacy in American Civ i l  War.  American Journal  of Health-
System Pharmacy.  2000; 57:475-489. 
 
Heal th Canada. Progressive Licensing Model .  Ot tawa, Ontar io:  Heal th Canada; 
2007.  
 
Hebert  PC. Progressive l icensing needs progressive open debate. Canadian 
Medical  Associat ion Journal .  2007; 176:1801 
 
Heemstra HE, de Vrueh RLA, van Weely S, Bul ler HA, Leufkens HGM. Orphan 
drug development across Europe:  bott lenecks and opportuni t ies.  Drug Discovery 
Today .  2008; 13:670-676.  
 
Ho DCK, Duffy VG, Shih HM. Total  qual i ty management: an empir ical  test  for  
mediat ion ef fect .  Internat ional  Journal  of  Product ion Research .  2001;  39:529-548.  
 
Hohman M, Gregory K, Chibale K, Smith PJ, Ekins S, Bunin B .  Novel web-based 
tools combining chemistry informat ics,  b iology and social  networks for drug 
discovery.  Drug Discovery Today .  2009:14:261-270. 
 
Howard M, Vidgen R, Powel l  P. Planning for  IS related industry t ransformat ion:  
The case of the 3DayCar.  The Ninth European Conference on Informat ion 
Systems. Bled,  Slovenia:  2001. 
 
Humer FB. The future of  heal thcare and the pharmaceut ical  industry:  a CEO view.  
Journal  of  Men’s Heal th and Gender .  2004; 1:107-109.  
 
Hunter J.  and Stephens S. Is  open innovat ion the way forward for big pharma? 
Nature Reviews  Drug Discovery .  2010; 9:87-88. 
 
ICH. The Value and Benef i ts  of  ICH to Drug Regulatory Author i t ies – advancing 
harmonizat ion for better heal th .  Internat ional Conference for Harmonisat ion, 
	136 
2010;  ht tp: / /www.ich.org/ ichnews/publ icat ions/browse/art ic le/ the-value-and-
benef i ts-of- ich-to-drug-regulatory-author i t ies.html .  Accessed June 8, 2011. 
 
ICH E6. Good Cl inical  Pract ice .  Internat ional  Conference for Harmonisat ion, 
1996;  ht tp: / /www.ich.org/products/guidel ines/eff icacy/art ic le/ef f icacy-
guidel ines.html .  Accessed June 8,  2011. 
 
ICH Q8.  Pharmaceut ical  Development .  Internat ional  Conference for 
Harmonisat ion,  2005; 
ht tp: / /www. ich.org/products/guidel ines/qual i ty/art ic le/qual i ty-guidel ines.html.  
Accessed June 8,  2011. 
 
ICH Q9. Pharmaceut ical  Qual i ty Risk Management .  Internat ional  Conference for  
Harmonisat ion,  2005; 
ht tp: / /www. ich.org/products/guidel ines/qual i ty /art ic le/qual i ty-guidel ines.html.  
Accessed June 8,  2011. 
 
ICH Q10. Pharmaceut ical  Qual i ty Systems .  Internat ional Conference for 
Harmonisat ion,  2008; 
ht tp: / /www. ich.org/products/guidel ines/qual i ty /art ic le/qual i ty-guidel ines.html.  
Accessed June 8,  2011. 
 
Inst i tute for  Al ternat ive Futures and the Draper Laboratory.  Envis ion a Small  
Future .  Alexandr ia,  VA: Inst i tute for Al ternat ive Futures; 2005.  
 
Inst i tute for  Crises Management.  News coverage of  business cr is is dur ing 2008 .  
Annual  ICM Cris is  Report .  Louisv i l le,  Kentucky:  2009. 
 
Jain KK. The role of  nanobiotechnology in drug discovery.  Drug Discovery Today .  
2005;  10:1435-1442.  
 
Joseph N, Rajendran C, Kamalanabhan TJ. An instrument for measur ing total 
qual i ty management  implementat ion in manufactur ing- based business uni ts in 
India.  Internat ional  Journal  of  Product ion Research .  1999;  37:2201-2215.  
 
Karvonen M, Kytola O, Kassi T.  New perspect ives on industry t ransformat ion 
through expansion of the technology base and creat ive cooperat ion.  IEEE 
Technology Management Counci l  Europe .  2008; June:1-5  
 
Kaye, M, Anderson R. Continuous improvement:  the ten essent ial  cr i ter ia.  
Internat ional  Journal  of  Qual i ty & Rel iabi l i ty  Management .  1999; 16:485-506. 
 
Kaynak H. The relat ionship between total  qual i ty management pract ices and their  
ef fects on f i rm performance. Journal  of  Operat ions Management .  2003; 21:405-
435. 
 
	137 
Kewal KJ. The role of  nanobiotechnology in drug discovery.  Drug Discovery 
Today .  2005; 10:1435-1442 
 
K ing JL and Lyyt inen K. Automot ive informat ics:  Informat ion technology and 
enterpr ise t ransformat ion in the automobi le industry .  Transforming Enterpr ise.  
MIT Press, Cambridge, MA: 2004 
 
Kontoghiorghes C, Gudgel  R.  Invest igat ing the associat ion between product iv i ty 
and qual i ty performance in two manufacturing set t ings.  The Qual i ty Management 
Journal .  2004; 11:8–20. 
 
Lai  K. Market or ientat ion in qual i ty-or iented organizat ions and i ts impact on their  
performance. Internat ional  Journal  of  Product ion Economics .  2003; 84:17-34. 
 
Lau RSM, Zhao X, Xiao M. Assessing qual i ty management in China wi th MBNQA 
cr i ter ia.  Internat ional  Journal  of  Qual i ty & Rel iabi l i ty  Management .  2004;  21:699-
713. 
 
Leal  J,  Wordsworth S, Legood R, Blair  E.  El ic i t ing Expert  Opinion for Economic 
Models:  An Appl ied Example.  Value in Heal th .  2007: 10:195-203. 
 
Lee MS. Cri t ical  success factors inf luencing the t ransformat ion of the agricultural  
b iotechnology indust ry in Taiwan. Agricultural  Economics Journal  Czech .  2012:  
58:249–263. 
 
Lexchin J.  Progressive Licensing of  Drugs -  Music or Noise.  Healthcare Pol icy .  
2008;  3:11-15.  
 
L i  Bassi L, Bertele V, Garat t ini  S. European regulatory pol ic ies on medic ines and 
publ ic  heal th needs.  European Journal  of  Publ ic Health .  2003; 13:246–251. 
 
Love B. Virtual  pharmaceut ical  R&D: a strategy for the mi l lennium? 
Pharmaceut ical Science and Technology Today .  1998; 1:89-90. 
 
Lundberg JM, Rei l ly C.  The road ahead for large Pharma: long-term science and 
innovat ion.  Drug Discovery Today .  2009; 14:439-441. 
 
Mack N,  Woodsong C, MacQueen KM, Guest G, Namey E. Qual i tat ive Research 
Methods:  A Data Collector ’s Fie ld Guide .  Fami ly Health Internat ional .  Research 
Tr iangle Park,  NC; 2005.  
 
Marrer E, Dieter le F.  Promises of  Biomarkers in Drug Development – A Real i ty 
Check.  Chemical  Biology & Drug Design .  2007;  69:381-394 
 
Mart inez-Lorente AR, Dewhurst  FW, Gal lego-Rodriguez A. Relat ing TQM, 
market ing and business performance:  an exploratory study. Internat ional  Journal  
of  Product ion Research .  2000; 38:3227-3246. 
 
	138 
Merr i l l  RA. Moderniz ing the FDA: An Incremental Revolut ion.  Health Af fai rs .  
1999;  18:96-111. 
 
Meyer AD, Brooks GR, Goes JB. Environmental Jol ts  and Industry Revolut ions: 
Organizat ional  Responses to Discont inuous Change.  Strategic Management 
Journal .  1990; 11(summer special  Issue: corporate entrepreneurship):93-110.  
 
Michelson S, Sehgal A, Fr iedr ich C. In s i l ico predict ion of c l in ical  ef f icacy. 
Current Opinion in Biotechnology .  2006; 17:666-670.  
 
Microsoft  Corporat ion.  2003 Microsoft  Excel  Help.  ht tp: / /of f ice.microsoft .com/en-
us/excel-help.  Accessed June 2012. 
 
Mi l ler R, Ewy W, Corr igan BW, Ouel let  D, Hermann D, Kowalski  KG, Lockwood P, 
Koup JR, Donevan S, El-Kattan A, Li  CS, Werth JL,  Fel tner DE, Lalonde RL. How 
model ing and s imulat ion have enhanced decis ion making in new drug 
development.  Journal  of  Pharmacokinet ics and Pharmacodynamics .  2005; 
32:185-197. 
 
Mi lne C-P. US and European regulatory ini t iat ives to improve R&D performance. 
Expert  Opinion on Drug Discovery .  2006;  1:11-14.  
 
Miyagawa M and Yoshida K. An empir ical  study of  TQM pract ices in Japanese-
owned manufacturers in China. Internat ional  Journal  of  Qual i ty & Rel iabi l i ty  
Management .  2005; 22:536-553.  
 
Mortehan O. The Role of  Firms' Col laborat ive Agreements in the Information 
Technology Industry Transformat ion. Technology Analysis & Strategic 
Management .  2004; 16: 53-71. 
 
Mulder J,  Fezza T, Marcel lo R. Reinvent ing Innovat ion in Large Pharma .  Deloi t te 
Development LLC; 2008.  
 
NIH Research 2009.  Translat ional  and Cl inical  Science .  Nat ional Inst i tute of 
Heal th, 2009;  https:/ /commonfund.nih.gov/ctsa/fundedresearch.aspx. Accessed 
June 8, 2011.  
 
O’Connel l  D, Robl in D. Translat ional  research in the pharmaceut ical  industry:  
f rom bench to bedside. Drug Discovery Today .  2006; 11:833-838.   
 
OECD. Principals on Good Laboratory Pract ice .  Organisat ion for  Economic Co-
operat ion and Development,  1997; 
ht tp: / /www.oecd.org/document/63/0,2340,en_2649_34381_2346175_1_1_1_1,00.
html.  Accessed June 8,  2011. 
 
Orwat C, Graefe A,  Faulwasser T. Towards pervasive computing in heal th care – 
A l i terature review. BMC Medical  Informat ics and Decis ion Making .  2008; 8:1-18. 
	139 
Osmani V, Balasubramaniam S, Botv ich D. Human act iv i ty recogni t ion in 
pervasive heal th-care:  Support ing eff ic ient  remote col laborat ion.  Journal  of  
Network and Computer Appl icat ions .  2008; 31:628-655 
 
Pandian PS, Mohanavelu K, Safeer KP, Kotresh TM, Shakunthala DT, Gopal  P,  
Padaki VC. Smart  Vest:  Wearable mult i -parameter remote physiological  
moni tor ing system. Medical  Engineer ing & Physics .  2008; 30:466-477.  
 
Peck JC, Crooks G, McQuade A. Pharma 2029:  Pharma’s Future Today .  Inst i tute 
for Al ternat ive Futures; 2007. 
 
Phan J,  Moff i t t  R, Stokes T,  Liu J,  Young AN, Nie S,  Wang MD. Convergence of 
biomarkers, b ioinformat ics and nanotechnology for indiv idual ized cancer 
t reatment.  Trends in Biotechnology .  2009; 27:350-358. 
 
Pharmaceut ical Manufactures of America.  PhRMA Statement on Heal th Care 
Reform Coal i t ion ;  Washington, DC: 2009. 
ht tp:/ /www.phrma.org/media/releases/phrma-statement-healthcare-reform-
coal i t ion. Accessed October 30, 2011.  
 
Pharmaceut ical Science and Cl inical  Pharmacology Advisory Commit tee Meet ing.  
Implementat ion of ICH Q8, Q9, and Q10 Qual i ty  Guidel ines- Topic Int roduct ion 
and FDA Perspect ive .  Rockvi l le,  MD: Food and Drug Administrat ion;  2009. 
 
PIC/S. Guide to manufactur ing pract ice for medic inal  products - PE009-8 (Part  I I ) .  
Pharmaceut ical Inspect ion Cooperat ion Scheme, 2009; 
ht tp: / /www.picscheme.org/publ icat ion.php?id=4. Accessed June 8, 2011. 
 
P latt  R, Wilson M, Chan KA, Benner JS, Marchibroda J,  McClel lan M. The New 
Sent inel  Network - Improving the Evidence of  Medical-Product Safety.  New 
England Journal  of  Medic ine .  2009; 361:645-647.  
 
Powel l  TC. Total  qual i ty management as compet i t ive advantage: a review and 
empir ical  study. Strategic Management Journal .  1995; 16:15–37. 
 
Prajogo DI,  Sohal  AS. The relat ionship between TQM pract ices,  qual i ty 
performance, and innovat ion performance: An empir ical  examinat ion.  
Internat ional  Journal  of  Qual i ty & Rel iabi l i ty  Management .  2003: 20:901–918. 
 
Prendergast J,  Yeomans M, Fraser HE. Pharma 2010 The value-creat ing supply 
chain .  Somers,  NY: IBM Global Serv ices; 2004.  
PricewaterhouseCoopers.  Pharma 2020:  Virtual  R&D Which path wi l l  you take? 
2008.  
 
Psaty BM, Burke SP. Protect ing the Health of  the Publ ic -  Inst i tute of  Medicine 
Recommendat ions on Drug Safety. New England Journal  of  Medic ine .  2006;  
355:1753-1755. 
	140 
Pussep A, M Schief ,  Schmidt B, Friedr ichs F. Topics in Software Industry 
Transformat ion Research:  A Topic Analys is of  Major IS Conferences.  Lecture 
Notes in Business Informat ion Processing .  2012; 114:128-140.   
 
Ramaprasad A and Johnson C. Transformat ion of  the heal th care industry by 
eMedic ine:  f rom low-tech low-touch to high-tech high-touch.  Research 
Chal lenges, 2000. Proceedings. Academia/ Industry Working Conference on .  
2000:177-182  
 
Rauwerda H, Roos M, Hertzberger BO, Brei t  TM. The promise of  a v i r tual  lab in 
drug discovery.  Drug Discovery Today .  2006; 11:228-236. 
 
Robson C. Real World Research .  2nd ed.  Oxford, UK: Blackwel l  Publ ishing;  2002.  
 
Rowley J,  Sneyd K. Total qual i ty research in the pharmaceut ical industry. 
Managing Serv ice Qual i ty .  1996; 6:31-35.  
 
Royal  Pharmaceut ical  Society.  History of  pharmacy. 
ht tp: / /www.rpharms.com/learning-resources/ informat ion-sheets.asp and 
ht tp: / /www.rpharms.com/about-pharmacy/history-of-pharmacy.asp. Accessed 26,  
Nov 2012. 
 
Rungtusanatham M, Forza C, Fi l ippini  R,  Anderson JC. A repl icat ion study of a 
theory of qual i ty management under ly ing the Deming method: ins ights f rom an 
I tal ian context .  Journal  of  Operat ions Management .  1998; 17:77-95. 
 
Sager B. Scenar ios on the future of  biotechnology.  Technological  Forecast ing & 
Social Change .  2001; 68:109-129. 
 
Saha D, Mukher jee A. Pervasive Computing: A Paradigm for the 21st Century.  
IEEE Computer Society .  2003; March:25-31. 
 
Sahoo SK, Parveen S, Panda JJ.  The present and future of  nanotechnology in 
human heal th care.  Nanomedic ine:  Nanotechnology, Biology, and Medic ine .  2007;  
3:20-31. 
 
Samson D, Terz iovski  M. The relat ionship between total  qual i ty management 
pract ices and operat ional  performance. Journal  of  Operat ions Management.  1999;  
17:393-409. 
 
Sanchez-Rodriguez C, Mart inez-Lorente AR. Qual i ty management  pract ices in 
the purchasing funct ion:  An empir ical study. Internat ional  Journal  of  Operat ions 
& Product ion Management .  2004; 24:666–687. 
 
Saraph JV, Benson GP, Schroeder RG. An instrument for  measuring the cr i t ical  
factors of  qual i ty management .  Decis ion Sciences .  1989;  20:810–829. 
 
	141 
Satyanarayanan M. Pervasive Comput ing: Vis ion and Chal lenges. IEEE Personal  
Communicat ions .  2001; 8:10-17. 
 
Scheff ler M, Hirt  E.  Wearable devices for te lemedic ine appl icat ions.  Journal  of  
Telemedic ine and Telecare .  2005: 11:11-14 
 
Schmid EF, Smith DA. Is pharmaceutical  R&D just a game of  chance or can 
st rategy make a di f ference? Drug Discovery Today .  2004; 9:18-26. 
 
Schwartzman D .  Innovat ion in the Pharmaceut ical  Industry ,  Johns Hopkins 
Universi ty Press.  Balt imore,  Maryland:  1976. 
 
Shah V, Besancon LJR, Stolk P, Tucker G, Crommel in DJA. The pharmaceut ical  
sc iences in 2020 - Report  of a conference organized by the Board of 
Pharmaceut ical Sciences of  the Internat ional  Pharmaceut ical  Federat ion (FIP).  
European Journal  of  Pharmaceut ical  Sciences .  2009; 38:419-425. 
 
Shuchman M. Commercial iz ing c l in ical  t r ia ls-r isks and benef i ts of  the CRO boom. 
New England Journal  of  Medic ine .  2007;  357:1365-1368. 
 
S later EE. Today’s FDA. The new England Journal  of  Medic ine .  2005;  352:293-
297. 
 
S loan K. Secur i ty in a v ir tual ized world.  Network Securi ty .  2009; 2009:15-18.  
 
Sneha S, Varshney U. Enabl ing ubiqui tous pat ient  moni tor ing:  Model,  decis ion 
protocols,  opportuni t ies and chal lenges. Decision Support  Systems .  2009; 
46:606-619. 
 
Sri ram J, Shin M, Kotz D, Rajan A, Sastry M, Yarvis M. Chal lenges in Data 
Qual i ty Assurance in Pervasive Heal th Monitor ing Systems .  Wiesbaden, Germany: 
Future of Trust in Comput ing; 2009.   
 
Struben J.  Technological Coevolut ion:  Cri t ical Dynamics in Industry 
Transformat ion .  DRUID 25th Celebrat ion Conference on Entrepreneurship and 
Innovat ion.  Copenhagen, Denmark.2008 
 
Sudhop T, Brandt S, K iesinger-Al lee KG, Kei tel  S.  Pharmaceut ical  innovat ion:  
Possibi l i t ies and l imits of  personal ized medicine. Bundesgesundheitsbl  – 
Gesundheitsforsch –Gesundheitsschutz .  2008;  51:675-688.  
 
Sun H. A comparison of qual i ty management pract ices in Shanghai  and 
Norwegian manufacturing companies. Internat ional  Journal  of  Qual i ty & 
Rel iabi l i ty  Management .  2000; 17:636-660. 
 
Talaga P. Open innovat ion:  share or die.  Drug Discovery Today .  2009;  14:1003-
1005 
 
	142 
Tamimi N. A second-order factor analys is of  cr i t ical TQM factors.  Internat ional  
Journal  of  Qual i ty Science .1998;  3:71–79.  
 
Tan KC. A structural  equat ion model of  new product design and development .  
Decis ion Sciences .  2001;  32:195-226.  
 
Tancer RS and Mosser i -Marl io C. Evolut ion of  Pharmaceut ical  Regulat ions and 
Their  Consequences in the European Union and the United States.  Thunderbird 
Internat ional  Business Review .  2002; 44:263-281. 
 
Tranf ie ld D, Denyer D, Smart P. Towards a Methodology for Developing 
Evidence-Informed Management Knowledge by Means of Systemat ic Review. 
Bri t ish Journal  of  Management .  2003; 14:207-222.  
 
US Congress. Food, Drug,  and Cosmet ic  Act ,  SEC. 505.  (21 USC §355) New 
Drugs .  2010.  FDCA Amendment.  Accessed 30 October 2011. 
 
US Government Accountabi l i ty Off ice. Improvement Needed in FDA’s Post-
market Decis ion-making and Overs ight Process .  Report  to Congressional  
Requesters; Washington,  DC: 2006.  
 
US Nat ional  Intel l igence Counci l .  Global  Trends 2015: A Dialogue About the 
Future With Nongovernment  Experts .  Washington, DC: US Government Pr int ing 
Off ice;  2000. 
 
US Supreme Court .  United States v.  Bacto-Unidisk ,  394 U.S. 784 (1969).  
ht tp:/ /supreme. just ia.com/cases/federal /us/394/784/case.html.  Accessed 30 
October 2011. 
 
V is iongain market research report .  Live-Licensing & In- l i fe test ing:  R&D 
Processes and Regulat ion for New Drugs, 2008-2020 .  London, England: 
V is iongain;  2008. 
 
Wal l is  GB. Cogni t ive Interv iewing – A “How To” Guide .  1999 Meet ing of  the 
American Stat ist ical  Associat ion. 
ht tp:/ /appl iedresearch.cancer.gov/areas/cognit ive/guides.html.  Accessed 8 June 
2011.  
 
Wagner V, Dul laart  A, Bock A-K, Zweck A. The emerging nanomedicine 
landscape.  Nature Biotechnology .  2006; 24:1211-1217.  
 
Wehl ing M. Translat ional  medic ine:  can i t  real ly fac i l i tate the t ransi t ion of 
research “from bench to bedside”? European Journal  of  Cl in ical  Pharmacology .  
2006;  62:91-95. 
 
Wiek A, Gasser L,  Siegrist  M. Systemic scenar ios of  nanotechnology:  
Sustainable governance of  emerging technologies.  Futures .  2009; 41:284-300.  
	143 
Woodcock J,  Buckman S, Goodsaid F, Walton MK, Zineh I .  Qual i fy ing biomarkers 
for use in drug development:  a US Food and Drug Administ rat ion overv iew. 
Expert  Opinion on Medical Diagnost ics .  2011: 5:369-374.  
 
Woodcock J,  Woosley R. The  FDA Cri t ical  Path Ini t iat ive and I ts Inf luence on 
New Drug Development.  Annual Review of  Medic ine .  2008; 59:1-12. 
 
Woodcock J.  The Role of  Biotechnology and Bioinformat ics in FDA’s Cri t ical  Path 
In i t iat ive .  Food and Drug Administ rat ion;  2007. 
ht tp:/ /www.sl idef inder.net / t / the_role_biotechnology_bioinformatics_fda/3066274.  
Accessed October 30 2011. 
 
Woosley RL, Cossman J.  Drug development and the FDA's Cr i t ical  Path Ini t iat ive. 
Clinical  Pharmacology & Therapeut ics .  2007; 81:129-133.  
 
World Heal th Organizat ion. 12t h  Internat ional  Conference of Drug Regulatory 
Authori t ies Recommendat ions.  ICDRA ;  2006. 
 
Worthen DB. American Pharmaceut ical  patents form a histor ical  perspect ive. 
Internat ional  Journal  of  Pharmaceut ical  Compounding .  2003; 7:36-41 
 
Wright JM. Progressive drug l icensing - An opportuni ty to achieve t ransparency 
and accountabi l i ty.  Canadian Medical Associat ion Journal .  2007; 176:1848-1849. 
 
Xu X, Zhang X, Yan C. Appl icat ions of  HACCP Methodology to Pharmaceut ical  
Qual i ty Risk Management .  Chinese Journal  of  Pharmaceut icals .  2010;  08. 
 
Yu LX. Pharmaceut ical  Qual i ty by Design: Product and Process Development,  
Understanding,  and Control .  Pharmaceut ical  Research .  2008; 25:781-791.  
 
Zerhouni EA. Translat ional  Research: Moving Discovery to Pract ice.  Clinical  
Pharmacology & Therapeut ics .  2007;  81:1621-1623 
 
Zu X, Fredendal l  LD, Douglas TJ.  The evolv ing theory of  qual i ty management:  
The role of Six Sigma, Journal  of  Operat ions Management .  2008; 26:630-650. 
 
 
 
 
 
 
 
 
 
 
	144 
APPENDIX A: Raw Data for Operational Evidence 
A1: Heal thcare Management Focused 
A2: Ful ly Integrated Pharma Network 
A3: Personal ised Medicine 
A4: V irtual R&D  
A5: Translat ional  Research 
A6: Adapt ive Cl inical  Tr ia ls 
A7: Regulatory Harmonisat ion 
A8: Science and Risk Based Approach 
A9: Progressive/Live Licensing  
A10: Regulatory Enforcement 
A11: B iotechnology  
A12: Nanomedic ine 
A13: B ioinformat ics 
A14: Pervasive/Cloud Comput ing 
A15: Ranking of Transformat ion Triggers 
 
 
	 
    
145 
A1: HEALTHCARE MANAGEMENT FOCUSED 
 
YEAR 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
ABT      
Rx Profits 7,614 8,962 11,719 13,990 12,756 14,632 16,708 16,486 20,087 20,603 21,124 21,646 21,202 20,365 
Non-Rx Profits 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Other Profits 7,666 8,318 7,961 8,348 9,720 11,282 12,820 14,279 15,678 16,385 16,960 17,310 17,642 17,939 
AZN                             
Rx Profits 17,343 18,318 20,866 23,303 25,741 28,713 30,677 31,905 33,310 34,212 33,029 33,180 32,860 32,929 
Non-Rx Profits 498 531 560 647 734 846 924 899 952 984 1,019 1,054 1,092 1,132 
Other Profits 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
 BAY                             
Rx Profits 6,631 6,600 5,509 5,657 9,432 12,475 13,048 13,308 13,546 13,768 14,156 14,841 15,906 16,752 
Non-Rx Profits 6,405 5,739 5,699 7,458 6,875 8,120 8,382 8,930 9,053 9,181 9,333 9,486 9,646 9,807 
Other Profits 27,243 27,396 21,170 24,973 23,968 24,450 24,356 21,114 22,118 22,849 23,605 24,405 24,996 25,604 
BMY                             
Rx Profits 12,069 14,126 14,712 14,303 12,948 14,593 16,675 17,902 18,942 19,546 16,633 14,553 14,617 13,575 
Non-Rx Profits 743 799 853 951 913 1,029 1,041 906 807 767 728 697 666 648 
Other Profits 5,294 5,969 3,816 3,351 3,395 3,726 2,882 0 0 0 0 0 0 0 
DAI                              
Rx Profits 3,703 3,834 3,426 6,754 8,663 8,247 8,458 9,672 10,527 10,856 12,075 11,862 12,741 12,752 
Non-Rx Profits 1,040 1,167 1,443 1,361 548 486 504 467 457 453 446 441 437 433 
Other Profits 1,347 1,371 1,413 1,780 722 673 37 35 34 34 33 33 33 32 
LLY                             
Rx Profits 10,055 11,494 12,719 13,386 14,317 17,170 18,806 19,940 21,031 21,354 20,080 19,715 18,138 18,488 
Non-Rx Profits 693 727 799 864 876 996 1,093 1,207 1,258 1,318 1,382 1,448 1,504 1,548 
Other Profits 329 362 340 395 498 468 473 665 693 742 715 783 932 1,018 
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Appendix A1 Continued 
YEAR 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
GILD                              
Rx Profits 424 836 1,242 1,809 2,588 3,733 5,085 6,469 7,710 8,667 9,769 10,702 11,079 11,396 
Non-Rx Profits 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Other Profits 43 31 82 219 438 497 251 542 560 302 286 346 330 343 
GSK                              
Rx Profits 28,077 28,263 26,680 29,116 31,327 29,899 31,800 37,000 35,218 36,887 37,777 39,166 40,772 41,410 
Non-Rx Profits 5,019 4,612 4,503 4,679 4,910 5,544 6,196 7,261 7,569 8,059 8,524 8,965 9,404 9,759 
Other Profits 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
JNJ                              
Rx Profits 17,275 19,517 22,128 22,322 23,267 24,866 24,567 22,520 22,232 22,014 22,268 23,073 23,724 24,455 
Non-Rx Profits 19,023 22,345 25,220 28,192 30,057 36,229 39,180 39,377 41,278 43,370 45,313 46,915 48,422 49,046 
Other Profits 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
MRK                              
Rx Profits 19,637 20,310 21,226 20,093 20,241 22,253 22,049 25,192 40,706 41,109 41,345 40,572 40,489 41,299 
Non-Rx Profits 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Other Profits 32,153 2,176 1,747 1,919 2,395 1,945 1,802 2,236 5,926 6,044 6,165 6,288 6,337 6,388 
NVS                              
Rx Profits 15,345 18,926 21,542 24,956 29,491 32,646 35,647 38,455 41,818 45,324 46,771 45,725 47,221 48,922 
Non-Rx Profits 5,532 5,938 6,705 6,049 4,902 5,426 5,812 5,812 6,213 6,490 6,727 6,929 7,177 7,379 
Other Profits 0 0 154 314 712 875 1,125 836 882 943 1,009 1,080 1,156 1,214 
NOVO                              
Rx Profits 4,644 4,886 5,422 6,306 7,236 7,813 8,508 9,540 10,376 11,144 12,079 12,831 13,623 14,310 
Non-Rx Profits 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Other Profits 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
PFE                             
Rx Profits 28,275 39,425 46,121 44,269 45,083 44,424 44,174 45,448 57,354 55,439 51,651 52,991 52,846 54,136 
Non-Rx Profits 3,581 4,547 1,953 2,206 2,311 2,639 2,825 3,449 8,651 9,216 9,771 10,316 10,883 11,469 
Other Profits 438 764 914 930 977 1,355 1,297 1,112 1,085 1,020 958 913 870 832 
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Appendix A1 Continued 
YEAR 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 
ROG                              
Rx Profits 15,936 18,227 19,991 25,126 30,679 33,894 33,136 35,933 36,605 38,928 40,805 42,677 44,362 45,778 
Non-Rx Profits 1,454 1,631 0 0 0 0 0 0 0 0 0 0 0 0 
Other Profits 9,750 8,910 7,212 7,596 8,060 8,616 8,898 9,265 9,735 10,218 10,696 11,185 11,657 12,040 
SNY                              
Rx Profits 9,842 10,634 19,650 36,088 37,491 37,067 36,377 38,773 38,552 38,427 37,592 36,735 36,503 36,519 
Non-Rx Profits 518 560 2,233 1,899 1,973 1,951 1,968 1,989 2,387 2,627 2,797 2,970 3,112 3,338 
Other Profits 0 0 0 1,672 1,552 1,607 1,737 2,007 2,003 2,075 1,401 857 835 838 
TEVA                              
Rx Profits 2,206 2,754 4,118 4,428 7,428 8,435 10,144 12,821 14,690 14,815 15,429 16,104 15,451 14,574 
Non-Rx Profits 313 522 681 822 980 973 941 1,078 1,125 1,175 1,224 1,264 1,299 1,330 
Other Profits 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
               
Rx Profits 199,075  227,112  257,072 291,907 318,688 340,859 355,858 381,366  422,703 433,092 432,583 436,372 441,532 447,659  
Non-Rx Profits 44,819  49,118  50,648 55,128 55,079 64,239 68,866 71,375  79,750 83,642 87,265 90,485 93,642 95,890  
Other Profits 84,263  55,297  44,809 51,495 52,439 55,492 55,677 52,091  58,714 60,611 61,829 63,200 64,787 66,248  
Div. Profits 129,082  104,415  95,457  106,623 107,518 119,731 124,543 123,466  138,463 144,252 149,094 153,686 158,429 162,139  
Div. Profits = Diversified Profits = Non-Rx Profits + Other Profits 
Rx = Prescription Drug Products 
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A2: FULLY INTEGRATED PHARMA NETWORK 
 
There are 2713 l ines of raw data which is too large for this appendix. Summary information describing the raw data is provided in 
table below. 
 
Product Source >15 years 11 to 15 years 5  to 10 years <5 years 
Acquired product 6 3 10 8 
Co-developed 7 8 14 67 
In-licensed 38 52 67 115 
Internal 149 78 96 133 
M&A 126 84 132 168 
Other external 5 14 41 59 
n/a 0 0 0 0 
     
 Very Old (>15) Old (11-15) Recent (5-10) New (<5) 
Internal 149 78 96 133 
External 182 161 264 417 
External / Internal 1.2 2.1 2.8 3.1 
 332 241 363 553 
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A3: PERSONALISED MEDICINE 
 
Orphan Drug  
Designation Year 
Number of Orphan Drugs  
Designated by the FDA 
1983 0 
1984 5 
1985 10 
1986 11 
1987 18 
1988 20 
1989 30 
1990 43 
1991 40 
1992 27 
1993 33 
1994 35 
1995 33 
1996 29 
1997 35 
1998 45 
1999 58 
Orphan Drug  
Designation Year 
Number of Orphan Drugs  
Designated by the FDA 
2000 56 
2001 62 
2002 48 
2003 75 
2004 95 
2005 104 
2006 126 
2007 107 
2008 160 
2009 157 
2010 188 
Total 1650 
<2000 472 
2000-2005 440 
>=2006 738 
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A4: VIRTUAL R&D 
 
There are 2713 l ines of raw data which is too large for this appendix. Summary information describing the raw data is provided in 
table below. 
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Big Pharma 564 487 71 0.9 0.13 10 118 303 56 255 
Mid Pharma 173 240 18 1.4 0.10 13 97 102 28 0 
Japan Pharma 219 236 27 1.1 0.12 1 102 127 6 0 
Biotech 96 74 3 0.8 0.03 6 31 27 10 7 
Generics 72 160 2 2.2 0.03 0 6 50 104 0 
External = Acquired products + In-licensed products + M&A products+ Other external products 
Externalization = External / Internal 
Collaboration = Co-developed / Internal 
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A5: TRANSLATIONAL RESEARCH 
 
Biomarker 
Drugs Associated 
with this Biomarker Other Associated Drugs Therapy Area 
FDA 
Approval 
Year 
Anaplastic Lymphoma Kinase (ALK) Crisotinib  Oncology 2011 
BRAF Vemurafenib  Oncology 2011 
CCR5 -Chemokine C-C motif receptor Maraviroc  Infectious Diseases 2007 
CD20 antigen Tositumomab   2003 
CD30 Brentuximab   2011 
Cerebro spinal fluid related biomarkers for drugs 
affecting amyloid burden   Central Nervous System 2011 
Cholinesterase gene Mivacurium   1992 
C-KIT expression Imatinib mesylate  Oncology 2003 
CYP2C19 Variants Clopidogrel  Cardiovascular 2008 
CYP2C19 Variants with alternate context Diazepam Diazepam Central Nervous System  
CYP2C19 Variants with alternate context Esomeprazole Esomeprazole Gastroenterology  
CYP2C19 Variants with alternate context Nelfinavir Nelfinavir Infectious Diseases  
CYP2C19 Variants with alternate context Omeprazole Omeprazole Gastroenterology  
CYP2C19 Variants with alternate context Pantoprazole Pantoprazole Gastroenterology  
CYP2C19 Variants with alternate context Rabeprazole Rabeprazole Gastroenterology  
CYP2C19 Variants with alternate context Voriconazole  Infectious Diseases 2002 
CYP2C19 Variants with alternate context (no 
effect of Variants) Prasugrel  Cardiovascular 2007 
CYP2C9 Variants Celecoxib  
Immunology & 
Inflammation 2003 
CYP2C9 Variants with alternate context Warfarin  Cardiovascular 2008 
CYP2D6 (UM) with alternate context Codeine Solfate  Central Nervous System 1991 
CYP2D6 Variants Atomoxetine  Central Nervous System 2005 
CYP2D6 Variants Risperidone Risperidone Central Nervous System  
CYP2D6 Variants Tamoxifen Tamoxifen Oncology  
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Appendix A5 Continued 
Biomarker 
Drugs Associated 
with this Biomarker Other Associated Drugs Therapy Area 
FDA 
Approval 
Year 
CYP2D6 Variants Timolol maleate Timolol maleate Ophthalmology  
CYP2D6 Variants Tiotropium bromide inhalation Tiotropium bromide inhalation Respiratory  
CYP2D6 Variants Venlafaxine Venlafaxine Central Nervous System  
CYP2D6 with alternate context Aripiprazol Aripiprazol Central Nervous System  
CYP2D6 with alternate context Carvedilol Carvedilol Cardiovascular  
CYP2D6 with alternate context Cevimeline Hydrochloride Cevimeline Hydrochloride 
Immunology & 
Inflammation  
CYP2D6 with alternate context Clozapine Clozapine Central Nervous System  
CYP2D6 with alternate context Fluoxetine HCL  Central Nervous System 1999 
CYP2D6 with alternate context Fluoxetine HCL & Olanzapine Fluoxetine HCL & Olanzapine Central Nervous System  
CYP2D6 with alternate context Metoprolol Metoprolol Cardiovascular  
CYP2D6 with alternate context Propafenone Propafenone Cardiovascular  
CYP2D6 with alternate context Propranolol Propranolol Cardiovascular  
CYP2D6 with alternate context Protriptyline Protriptyline Central Nervous System  
CYP2D6 with alternate context Terabenazine Terabenazine Central Nervous System  
CYP2D6 with alternate context Terbinafine Terbinafine Infectious Diseases  
CYP2D6 with alternate context Thioridazine Thioridazine Central Nervous System  
CYP2D6 with alternate context Tolterodine Tolterodine Genitourinary  
CYP2D6 with alternate context Tramadol + Acetaminophen Tramadol + Acetaminophen Central Nervous System  
CYPA2     
Deletion of Chromosome 5q(del(5q))  Lenalidomide  Oncology 2006 
DPD Deficiency Capecitabine  Oncology 2004 
DPD Deficiency Fluorouracil Cream Fluorouracil Cream Dermatology  
DPD Deficiency 
Fluorouracil Topical Solution & 
Cream 
Fluorouracil Topical Solution & 
Cream Dermatology  
EGFR expression Erlotinib  Oncology 2005 
EGFR expression with alternate Context Cetuximab  Oncology 2004 
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Appendix A5 Continued 
Biomarker 
Drugs Associated 
with this Biomarker Other Associated Drugs Therapy Area 
FDA 
Approval 
Year 
EGFR expression with alternate Context Gefitinib Gefitinib Oncology  
Estrogen Receptor   Oncology  
Familial Hypercholestremia  Atorvastatin  Cardiovascular 2002 
G6PD Deficiency Dapsone Dapsone Dermatology  
G6PD Deficiency Rasburicase  Genitourinary 2002 
G6PD Deficiency with alternate Context Chloroquine Chloroquine Infectious Diseases  
G6PD Deficiency with alternate Context Primaquine  Infectious Diseases 2003 
Her2/neu Over-expression Lapatinib Lapatinib Oncology  
Her2/neu Over-expression Trastuzumab  Oncology 2004 
HLA-B*1502 allele presence Carbamazepine  Central Nervous System 2004 
HLA-B*5701 allele presence Abacavir  Infectious Diseases 2007 
IL28B    2011 
KRAS mutation  Cetuximab Cetuximab Oncology  
KRAS mutation  Panitumumab  Oncology 2008 
NAT Variants 
Isosorbide dinitrate and Hydralazine 
hydochloride 
Isosorbide dinitrate and Hydralazine 
hydochloride Cardiovascular  
NAT Variants Rifampin, isoniazid, and pyrazinmide   Infectious Diseases 2001 
Novel Renal Biomarkers for Toxicity   Nephrology 2010 
Philadelphia Chromosome- positive responders 
with alternate context Dasatinib  Oncology 2007 
Philadelphia Chromosome- positive responders 
with alternate context Nilotinib Nilotinib Oncology  
Philadelphia Chromosome-positive responders  Busulfan  Oncology 2002 
PML/RAR alpha gene expression  Arsenic Trioxide Arsenic Trioxide Oncology  
PML/RAR alpha gene expression  Tretinoin  Oncology 2000 
Protein C deficiencies  Warfarin  Cardiovascular 1996 
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Appendix A5 Continued 
Biomarker 
Drugs Associated 
with this Biomarker Other Associated Drugs Therapy Area 
FDA 
Approval 
Year 
TPMT Variants Azathioprine  
Immunology & 
Inflammation 1995 
TPMT Variants Mercaptopurine Mercaptopurine Oncology  
TPMT Variants Thioguanine Thioguanine Oncology  
UGT1A1 Variants Irinotecan  Oncology 2004 
UGT1A1 variants with alternate context Nilotinib  Oncology 2007 
Urea Cycle Disorder (UCD) Deficiency Valporic acid  Central Nervous System 1999 
Vitamin K epoxide reductase (VKORC1) 
Variants Warfarin  Cardiovascular 2008 
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A6: ADAPTIVE TRIALS 
Year Received  Clinical Study Description (source: ClinicalTrials.gov) 
2006 An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine Condition:  Migraine  
2009 
Active, not recruiting  Adaptive-design Dose Finding Study to Assess the Antiviral Efficacy and Safety of NIM811 Administered in Combination With 
Standard of Care (SOC) in Relapsed Hepatitis C Virus 1 (HCV-1) Infected Patients Condition:  Chronic Hepatitis C Genotype-1 Relapse  
2009 Recruiting  Clinical Study to Test a New Drug to Treat Major Depression Condition:  Major Depressive Disorder (MDD)  
2007 Active, not recruiting  Safety/Efficacy Study of Rexin-G to Treat Pancreatic Cancer Condition:  Pancreatic Cancer  
2007 Active, not recruiting  Safety and Efficacy Study Using Rexin-G for Breast Cancer Condition:  Breast Cancer  
2007 Active, not recruiting  Safety and Efficacy Study Using Rexin-G for Sarcoma Condition:  Sarcoma  
2007 
Recruiting  To Evaluate Antiviral Efficacy of Telbivudine in Hepatitis B Antigen Positive (HbeAg-positive) Compensated Chronic Hepatitis B (CHB) 
Condition:  Hepatitis B, Chronic  
2009 Suspended  A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence Condition:  Alcohol Dependence  
2008 Recruiting  Study of Pegylated Human Recombinant Arginase for Liver Cancer Conditions:  Neoplasm;   Hepatocellular Carcinoma  
2009 
Recruiting  A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects. Conditions:  Diabetes Mellitus, Type 2;   Renal 
Impairment  
2009 
Recruiting  A Study in Cancer Patients to Evaluate the Bioequivalence of Alternative Formulations of Lapatinib Conditions:  ErbB2 Overexpressing;   
Metastatic Breast Cancer;   Solid Tumors  
2008 Terminated  A Dose-Ranging Study of ATI 7505 in Patients With Postprandial Distress Syndrome Condition:  Post Prandial Distress Syndrome  
2008 
Terminated Has Results  A Study Evaluating Desvenlafaxine Sustained Release (DVS SR) in Adult Female Outpatients With Fibromyalgia Condition:  
Fibromyalgia  
2009 
Recruiting  Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections Condition:  Acute Bacterial Skin Structure 
Infections  
2009 Completed  Single Dose Study of N1539 in the Treatment of Pain Secondary to Dental Impaction Surgery Condition:  Dental Pain  
2007 Completed  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QAU145 in Patients With Cystic Fibrosis Condition:  Cystic Fibrosis  
2006 Terminated  Study Evaluating the Efficacy of DVS-233 in Fibromyalgia Condition:  Fibromyalgia  
2009 Recruiting  EFFicacy Optimization Research of Telbivudine Therapy Condition:  Compensated Chronic Hepatitis B  
2007 Terminated  Safety and Efficacy Study of ABT-089 in Adults With Mild to Moderate Alzheimer's Disease Condition:  Alzheimer's Disease  
2010 
Recruiting  Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease Conditions:  Alzheimer's 
Disease;   Central Nervous System Diseases;   Cognition  
2009 
Recruiting  Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis Start 
Date: March 2009  
2007 Terminated  Study Evaluating Vabicaserin in Subjects With Schizophrenia Start Date: December 2007  
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Appendix A6 Continued 
Year Received  Clinical Study Description (source: ClinicalTrials.gov) 
2009 
Recruiting  Long-Term Extension Study of the Effects of SCH 527123 in Subjects With Moderate to Severe COPD (P05575AM2) Start Date: October 
2009  
2006 
Terminated Has Results  Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With 
Diabetic Peripheral Neuropathy Start Date: March 2006  
2008 Recruiting  Phase II Study Evaluating the Safety and Efficacy of GSK315234 in Patients With Rheumatoid Arthritis Start Date: April 2008  
2008 Recruiting  Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women Start Date: January 2008  
2006 Recruiting  Randomised Trial of Two Different Strategies to Treat Paroxysmal Atrial Fibrillation Start Date: February 2006  
2009 
Completed  The Effect of a New Specific Enteral Formula Compared to a Standard Formula on the Tolerability of a Combined Radio- and 
Chemotherapy in Cancer Patients Start Date: September 2006  
2005 Completed  SB-773812 Administered In Adults With Schizophrenia Start Date: September 2005  
2008 Terminated  Safety and Efficacy of Cethrin® in Adult Subjects With Acute Cervical Spinal Cord Injury Start Date:   
2010 Not yet recruiting  Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth Start Date: July 2010  
2008 
Active, not recruiting  A Multiple Ascending Dose Study of RO4905417 in Healthy Volunteers and Patients With Peripheral Arterial Disease (PAD). 
Start Date: September 2008  
2007 LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA) Start Date: August 2007  
2009 Efficacy and Safety Study of the Misoprostol Vaginal Priming Insert (MVPI) Prior to Hysteroscopy Start Date: January 2010  
2009 [11C]Carfentanil PET Study of GSK1521498 Start Date: June 2009  
2008 Enhancing Fitness in Older Overweight Vets With Impaired Fasting Glucose Start Date: October 2008  
2010 
An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain DAT and SERT Occupancy,Pharmacokinetics 
and Safety of Single Oral Doses of GSK1360707, Using 11C- PE2I and 11C-DASB as PET Ligands Start Date: April 2009  
2010 Recruiting  Safety and Pharmacokinetic Study of Oral ON 01910.Na in Patients With Myelodysplastic Syndrome 
2010 
Not yet recruiting  A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-
3415A-001 AM2) Condition:  Clostridium Difficile Infection  
2010 
Active, not recruiting  A Study to Investigate the Impact of Dose and Dosing Frequency of AZD8848 on the Response on Biomarkers Condition:  
Healthy Volunteers  
2010 
Recruiting  Comparing the Efficacy, Safety, and Tolerability of Combination Antivirals (Amantadine, Ribavirin, Oseltamivir) Versus Oseltamivir for the 
Treatment of Influenza in Adults at Risk for Complications Condition:  Influenza  
2010 Recruiting  Novel Approach to Stimulant Induced Weight Suppression and Its Impact on Growth Conditions:  ADHD;   Growth  
2010 
Recruiting  Study to Evaluate the Efficacy and Safety of Three Different Doses of SCV 07 in Attenuating Oral Mucositis in Subjects With Head and 
Neck Cancer Condition:  Oral Mucositis  
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A7: GLOBAL HARMONIZATION 
 
ICH Guideline Topic Sub-Topic Publication Year Status 
Q1A(R2) Quality Stability 2003 Implementation 
Q1B Quality Stability 1996 Implementation 
Q1C Quality Stability 1996 Implementation 
Q1D Quality Stability 2002 Implementation 
Q1E Quality Stability 2003 Implementation 
Q2(R1) Quality Analytical Validation 1994 Implementation 
Q3A(R2) Quality Impurities 2006 Implementation 
Q3B(R2) Quality Impurities 2006 Implementation 
Q3C(R4) Quality Impurities 2009 Implementation 
Q4B Quality Pharmacopoeias 2007 Implementation 
Q4B Annex 1 Quality Pharmacopoeias 2007 Implementation 
Q4B Annex 2 Quality Pharmacopoeias 2008 Implementation 
Q4B Annex 3 Quality Pharmacopoeias 2008 Implementation 
Q4B Annex 4A Quality Pharmacopoeias 2008 Implementation 
Q4B Annex 4B Quality Pharmacopoeias 2008 Implementation 
Q4B Annex 4C Quality Pharmacopoeias 2008 Implementation 
Q4B Annex 5 Quality Pharmacopoeias 2009 Implementation 
Q4B Annex 6 Quality Pharmacopoeias 2008 Consultation 
Q4B Annex 7 Quality Pharmacopoeias 2009 Implementation 
Q4B Annex 8 Quality Pharmacopoeias 2009 Implementation 
Q4B Annex 9 Quality Pharmacopoeias 2009 Implementation 
Q4B Annex 10 Quality Pharmacopoeias 2009 Implementation 
Q4B Annex 11 Quality Pharmacopoeias 2010 Consultation 
Q4B Annex 12 Quality Pharmacopoeias 2010 Consultation 
Q4B Annex 13 Quality Pharmacopoeias 2010 Consultation 
Q4B Annex 14 Quality Pharmacopoeias 2010 Consultation 
Q5A(R1) Quality Quality of Biotechnological Products 1997 Implementation 
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Appendix A7 Continued 
ICH Guideline Topic Sub-Topic Publication Year Status 
Q5B Quality Quality of Biotechnological Products 1995 Implementation 
Q5C Quality Quality of Biotechnological Products 1995 Implementation 
Q5D Quality Quality of Biotechnological Products 1997 Implementation 
Q5E Quality Quality of Biotechnological Products 2004 Implementation 
Q6A Quality Specifications 1999 Implementation 
Q6B Quality Specifications 1999 Implementation 
Q7 Quality Good Manufacturing Practice 2000 Implementation 
Q8(R2) Quality Pharmaceutical Development 2005 Implementation 
Q9 Quality Quality Risk Management 2005 Implementation 
Q10 Quality Pharmaceutical Quality System 2008 Implementation 
S1A Safety Carcinogenicity Studies 1995 Implementation 
S1B Safety Carcinogenicity Studies 1997 Implementation 
S1C(R2) Safety Carcinogenicity Studies 2008 Implementation 
S2(R1) Safety Genotoxicity Studies 2008 Consultation 
S3A Safety Toxicokinetics and Pharmacokinetics 1994 Implementation 
S3B Safety Toxicokinetics and Pharmacokinetics 1994 Implementation 
S4 Safety Toxicity Testing 1994 Implementation 
S5(R2) Safety Reproductive Toxicology 1993 Implementation 
S6 Safety Biotechnological Products 1997 Implementation 
S6(R1) Safety Biotechnological Products 2009 Implementation 
S7A Safety Pharmacology Studies 2000 Implementation 
S7B Safety Pharmacology Studies 2005 Implementation 
S8 Safety Immunotoxicology Studies 2005 Implementation 
S9 Safety Immunotoxicology Studies 2009 Consultation 
E1 Efficacy Clinical Safety 1994 Implementation 
E2A Efficacy Clinical Safety 1994 Implementation 
E2B(R3) Efficacy Clinical Safety 2000 Implementation 
E2C(R1) Efficacy Clinical Safety 1996 Implementation 
E2D Efficacy Clinical Safety 2003 Implementation 
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Appendix A7 Continued 
ICH Guideline Topic Sub-Topic Publication Year Status 
E2E Efficacy Clinical Safety 2004 Implementation 
E2F Efficacy Clinical Safety 2008 Consultation 
E3 Efficacy Clinical Study Reports 1995 Implementation 
E4 Efficacy Dose-Response Studies 1994 Implementation 
E5(R1) Efficacy Ethnic Factors 1998 Implementation 
E6(R1) Efficacy Good Clinical Practice 1996 Implementation 
E7 Efficacy Clinical Trials 1993 Implementation 
E8 Efficacy Clinical Trials 1997 Implementation 
E9 Efficacy Clinical Trials 1998 Implementation 
E10 Efficacy Clinical Trials 2000 Implementation 
E11 Efficacy Clinical Trials 2000 Implementation 
E12 Efficacy Guidelines for Clinical Evaluation by Therapeutic Category 2001 Implementation 
E14 Efficacy Clinical Evaluation 2008 Implementation 
E15 Efficacy Pharmacogenomics 2007 Implementation 
E16 Efficacy Pharmacogenomics 2009 Consultation 
M1 Multidisciplinary MedDRA Draft stage in 2011 Draft 
M2 Multidisciplinary MSTRI Draft stage in 2011 Draft 
M3 Multidisciplinary Nonclinical Safety Studies 2009 Implementation 
M4 Multidisciplinary CTD 2003 Implementation 
M5 Multidisciplinary Data Elements and Standards for Drug Dictionaries ?? Consultation 
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A8: SCIENCE AND RISK BASED REGULATIONS 
 
FDA Centre Collaborator(s) Title of FDA  Cooperative Research and Development Agreements (CRADA) Research Focus 
CBER Alliance Biosecure Research 
Foundation 
Infectivity Titrations of Blood Components from Chimpanzees Infected with the Agent of 
Gerstmann-Sträussler-Scheinker Syndrome in Mice and Comparison of Sensitivity of 
Mouse Bioassays 
- 
CBER PATH Vaccine Solutions Development of Conjugation Technology for Pneumococcal Conjugate Vaccines Biotechnology 
CBER Muscular Dystrophy Association Remote Therapeutic Delivery for Spinal Muscular Atrophy Pervasive 
Computing 
CBER Nanosphere, Inc. Development of a Nano-Particle Influenza Assay Nanotechnology 
CDRH Fraunhofer USA, Inc. - CESE Software Re-engineering and Forensic Analysis Bioinformatics 
CDRH Cytel, Inc. Software for Bayesian Clinical Trials Bioinformatics 
OC, OCPP GlobalSubmit, Inc. Study Design Software Bioinformatics 
CDER Eli Lilly and Company Development of Standards, Data Integration, and Applications for Analyzing and 
Visualizing Heterogeneous Datasets 
Bioinformatics 
CDER Mosaiques Diagnostics Identification and Validation for Urinary Biomarkers for Drug Toxicity Personalised 
Medicine 
CDRH Ginzton Technology Centre--Varian 
Medical Systems, Inc. 
X-ray Detector Models for Imaging Breast Cancer - 
CDER Adaptive Pharmacogenomics, LLC, 
and GlaxoSmithKline R&D 
Development of a General Purpose Software Tool that Optimises Clinical Study Design 
with Biomarkers 
Bioinformatics 
CBER Program for Appropriate Technology 
in Health 
Bioassays to Predict the Biological Activity, Safety, and Virulence of Live Attenuated 
Plasmodium Falciparum Sporozoite 
- 
CDRH Eyelight Diagnostics, Inc. Non-Invasive Assessment of Individuals at Risk for Diabetes Pervasive 
Computing 
CBER Protox Therapeutics, Inc. Development and Characterization of Novel Protein Toxin Therapeutics Targeting IL-4 
Receptor 
- 
CDER American Association of 
Pharmaceutical Scientists (AAPS) 
Enhancing IND/NDA Review Quality via Quantifying Prior Knowledge Bioinformatics 
CDER Ingenuity, Inc. Reference Database Exploration Tool for Regulatory Review of Biomarker, 
Pharacogenomic, and Toxicogenomic Data 
Bioinformatics 
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Appendix A8 Continued 
FDA Centre Collaborator(s) Title of FDA  Cooperative Research and Development Agreements (CRADA) Research Focus 
CDER Infrastructures for Information, Inc. 
(i4i) 
FACTS@FDA Label and Listing Collaboration System Critical Path 
CDER Eli Lilly and Company An Integrated Approach to Evaluation of Viral Clearance for Monoclonal Antibodies Biotechnology 
CDER Entelos, Inc. Development of Drug-Induced Liver Injury (DILI) PhysioLab Platform - 
CDRH Raydiance, Inc. Medical Applications of a High Energy Femtosecond Laser - 
CDRH Epicor/St. Jude Medical Optical Techniques for the Non-Invasive 3D Characterization of Biomedical Ultrasound 
Beams 
Pervasive 
Computing 
CDER Affymetrix, Inc. Toxigenomic Signature Analysis of Drug-Induced Phospholipidosis - 
CBER Novartis Env-Gp41 Oligomeric Immunogen - 
CDER Pfizer, Inc. Evaluation of Biomarkers of Drug-Induced Vascular Injury Personalised 
Medicine 
CDRH FIMI/Phillips, Inc. High-Dynamic-Range Display of Medical Images - 
CBER National Hemophilia Foundation Genetics of Inhibitor Antibody Response - 
CDER ChemImage Raman Chemical Imaging of Pharmaceutical Solids Process Analytical 
Technology (PAT) 
CDER Lhasa Limited Development of FDA Toxicology Databases Suitable for Human Expert Rule 
Development and Mechanistic Understanding of Chemical-Induced Toxicity 
Bioinformatics 
CDER, CDRH Novartis Co-Development of Drugs and Pharmacogenomic Tests Personalised 
Medicine 
CBER US Civilian Research & Development 
Foundation 
Test Kit for Quantitative Genotyping of Subtypes of HCV Personalised 
Medicine 
CDER Pharsight Corporation Enhancing IND/NDA Study Data Review Process Bioinformatics 
CDER US Pharmacopeia Substance Registration Project Critical Path 
CDRH Biophan Laboratories Measurement and Computer Modeling to Evaluate the Safety of Medical Implants in the 
Presence of Electromagnetic Fields from Magnetic Resonance Imaging 
- 
CDER LightPharma, Inc. Understanding manufaturing Science to Caprture Opportunities on the Critical Path for 
Chemistry, Manufacturing, and Controls (CMC) 
Critical Path 
CBER Albert Einstein College of Medicine Characterization of Novel Live Attenuated TB Vaccine Strains Biotechnology 
CDER Leadscope, Inc. Development of Toxicology and Clinical Effects Databases Bioinformatics 
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Appendix A8 Continued 
FDA Centre Collaborator(s) Title of FDA  Cooperative Research and Development Agreements (CRADA) Research Focus 
CBER American Type Culture Collection 
(ATCC) 
Oligonucleotide Microarrays for Identification and Genotyping of Mycoplasma - 
CDER Novartis Institutes for Biomedical 
Research, Novartis, Inc. 
Criteria for Drug Evaluation of Genomic Biomarkers of Safety Personalised 
Medicine 
CBER Meriture, Inc. Development of Analysis or Peptides for Antiviral Effect on Ebola Virus Infection - 
CDRH The Foundation for Research on 
Information Technologies in Society--
IT'IS 
Numerical Models and Tools Bioinformatics 
CDER Texas A&M University, Kingsville Creation of "Design Space" for Novel Targeted Dosage Forms QbD 
CDER Novartis, Inc. Application of PAT Tools During Manufacturing PAT 
CDER Conformia, Inc. Survey of Pharmaceutical Needs Critical Path 
CBER Aeras Global TB Vaccine Foundation Development of Preclinical Assays for Safe Use of TB Vaccines - 
CBER Technion Research and Development 
Foundation 
Use of Microarray Technology to Identify New Genes - 
CBER University Michigan Medical School IL-13 Fusion Cytotoxin as a Targeted Therapeutic - 
CDRH NanoSonic, Inc. Optical Fiber-Based Instrumentation for Monitoring Breath Biomarkers Personalised 
Medicine 
CDRH Univ. of Pennsylvania Biomechanics and Genomics of Vascular Dysfunction and Healing Personalised 
Medicine 
CBER Alpha-1 Foundation Investigation of Alpha-1-PI Polymer Structure - 
CBER Program for Appropriate Technology 
in Heath (PATH) 
High Yield Group A Meningococcal Polysaccharide-Tetanus Toxoid Conjugates - 
CDER MultiCASE Enhancement of the Performance of the MultiCASE (Q)SAR Software and FDA 
Toxicology Prediction Models 
Bioinformatics 
CDER Parenteral Drug Assn. Large Virus Filter Nomenclature Standardization Bioinformatics 
CDER Mortara Instrument Design and Development of a Customised ECG Warehouse - 
CBER NeoPharm, Inc. and NIH/NINDS Convection-enhanced Delivery of IL13-PE38QQR for Treatment of Diffuse Brainstem 
Gliomas 
- 
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Appendix A8 Continued 
FDA Centre Collaborator(s) Title of FDA  Cooperative Research and Development Agreements (CRADA) Research Focus 
CBER HemaTech, LLC Analysis of Anthrax Antibody Production in Conventional and Transchromosomal Cows - 
CBER Scripps Research Institute Expression and Function of the Human PERV A Receptor - 
CBER University of Illinois Rational Design of Anti-Meningococcal Polysaccharide Conjugate Vaccine Biotechnology 
CDRH LifeSpan, Inc. Explant Pathology Studies of Small Intestinal Submucosa Fabricated Pulmonary and 
Mitral Valve Replacements Implanted in Sheep 
- 
CBER American Type Culture Collection 
(ATCC) 
Analysis of Gene Expression by Microarray on Various Cell Lines - 
CBER Holland Laboratory, American Red 
Cross 
Transgenic Mouse Model for the Study of Variant Creutzfeldt-Jakob Disease - 
CDER Pfizer, Inc. Assessment of On-line or At-line Vibrational Spectroscopy and Chemical Imaging 
Techniques in Pharmaceutical Manufacturing for Controlling Critical Quality Attributes 
PAT 
CDER MDL, Inc. Development of Toxicology Prediction Modeling Modules Bioinformatics 
CDER IBM Development of a Physical Database for Study Data for Clinical and Non-Clinical Data at 
FDA 
Bioinformatics 
CBER Johns Hopkins University Development of Biochip-Based Technologies for Detection of Pathogenic Bacteria and 
Viral Agents and Establishment of a Secure Central Repository for Microarray Data 
Pervasive 
Computing 
CBER Research Triangle Institute Porin Gene Variable Region Typing of Neisseria gonorrhoeae - 
CDRH Mobile Manufacturers Forum Medical Device Electromagnetic Interference. (EMI) from Wireless Data Devices and 
Interlaboratory Comparison of Radiofrequency (RF) Dosimetry Data from Handheld 
Transmitters 
- 
CDER Lincoln Technologies Advanced Analytical Tools for Drug Safety Risk Assessment PAT 
CDER OxfordGlycoSciences, Inc. Development of Improved Biomarkers for Early Detection of Mycocardial Injury, Vascular 
Injury,and Liver Injury 
Personalised 
Medicine 
CDER DataPharm Foundation Electronic Collection, Processing and Distribution of Drug Product Infomation Critical Path 
CDER Lincoln Technologies, Inc. Design and Development of a Prototype Integrated Submissions Data Repository and 
Data Validation and Transformation Tool for eSubmission CRT Data 
Critical Path 
CDER Schering Plough Identification and Evaluation of Vasculitis Induced by SCH351591 - 
CDER PharmQuest, Inc. Development of Carcinogenicity and Toxicology Data Management System Bioinformatics 
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Appendix A8 Continued 
FDA Centre Collaborator(s) Title of FDA  Cooperative Research and Development Agreements (CRADA) Research Focus 
CBER NIH/National Cancer Institute and 
Correlogic Systems, Inc. 
Use of Pattern Discovery Technology to Identify Patterns of Protein Expression 
Associated with Specific Disease States 
Bioinformatics 
CDER PPD Informatics/PPD Development, 
Inc. 
Automation of Patient Profiles for Use with Submission Data Interface and Automated 
Import Screening 
Critical Path 
CBER Agilent Technologies, Inc. Synthesis of Oligonucleotides on Planar Glass Surfaces - 
CDER, CBER, 
CVM 
Pharsight Corp. Enhanced Clinical Drug Trial Simulation and Population PK Analysis Software Bioinformatics 
CBER Coley Pharmaceuticals Group, Inc. CpG Oligonucleotides Optimised for Activity in Humans - 
CDER US Pharmacopeia (USP) Collaboration Regarding USP Reference Standards - 
CDRH Cellular Telecommunications Industry 
Assn. (CTIA) 
Health Effects of RF Emissions from Wireless Phones - 
CDER Boehringer Ingelheim 
Pharmaceuticals, Inc. 
Immune Biomarkers for Monitoring Drug-Induced Vasculitis Personalised 
Medicine 
CDRH Program for Appropriate Technology 
in Health (PATH) 
Effects of Storage, Materials and Stress on Latex Glove Integrity - 
CBER Neurocrine Biosciences, Inc. A Circular Permuted IL-4 Pseudomona Exotoxin as an Anti-Cancer Agent - 
CDER Boehringer Ingelheim 
Pharmaceuticals, Inc. 
Transgenic Mouse Model as a Short-term Alternative to Predicting the Carcinogenecity of 
Pharmaceuticals 
- 
CDRH Safeskin Corporation Frequent Use of C Latex Products that may Play a Role in the Rate of Sensitization and 
the Intensity of Reaction to Latex Products 
- 
CDRH Institute of Electrical and CDP 
Electronics Engineers (IEEE) 
Improvement in the Quality of Software that is Used in Medical Devices to Increase Their 
Safety and Effectiveness 
- 
CDER Multi/CASE Multi/CASE Software Program Database Modules to Enhance Their Application for 
Predicting and Characterizing Toxicity of Pharmaceuticals 
Bioinformatics 
CBER NeoPharm, Inc. Interleukin-13 Pseudomonas Exotoxin as Anticancer Agent - 
CDRH, CBER, 
ORA 
Diagnostic Products Corporation Testing Human Sera for Total IgE and Specific IgE for Detection and Survey of Allergenic 
Disease 
Personalised 
Medicine 
CDRH Organ, Inc. Rapid and Uniform Heating of Vitrified Organs Under 1000 Atmoshperes of Pressure - 
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Appendix A8 Continued 
FDA Centre Collaborator(s) Title of FDA  Cooperative Research and Development Agreements (CRADA) Research Focus 
CDER Medifacts, Inc. Ambulatory Blood Pressure Monitoring Pervasive 
Computing 
CBER Tulane University Development of Non-Human Primate Model for Krebbe's Disease - 
CBER SNS, Inc. Auto On-Line Hydrolysis System PAT 
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A9: PROGRESSIVE/LIVE LICENSING 
 
No operat ional  ev idence was found in support  of  th is t r igger.  
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A10: REGULATORY ENFORCEMENT 
 
Company Name FDA Warning Letter  (WL) Subject WL Issue Date 
Austrade Inc.  Energy Drinks/Failure to Hold an Entry Intact   8/10/2000 
Appalachina Medical Equipment Co. Inc.  Medical Oxygen / CGMP  8/30/2000 
Ayundantes Inc.  Narcotic Treatment Program Standards   9/21/2000 
Brigham Radiology Group  Mammography Standards  10/4/2000 
Abkit Inc.  Alpha Betic Multi-Vitamin Supplement with Alpha Lipoic Acid/Labeling/Lacks NDA/Misbranded   10/30/2000 
Batshaw Mark L. M.D.  Clinical Investigator  11/30/2000 
Chemrich Holdings Inc.  Manufacturing Facility/Current Good Manufacturing Practices for Finished 
Pharmaceuticals/Adulterated   
12/11/2000 
Holy Cross Hospital  Mammography Standards  12/11/2000 
Everett Clinic  Mammography Standards  12/13/2000 
Airgas Norpac  Medical Gas/Adulterated  12/14/2000 
Genentech Inc.  Good Manufacturing Practices for Finished Pharmaceuticals/Biological Products General 
Provisions 
12/14/2000 
Intercoastal Medical Group  Mammography Standards  12/14/2000 
ADI Corporation  Television/Computer Monitor Factories/Automatic Detention  12/18/2000 
Blue Light Inc.  New Drug/Misbranded/Adulterated   12/18/2000 
Coram Healthcare  Liquid Medical Oxygen/Adulterated   12/18/2000 
E.A. Conway Medical Centre  Mammography Standards  12/19/2000 
Alexander Community Hospital  Mammography Standards  12/20/2000 
Banco de Sangre Humacao Inc.  Good Manufacting Practices for Blood and Components   12/20/2000 
Elcat Company  Methamphetamine Hydrochloride/Active Pharmaceutcal Ingredients/Adulterated   12/20/2000 
Advanced Health Care  Mammography Standards  12/22/2000 
Beverly Hills Diagnostic Breast Centre  Mammography Standards  12/22/2000 
East Palestine Family Medical Clinic Inc.  Mammography Standards  12/22/2000 
American Bio Medica Corporation  Rapid Drug Screen/Adulterated/Lacks Premarket Approval/Misbranded   12/26/2000 
Fox Chase Cancer Centre  Mammography Standards  12/28/2000 
Fox Chase Cancer Centre  Mammography Standards  12/28/2000 
Haribo of America Inc.  Jellied Candy/Lacks  12/28/2000 
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Appendix A10 Continued 
Company Name FDA Warning Letter  (WL) Subject WL Issue Date 
Leiner Health Products Inc.  Good Manufacturing Practice for Finished Pharmaceuticals/Adulterated   12/11/2000 
Radiology Clinics of Laredo  Mammography Standards  12/11/2000 
Scholzen Products Company Inc.  GMP for Finished Pharmaceuticals/Gas & Liquid Medical Oxygen/Adulterated   12/12/2000 
University OB-GYN Specialties Inc.  Mammography Standards  12/12/2000 
San Dimas Community Hospital  Mammography Standards  12/14/2000 
Tianjin Xin Xin Pharmaceutical Corporation  Active Pharmaceutical Ingredient/Adulterated/FMP's Manufacturing Processing Packing etc.   12/14/2000 
Murex Diagnostics Inc.  Quality System Regulation  12/15/2000 
Ultralite Enterprises Inc.  Quality System Regulation/Phototherapy Units/Adulterated   12/15/2000 
Ultralite Enterprises Inc.  Quality System Regulation/Phototherapy Units/Misbranded/MDR Reporting/Adulterated   12/15/2000 
Xinjiang Pharmaceutical Factory  Active Pharmaceutical Ingredient Mfr Facility/Adulterated/Manufactu ring Processing Packaging 
etc.   
12/18/2000 
Organon Teknika BV  Postmarketing Adverse Drug Experience Reporting Requirements   12/20/2000 
St. Mary's Gateway Health Centre  Mammography Standards  12/20/2000 
St. Mary's Centre for Women's Health  Mammography Standards  12/21/2000 
Westerly Hospital  Mammography Standards  12/21/2000 
Spectrum Health Betty Ford Breast Care 
Services  
Mammography Standards  12/22/2000 
Allina Medical Group  Mammography Standards  01/05/2001 
AJ Slenders Dairy  New Animal Drug/Held Under Insanitary Conditions/Adulterated   01/10/2001 
Allison Breast Centre at Monument Radiology  Mammography Standards  01/19/2001 
Barnes Health Care Services  Medical Oxygen/Adulterated  03/07/2001 
Biogen Inc.  Labeling/False & Misleading/Avonex   03/29/2001 
Albert Lea Medical Centre  Mammography Standards  03/30/2001 
Aventis Pasteur Inc.  GMP for Mfr Processing Packing Holding Drugs/Biological Products   04/09/2001 
Albermarle Hospital  Mammography Quality Standards  04/24/2001 
Colgate Palmolive Company  CGMP for Finished Pharmaceutical/Adulterated   05/04/2001 
Alta District Hospital  Mammography Quality Standards  05/18/2001 
Adventist Health Walla Walla General Hospital  GMP for Blood & Blood Components/General Biological Standards   07/13/2001 
Aventis Bio-Sciences  Good Manufacturing Practice Regulations for Blood and Blood Components   07/13/2001 
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Appendix A10 Continued 
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Allergan, Inc.  Violative Promotion Advertising/Lacking Fair Balance/Misleading   08/22/2001 
Bourbon County Hospital  Mammography Quality Standards  09/10/2001 
AirTran Airways  Interstate Conveyance Sanitation Regulations   09/18/2001 
ADAC Laboratories  CGMP requirements for the Quality System Regulation/Medical Device Reporting / Adulterated/ 
Misbranded  
10/25/2001 
Gorman, John F., M.D.  Mammography Quality Standards  11/01/2001 
All Care Medical Group, Inc.  Mammography Quality Standards  11/19/2001 
Dallas County Hospital District  Mammography Quality Standards  12/13/2001 
Dextrum Laboratories Inc  CGMP for Drugs/Manufacture Processing Packing Holding/Adulterated   12/13/2001 
Biorem s.r.l.  Medical Device/Lacks Premarket Approval/Adulterated/Misbranded   12/14/2001 
Bollinger Quick Repair, Inc.  Interstate Conveyance Sanitation Regulations   12/14/2001 
Atlantic General Hospital  Mammography Quality Standards Act   12/18/2001 
Community Radiology Inc.  Mammography Quality Standards  12/18/2001 
Diagnostic Medical Imaging Associates  Mammography Quality Standards  12/19/2001 
Breast Cancer Detection Centre of Alaska  Mammography Quality Standards  12/20/2001 
Feldman Mark H. D.P.M.  Clinical Investigator  12/21/2001 
Forever Young Products, Inc.  Current Good Manufacturing Practice Regulation for Finished Pharmaceuticals   12/21/2001 
2-2-0 Laboratories  Current Good Manufacturing Practices for Finished Pharmaceuticals/Adulterated   12/27/2001 
Island Kinetics Inc  CGMP for Finished Pharmaceutical/Adulterated   12/27/2001 
Green Gold Wholesale Produce Inc.  Avocados/Lacks  12/28/2001 
Hen-Lin Dairy  Animal Drug/Adulterated  12/28/2001 
Merck & Co. Inc.  GMP for Finished Pharmaceuticals/Biologics Licensing   02/09/2001 
Medical Device Services, Inc.  Quality System/Good Manufacturing Practice for Medical Devices/Adulterated   12/13/2001 
Providence Milwaukie Hospital  Mammography Quality Standards  12/13/2001 
Wise Regional Health  Mammography Quality Standards  12/13/2001 
Natural Technology, Inc.  Current Good Manufacturing Practices for Finished Pharmaceuticals/Adulterated   12/14/2001 
Rowan Animal Clinic  Illegal Drug Residue/Adulterated   12/14/2001 
Shelly Smith Farm  Illegal Drug Residue/Adulterated   12/14/2001 
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Trusted Care  Current Good Manufacturing Practices for Finished Pharmaceuticals/Adulterated   12/14/2001 
Van Haitsma Dairy Farm  Illegal Drug Tissue Residue/Adulterated   12/14/2001 
Sibley Medical Associates  Mammography Quality Standards  12/17/2001 
Women's Diagnostic Imaging Centre  Mammography Quality Standards  12/17/2001 
Multidata Systems International Corporation  Electronic Product Radiation Control/Premarket Notification 
Requirements/Adulterated/Misbranded   
12/18/2001 
The Medical Group  Mammography Quality Standards  12/19/2001 
Wayzata Bay Products Inc  Good Manufacturing Practice for Finished Pharmaceuticals/Adulterated   12/19/2001 
Medical Centre at Lancaster  Mammography Quality Standards  12/20/2001 
Misonix, Inc.  GMP Requirements for the Quality System Regulation/Adulterated   12/20/2001 
NCOIC  Mammography Quality Standards  12/20/2001 
Norton Suburban Hospital  Mammography Quality Standards  12/20/2001 
Van de Graaf Racnhes, Inc.  Current Good Manufacturing Practice for Medicated Feeds/Adulterated   12/20/2001 
West Agro, Inc.  Current Good Manufacturing Practices for Finished Pharmaceuticals/Adulterated   12/21/2001 
N TECH Instrument Repair, Inc.  Quality System Regulation for Medical Devices/Adulterated   12/27/2001 
Trotters Importers  Dried Fig Spread/Lacks  12/28/2001 
Matthews, Dana C., M.D.  Sponsor/Clinical Investigator  12/31/2001 
Aspen Medical Group  Mammography Quality Standards  01/14/2002 
Berlex Laboratories, Inc.  Quinaglute Dura-Tabs/CGMP for Finished Pharmaceuticals/Adulterated   03/11/2002 
Americaloe, Inc.  Seasilver/New Drug/Labeling/Misbranded   04/03/2002 
Ashland Drug  Nicotine Lollipops/New Drug/Misbranded   04/09/2002 
Arizona Institue of Medicine & Surgery  Mammography Quality Standards  04/30/2002 
America West Airlines, Inc.  Control of Communicable Diseases and Interstate Conveyance Sanitation   05/08/2002 
Allosource, Inc.  Human Issue Intended for Transplantation   07/02/2002 
BCS Farms  Drug Residue in Animal Tissue/Adulterated   08/08/2002 
Automatic Liquid Packaging, Inc.  GMP for Finished Pharmaceuticals/Adulterated   09/23/2002 
Allscripts Healthcare Solutions  Certain Drugs Accord New Drug Status through Rulemaking Procedures/Guaifenesin   10/11/2002 
Alphagen Laboratories Inc.  Certain Drugs Accord New Drug Status through Rulemaking Procedures/Guaifenesin   10/11/2002 
Ambi Pharmaceuticals  Certain Drugs Accord New Drug Status through Rulemaking Procedures/Guaifenesin   10/11/2002 
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ChemSource Corporation  Current Good Manufacturing Practice of Active Pharmaceutical Ingredients /Adulterated   11/15/2002 
Blond, Scott, D.V.M  Illegal Tissue Residue/Extra-label Use/Adulterated   12/02/2002 
Charles L. Earsing Dairy Farm  Illegal Tissue Residue/Extra-label Use/Adulterated   12/02/2002 
Hoogendam Dairy  Illegal Drug Tissue Residue/Adulterated   12/02/2002 
Classic Medical, Inc.  Medical Oxygen/CGMP for Finished Pharmaceuticals/Adulterated/Mi sbranded   12/03/2002 
Desert Advanced Imaging Centre  Mammography Quality Standards  12/05/2002 
Hobart Laboratories, Inc.  CGMP in Manufacturing, Processing, Packing or Holding/CGMP for Finished 
Pharmaceuticals/Adulterated   
12/06/2002 
E.M. Adams Co., Inc.  Quality System Reguation/Adulterated   12/09/2002 
Beaumont Products, Inc.  Unapproved New Drug/GMP for Finished Pharmaceuticals/Misbranded   12/11/2002 
Gulf Medical Services  CGMP for Finished Pharmaceuticals/CGMP in Manufacturing, Processing, Packing, or 
Holding/Adulterated   
12/16/2002 
Eastern Medical Equipment Distributors, Inc.  CGMP for Finished Pharmaceuticals/CGMP in Manufacturing, Processing, Packing, or Holding/ 
Adulterated   
12/17/2002 
Gateway Blood Association  Blood Products/Lacks Approved License for Interstate Commerce   12/18/2002 
Costa View Farms  Illegal Edible Tissue Residue/Adulterated   12/19/2002 
Coulter Corporation  GMP for Blood and Blood Products/Quality System Regulation   12/19/2002 
Edward W. McCready Memorial Hospital  Mammography Quality Standards  12/20/2002 
DBA Zacharias Holsteins  Drug in Edible Tissue/Extra label Use/Adulterated   12/23/2002 
Hoover Feed Service, Inc.  New Drug/Adulterated  12/24/2002 
Boersma #2 Dairy  Illegal Edible Tissue Residue/Adulterated   12/26/2002 
Fischer Imaging Corporation  Quality System Regulation/Good Manufacturing Practice for Medical Devices/Adulterated   12/27/2002 
Diamond Pacific  CGMP for Licensed Medicated Feeds/Adulterated   12/28/2002 
Medina General Hospital  Mammography Quality Standards  09/17/2002 
Softchrome, Inc.  Listing Color Additives Exempt from Certification/Lacks Premarket Application/Adulterated/Misbra 
nded   
09/26/2002 
Riverside Medical Clinic, Inc.  Mammography Quality Standards  11/06/2002 
Navajo Manufacturing Company, Inc.  CGMP in Manufacturing, Processing, Packing or Holding/CGMP for Finished 
Pharmaceuticals/Adulterated   
12/02/2002 
Medical Diagnostic Centre (Southside)  Mammography Quality Standards  12/03/2002 
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Walk, William M.  Edible Tissue/Adulterated  12/06/2002 
Serv-A-Pure Company  Quality System Regulation/Water Purification Systems/Adulterated   12/10/2002 
Superior Uniform Group, Inc.  QSR/Lack Premarket Approval/Registration Listing/Adulterated/Misbranded   12/10/2002 
Metropolitan Hospital Centre  Mammography Quality Standards  12/11/2002 
VISX Inc  Premarket Approval/Misbranded/Adulterate d   12/11/2002 
Land O'Lakes  Extra label Drug Use in Animals/Adulterated   12/12/2002 
Primary Care Plus  Mammography Quality Standards  12/12/2002 
Southern Herb Acquisition Co., LLC  New Drug/Misbranded  12/12/2002 
VBM Medizintechnik GMBH  Quality System Regulation/Adulterated   12/13/2002 
Minneapolis Radiology Associates, Ltd.  Mammography Quality Standards  12/17/2002 
Paul Ramer Construction  New Drug/Adulterated  12/17/2002 
Vet Pharm, Inc.  Extra label Drug Use in Animals/Adulterated   12/18/2002 
Southwest Pharmacy / DBA Anchor   CGMP/Oxygen Compressed/Adulterated   12/19/2002 
McAnally Enterprises LLC  CGMP for Licensed Medicated Feeds/Adulterated   12/20/2002 
Wallach Surgical Devices, Inc.  CGMP for Finished Pharmaceuticals/CGMP in Manufacturing, Processing, Packing, or 
Holding/Adulterated   
12/20/2002 
William M. Vargulick Dairy Farm  Illegal Drug Residue/Adulterated   12/24/2002 
Searle, Ltd.  Current Good Manufacturing Practices for Finished Pharmaceuticals/Adulterated   12/27/2002 
Reyncrest Farms, Inc.  Extra label Drug Use in Animals/Adulterated   12/30/2002 
Vukman, Gerald R., D.V.M.  Illegal Tissue Residue/Extra label Drug Use in Animals/Adulterated   12/30/2002 
1-Supplements.net  Dietary Supplement/Labeling/Misbranded   02/28/2003 
Crown Laboratories, Inc.  Current Good Manufacturing Practices for Finished Pharmaceuticals/Adulterated   02/28/2003 
Alvieira Dairy  Illegal Drug Tissue Residue/Adulterated   03/14/2003 
Baltimore Imaging Centres  Mammography Quality Standards  03/20/2003 
Hoffman-La Roche Inc  Misleading Promotional Materials   05/29/2003 
Criado, Frank J. M.D.  Clinical Investigator  06/19/2003 
Astro Instrumentation LLC  Quality System Regulation/Adulterated   08/21/2003 
Applied Laboratories, Inc.  Quality System Regulation/Adulterated   11/19/2003 
American Medical Devices, Inc.  Quality System Regulation  11/24/2003 
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Dairyland Milk Company  Illegal Drug Residue/Adulterated   12/04/2003 
Caldwell, Stephen H., M.D.  Clinical Investigator  12/11/2003 
Absolute Packaging Inc  CGMP for Drugs/Manufacture, Processing, Packing, Holding/Adulterated   12/15/2003 
Central Missouri Agri-Service LLC  Medicated Feeds/Adulterated  12/15/2003 
Joharra Dairy Farms  Illegal Drug Residue Animal Tissue/Adulterated   12/17/2003 
Joe M. Simoes Family Dairy  Illegal Drug Residue in Animal Tissue/Extralabel Drug Use/Adulterated   12/18/2003 
Custom Compounding Centres  Pharmacy Compounding/GMP for Finished Pharmaceuticals   12/23/2003 
Eldon Biologicals A/S  CGMP Requirements of the Quality System Regulations/Adulterated   12/23/2003 
H.B. Williams, Inc.  Illegal Drug Residue/Adulterated   12/23/2003 
IND Diagnostic, Inc.  CGMP Requirements of the Quality System Regulations/Adulterated   12/23/2003 
Kos Pharmaceuticals, Inc.  Good Manufacturing Processing, Packing, Holding/Finished Pharmaceuticals/Adulterated   12/29/2003 
Aqua Micron LLC  CGMP/Finished Pharmaceuticals/Adulterated   12/31/2003 
Shiro and Associates  FD&C Yellow No. 5/Undeclared Color Additive/Adulterated/Misbrande d   01/30/2003 
Skaggs, David, M.D.  Institutional Review Board  02/14/2003 
Mary's Malasadas, Inc.  Color Additive Undeclared/Misbranded   03/18/2003 
Kral X-Ray, Inc  Performance Standard for Ionizing Radiation Emitting Products   12/03/2003 
Medron, Inc.  Quality System Reguation/Adulterated   12/03/2003 
Odyssey Medical Inc.  Quality System Regulation for Medical Devices/Adulterated   12/04/2003 
Sun Valley Jerseys  Illegal Drug Residue Animal Tissue/Extralabel Use/Adulterated   12/04/2003 
Western Missouri Medical Centre  Blood Bank/GMP for Blood & Blood Components   12/08/2003 
Southside Community Hospital  Blood & Blood Products/Adulterated   12/09/2003 
New York Eye & Ear Infirmary  Institutional Review Board  12/11/2003 
Smith Sterling Dental Laboratory, Inc.  Quality System Regulation/Adulterated   12/11/2003 
Nutralife Laboratories  New Drug/Nutrition Labeling Dietary Supplements/Misbranded   12/16/2003 
Schell's Pine Grove Dairy  Illegal Drug Residue in Animal Tissue/Extralabel Drug Use/Adulterated   12/18/2003 
Prescript Pharmaceuticals, Inc.  CGMP for Drugs/Manufacture, Processing, Packing, Holding/Adulterated   12/22/2003 
Staar Surgical Company  Current Good Manufacturing Practice Requirements for Medical Devices/Quality System 
Regulation   
12/22/2003 
Rusk County Memorial Hospital  GMP for Blood & Blood Components/Adulterated   12/23/2003 
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Turner County Dairy, LLP  Illegal Drug Residue in Animal Tissue/Extralabel Drug Use/Adulterated   12/23/2003 
Lordex Inc  Current Good Manufacturing Practice Requirements for Medical Devices/Quality System 
Regulation   
12/29/2003 
Orleans Poverty Hill Farm  Illegal Drug Residue in Animal Tissue/Extralabel Drug Use/Adulterated   12/29/2003 
TJ Candy Corporation  Import/Lacks  12/29/2003 
Xttrium Laboratories, Inc.  Post-marketing Reporting of Adverse Drug Experience   12/30/2003 
Acuderm Inc  QSR for Medical Devices/Medical Device Reporting/Adulterated   01/08/2004 
Electro Therapeutic Devices, Inc.  QSR for Medical Devices/Medical Device Reporting/Misbranded/Adulterated   04/05/2004 
American Sports Nutrition  Unapproved New Drug/Adulterated   06/24/2004 
Higher Power, Inc.  Unapproved New Drug/Adulterated   06/25/2004 
Affordable Supplements  Unapproved New Drug/Adulterated   06/28/2004 
Amstutz, Harlan C., M.D.  Clinical Investigator  07/19/2004 
E. Franco & Co.  Labeling/Adulterated/Misbrande d   09/14/2004 
3TP LLC  Premarket Approval/Misbranded  10/05/2004 
Alveolus, Inc.  CGMP Requirements for Medical Devices/Quality System Regulations/Adulterated   11/10/2004 
Colloids for Life, LLC  Labeling/Promotional Claims False & Misleading/New Drug   12/02/2004 
Chiron Corporation  CGMP for Finished Pharmaceuticals/CGMP in Manufacturing, Processing, Packing, or Holding/ 
Adulterated   
12/09/2004 
Danlee Medical Products, Inc.  Quality System Regulation for Medical Devices/Adulterated/Misbranded   12/09/2004 
Collins, Tyrone J., M.D.  Clinical Investigator  12/10/2004 
Jean's Greens  Labeling/Promotional Claims False & Misleading/Misbranded   12/10/2004 
Can-x Products  Lacks New Drug Approval /Misbranded   12/14/2004 
Kling, Mitchel A., M.D.  Clinical Investigator  12/15/2004 
Borawski, Lawrence A.  Labeling/False & Misleading Claims/Misbranded   12/21/2004 
Denver Tofu Company, Inc.  Labeling/Promotional Claims False & Misleading/Misbranded   12/21/2004 
Advanced Sterilization Products  Good Manufacturing Practice Requirement for the Quality System Regulation/Adulterated   12/22/2004 
Cyberonics, Inc.  CGMP Requirement of the Quality System Regulation for Medical Devices/Adulterated   12/22/2004 
Huebner Farm  Extralabel Drug Use in Animals/Adulterated   12/22/2004 
Best Veterinary Solutions, Inc.  Labeling/Adulterated  12/23/2004 
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BioHorizons Implant Systems, Inc.  CGMP Requirements for Medical Devices/Quality System Regulations/Adulterated   12/27/2004 
Pyng Medical Corporation  Medical Device Reporting/Misbranded   04/09/2004 
Old Hickory Medicine Company, Inc.  Current Good Manufacturing Practice for Finished Pharmaceuticals/Misbranded/Adu lterated   04/21/2004 
Sunder Biomedical Tech Co.  Quality System Regulation/Adulterated   04/23/2004 
Our Lady of the Lake Hospital, Inc.  GMP for Blood & Blood Components/Adulterated   05/07/2004 
Scientific Botanicals Co., Inc.  Dietary Supplement Regulations/Misbranded   05/21/2004 
Prime Nutrition  Unapproved New Drug/Adulterated   06/28/2004 
SmartBodyz Nutrition  Unapproved New Drug/Adulterated   06/28/2004 
RPM Total Vitality  Unapproved New Drug/Adulterated   06/29/2004 
World Class Nutrition  Unapproved New Drug/Adulterated   06/29/2004 
OST Medical, Inc.  Lacks Premarket Approval/Adulterated/Misbrande d   07/19/2004 
Ortho-McNeil Pharmaceutical, Inc.  Promotional Claims/False & Misleading   09/15/2004 
Lifecore Biomedical, Inc.  Medical Device Reporting/Misbranded   10/08/2004 
Pharmachem Laboratories, Inc.  Dietary Supplement/Labeling/False & Misleading Claims/Misbranded   11/19/2004 
Purest Colloids, Inc.  Promotional Claims/False & Misleading/Misbranded   12/02/2004 
Lex, Inc.  CGMP for Drugs/Manufacture, Processing, Packing, Holding/Adulterated/Misbranded   12/07/2004 
Veterinary Enterprises of Tomorrow, Inc.  Active Pharmaceutical Ingredient/Adulterated   12/08/2004 
Lincare, Inc.  Pharmacy Compounding/Misbranded   12/09/2004 
Sunshine Mills, Inc.  Animal Proteins Prohibited in Ruminant Feed/Misbranded   12/09/2004 
The Sanapac Co., Inc.  Dietary Supplement/Promotional Claims False & Misleading/Adulterated/Misbran ded   12/10/2004 
Nolan Livestock  Extralabel Drug Use in Animals/Adulterated   12/15/2004 
Precision Piece Parts, Inc. CGMP Requirement of the Quality System Regulation for Medical Devices/Adulterated 12/15/2004 
Prime Veal Feed, Ltd.  Extralabel Drug Use in Animals/Misbranded   12/15/2004 
White Egret Farm  Control of Communicable Disease   12/15/2004 
Red River Pharmacy Services, Inc.  Active Pharmaceutical Ingredient/Adulterated   12/17/2004 
U R Farms  Extralabel Drug Use in Animals/Adulterated   12/17/2004 
Respi Care Group of Puerto Rico  Unapproved New Drug/Adulterated/Misbranded   12/20/2004 
N64 Neutraceutica  Labeling/False & Misleading Claims/Misbranded   12/21/2004 
Nelson Laboratories, Inc.  Good Laboratory Practices  12/21/2004 
	 
    
176 
Appendix A10 Continued 
Company Name FDA Warning Letter  (WL) Subject WL Issue Date 
Medefil, Inc.  Quality System Regulation for Medical Devices/Adulterated   12/29/2004 
Basic Research, LLC  Labeling/Promotional Claims False & Misleading/New Drug   01/14/2005 
GlaxoSmithKline  Labeling/Promotional Claims False & Misleading/Misbranded   01/31/2005 
Amgen Inc.  Labeling/Promotional Claims False & Misleading/Misbranded   02/18/2005 
Animas Corporation  CGMP Requirements for Medical Devices/Quality System Regulations/Adulterated   02/24/2005 
Assistive Technology, Inc.  Quality System Regulation/Adulterated/Misbran ded   03/21/2005 
Bar-B-R Farm  Extralabel Drug Use in Animals/Adulterated   04/15/2005 
Boston Scientific Corporation  Current Good Manufacturing Practice Regulation/Adulterated   05/18/2005 
Allergan, Inc.  Labeling/Promotional Claims False & Misleading/Misbranded   09/06/2005 
Houchin Blood Services  Current Good Manufacturing Practices Regulations for Blood & Blood Components/Adulterated   09/21/2005 
BioHarmonics Research and Consulting  Lacks Premarket Approval Application Misbranded   10/14/2005 
Amon Orchards  Labeling and Promotional Violations   10/17/2005 
Corin USA  Lacks Premarket Approval Application Adulterated   11/22/2005 
G&S Instrument Company  CGMP Requirements for Medical Devices/Quality System Regulations/Adulterated   11/22/2005 
BODeSTORE.com  Labeling/Promotional Claims False & Misleading/New Drug/Misbranded   11/29/2005 
Chozyn, LLC  Labeling/Promotional Claims False & Misleading/New Drug/Misbranded   11/29/2005 
Healthworks 2000  Labeling/Promotional Claims False & Misleading/New Drug/Misbranded   11/30/2005 
Iceland Health, Inc  Labeling/Promotional Claims False & Misleading/New Drug/Misbranded   11/30/2005 
Carrington Laboratories, Inc  Insanitary Conditions/Adulterated/Misbran ded   12/05/2005 
IIT Research Institute  GLP Regulations  12/05/2005 
Ise Newberry, Inc.  Control of Communicable Diseases/Adulterated   12/13/2005 
Baltimore City Health Department  Institutional Review Board (IRB)   12/15/2005 
Clarkdale Fruit Farms Inc.  Juice HACCP  12/21/2005 
Dore, David D., M.D.  Clinical Investigator  12/21/2005 
Gold Eagle Cooperative  Animal Proteins Prohibited in Ruminant Feed/Misbranded   12/21/2005 
Guidant Corporation  CGMP for Medical Devices/QS/Adulterated   12/22/2005 
Edgar Martin Dairy  Illegal Drug Residue /Adulterated   12/29/2005 
Nichols, Trent M.D.  Clinical Investigator  02/24/2005 
Rapid Recovery Health Services Inc.  Lacks Premarket Approval/Adulterated/Misbrande d   03/07/2005 
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RealPure Beverage Group, LLC  Juice HACCP/Adulterated  03/10/2005 
Lydall, Inc.  CGMP/Adulterated  05/27/2005 
Panbio, Inc.  Lacks Premarket Approval Application/Misbranded   10/05/2005 
Professional Hair Institute, Inc.  Lacks Approved New Drug Application/Misbranded   10/13/2005 
Weese-Mayer, Debra E., M.D.  Clinical Investigator  10/14/2005 
Normed Medizin-Technik GmbH  CGMP for Medical Devices/QSR/Adulterated/Misbra nded   11/18/2005 
Revival Animal Health, Inc.  Promotional Claims False & Misleading/Adulterated/Misbran ded   11/21/2005 
Kramer Laboratories Inc.  Labeling/Promotional Claims False & Misleading/New Drug/Misbranded   11/22/2005 
Milbank Mills Inc  CGMP for Medicated Feeds/Adulterated   11/22/2005 
NativeRemedies.com  Promotional Claims False & Misleading/Misbranded   11/22/2005 
PRB Pharmaceuticals  Labeling/Promotional Claims False & Misleading/New Drug/Misbranded   11/23/2005 
PolyCil Health Inc  Labeling/Promotional Claims False & Misleading/New Drug/Misbranded   11/23/2005 
The Electrode Store, Inc.  Current Good Manufacturing Practices Requirements for Medical Devices/Adulterated   11/23/2005 
Sacred Mountain Management Inc  Labeling/Promotional Claims False & Misleading/New Drug/Misbranded   11/28/2005 
Spectrum Chemicals & Laboratory Products Active Pharmaceutical Ingredients/Misbranded   11/28/2005 
Vitacost.com  Labeling/Promotional Claims False & Misleading/New Drug/Misbranded   11/30/2005 
YSIS, Incorporated  Current Good Manufacturing Practice for Medical Devices/Adulterated/Misbranded   11/30/2005 
Samson Medical Technologies, Inc.  Labeling/New Drug/Misbranded  12/01/2005 
Restorative Products, Inc.  Medical Device Reporting Regulations/Quality System Regulation/Adulterated/Misbranded   12/02/2005 
Rite-Dent Manufacturing Corp.  Medical Device Reporting Regulations/Quality System Regulation/Adulterated/Misbranded   12/02/2005 
WaJa Farms, Inc  New Animal Drugs/Extra label Drug Use in Animals/Adulterated/Misbranded   12/06/2005 
LifeScan, Inc.  CGMP requirements for the Quality System Regulation/Medical Device 
Reporting/Adulterated/Misbrand ed   
12/07/2005 
Michael Mumbulo  New Animal Drugs/Extra label Drug Use in Animals/Adulterated/Misbranded   12/08/2005 
MCT Medical Products  Current Good Manufacturing Practice for Medical Devices/Adulterated   12/09/2005 
Milk Flow Dairy  Illegal Drug Residue /Adulterated   12/09/2005 
Morrell Farm  New Animal Drugs/Extra label Drug Use in Animals/Adulterated/Misbranded   12/12/2005 
Shelhigh, Inc.  CGMP Requirement for Medical Devices/Lacks Premarket Approval Application/Adulterated   12/14/2005 
Seecor, Inc.  CGMP Requirements for Medical Devices/Quality System Regulations/Adulterated   12/16/2005 
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Tidman, Raymond E., M.D.  Clinical Investigator  12/19/2005 
Lawsons Farm  Illegal Drug Residue /Adulterated   12/21/2005 
Paradise Farm Corporation  Juice HACCP/Adulterated  12/22/2005 
Siouxland Community Blood Bank  Current Good Manufacturing Practices Regulations for Blood & Blood Components/Adulterated   12/23/2005 
Wellness Resources, Inc.  Labeling/Promotional Claims False & Misleading/New Drug/Misbranded   12/27/2005 
Cache Commodities, Inc.  CGMP Requirements For Medicated Feeds/Adulterated   01/13/2006 
Del-Immune V  Labeling/Promotional Claims False & Misleading/New Drug   01/26/2006 
Community Blood Centre of Greater Kansas  Current Good Manufacturing Practices Regulations for Blood & Blood Components/Adulterated   03/09/2006 
Chocolate Cottage, Inc.  Labeling/Misbranded  04/25/2006 
Bioesl Packing Company, Inc.  Lacks New Animal Drug Application/Adulterated   06/14/2006 
Guilin Pharmaceutical Corporation, Limited  Current Good Manufacturing Practices/Active Pharmaceuticals Ingredient/Adulterated   06/23/2006 
Hohmann, Elizabeth L., M.D.  Clinical Investigator  07/10/2006 
Concord Laboratories, Inc  Current Good Manufacturing Practices for Finished Pharmaceuticals/Adulterated   07/11/2006 
Boulder Natural Labs, LLC  Labeling/Promotional Claims False & Misleading Claims/New Drug/Misbranded   07/19/2006 
Black Henna Ink, Inc.  Color Additive/Adulterated  08/14/2006 
ALK-Abello, Inc.  Promotional Claims False & Misleading/Misbranded   09/06/2006 
Banner Pharmacaps, Inc.  Drug Manufacturing Operations/CGMP deviations   09/28/2006 
Benchmark Medical, Inc.  Labeling/OTC Human Use/New Drug/Misbranded   11/03/2006 
Conti, Ralph M., M.D.  Clinical Investigator  11/22/2006 
Craftmatic Organization, Inc.  CGMP Requirements for Medical Devices/Quality System Regulation   11/27/2006 
Health Dimensions, Inc.  Pharmacy Compounding/New Drug/Misbranded   11/27/2006 
HemoSense, Inc.  CGMP for Medical Devices/QS/Adulterated   11/29/2006 
Customs Scripts Pharmacy  Pharmacy Compounding/New Drug/Misbranded   12/04/2006 
Feenstra, John  Extra label Drug Use/Adulterated   12/04/2006 
Hal's Compounding Pharmacy, Inc  Pharmacy Compounding/New Drug/Misbranded   12/04/2006 
INCELL Corporation, LLC  GLP/Bioresearch Monitoring Program/Investigational drugs   12/06/2006 
Biotecx Laboratories, Inc.  CGMP/QSR/Medical Device Reporting/Adulterated   12/08/2006 
Ganeden Biotech Inc.  Misbranded/Labeling/Unauthorised Health Claims   12/08/2006 
GSCM Ventures Inc.  Labeling/Promotional Claims False & Misleading/New Drug/Misbranded   12/12/2006 
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Biora AB  CGMP/QSR/Medical Devices/Adulterated   12/18/2006 
Colusa Regional Medical Centre  Mammography Quality Standards  12/21/2006 
Abraxis Bioscience, Inc.  Deviations from CGMP for Finished Pharmaceuticals   12/26/2006 
Applied Water Engineering, Inc.  CGMP/QSR/Medical Device Reporting/Adulterated   12/27/2006 
Southern Meds Joint Venture, LLC  CGMP for Finished Pharmaceuticals/Misbranded/Adulterated   02/15/2006 
PrimaPharm Inc  Labeling/False & Misleading Claims/Misbranded   06/29/2006 
Nardi, Claudia  Lacks Premarket Approval Application   11/21/2006 
Natren Inc.  Labeling/Promotional Claims False & Misleading/Misbranded/Adulterated   11/21/2006 
Trionix Research Laboratory, Inc.  CGMP Requirements of the Quality System Regulations/Adulterated   11/21/2006 
Meyer Farm  Illegal Drug Residue /Adulterated   11/22/2006 
Nestle S.A.  Infant Formula/Labeling/Misbranded   11/27/2006 
Skytron  Current Good Manufacturing Requirements for Medical Devices/Adulterated   11/29/2006 
Steris Corporation  Medical Device Reporting (MDR) Regulation Misbranded/Adulterated   11/29/2006 
Spoonamore Drug Co., Inc.  Pharmacy Compounding/New Drug/Adulterated/Misbranded   12/01/2006 
Lamb Farms, Inc.  Extralabel Drug Use/Adulterated   12/04/2006 
New England Compounding Centre  Pharmacy Compounding/New Drug/Misbranded   12/04/2006 
Ritch, Robert M.D.  Clinical Investigator  12/04/2006 
Ritch, Robert MD  Clinical Investigator  12/04/2006 
Triangle Compounding Pharmacy  Pharmacy Compounding/New Drug/Misbranded   12/04/2006 
University Pharmacy  Pharmacy Compounding/New Drug/Misbranded   12/04/2006 
MRL Inc.  CGMP For Medical Device Report/Adulterated   12/08/2006 
Nasiff Associates, Inc.  CGMP/Adulterated  12/08/2006 
Quick-Fill Mobile Oxygen, Inc.  CGMP for Finished Pharmaceuticals/Adulterated   12/08/2006 
Ratcliff, David C, M.D.  Institutional Review Board (IRB)   12/08/2006 
Schumacher's  Extralabel Drug Use/Adulterated   12/08/2006 
Viasys Healthcare  CGMP/Requirements for Medical Devices/QSR/Adulterated   12/12/2006 
Sharma, Baljit K., M.D.  Clinical Investigator  12/20/2006 
TMJ Implants, Inc.  Lacks Premarket Approval Application/Adulterated/Misbranded   12/20/2006 
Williams Farms Inc.  Animals for sale for slaughter/Adulterated   12/20/2006 
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Palmer Farms  Animals for sale for slaughter/Adulterated   12/21/2006 
Lee Laboratories, Inc.  CGMP Requirements of the Quality System Regulations/Adulterated   12/26/2006 
Rickland Farms, LLC  Animals for sale for slaughter/Adulterated   12/27/2006 
Advanced Reproductive Laboratory  Deviations/CFR/Regulations for Human Cells, Tissues & Cellular Products   01/09/2007 
Forest Grove Dairy  PHS Act/Violation  02/08/2007 
Beehive Botanicals, Inc.  Dietary Supplements  03/02/2007 
Abbott Laboratories, Inc.  QSR/Medical Devices/Adulterated/Misbranded   03/13/2007 
Fusion Brands International SRL  Drug Products/Labeling  04/24/2007 
Cytosol Laboratories, Inc.  CGMP/Deviations/Adulterated  10/30/2007 
International Technidyne Corporation  CGMP/QSR/Medical Device Reporting/Adulterated   10/30/2007 
Fisheries Research Laboratory- SIU-C  GLP/Bioresearch Monitoring Program   11/02/2007 
Amerifit Brands, Inc  CGMP for Drugs/Manufacture, Processing, Packing, Holding/Adulterated/Misbranded   11/07/2007 
Ben Venue Laboratories, Inc.  CGMP/Deviations/Adulterated  11/16/2007 
Custom Assemblies, Inc.  CGMP/QSR/Medical Devices/Adulterated/Misbranded   11/16/2007 
GE Healthcare/General Electric Company  Devices/X-ray Equipment  11/16/2007 
GlaxoSmithKline  Drug Labeling/Promotional Claims/Misbranded   11/21/2007 
E-Med Future, Inc.  Devices/Quality System Regulation   11/29/2007 
Avicenna Laser Technology Inc  CGMP/QSR/Manufacture/Packing/Storage/Installation/Adulterated   11/30/2007 
G. Dundas Company Inc  CGMP/QSR/Medical Devices/Adulterated/Misbranded   12/13/2007 
Abbott Vascular, Inc.  Medical Devices/Adulterated/Misbranded   12/19/2007 
Schering-Plough Animal Health Corporation  Promotional Claims/False & Misleading/Misbranded   07/11/2007 
Leiner Health Products, LLC  CGMP for Finished Pharmaceuticals/Deviations/Adulterated   08/28/2007 
SCM True Air Technologies LLC  CGMP/QSR/Medical Devices/Adulterated   09/24/2007 
Northeast General Pharmaceutical Factory  Current Good Manufacturing Practice Regulation/Adulterated   10/31/2007 
Troy Innovative Instruments, Inc.  CGMP for Medical Devices/QS/Adulterated   11/01/2007 
Nurse Assist, Inc.  CGMP/QSR/Medical Devices/Adulterated   11/09/2007 
Venosan North America  Medical Device Reporting  11/21/2007 
Precision Biometrics, Inc.  Device/Lacks Premarket Approval Application/Adulterated/Misbranded   11/28/2007 
Stryker Orthopaedics Corp.  CGMP/QSR/Manufacture/Packing/Storage/Installation/Adulterate d   11/28/2007 
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Pacific Consolidated Industries LLC  CGMP For Manufacturing, Packing, Storage or Installation/Adulterated   12/03/2007 
Wheatley, Susan J., M.D.  Clinical Investigator  12/05/2007 
Polychrome Medical, Inc  CGMP/QSR/Manufacture/Packing/Storage/Installation/Adulterate d   12/07/2007 
Spinal, USA  CGMP For Manufacturing, Packing, Storage or Installation/Adulterated/Misbranded   12/07/2007 
Wyeth Pharmaceuticals Inc.  DDMAC/Promotional Claims False & Misleading/Misbranded   12/10/2007 
Morton Grove Pharmaceuticals, Inc.  DDMAC/Promotional Claims False & Misleading/Misbranded   12/13/2007 
Siemens Medical Solutions Premarket Approval/Misbranded/Adulterate d   12/17/2007 
P-Ryton Corporation  CGMP/QSR/Manufacture/Packing/Storage/Installation/Adulterate d   12/18/2007 
Universal Enterprises Inc. Interstate Conveyance Sanitation Regulations/Provisional   12/20/2007 
Medical Device Resource Corporation  Premarket Approval/Misbranded/Adulterate d   12/21/2007 
Northwest Medical Physics Equipment, Inc.  CGMP/QSR/Manufacture/Packing/Storage/Installation/Adulterate d   12/21/2007 
Adams, Mark M.D.  Investigational Device Exemptions   01/23/2008 
Atlantic Southeast Airlines  Interstate Conveyance Sanitation Regulations/Provisional   05/02/2008 
Allez Spine, LLC  CGMP/QSR/Medical Devices/Adulterated   08/08/2008 
Caraco Pharmaceutical Laboratories, Ltd  CGMP Deviations  10/31/2008 
Deltex Pharmaceuticals Inc  CGMP/OTC Drug Products/Adulterated   10/31/2008 
Innovative Neurotronic, Inc.  CGMP/QSR/Medical Devices/Adulterated   11/04/2008 
American Association of Acupuncture Institutional Review Board (IRB)   11/13/2008 
Eagle Parts and Products  CGMP/QSR/Medical Devices/Adulterated   11/14/2008 
Jeffrey Steinberg MD Inc. Human Cells, Tissues & Cellular Products   11/18/2008 
Goosefoot Acres, Inc.  Labeling/False & Misleading Claims/New Drug/Misbranded   11/19/2008 
Contract Medical Manufacturing  CGMP/QSR/Medical Devices/Adulterated   11/20/2008 
Actelion Pharmaceuticals US, Inc.  DDMAC/Promotional Claims False & Misleading/Misbranded   11/24/2008 
Kids Company Ltd Yugengaisha Kids  Device/Lacks Approved Premarket Application/Adulterated/Misbranded   12/03/2008 
Carib Supply of St. Croix, Inc.  CGMP Manufacture, Processing, Packing or Holding of Human Drugs/Adulterated   12/04/2008 
Haemonetics Corporation  CGMP/QSR/Medical Devices/Adulterated   12/04/2008 
Craig General Hospital  Deviation from Good Manufacturing Practice   12/15/2008 
Civic Centre Pharmacy  New Drug, Unapproved  12/16/2008 
Columbia Presbyterian Medical Centre  Deviation/Adulterated  12/22/2008 
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I-Flow Corporation  CGMP/QSR/Medical Devices/Adulterated   12/22/2008 
Dongkuk Techco Rubber Ind. Sdn Bhd  CGMP/QSR/Adulterated  12/30/2008 
Pacifica Pharmacy  New Drug/False Misleading/Labeling/Misbranded   01/07/2008 
Reed's Compounding Pharmacy  New Drug/False Misleading/Labeling/Misbranded   01/07/2008 
Village Compounding Pharmacy  New Drug/False Misleading/Labeling/Misbranded   01/07/2008 
Michael S. Miller, D.O.  Investigational Device Exemptions (Clinical Investigator)   02/12/2008 
Midland Pharmaceutical LLC  CGMP for Finished Pharmaceutical/Adulterated   03/03/2008 
Merck & Company, Inc.  CGMP Manufacture of Licensed Biological Vaccine Products/Bulk Drug Substances/Components   04/28/2008 
Steris Corporation  Premarket Approval/Adulterated   05/15/2008 
Safer Sleep, LLC  CGMP/QSR/Medical Devices/Adulterated   05/27/2008 
Laboratory Corporation of America  Device Lacks Marketing Clearance Approval/Adulterated/Misbranded   09/29/2008 
PrimaPharm Inc.  Unapproved New Drug/Adulterated/Misbranded   10/31/2008 
Spacelabs Healthcare Incorporated  CGMP/QSR/Medical Devices/Adulterated   11/03/2008 
Steven's Pharmacy  New Drug/Labeling/False & Misleading Claims   11/12/2008 
Lam, Fred M.D.  Institutional Review Board (IRB)   11/13/2008 
Rezai, Ali R, M.D  Clinical Investigator  11/13/2008 
Saudek, Christopher D. MD  Clinical Investigator  11/13/2008 
Saudek, Christopher D., M.D.  Clinical Investigator  11/13/2008 
Shinogi USA, Inc.  DDMAC/Promotional Claims False & Misleading/Misbranded   11/14/2008 
RHG & Company, Inc., dba Vital Nutrients  New Drug/Labeling/False & Misleading Claims/Misbranded   11/18/2008 
Surgical Implant Generation Network  CGMP for Medical Devices/QS/Adulterated   11/18/2008 
PDS Manufacturing, Inc.  CGMP/QSR/Medical Devices/Adulterated   11/24/2008 
Perich, Larry M  Clinical Investigator  12/01/2008 
Vital Signs, Inc.  Premarket Approval/Misbranded/Adulterate d   12/01/2008 
Pneumex, Incorporated  Premarket Approval/Misbranded/Adulterate d   12/05/2008 
RGI Medical Manufacturing, Inc.  CGMP/QSR/Manufacture/Packing/S torage/Installation/Adulterate d   12/08/2008 
Savec Health Systems  Premarket Approval/Misbranded/Adulterate d   12/10/2008 
Virbac Inc.  CGMP For Manufacturing, Packing, Storage or Installation/Adulterated/Misbr anded   12/10/2008 
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Biomed Devices Corporation (AKA: Medlens 
Innovations, Inc.)  
CGMP/Quality System/Adulterated   02/02/2009 
BestLife International, Inc.  New Drug/Labeling/False & Misleading Claims   02/04/2009 
American Mammographics Inc  CGMP/QSR/Medical Devices/Adulterated   03/16/2009 
Cargill Flavor Systems Puerto Rico Inc.  Juice HACCP/Adulterated  03/30/2009 
Amrex-Zetron, Inc.  CGMP/QSR/Medical Devices/Adulterated   04/14/2009 
Amrita Aromatherapy, Inc  Unapproved/Uncleared/Unauthori zed Products Related to the H1N1 Flu Virus   05/28/2009 
Americell-labs.com VMG Global Inc  Dietary Supplements/Adulterated/Misbra nded   07/27/2009 
ANIP Acquisition Company  CGMP for Drugs/Manufacture, Processing, Packing, Holding/Adulterated/Misbranded   08/21/2009 
Customed, Inc 9/11/09  CGMP/QSR/Medical Devices/Adulterated   09/11/2009 
East Wind Community, Inc  Manufacturing Facility/Adulterated/Insanitar y conditions   10/05/2009 
Han, Jeffrey  Tobacco Products/Adulterated  11/02/2009 
Chavez, Inc.  Tobacco Products/Adulterated/Misbrande d   11/03/2009 
Durango Smoke Shop, Inc.  Tobacco Products/Adulterated/Misbrande d   11/03/2009 
Gibson Laboratories Inc  CGMP for Medical Devices/QS/Adulterated   11/03/2009 
H.J. Bailey Co.  Tobacco Products/Adulterated  11/03/2009 
Centra Health Inc Irb  Investigational Device Exemptions   11/20/2009 
Buettner, Craig M., MD  Clinical Investigator  11/24/2009 
Gazda, Thomas M.D.  Clinical Investigator  11/24/2009 
GDMI, Inc  CGMP for Finished Pharmaceuticals/Adulterated/Mi sbranded   11/27/2009 
ICON Clinical Research, Inc.  Bioresearch Monitoring Program   11/27/2009 
Aluwe, LLC  Unapproved New Drug/Misbranded   11/30/2009 
Aregenius Worldwide LLC  Unapproved/Uncleared/Unauthori zed Products Related to the H1N1 Flu Virus   11/30/2009 
Kenshin Trading Corporation  Premarket Approval/Misbranded/Adulterate d   12/08/2009 
Freeman Manufacturing Company  Medical Devices/Adulterated/Misbranded   12/09/2009 
Heartsine Technologies Inc  Device/Misbranded  12/10/2009 
Interacoustics A/S  CGMP/QSR/Adulterated/Misbrande d   12/10/2009 
Indonesia Clove Cigarettes  Tobacco Products/Adulterated/Misbrande d   12/14/2009 
Florida Atlantic University IRB  Institutional Review Board (IRB)   12/17/2009 
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Balchem Corporation  Current Good Manufacturing Practice Regulation for Finished Pharmaceuticals   12/22/2009 
Arteriocyte Medical Systems Inc  Device/Lacks Approved Premarket Application/Adulterated/Misbra nded   12/23/2009 
Genetics & IVF Institute IRB  Institutional Review Board (IRB)   12/23/2009 
Branan Medical Corp. Inc.  Premarket Approval/Misbranded/Adulterate d   12/28/2009 
Crothall Healthcare, Inc.  CGMP/QSR/Medical Devices/Adulterated/Misbranded   12/29/2009 
Prodesse, Inc  Unapproved/Uncleared/Unauthori zed Products Related to the H1N1 Flu Virus   05/11/2009 
Nozin LLC  Unapproved/Uncleared/Unauthori zed Products Related to the H1N1 Flu Virus   05/22/2009 
Matrixx Initiatives, Inc. AKA Zicam LLC  OTC Drug Labeling/New Drug/Misbranded   06/16/2009 
Mgs Soapopular  Unapproved/Uncleared/Unauthori zed Products Related to the H1N1 Flu Virus   07/15/2009 
Q-Based Solutions  Unapproved/Uncleared/Unauthori zed Products Related to the H1N1 Flu Virus   07/22/2009 
Platinum Strategies, Inc.  Labeling/Promotional Claims False & Misleading/New Drug/Misbranded   09/23/2009 
Tampa Peanut Distributors  CGMP for Deviations/Adulterated   10/08/2009 
www.novalistintegra.com  Unapproved/Uncleared/Unauthori zed Products Related to the H1N1 Flu Virus   10/08/2009 
Li Ning  Tobacco Products/Adulterated/Misbrande d   11/02/2009 
Smoke Shop USA Ltd  Tobacco Products/Adulterated/Misbrande d   11/02/2009 
Texas Wholesale  Tobacco Products/Adulterated/Misbrande d   11/03/2009 
Silver Soft for Skin  Unapproved/Uncleared/Unauthori zed Products Related to the H1N1 Flu Virus   11/04/2009 
www.bestswinefluvaccine.com  Unapproved/Uncleared/Unauthori zed Products Related to the H1N1 Flu Virus   11/30/2009 
Tetracore, Inc.  CGMP/QSR/Medical Devices/Adulterated   12/01/2009 
www.secretsofbetterhealth.com  Unapproved/Unauthorised Products Related to the H1N1 Flu Virus   12/01/2009 
P.M.T. Corp  CGMP/QSR/Medical Devices/Adulterated   12/03/2009 
Ward, John A., M.D.  Clinical Investigator  12/03/2009 
Z-Medica, LLC  CGMP/QSR/Medical Devices/Adulterated   12/03/2009 
MyKretek.com  Flavored cigarettes/Misbranded/Adulterated   12/07/2009 
M W Laboratories Inc  OTC Drug Labeling/New Drug/Misbranded   12/09/2009 
www.sharco.tv  Biological Products Standards  12/09/2009 
LSG SkyChefs DEN 235  PHS Act & Control of Communicable Diseases & Interstate Conveyance Sanitation Violations   12/10/2009 
Teva Parenterals Medicines, Inc.  CGMP for Finished Pharmaceuticals/Adulterated   12/11/2009 
Langit Bali  Tobacco Products/Adulterated/Misbranded   12/14/2009 
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Micromed Technology, Inc  Medical Device Reporting/Misbranded   12/15/2009 
Sibley Memorial Hospital  CGMP for Blood & Blood Products/Adulterated   12/15/2009 
Ohm Laboratories, Inc.  CGMP for Finished Pharmaceuticals/Adulterated   12/21/2009 
Victus, Inc.  Medical Device/CGMP Requirements of Quality System Regulation   12/21/2009 
Micro Current Technology, Inc.  Device Lacks Marketing Clearance Approval/Adulterated/Misbranded   12/24/2009 
Penumbra, Inc.  CGMP/QSR/Medical Devices/Adulterated/Misbranded   12/31/2009 
Ewin Soft and Trade SRL  Tobacco Products/Adulterated/Misbranded   01/05/2010 
Baxter Biosciences  CGMP Deviations  01/15/2010 
Home Remedies Solutions  Premarket Approval/Misbranded/Adulterate d   02/17/2010 
Actavis Elizabeth LLC  Labeling/Promotional Claims False & Misleading/Misbranded   02/18/2010 
HMI Industries, Inc.  CGMP/QSR/Adulterated/Misbranded   02/23/2010 
Karl Storz  CGMP/QSR/Medical Devices/Adulterated   02/23/2010 
Centrix Pharmaceutical Inc  New Drug/Adulterated  02/24/2010 
Guidewire Technologies, Inc.  CGMP/QSR/Medical Devices/Adulterated   02/26/2010 
Edwards Lifesciences, LLC  Device/Misbranded  03/01/2010 
Clearwater Products, LLC  Medical Devices/Adulterated/Misbranded   03/10/2010 
ISTA Pharmaceuticals Inc  Labeling/Promotional Claims False & Misleading/Misbranded   03/10/2010 
Advanced Sterilization Products  CGMP/QSR/Medical Devices/Adulterated   03/12/2010 
BTL Industries, Inc.  Premarket Approval/Misbranded/Adulterate d   03/12/2010 
Endogastric Solutions Inc  Medical Device Reporting (MDR) Regulation Misbranded/Adulterated   03/12/2010 
Intervet International Gmbh  New Animal Drug Application  03/12/2010 
Healthy Body Forero  New Drug/Labeling/False & Misleading Claims/Misbranded   03/15/2010 
Amerilab Technologies, Inc  Labeling/New Drug/Misbranded  03/16/2010 
Glenmark Pharmaceuticals Inc. 3/16/10  Unapproved New Drug/Misbranded   03/16/2010 
Konec Inc. 3/16/10  Unapproved New Drug/Misbranded   03/16/2010 
Chawla, Sant P., M.D.  Clinical Investigator  03/17/2010 
James P. Johnston, CO,  Device/Misbranded,  03/17/2010 
KHL Inc  Device/Misbranded  03/17/2010 
3CPM Company Inc  CGMP/QSR/Medical Devices/Adulterated   03/25/2010 
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Apotex Inc.  CGMP for Finished Pharmaceuticals/Adulterated   03/29/2010 
IVF Phoenix  Human Cells, Tissues & Cellular Products   03/29/2010 
Coats International Holdings, Inc  CGMP Manufacture, Processing, Packing or Holding/Adulterated   03/30/2010 
Deitz, Robert, M.D.  Clinical Investigator  04/01/2010 
7Seas LLC  Dietary Supplement Regulations/Misbranded   04/05/2010 
All About You Medspa, LLC  Lipodissolve/False & Misleading Claims/Misbranded   04/05/2010 
Innovative Directions in Health  Lipdissolve/False & Misleading Claims/Misbranded   04/05/2010 
Aloha Medicinals Inc.  New Animal Drug/Labeling/Misbranded/Adulterated   04/06/2010 
Bryant Ranch Prepack Inc.  New Drug/Labeling/Misbranded/Adulterated   04/08/2010 
Children's Hospital Assoc.  CGMP for Blood & Blood Products/Adulterated   04/08/2010 
E-holistic Health /Hanna Cooper  Unapproved/Unauthorised Products Related to the H1N1 Flu Virus   04/12/2010 
Hospira, Inc.  CGMP for Finished Pharmaceuticals/Deviations/Adulterated   04/12/2010 
GlaxoSmithKline  Labeling/Promotional Claims False & Misleading/Misbranded   04/19/2010 
Brookwood Medical Centre  Institutional Review Board (IRB)   04/22/2010 
Accurate Set Inc.  CGMP/QSR/Adulterated/Misbranded   04/26/2010 
Ephraim McDowell Regional Medical Centre  Institutional Review Board (IRB)   04/26/2010 
Darr Feedlot Inc  CGMP for Medicated Feeds/Adulterated   04/30/2010 
Braintree Laboratories Inc  CGMP For Manufacturing, Processing, Packing, Storage & Holding/Adulterated   05/10/2010 
Healthy World Distributing  Promotional Claims/Misbranded  05/11/2010 
CMC Commodity Transport Inc.  Animal Feed/Adulterated with shredded tire chips   05/12/2010 
Cogent Solutions Group LLC  New Drug/Labeling/Misbranded  05/12/2010 
Endocare  CGMP for Medical Devices/Adulterated   05/17/2010 
Hyperbaric for Life LLC  Medical Device Reporting Regulation/Misbranded   05/20/2010 
AVEVA Drug Delivery Systems, Inc.  CGMP for Finished Pharmaceuticals/Adulterated   05/21/2010 
Dexcom Inc  Medical Device Reporting/Misbranded   05/21/2010 
Feel Good Natural Health  Unapproved/Unauthorised Products Related to the H1N1 Flu Virus   05/21/2010 
K. C. Pharmaceuticals Inc.  CGMP/QSR/Medical Devices/Finished Pharmaceuticals/Adulterated   05/21/2010 
Flexcin International, Inc.  New Drug/Labeling/False & Misleading Claims   05/25/2010 
Encompass Group, LLC  Medical Device Reporting (MDR) Regulation Misbranded   06/02/2010 
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Baxter Healthcare Corporation  Medical Device Reporting (MDR) Regulation/Adulterated   06/03/2010 
Atlas Operations, Inc.  CGMP for Drugs/Manufacture, Processing, Packing, Holding/Adulterated   06/04/2010 
Arizant Inc  CGMP/QSR/Medical Device Reporting/Misbranded   06/07/2010 
Homeopathy For Health  Unapproved/Unauthorised Products Related to the H1N1 Flu Virus   06/08/2010 
Adamis Pharmaceuticals  Unapproved New Drug/Misbranded   06/09/2010 
Artegraft, Inc.  CGMP/QSR/Medical Devices/Adulterated   06/11/2010 
Beckman Coulter Inc.  Premarket Approval/Misbranded  06/21/2010 
Cornerstone Therapeutics, Inc.  False & Misleading Claims/Misbranded   06/22/2010 
AMPAC Fine Chemicals, LLC  CGMP For Manufacturing, Processing, Packing, Storage & Holding/Adulterated   06/25/2010 
Arasys Perfector Inc  Medical Device Reporting (MDR) Regulation Misbranded/Adulterated   06/28/2010 
Hi-Tech Pharmacal Co., Inc.  CGMP for Finished Pharmaceuticals/Adulterated/Misbranded   06/28/2010 
Abbott Diabetes Care, Inc.  CGMP for Medical Devices/QS/Adulterated   07/02/2010 
Country Road Veterinary Services LLC  New Animal Drug/Adulterated/Labeling/Misbranded   07/06/2010 
Jazz Pharmaceuticals  Promotional Claims False & Misleading/Misbranded   07/06/2010 
Florida Bottling, Inc.  New Drug/Drug Labeling/Misbranded   07/08/2010 
AXCAN Scandipharm Inc  DDMAC/Promotional Claims False & Misleading/Misbranded   07/13/2010 
Cincinnati Sub-Zero Products Inc  CGMP For Manufacturing, Processing, Packing, Storage & Holding/Adulterated   07/13/2010 
ARJ Medical, Inc.  CGMP for Medical Devices/QS/Adulterated   07/16/2010 
Independent Review Consulting, Inc  Institutional Review Board (IRB)   07/19/2010 
Haw Par Healthcare Limited  CGMP for Finished Pharmaceuticals/OTC Drug Manufacturing/Adulterated/Misbranded   07/20/2010 
Biomet, Inc.  Premarket Approval/Misbranded/Adulterate d   07/27/2010 
Eaton Manufacturing Corporation Medical Device Reporting/Misbranded   07/27/2010 
Cosmed Labs, Inc.  CGMP for Finished Pharmaceuticals/Adulterated/Misbranded   08/03/2010 
Juice Pac Inc  Juice/HACCP/Adulterated  08/13/2010 
Providence Hospital IRB Clinical Investigator  01/06/2010 
Xian Libang Pharmaceutical Co., Ltd.  CGMP/Manufacturing Facility/Active Pharmaceutical Ingredient   01/28/2010 
Punjwani, Sohail S., M.D.  Bioresearch Monitoring Program   02/04/2010 
Summers, Timothy, MD  Clinical Investigator  02/04/2010 
LASIK Vision Institute LLC  Medical Device Reporting Regulation/Misbranded   02/12/2010 
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Nature'S Gift Inc  Unapproved//Unauthorised Products Related to the H1N1 Flu Virus   02/16/2010 
Unisource, Inc.  Unapproved New Drug/Misbranded   02/17/2010 
Lucky Farm Inc  Adulterated  02/18/2010 
Rx Development Resources, LLC  Labeling/Promotional Claims False & Misleading/Misbranded   02/18/2010 
Vertical Pharmaceuticals, Inc.  Premarket Approval/Misbranded/Adulterate d   02/18/2010 
Tri-Med Laboratories Inc  Current Good Manufacturing Practice Regulation for Finished Pharmaceuticals   02/23/2010 
Mueller Water Conditioning, Inc  CGMP/QSR/Medical Devices/Adulterated   02/24/2010 
Olympus Temmo Biomaterials Corporation CGMP/QSR/Medical Devices/Adulterated   02/25/2010 
Paddock Laboratories, Inc.  New Drugs  03/01/2010 
Perez-Cruet, Miguelangelo J., M.D., M.S.  Investigational Device Exemptions (Clinical Investigator)   03/02/2010 
Sun Technologies, Inc.  Tanning Facility/Federal Performance Standard for Sunlamp Products/Misbranded   03/04/2010 
Otologics LLC  Investigational Device Exemptions (Sponsor)   03/05/2010 
Lin, Henry, M.D.  Clinical Investigator  03/08/2010 
Toledo, Charles H., M.D.  Bioresearch Monitoring Program/IRB   03/11/2010 
Medispec, Ltd.  Device/Lacks Premarket Approval Application/Adulterated/Misbranded   03/12/2010 
Medline Industries Inc.  Medical Devices/Adulterated/Misbranded   03/12/2010 
Orthotic & Prosthetic Lab Inc.  Device/Misbranded  03/17/2010 
Orthotic & Prosthetic Lab, Inc.  Device/Lacks Annual Registration/Misbranded   03/17/2010 
Tinnitus Control, Inc.  Device/Misbranded  03/17/2010 
Tinnitus Control, Inc.  Device/Lacks Annual Registration/Misbranded   03/17/2010 
Vulcon Technologies Inc  Device/Misbranded  03/17/2010 
Paragon Dx, LLC  Premarket Approval/Misbranded/Adulterate d   03/18/2010 
Salix Pharmaceuticals, Inc.  Labeling/Promotional Claims False & Misleading/Misbranded   03/19/2010 
Slate Pharmaceuticals  DDMAC/Promotional Claims False & Misleading/Misbranded   03/24/2010 
Pierre Fabre Medicament Production  CGMP for Finished Pharmaceuticals/Adulterated   03/26/2010 
Wisconsin Brother's Bakery, Inc  Labeling/False & Misleading Claims/Misbranded   03/30/2010 
Medical Cosmetic Enhancements  Lipodissolve/False & Misleading Claims/Misbranded   04/05/2010 
Monarch Med Spa  Lipodissolve/False & Misleading Claims/Misbranded   04/05/2010 
Spa 35  Lipodissolve/False & Misleading Claims/Misbranded   04/05/2010 
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Company Name FDA Warning Letter  (WL) Subject WL Issue Date 
Pure Med Spa  Lipodissolve/False & Misleading Claims/Misbranded   04/06/2010 
Wake Forest University Medical Centre  Device/Adulterated  04/07/2010 
Physician Therapeutics, LLC  New Drug/Labeling/Misbranded/Adulterated   04/08/2010 
Shamrock Medical Solutions Group LLC  CGMP for Finished Pharmaceuticals/Misbranded/Adulterated   04/08/2010 
Storz Medical, AG  Premarket Approval/Misbranded/Adulterate d   04/08/2010 
Pfizer Inc.  Sponsor  04/09/2010 
Mid South Produce Distributors, LLC  CGMP/Adulterated  04/13/2010 
Shreeji Homeo Clinic  Unapproved/Unauthorised Products Related to the H1N1 Flu Virus   04/13/2010 
Super Body Care  Unapproved/Unauthorised Products Related to the H1N1 Flu Virus   04/13/2010 
Templeton Feed & Grain Inc.  CGMP for Medicated Feeds/Adulterated   04/13/2010 
Wayne State University IRB  Institutional Review Board (IRB)   04/15/2010 
Lasik Vision Institute (Boca Raton, FL)  Medical Device Reporting Regulation/Misbranded   04/20/2010 
Milky Way Farm  PHS Act Violation  04/20/2010 
Rainbow Acres Farm  PHS Act Violation  04/20/2010 
TLC Vision Corporation  Medical Device Reporting/Misbranded   04/20/2010 
Uv Flu Technologies, Inc.  Unapproved//Unauthorised Products Related to the 2009 H1N1 Flu Virus   04/20/2010 
Vision Care Holdings, LLC  Medical Device Reporting/Misbranded   04/20/2010 
Novartis Oncology  False & Misleading Claims/Unapproved Use/Misbranded   04/21/2010 
L. Perrigo Company  CGMP for Finished Pharmaceuticals/Adulterated   04/29/2010 
Vision Pharm, LLC  Lacks Approved New Drug Application/Adulterated/Misbranded   04/29/2010 
Medtronic Navigation, Inc  Medical Device/Lacks Premarket Approval/Adulterated/Misbranded   05/07/2010 
Midstate Veterinary Services, PLLC  Extra label Drug Use in Animals/Adulterated   05/10/2010 
River's Edge Pharmaceuticals, LLC  CGMP for Finished Pharmaceuticals/Adulterated/Misbranded   05/20/2010 
Syntron Bioresearch Inc.  CGMP/QSR/Medical Device Reporting/Adulterated   05/24/2010 
Toby's Nose Filters, Inc.  Premarket Approval/Adulterated   05/25/2010 
Pfizer, Inc.  Post-marketing Adverse Drug Experience Reporting Requirements   05/26/2010 
Ribbon SRL  CGMP Regulation for Finished Pharmaceuticals/Adulterated   05/27/2010 
Yancey, Samuel DVM  Extra label Drug Use in Animals/Adulterated   05/28/2010 
Piezosurgery Inc.  CGMP for Medical Devices/QS/Adulterated   06/08/2010 
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Company Name FDA Warning Letter  (WL) Subject WL Issue Date 
Libido Edge Labs, Llc  Unapproved New Drug Promotional Claims/Misbranded   06/10/2010 
Medefil Incorporated  CGMP/QSR/Medical Devices/Adulterated   06/10/2010 
Optovue Inc.  CGMP/QSR/Medical Devices/Adulterated/Misbranded   06/11/2010 
Pozner, Jason M.D.  Investigational Device Exemptions (Clinical Investigator)   06/25/2010 
Nemechek Do Pa, Patrick  Institutional Review Board (IRB)   06/28/2010 
Regancrest Holsteins, Inc.  Extra label Drug Use in Animals/Adulterated   07/02/2010 
Replication Medical Inc  Medical Device/Lacks Premarket Approval/Adulterated/Misbranded   07/02/2010 
Western Milling Company  CGMP for Medicated Feeds/Adulterated/Misbranded   07/06/2010 
Med Prep Consulting, Inc  Failure to Register and List/Misbranded   07/09/2010 
Stuart Harlin, Md  Clinical Investigator  07/21/2010 
Nitrox, Inc.  CGMP for Finished Pharmaceuticals/Adulterated/Misbranded   07/26/2010 
Life Recovery Systems HD, LLC  Medical Device/Lacks Premarket Approval/Adulterated/Misbranded   07/28/2010 
Scully, Sean M.D.  Investigational Device Exemptions (Clinical Investigator)   07/30/2010 
MP Biomedicals LLC  CGMP/QSR/Manufacture/Packing/Storage/Installation/Adulterate d/Misbranded   08/02/2010 
Pioneer Surgical Technology  Sponsor/Clinical Investigator  08/03/2010 
Starion Instruments  Device/Adulterated  8/10/2010 
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A11: BIOTECHNOLOGY 
There are 2713 l ines of  raw data which is too large for  th is appendix.  Summary informat ion describ ing the raw data is provided in table 
below 
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Small Molecule (SM) Product 
Launch    
2002 40 33 7 15 24 2 16 39 8 9 12 205  
2003 18 14 10 4 23 0 6 18 3 16 7 119  
2004 13 37 5 10 26 4 13 28 12 14 9 171  
2005 16 43 11 7 14 4 8 41 7 12 9 172  
2006 32 35 8 4 30 0 7 22 1 30 4 173  
2007 33 21 12 11 9 6 16 31 7 23 21 190  
2008 26 32 6 9 6 0 1 12 7 19 13 131  
2009 42 56 11 7 16 2 7 15 4 24 11 195  
2010 29 60 9 6 22 0 5 17 3 32 14 197  
2011 56 62 17 4 19 3 7 31 7 41 9 256  
2012 14 21 22 5 19 0 10 20 0 49 18 178  
2013 26 24 18 3 2 0 2 6 0 29 9 119  
2014 9 9 7 3 2 3 0 11 4 17 7 72  
<2002 424 359 81 104 188 44 123 317 19 129 161   
>2015 88 224 117 13 22 31 66 109 3 203 155   
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Large Molecule (LM) Product 
Launch    
2002 1 1 4 0 0 0 5 5 0 6 0 22  
2003 0 0 7 0 0 0 10 3 0 0 2 22  
2004 0 2 7 0 2 2 3 1 0 15 0 32  
2005 0 1 8 0 1 0 5 8 0 2 3 28  
2006 0 3 14 0 3 0 3 17 0 2 0 42  
2007 0 0 8 0 0 4 1 3 0 1 0 17  
2008 0 0 0 0 1 7 8 2 0 5 0 23  
2009 0 0 5 0 0 2 17 7 0 10 1 42  
2010 4 0 7 0 4 0 7 17 4 8 0 51  
2011 3 2 2 0 0 5 8 9 0 7 2 38  
2012 1 12 6 0 0 4 10 2 0 27 0 62  
2013 0 9 9 0 0 4 7 0 0 10 0 39  
2014 0 17 7 0 0 1 10 5 0 13 0 53  
<2002 19 15 72 7 10 35 32 103 0 50 4   
>2015 14 32 35 0 3 0 70 59 9 122 24   
Launch Year 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 
SM Launch (ALL markets) 205 119 171 172 173 190 131 195 197 256 178 119 72 
LM Launch (ALL markets) 22 22 32 28 42 17 23 42 51 38 62 39 53 
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A12: NANOMEDICINE 
 
Therapy Area 
Marketed 
Nanomedicine Products 
Cardiology 3 
Central Nervous System 2 
Genitourinary 2 
Immunology & Inflammation 3 
Infectious Diseases 10 
Metabolic Disorders 3 
Musculoskeletal 3 
Oncology 8 
Ophthalmology 2 
Total 36 
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A13: BIOINFORMATICS 
 
Patent Number Title Country Year 
EP1607898 (A2) A bioinformatics system for functional proteomics modeling EP 2005 
WO2008000186 (A1) A method for identifying novel gene And the resulting novel genes WO 2008 
CN101234113 (A) Anti-tumor small molecular compound targeting to phosphatidylethanolamine conjugated protein 4 of human CN 2008 
7062076 Artificial intelligence system for genetic analysis  US 2006 
6876930 Automated pathway recognition system  US 2005 
US2009048125 (A1) Biochip micro-system for bioinformatics recognition and analysis US 2009 
US2004236516 (A1) 
Bioinformatics based system for assessing a condition of a performance animal by analyzing nucleic acid 
expression 
US 2004 
US2008133474 (A1) Bioinformatics computation using a map-reduce-configured computing system US 2008 
US2009138251 (A1) Bioinformatics research and analysis system and methods associated therewith US 2009 
US2008033999 (A1) Bioinformatics system architecture with data and process integration US 2008 
US2003176976 (A1) Bioinformatics system architecture with data and process integration for overall portfolio management US 2003 
US2003149595 (A1) Clinical bioinformatics database driven pharmaceutical system US 2003 
7294487 Combinatorial oligonucleotide PCR: a method for rapid, global expression analysis  US 2007 
7332282 Compositions and methods for detecting and treating neurological conditions  US 2008 
7527930 Compositions and methods of use of standardised mixtures for determining an amount of a nucleic acid  US 2009 
US2004224345 (A1) Computational method and system for modeling, analyzing, and optimizing DNA amplification and synthesis US 2004 
CN101320404 (A) Computer automatic sorting method of biological virus CN 2008 
US2009018809 (A1) Computer gene US 2009 
7031843 Computer methods and systems for displaying information relating to gene expression data  US 2006 
US2008097939 (A1) Data mining platform for bioinformatics and other knowledge discovery US 2008 
US2004003132 (A1) Data pool architecture, system, and method for intelligent object data in heterogeneous data environments US 2004 
US6631331 (B1) Database system for predictive cellular bioinformatics US 2003 
US2007005263 (A1) Database system including computer code for predictive cellular bioinformatics US 2007 
7392199 Diagnosing unapparent diseases from common clinical tests using Bayesian analysis  US 2008 
7472121 Document comparison using multiple similarity measures  US 2008 
7603304 Domain specific return on investment model system and method of use  US 2009 
US2003099973 (A1) E-GeneChip online web service for data mining bioinformatics US 2003 
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Patent Number Title Country Year 
JP2008117363 (A) Execution method of bioinformatics analysis and bioinformatics analysis platform JP 2008 
7542959 Feature selection method using support vector machine classifier  US 2009 
7049072 
Gene expression analysis of pluri-differentiated mesenchymal progenitor cells and methods for diagnosing a 
leukemic disease state  
US 
2006 
6912470 Genes and proteins involved in the biosynthesis of enediyne ring structures  US 2005 
7625699 Genetic polymorphisms associated with coronary stenosis, methods of detection and uses thereof  US 2009 
7321830 Identifying drugs for and diagnosis of benign prostatic hyperplasia using gene expression profiles  US 2008 
7604955 Immunoglobulin E vaccines and methods of use thereof  US 2009 
US2009063259 (A1) Information system for biological and life sciences research US 2009 
7493265 Integrated biomedical information portal system and method  US 2009 
7617163 Kernels and kernel methods for spectral data  US 2009 
7370021 Medical applications of adaptive learning systems using gene expression data  US 2008 
6970790 
Method and apparatus for analysis of molecular combination based on computational estimation of electrostatic 
affinity using basis expansions  
US 
2005 
US2006045348 (A1) Method and apparatus for automated cellular bioinformatics US 2006 
6141657 Method and apparatus for identifying classifying or quantifying DNA sequences in a sample without sequencing  US 2000 
6453245 
Method and apparatus for identifying, classifying, or quantifying protein sequences in a sample without 
sequencing  
US 
2002 
US2004229210 (A1) Method and apparatus for predictive cellular bioinformatics US 2004 
US2002012456 (A1) Method and apparatus for providing a bioinformatics database US 2002 
7356416 
Method and system for automated inference creation of physico-chemical interaction knowledge from 
databases of co-occurrence data  
US 2008 
6768982 Method and system for creating and using knowledge patterns  US 2004 
7467153 Method and system for efficient collection and storage of experimental data  US 2008 
6813615 Method and system for interpreting and validating experimental data with automated reasoning  US 2004 
6516288 Method and system to construct action coordination profiles  US 2003 
6853952 Method and systems of enhancing the effectiveness and success of research and development  US 2005 
7565247 Method for acquisition, storage, and retrieval of cell screening data on a computer system  US 2009 
6721663 Method for manipulating protein or DNA sequence data in order to generate complementary peptide ligands  US 2004 
6996473 Method for screening and producing compound libraries  US 2006 
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Patent Number Title Country Year 
US2004068381 (A1) Method of handling database for bioinformatics US 2004 
US2010030719 (A1) Method and apparatus related to bioinformatics data analysis US 2010 
6855554 Methods and compositions for detection of breast cancer  US 2005 
6355423 Methods and devices for measuring differential gene expression  US 2002 
6873914 Methods and systems for analyzing complex biological systems  US 2005 
7415359 
Methods and systems for the identification of components of mammalian biochemical networks as targets for 
therapeutic agents  
US 
2008 
6511808 Methods for designing exogenous regulatory molecules  US 2003 
7620502 Methods for identifying sets of oligonucleotides for use in an in vitro recombination procedure  US 2009 
7058515 Methods for making character strings, polynucleotides and polypeptides having desired characteristics  US 2006 
7206699 Methods for measuring therapy resistance  US 2007 
7089121 Methods for monitoring the expression of alternatively spliced genes  US 2006 
7217510 Methods for providing bacterial bioagent characterizing information  US 2007 
7599799 Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns  US 2009 
6882990 Methods of identifying biological patterns using multiple data sets  US 2005 
7117188 Methods of identifying patterns in biological systems and uses thereof  US 2006 
US2003177143 (A1) Modular bioinformatics platform US 2003 
EP1466289 (A2) Nonlinear system identification for class prediction in bioinformatics and related applications EP 2004 
CN101627989 (A) Novel anti-tumor application of organic small-molecular compound JFD-03169 CN 2010 
CN101627994 (A) Novel anti-tumor application of organic small-molecular compound JFD-03554 CN 2010 
6647358 Pharmacokinetic-based drug design tool and method  US 2003 
US6677114 (B1) Polypeptide fingerprinting methods and bioinformatics database system US 2004 
7475048 Pre-processed feature ranking for a support vector machine  US 2009 
7379822 Protein design automation for protein libraries  US 2008 
7177766 
Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to 
preselected sites  
US 
2007 
6389428 System and method for a precompiled database for biomolecular sequence information  US 2008 
7356521 System and method for automatic molecular diagnosis of ALS based on boosting classification  US 2008 
US2004249847 (A1) System and method for identifying coherent objects with applications to bioinformatics and E-commerce US 2004 
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Patent Number Title Country Year 
US2010094889 (A1) System, method and computer program for non-binary sequence comparison US 2010 
US2010130371 (A1) 
System, method, device, and computer program product for extraction, gathering, manipulation, and analysis of 
peak data from an automated sequencer US 2010 
7425700 Systems and methods for discovery and analysis of markers  US 2008 
US2003176929 (A1) User interface for a bioinformatics system US 2003 
JP2010249831 (A)    2010 
CN101812500 (A)   CN 2010 
JP2010142230 (A)  JP 2010 
CN101810608 (A)  CN 2010 
US2008270438 (A1)  US 2010 
CN101320404 (B)   CN 2010 
US7711491 (B2)  US 2010 
7546210 Visual-serving optical microscopy  US 2009 
 
	 
    
198 
A14: PERVASIVE/CLOUD COMPUTING 
 
Patent Number Title Issue 
Year 
7520611 system for vision examination utilizing telemedicine  2009 
7500795 apparatuses, systems and methods for enhancing telemedicine, video-conferencing, and video-based sales  2009 
7232220 system for vision examination utilizing telemedicine  2007 
6949073 dyspnea monitor, and telemedicine system and method  2005 
6820057 telemedicine system  2004 
6610010 portable telemedicine device  2003 
6575900 meter with integrated database and simplified telemedicine capability  2003 
6409660 portable telemedicine device  2002 
6038465 telemedicine patient platform  2000 
6033076 visual field testing via telemedicine  2000 
6027217 automated visual function testing via telemedicine  2000 
7742811 implantable device and method for the electrical treatment of cancer  2010 
7582080 implantable, tissue conforming drug delivery device  2009 
7526335 communications system for an implantable device and a drug dispenser  2009 
7519409 implantable cell/tissue-based biosensing device  2009 
7505869 non-conformance monitoring and control techniques for an implantable medical device  2009 
7415384 therapy management techniques for an implantable medical device  2008 
7285304 fluid treatment of a polymeric coating on an implantable medical device  2007 
7072802 therapy management techniques for an implantable medical device  2006 
7054782 non-conformance monitoring and control techniques for an implantable medical device  2006 
7052488 implantable drug delivery device  2006 
6799149 therapy management techniques for an implantable medical device  2004 
6738663 implantable device and method for the electrical treatment of cancer  2004 
6615083 implantable medical device system with sensor for hemodynamic stability and method of use  2003 
6512949 implantable medical device for measuring time varying physiologic conditions especially edema and for responding thereto 2003 
7632234 implantable biosensor devices for monitoring cardiac marker molecules  2009 
7433727 implantable biosensor  2008 
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Patent Number Title Issue 
Year 
7223237 implantable biosensor and methods for monitoring cardiac health  2007 
7146203 implantable biosensor and methods of use thereof  2006 
6965791 implantable biosensor system, apparatus and method  2005 
6699186 methods and apparatus for deploying and implantable biosensor  2004 
7676263 minimally invasive system for selecting patient-specific therapy parameters  2010 
7630986 secure data interchange  2009 
7616117 reconciliation mechanism using rfid and sensors  2009 
7593952 enhanced medical treatment system  2009 
7587368 information record infrastructure, system and method  2009 
7587259 items dispenser  2009 
7575770 continuous production and packaging of perishable goods in low oxygen environments  2009 
7502664 system and method for interactive items dispenser  2009 
7502643 method and apparatus for measuring heart related parameters  2009 
7436311 adaptive communication methods and systems for facilitating the gathering, distribution and delivery of information related 
to medical care  
2008 
7415428 processing meat products responsive to customer orders  2008 
7205016 packages and methods for processing food products  2007 
7181017 system and method for secure three-party communications  2007 
7155306 medication administration system  2006 
7107155 methods for the identification of genetic features for complex genetics classifiers  2006 
7061831 product labeling method and apparatus  2006 
7043415 interactive graphical environment for drug model generation  2006 
7034691 adaptive communication methods and systems for facilitating the gathering, distribution and delivery of information related 
to medical care  
2006 
6986739 architecture tool and methods of use  2006 
6965816 pfn/trac system faa upgrades for accountable remote and robotics control to stop the unauthorised use of aircraft and to 
improve equipment management and public safety in transportation  
2005 
6889165 application specific intelligent microsensors  2005 
6842877 contextual responses based on automated learning techniques  2005 
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Patent Number Title Issue 
Year 
6817980 automated diagnostic system and method including disease timeline  2004 
6767325 automated diagnostic system and method including synergies  2004 
6764447 automated diagnostic system and method including alternative symptoms  2004 
6746399 automated diagnostic system and method including encoding patient data  2004 
6730027 automated diagnostic system and method including multiple diagnostic modes  2004 
6569093 automated diagnostic system and method including disease timeline  2003 
6527713 automated diagnostic system and method including alternative symptoms  2003 
6524241 automated diagnostic system and method including multiple diagnostic modes  2003 
6522945 customer specific packaging line  2003 
6519601 relational database compiled/stored on a memory structure providing improved access through use of redundant 
representation of data  
2003 
6475143 automated diagnostic system and method including encoding patient data  2002 
6468210 automated diagnostic system and method including synergies  2002 
6401085 mobile communication and computing system and method  2002 
6373786 cap for a hermetically sealed container  2002 
6356905 system, method and article of manufacture for mobile communication utilizing an interface support framework  2002 
6317648 customer specific packaging line having containers with tag means containing medication order information  2001 
6199099 system, method and article of manufacture for a mobile communication network utilizing a distributed communication 
network  
2001 
6132724 allelic polygene diagnosis of reward deficiency syndrome and treatment  2000 
6051249 dressing having a three-dimensional part and processes for the preparation of such a dressing  2000 
7594889 integrated data collection and analysis for clinical study  2009 
7177699 lifestyle management system  2007 
7087027 device and method for monitoring respiration  2006 
6917829 method and system for a distributed analytical and diagnostic software over the intranet and internet environment  2005 
6805667 information remote monitor (irm) medical device  2004 
6735479 lifestyle management system  2004 
6454708 portable remote patient telemonitoring system using a memory card or smart card  2002 
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Patent Number Title Issue 
Year 
6416471 portable remote patient telemonitoring system  2002 
6334778 remote psychological diagnosis and monitoring system  2002 
US2010331711 (A1) - 2010 
US2010318380 (A1) - 2010 
US2010279718 (A1) - 2010 
EP2238552 (A1)  - 2010 
KR20100107266 (A) - 2010 
EP2207479 (A1) telemedicine care 2010 
KR20100055261 (A) total telemedicine system for hospital using a docking station and ultra mobile personal computer and management 
method threrof 
2010 
AU2008322641 (A1) a telemedicine application for remote monitoring, viewing and updating of patient records 2009 
KR20100005880 (A) telemedicine device and core body predictor by telemedicine device 2010 
US2010063395 (A1) telemedicine platform for standardised interpretation of vascular data using vascular analysis 2010 
EA008266 (B1) telemedicine system 2007 
WO2009138968 (A2) improved devices and method for safe remote healthcare delivery through telemedicine 2009 
WO2009126399 (A1) telemedicine system and method 2009 
US2009167842 (A1) apparatuses, systems and methods for enhancing telemedicine 2009 
WO2009095021 (A1) telemedicine unit 2009 
US2009112070 (A1) telemedicine device and system 2009 
CN101569521 (A) telemedicine monitoring system 2009 
US2009167838 (A1) method and apparatus for cleaning a telemedicine station 2009 
WO2008043341 (A1) telemedicine system, especially for chronic diseases 2008 
US2009083066 (A1) method for routing user service requests from a telemedicine station 2009 
WO2008031067 (A2) mobile telemedicine vehicle 2008 
WO2008028912 (A2) method and device for deriving and evaluating cardiovascular information from curves of the cardiac current, in particular 
for applications in telemedicine 
2008 
WO2008022423 (A2) telemedicine system for remote monitoring of patients 2008 
KR20090003459 (A) system and method for controlling telemedicine 2009 
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Year 
US2007195267 (A1) system for vision examination utilizing telemedicine 2007 
CN101239004 (A) telemedicine image digital acquisition device and method thereof 2008 
WO2007056601 (A2) methods and apparatus for context-sensitive telemedicine 2007 
JP2007073065 (A) telemedicine system and terminal used for the same 2007 
KR20080029391 (A) system for telemedicine with wireless transmission, method for telemedicine using this system and recording medium 
thereof 
2008 
JP2007293499 (A) telemedicine system using multifunctional video telephone 2007 
KR100763757 (B1) system for telemedicine by load balancing and method service providing thereof 2007 
US2006167346 (A1) telemedicine system 2006 
WO2006088574 (A2) multifunction telemedicine software with integrated electronic medical record 2006 
DE102005048752 (A1) method for interactive picture and sound transmission in telemedicine, involves picture presentation and bi-directional 
audio connection which are enabled by means of standard browser software of computer attached to computer network 
2007 
US2006122466 (A1) telemedicine system comprising a modular universal adapter 2006 
JP2006021031 (A) telemedicine system and artificial pancreas system 2006 
KR20050049448 (A) residential district Centre of telemedicine system by internet and its method 2005 
US2005149364 (A1) multifunction telemedicine software with integrated electronic medical record 2005 
DE102004059713 (A1) road accident telemedicine initiation system has network connected portable modular emergency box for cars with 
communications and data interfaces to call centre and regional emergency centre 
2005 
KR20060044054 (A) method and system for providing telemedicine service by using mobile communication terminal 2006 
US2005043969 (A1) telemedicine system, and method for communication with remotely located patients 2005 
US2006064319 (A1) method for telemedicine services 2006 
JP2005352969 (A) telemedicine support system 2005 
JP2005346552 (A) telemedicine audit system and telemedicine audit method 2005 
KR20050115510 (A) telemedicine system for heart disease 2005 
KR100439442 (B1) method for reserving telemedicine depending on patient condition using communication network 2004 
US2004153340 (A1) method for monitoring telemedicine healthcare services 2004 
DE10342823 (A1) implanted prosthesis seat check has two axis acceleration sensor with wireless data transmission to telemedicine centre 
to determine movement relative to bone 
2005 
US2005049898 (A1) telemedicine system using the internet 2005 
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Patent Number Title Issue 
Year 
US2004039606 (A1) telemedicine system 2004 
WO03101289 (A1) deployable telemedicine system 2003 
US2004054760 (A1) deployable telemedicine system 2004 
KR20040098982 (A) system for automatically paging telemedicine by using wireless sub terminal, and automatic telemedicine method using 
the same 
2004 
FR2853100 (A1) interlocutor emotional state transmission device for e.g. telemedicine, has sensors obtaining sensory information e.g. heart 
beat, of interlocutor, and coding circuit transforming information to emotional state code 
2004 
WO03085508 (A1) electronic needle mouse and telemedicine service system using it 2003 
WO03073922 (A1) system for vision examination utilizing telemedicine 2003 
RU2251965 (C2) data analysis system in the field of telemedicine 2005 
DE10303665 (A1) telemedicine system for remote collection of patient data whereby system access is controlled so that it can be ensured 
medical measurement data is collected in a correct manner 
2004 
KR20040057317 (A) system for telemedicine service based on high quality multimedia using mpeg method 2004 
WO03053232 (A1) telemedicine system, use thereof and telemedicine patient care 2003 
DE10254939 (A1) telemedicine system for providing online disease diagnosis by a certificated or authenticated grader of medical images or 
signals, whereby images are entered at one point and a previously authorised person accesses them remotely 
2004 
DE10247440 (A1) computer and network based telemedicine therapy system in which a control data packet is sent at the beginning of each 
therapy session to a patient computer that includes instructions relating to any changes in therapy 
2003 
KR20040017579 (A) method for telemedicine serive using digital set-top box 2004 
KR20040017031 (A) pda based mobile telemedicine system 2004 
AU2002300622 (B2) telemedicine system 2004 
EP1282062 (A2) method for mediating for a telemedicine healthcare service provider 2003 
JP2004054489 (A) remote medical information system, information processing method, computer program, recording medium for computer 
program, and telemedicine system 
2004 
KR20040007003 (A) telemedicine system and controlling method thereof 2004 
JP2004041472 (A) telemedicine information system 2004 
WO03003912 (A1) telemedicine system 2003 
EP1267297 (A2) method for controlling and monitoring the process flow to determine the performance of a telemedicine healthcareservice 2002 
US2002115916 (A1) portable telemedicin device 2002 
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US2003184649 (A1) telemedicine booking station for mass casualty intake facility, relocation Centre, or the like, arising from bioterror hostage 
standoff, civil disobedience, or the like 
2003 
WO02073829 (A1) maritime telemedicine system using satellite communication network 2002 
KR20030060273 (A) method and system for telemedicine using local area wireless interface 2003 
DE10154908 (A1) telemedicine system comprising doctor-side consultation Centre and mobile patient-side telemedicine devices that have a 
number of functional modules for recording medical data that can be linked to a base and communications module 
2003 
US2001056226 (A1) integrated telemedicine computer system 2001 
CA2343497 (A1) virtual cosmetic autosurgery via telemedicine 2001 
KR20020047586 (A) method for operating telemedicine service using wireless communication terminal 2002 
CA2323685 (A1) autointerpretation of medical diagnostic tests via telemedicine 2001 
KR20020016289 (A) method and system for telemedicine using internet 2002 
KR20020013311 (A) method for real time telemedicine using data communication service of mobile communication network 2002 
KR20020009302 (A) telemedicine method and system 2002 
KR20020005884 (A) telemedicine method using internet 2002 
US6575900 (B1) meter with integrated database and simplified telemedicine capability 2003 
WO0057774 (A1) meter with integrated database and simplified telemedicine capability 2000 
WO0022388 (A1) telemedicine patient platform 2000 
US6820057 (B1) telemedicine system 2004 
US6409660 (B1) portable telemedicine device 2002 
US6033076 (A) visual field testing via telemedicine 2000 
US6027217 (A) automated visual function testing via telemedicine 2000 
TW400503 (B) a packet-based telemedicine system for communicating information between central monitoring stations and remote 
patient monitoring stations 
2000 
EP1027459 (A1) telemedicine 2000 
AU747299 (B2) telemedicine system 2002 
SE513506 (C2) portable telemedicine apparatus used in preliminary diagnostic procedures 2000 
US2010023071 (A1) systems and devices for neural stimulation and controlled drug delivery 2010 
US2008228133 (A1) delivery of a sympatholytic cardiovascular agent to the central nervous system 2008 
US2008058772 (A1) personal paramedic 2008 
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Year 
WO2007035445 (A1) implantable co-fired electrical feedthroughs 2007 
WO2007035443 (A1) miniaturised co-fired electrical interconnects for implantable medical devices 2007 
WO2007035332 (A1) implantable co-fired electrical interconnect systems and devices and methods of fabrication therefor 2007 
US2007265662 (A1) implantable electromagnetic interference tolerant, wired sensors and methods for implementing same 2007 
US2007060974 (A1) cognitive function within a human brain 2007 
US2008168921 (A1) method for making device for controlled reservoir opening by electrothermal ablation 2008 
WO2005041767 (A2) medical device for sensing glucose 2005 
US2005096587 (A1) medical device for sensing glucose 2005 
WO2004033034 (A1) medical device for neural stimulation and controlled drug delivery 2004 
US2002013545 (A1) synthetic muscle based diaphragm pump apparatuses 2002 
US2010128104 (A1) communication system for remote patient visits and clinical status monitoring 2010 
US2010106046 (A1) device and method for predicting and preventing pulmonary edema and management of treatment thereof 2010 
US2008281633 (A1) periodic evaluation and telerehabilitation systems and methods 2008 
US2008249801 (A1) distributed system for monitoring patient video, audio and medical parameter data 2008 
CN101099666 (A) method and system for clinical interpretation and review of patient data 2008 
GB2440019 (A) clinical interpretation and review of patient data 2008 
US2007203415 (A1) system and method for determining edema through remote patient monitoring 2007 
US2008255874 (A1) system and method for delivering clinical notifications 2008 
WO2006104843 (A1) integrated data collection and analysis for clinical study 2006 
CN1788676 (A) radio remote monitoring system for cardiogram 2006 
WO2006033927 (A1) clinic dashboard monitor 2006 
US2006224421 (A1) integrated data collection and analysis for clinical study 2006 
JP2005253981 (A) patient monitoring apparatus 2005 
US2005200486 (A1) patient visual monitoring system 2005 
US2004199221 (A1) lifestyle management system 2004 
CN1524489 (A) long range real-time monitoring system of a clinical monitoring equipment 2004 
WO03020127 (A1) lifestyle management system 2003 
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Patent Number Title Issue 
Year 
US2004006265 (A1) wireless transmission-st-segment preserved of the standard 12 leads ekg apparatus for the remote administration of 
thrrombolytic therapy under severe cellular channel impairment 
2004 
US2003199780 (A1) device and method for monitoring respiration 2003 
JP2002245578 (A) hazardous event automatic notifying system and method 2002 
WO0212981 (A2) method and system for a distributed analytical and diagnostic software over the intranet and internet environment 2002 
US2002107452 (A1) method and system for a distributed analytical and diagnostic software over the intranet and internet environment 2002 
WO0193756 (A2) portable remote patient telemonitoring system using a memory card or smart card 2001 
US2003036683 (A1) method, system and computer program product for internet-enabled, patient monitoring system 2003 
US2001048077 (A1) apparatus and method for spectroscopic analysis of human or animal tissue or body fluids 2001 
KR20010095353 (A) maritime remote medical system using satellite communication network 2001 
WO0156467 (A1) information remote monitor (irm) medical device 2001 
US2002045804 (A1) information remote monitor (irm) medical device 2002 
JP2001222445 (A) device and method for operating failure diagnosis, maintenance and upgrade work from remote site of device system for 
implantation 
2001 
US6454708 (B1) portable remote patient telemonitoring system using a memory card or smart card 2002 
US6334778 (B1) remote psychological diagnosis and monitoring system 2002 
WO2010107243 (A3) - 2010 
US2010274101 (A1) - 2010 
US2010228110 (A1)  - 2010 
CA2701006 (A1) implantable biosensor and methods of use thereof 2008 
WO2010056624 (A2) long-term implantable biosensor 2010 
US2010056885 (A1) implantable biosensor devices for monitoring cardiac marker molecules 2010 
US2010056888 (A1) implantable biosensor and sensor arrangement 2010 
WO2009008932 (A2) implantable wireless cmos biosensor 2009 
US2009221882 (A1) implantable biosensor assembly and health monitoring system and method including same 2009 
US2006241365 (A1) implantable biosensor and methods of use thereof 2006 
WO2006113352 (A2) implantable biosensor 2006 
WO2006062668 (A2) catheter-free implantable needle biosensor 2006 
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US2005183954 (A1) implantable biosensor system, apparatus and method 2005 
EP1588737 (A1) implantable biosensor and methods for monitoring cardiac health 2005 
US2005107677 (A1) implantable biosensor 2005 
GB2441078 (A) systems biology based therapeutic modeling and implantable devices 2008 
WO2005011490 (A1) implantable biosensor 2005 
US2005123680 (A1) micro reference electrode of implantable continuous biosensor using iridium oxide, manufacturing method thereof, and 
implantable continuous biosensor 
2005 
WO03091701 (A2) implantable biosensor from stratified nanostructured membranes 2003 
US2004023317 (A1) implantable biosensor from stratified nanostructured membranes 2004 
US6699186 (B1) methods and apparatus for deploying and implantable biosensor 2004 
JP2010279707 (A)  2010 
WO2010138875 (A1)  2010 
WO2010126535 (A1)  2010 
WO2010124137 (A1)   2010 
US2010274587 (A1)  2010 
US2010179820 (A1) automated analysis of data collected by in-vivo devices 2010 
US2010179828 (A1) presenting related results during medication administration documentation 2010 
WO2010054205 (A2) smart medicine container 2010 
WO2010042444 (A1) devices and methods for determining a patient's propensity to adhere to a medication prescription 2010 
US2010070304 (A1) system and method for recognizing medication side effects in patients 2010 
JP2009273502 (A) medication monitoring apparatus 2009 
US7630908 (B1) wireless electronic prescription scanning and management system 2009 
US2009276243 (A1) healthcare notification method and system including a healthcare website 2009 
JP2009142674 (A) medication delivery system 2009 
US2009265189 (A1) medication therapy review methods 2009 
JP2009009609 (A) medical examination support device 2009 
US2009012822 (A1) medical records, documentation, tracking and order entry system 2009 
US2008306768 (A1) healthcare notification method and system including a healthcare website 2008 
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Year 
US2008275425 (A1) method of controlling a medication delivery system with a removable label containing instructions for setting medication 
delivery rate overlying a second label with patient instructions 
2008 
WO2009009149 (A1) electronic patient compliance device 2009 
US2008215374 (A1) clinical management system and methods 2008 
US2008183091 (A1) cardiac event categorization system 2008 
US2008154646 (A1) system and program for electronically maintaining medical information between patients and physicians 2008 
US2008208914 (A1) centralised mining of remote medical records databases 2008 
JP2009146367 (A) system for protecting member personal information with limited leak of individual non-specification information even in 
database information leak by writing information for treatment, contraindicated drug or individual specification into 
electronic information storage area of ic chip type member card in easily browsable, confirmable and changeable manner 
at medical institution and by storing only individual non-specification information in external disclosure database 
2009 
US2009144087 (A1) medication identifying and organizing system 2009 
US2009106313 (A1) interactive prescription processing and managing system 2009 
US2008059528 (A1) patient care order and scanned document processing system 2008 
US2008053040 (A1) assembly, production and quality assurance processes respecting electronic compliance monitor (ecm) tags 2008 
US2008015897 (A1) method and system for delivering prescription medicine 2008 
US2008312965 (A1) medical compliance software based system and computer writeable medium 2008 
US2009151721 (A1) dispensing device 2009 
US2008255874 (A1) system and method for delivering clinical notifications 2008 
WO2007106458 (A2) methods and systems for using practice management data 2007 
JP2007073074 (A) medical information processing system, medical information processing method, information processor and information 
processing method 
2007 
WO2008016319 (A1) a portable patient control system with storage box 2008 
WO2007013952 (A2) medication compliance system and associated methods 2007 
US2007123772 (A1) medication compliance system and associated methods 2007 
KR20070117166 (A) electonic medical record system 2007 
US2007033073 (A1) system and user interface for monitoring patient treatment orders 2007 
WO2006094288 (A2) method and apparatus for mobile health and wellness management incorporating real-time coaching and feedback, 
community and rewards 
2006 
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Patent Number Title Issue 
Year 
WO2006069268 (A1) system and method for analysis of neurological condition 2006 
US2006136806 (A1) system and method for analysis of neurological condition 2006 
US2006080145 (A1) method for reviewing electronic patient medical records to assess and improve the quality and cost effectiveness of 
medical care 
2006 
JP2007074068 (A) video apparatus, system of supervised administration of medication, method of supervised administration of medication 
with video apparatus, and program thereof 
2007 
WO2006056002 (A1) patient medication management system 2006 
US2005119604 (A1) medicament dispenser 2005 
CA2565210 (A1) installation for filling packaging units with medicaments for patients according to the prescribed weekly requirements 2005 
US2006136261 (A1) system and method for maintaining the association of healthcare orders from a healthcare plan in a computerised medical 
administration record 
2006 
JP2006149797 (A) patient information network system 2006 
JP2006146820 (A) information display method in electronic medical chart system and electronic medical chart 2006 
US2005182656 (A1) on-line prescription service system and method 2005 
JP2006051244 (A) system for supporting infusion of medicine or the like in home 2006 
US2004143171 (A1) method for generating patient medication treatment recommendations 2004 
US2004081587 (A1) marker detection method and apparatus to monitor drug compliance 2004 
EP1422649 (A2) method for monitoring the taking of medicines 2004 
US2005086077 (A1) physician workstation computer software program: system and method for making prescription writing and other medical 
tasks simple and easy 
2005 
US2005027560 (A1) interactive multi-user medication and medical history management method 2005 
WO2004006062 (A2) prescription data exchange system 2004 
JP2004348271 (A) clinical trial data outputting device, clinical trial data outputting method, and clinical trial data outputting program 2004 
US2004010204 (A1) electronic/fiberoptic tissue differentiation instrumentation 2004 
JP2004252535 (A) method and system of electronic pharmacy 2004 
US2004162740 (A1) digitised prescription system 2004 
JP2003248722 (A) method and system for managing medical care register 2003 
JP2004212504 (A) prescription using electronic paper with ic 2004 
US2003154104 (A1) method of operating a savings plan for health care services 2003 
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Year 
US2003208382 (A1) electronic medical record system and method 2003 
EP1389476 (A1) programming device for a pump for injecting medicaments 2004 
US2003089733 (A1) medication monitoring device 2003 
MXPA02004618 (A) marker detection method and apparatus to monitor drug compliance. 2002 
US2003139778 (A1) rapid response system for the detection and treatment of cardiac events 2003 
WO0241825 (A2) medication monitoring device 2002 
US2002046346 (A1) electronic medical records system 2002 
JP2003099536 (A) mobile electronic medication history management system 2003 
JP2003099533 (A) electronic medication history system 2003 
JP2003036312 (A) electronic medical record-processing device and program for electronic medical record processing 2003 
WO0203298 (A1) electronic medical record system and method 2002 
US6468263 (B1) implantable responsive system for sensing and treating acute myocardial infarction and for treating stroke 2002 
US2002004729 (A1) electronic data gathering for emergency medical services 2002 
US2002147526 (A1) web-enabled medication dispenser 2002 
DE10111113 (A1) recording and transferring medical data from electronic patient care systems involves linking of systems with data transfer 
units, and provision of an overall automated control system 
2002 
WO0167345 (A1) automated electronic encrypted prescription filling and record keeping and retrieval system 2001 
US6347329 (B1) electronic medical records system 2002 
JP2002024391 (A) system and method for medication management 2002 
JP2001344342 (A) storage and display method for electronic medical record 2001 
WO0064517 (A1) electronic monitoring medication apparatus and method 2000 
US6680999 (B1) interactive telephony system 2004 
FR2803210 (A3) extra-corporal apparatus uses heat treatment to destroy infectious pathogenic germs in patient's blood before cooling and 
reintroduction 
2001 
US6305377 (B1) system and method for improving compliance of a medical regimen 2001 
JP2000342638 (A) patient identification system 2000 
US6314384 (B1) medication management apparatus 2001 
US6167302 (A) device for transcutaneous administration of medications using iontophoresis 2000 
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US6158613 (A) voice based pharmaceutical container apparatus and method for programming 2000 
US6088429 (A) interactive telephony system 2000 
US6075755 (A) medical reminder system and messaging watch 2000 
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A15: RANKING OF TRANSFORMATION TRIGGERS 
The pervasiveness and relat ive ranking of the t ransformat ion t r iggers in the pr imary and derived art ic les. 
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1 Acd 2006 8     116          
2 Acd 2004 4  42 82 40      37     
3 Con 2005 2 33    27 24         
4 Org 2007 3 13    12 11         
5 Con 2009 0 58 55             
6 Acd 2008 0  80             
7 Gov 2004 30   14     127  126   125  
8 Gov 2005 2       63 62       
9 Gov 2009 0   108  97  94    88 86   
10 Gov 2007 0   121     92  89   85  
11 Acd 2008 47  146 142  138  137      133  
12 Acd 2006 4   53  74  72       64 
13 Acd 2009 18  145 39            
14 Acd 2003 490  122 141            
15 Acd 2009 3  81 119            
16 Acd 2010 4              36 
22 Con 2007 3 60 57    48         
23 Con 2002 1  56           43  
24 Acd 2009 7  123  117           
25 Ind 2009 1  30   26          
26 Org 2005 15 31 29   25          
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27 Acd 2007 10  124 99            
28 Ind 2004 0   2            
30 Acd 2009 2   54  76        68  
31 Ind 2007 50 111  143            
32 Acd 2009 8   98            
33 Con 2006 4   144            
34 Con 2008 0 59  78 50 49          
35 Ind 2001 112   79  75          
36 Ind 2006 11     107          
37 Acd 2007 21   77            
38 Ind 2006 7     73          
40 Acd 2006 14     139          
41 Con 2003 343              102 
42 Ind 2001 19           105    
43 Acd 2004 4              35 
44 Acd 2005 10              101 
45 Acd 2008 4              66 
46 Acd 2003 21              113 
47 Acd 2008 16              128 
48 Acd 2005 24              110 
49 Acd 2009 1              65 
50 Acd 2008 9              112 
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51 Acd 2009 64              131 
52 Con 2009 0              41 
53 Acd 2009 1              67 
54 Ind 2009 0 32            15  
55 Ind 2008 0 34       20 18      
56 Acd 2007 37    140          130 
57 Con 2008 2 61   51     46    44  
58 Org 1998 3    1           
59 Acd 2008 4   120            
60 Con 2006 0      47         
61 Acd 2005 42             114  
62 Con 2002 5      106         
63 Con 2004 0      22  19       
64 Acd 2009 1  83             
65 Ind 2009 1       21        
66 Org 2009 0       10        
67 Org 2006 6  28    23         
68 Gov 2006 0  100 118  96 95 93 91   87  84  
69 Acd 2008 16        136       
70 Ind 2008 5        71       
71 Con 2008 0         45      
72 Gov 2007 3         90      
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73 Acd 2007 3         69      
74 Acd 2007 1         38      
75 Acd 2008 0         70      
76 Org 2009 0          9     
77 Org 2009 0          8     
78 Con 2001 21           104    
79 Org 2000 35           17    
80 Ind 2009 0           16    
81 Acd 2001 83           115    
82 Acd 2006 153            134   
83 Org 2006 0            7  5 
84 Acd 2007 36            135   
85 Org 2009 1            6   
86 Org 2005 0   129          4  
87 Acd 2006 33             132  
88 Org 2003 3              3 
N 146  n 11 16 22 6 15 8 7 8 7 5 7 6 11 17 
sample size = 
82 
# of triggers 
K=14 Rank 7 3 1 12 4 13 9 6 11 14 8 10 5 2 
 
 
	216 
APPENDIX B: Survey Material 
B1 Part ic ipant Informat ion Leaf let  
B2 Pilot  Questionnaire 
B3 Summary of Completed Pi lot  Survey Quest ionnaires 
B4 Study Protocol for  Expert  Opinion Survey 
B5 Pilot  Part ic ipant  Comments dur ing the Cogni t ive Interv iews 
	217 
B1 - PARTICIPANT INFORMATION LEAFLET 
 
PARTICIPANT INFORMATION LEAFLET 
A Survey of expert opinion on Pharmaceutical Quality Risks 
We would like to invite you to take part in research to better understand the quality risks in the 
pharmaceutical industry due to business, technology and regulatory transformation currently 
underway. This leaflet gives you more information about the study – please read it carefully before 
deciding whether to take part or not. If you would like to take part in the study: 
 You will received an e-mail asking to complete a questionnaire 
 You will be required to attend a 30 minutes teleconference to learn about the study and the 
questionnaire 
 Your return of the completed questionnaire to the investigator will indicate your consent 
 You will receive the anonymised version of the survey results   
 
What is the purpose of the study? 
The ongoing transformational and disruptive changes in Pharma business, technology and 
regulations are having significant impact on pharmaceutical quality. Open innovation is a key 
characteristic of the ongoing industry transformation and it will pose new challenges to 
Pharmaceutical Quality. The aim of this research is to identify transformation-induced quality risks 
and develop a Theoretical Quality Risk Model to characterise the relationship between 
transformation-induced quality risks and the regulatory compliance outcomes. The aim of this 
survey is to support the outlined research by determining the opinions of experts in the field of 
pharmaceutical innovation regarding transformation-induced quality risks and its impact / influence 
on regulatory compliance. 
Why have I been invited? 
You are invited to contribute to this original research because you are a recognised expert in the 
field of pharmaceutical quality and your opinion will greatly benefit the outcome of this research.  
Do I have to take part? 
No. It is up to you to decide whether to take part. Before you decide, we ask you to read this 
information leaflet. If there is anything that is not clear or if you would like more information, please 
contact the principal investigator using the details given at the end of this leaflet. You can withdraw 
from the study at any time. 
What are the possible benefits of taking part? 
As a pharmaceutical quality expert you will contribute to and shape needed research in the field of 
pharmaceutical quality by sharing your expert opinion via this survey. You will receive a summary 
of the anonymised findings and conclusions of the survey.   
What are potential risks? 
Since the study involves a Questionnaire completed at participant’ convenience it is unlikely that 
any adverse effects, risks or hazards are involved.  
Will my taking part in the study be kept confidential? 
Yes, in order to conceal your identity the questionnaires will be anonymised. Safeguards are in 
place to prevent other participants from connecting your responses to you. No information you 
provide will be attributable or provided to other individual participants. 
What will happen to the results of the study? The anonymised results will be used in the 
development of a PhD thesis and research papers, which will be submitted to international journals.  
 
For further information on any aspect of the study contact:   
Nader Shafiei     Tel: +1 (908) 391-1206    e-mail: 
( N.Shafiei@2009.ljmu.ac.uk )  
 
In case of complaints contact Director of studies: 
Professor James L. Ford Tel: +44 (151) 231-2096   e-mail: (J.L.Ford@ljmu.ac.uk )  
 
Thank you: we hope that you will take part in this study. 
 
This study is sponsored by the Liverpool John Moores University and has been given a Favourable 
ethical opinion by LJMU Research Ethics Committee (11/PBS/004).     Ref: 
NS_PhD_LJMU_PIL_1.1 
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B2 - PILOT QUESTIONNAIRE  
 
 
A survey of expert opinion on 
Pharmaceutical Quality Risks 
 
 
This survey is the empir ical  component of  the research being conducted by Nader Shaf ie i ,  a PhD student in the School of  Pharmacy and 
Biomolecular Sciences, Liverpool  John Moores Univers ity.  
 
The aim of  th is survey research is to determine the opinions of experts in the f ield of  pharmaceut ical innovat ion regarding t ransformat ion-
induced qual i ty r isks and i ts impact /  inf luence on regulatory compl iance. 
 
 
Complet ing the quest ionnaire should take no longer than 60 minutes.  
 
 
Part ic ipat ion in th is study is voluntary and complet ion of  th is quest ionnaire impl ies consent.  The quest ionnaire and data are anonymised. 
Publ icat ion of study results wi l l  be managed using the anonymised data.  This study has received uncondi t ional  ethical  approval  f rom 
Liverpool  John Moores Research Ethics Commit tee – Ref:  11/PBS/004. 
 
 
Thank you for completing this questionnaire.  Ref:  NS_PhD_LJMU_QAR_1.0 
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SECTION A – Definitions and Instructions 
 
This first section of the questionnaire provides you with definition of some key terms used throughout this document plus instructions on how 
to complete the questionnaire. 
Definitions /  Acronyms Source 
GxP  – Good Laboratory, Cl inical ,  Manufactur ing Pract ices  
ICH – Internat ional  Conference on Harmonizat ion  
Innovation  – the int roduct ion of new technologies or methodologies ICH Q10 
Open Innovation -  the pract ice of  leveraging the discovery of  others and not rely 
exclusively on own R&D for innovat ion 
Chesbrough H, Kardon Crowther A. (2006).  
“Beyond high tech: early adopters of  open 
innovat ion in other industr ies” 
Pervasive Technologies  – smart  implantable devices used for product  t racking, remote 
pat ient  moni tor ing or drug del ivery Blended def in i t ion 
Pharma Transformation  -  is  concerned wi th ongoing disrupt ive changes current ly 
shaping the operat ional  concepts, organizat ion, and technologies impact ing 
pharmaceut ical innovat ion and the abi l i ty  to meet the demands of a changing heal thcare 
environment 
Blended def in i t ion 
Post-market Surveil lance  – Regulatory agency r isk assessment act iv i t ies that  take place 
after approval of the drug product  FDA 
Pre-market Assessment  – Regulatory agency r isk assessment act iv i t ies that take place 
prior to approval  of  the drug product FDA 
Product Lifecycle - al l  phases in the l i fe of the product f rom the ini t ia l  development 
through market ing unt i l  the product ’s discont inuat ion  ICH Q9 
Quality  – the degree to which a set  of  inherent propert ies of  a product,  system or process 
ful f i ls requirements ICH Q9 
Quality Risk  – a GxP act iv i ty that  i f  not  performed proper ly may have the potent ia l  to 
resul t  in adverse events impact ing product qual i ty,  data integr i ty or pat ient safety Blended def in i t ion  
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Instructions:  
This quest ionnaire has been designed to be f i l led electronical ly in MSWord or manual ly by hand wri t ten means.  Specif ic  instruct ions are 
provided in each sect ion.  Here we provide some guidance on how to complete the quest ionnaire and i ts subsequent t ransmission to the 
principal  invest igator.  
 
When f i l l ing electronical ly,  to make your select ion please double c l ick on the select ion box and under the “defaul t  value” sect ion select  the 
“checked” radio but ton.  Save the completed quest ionnaire in your PC hard dr ive.  
 
When f i l l ing manual ly please scan the completed quest ionnaire and save i t  in your PC hard dr ive.  
 
Please return the completed questionnaire (electronic version or scanned copy) via e-mail to the principal investigator at 
N.Shafiei@2009.l jmu.ac.uk.   
 
SECTION B - Participant Details 
 
This section of the questionnaire requires you to give some information about your expertise and type of organization you represent. It is 
important that we are able to categorise your opinion in relation to your business, regulatory and quality perspective. 
 
Please complete the quest ion 2 wi th the relevant  informat ion. For quest ions 3 to 5 check/ t ick al l  that  apply.  
1. Expert  ident i f icat ion code:  EE-SS-CC-RR-NN - assigned by the invest igator 
2. Organizat ion name:        
3. Regulatory domain of  expert ise:  US–FDA  EU-EMA        Other  
4. Organizat ion type:  
Big Pharma  Smal l  Pharma           
Consul t ing  Contract R/M Organizat ion  
   R/M - Research/Manufacturing 
Other:   P lease specify                                      
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5. Experience in:  Pharmaceut icals  B iopharmaceuticals   
6. Qual i ty  domain of  expert ise:  
GLP   GCP            
GMP   GxP     
SECTION C – Pharma Transformation Triggers and Risks 
This section asks a number of questions to elicit your opinion about factors that characterise pharmaceutical transformation currently 
underway in the industry. 
Please answer quest ions 6 to 8 by placing a check/t ick in the relevant boxe(s) that indicate your answer.  I f  you also select “other” please 
specify your answer.     
6. Which of the fol lowing is a key dr iver for the current Pharmaceut ical  Transformat ion?  
 Business Environment     Regulatory Environment   
 Open Innovat ion         
 Other (please speci fy):  
        
7.  Which of the fol lowing Open Innovat ion trends do you think is current ly pract iced in the  pharmaceut ical  industry? 
 Commercial  Partnerships    Increased In Licensing    
 Research Partnerships     Research Informat ion Shar ing   
 Focus on Combinat ion Products   Focus on Biological Products   
 Focus on Pervasive Technologies   External izat ion of S/W Appl icat ions  
 Other (please Specify):  
       
8.  Lack of  which of  the fol lowing wi l l  pose a GxP Risk in an Open Innovat ion environment? 
 Ef fect ive Due Di l igence     Effect ive Product Transfer   
 Mul t id isc ipl inary Regulatory Knowledge  Effect ive Product Characterizat ion  
 Technology Val idat ion     Data Securi ty and Integr i ty   
 Other (please Specify)         
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SECTION D – Open Innovation and Regulatory Compliance 
This section asks a number of questions regarding your experience and opinion on impact of Open Innovation on GxP related activities the 
relationship between Regulation and Innovation drive in the industry.  
 
Please answer quest ions 9 to 16 by placing a check/t ick in the box that  best represents your answer.  Opt ional ly use “Comments” f ie ld 
expand on your opinion.     
9. Open Innovat ion wi l l  have s igni f icant impact on external  partner/al l iance select ion and  oversight? 
 Very Unl ikely  Unl ikely      L ikely     Very Likely    Don’t  Know  
 Comments       
10.  Open Innovat ion wi l l  have s igni f icant impact on legal  f ramework for exchange of  research  informat ion? 
 Very Unl ikely  Unl ikely      L ikely     Very Likely    Don’t  Know  
 Comments       
11.  Open Innovat ion wi l l  have s igni f icant impact on data management in the context  of  data secur i ty,  integr i ty and privacy? 
 Very Unl ikely  Unl ikely      L ikely     Very Likely    Don’t  Know  
 Comments       
12.  Biological /Biotech products wi l l  become major part  of the project and product port fo l io? 
 Very Unl ikely  Unl ikely      L ikely     Very Likely    Don’t  Know  
 Comments       
13.  Prevalence of  pervasive technologies wi l l  require mul t idisc ipl inary knowledge and ski l ls to deal  wi th convergent  scient i f ic discipl ines 
(e.g.  smart  implantable drug del ivery devices)? 
 Very Unl ikely  Unl ikely      L ikely     Very Likely    Don’t  Know  
 Comments       
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14.  Exist ing regulatory approaches are adversely impact ing the innovat ion dr ive in the indust ry? 
 Very Unl ikely  Unl ikely  L ikely     Very Likely   Don’t  Know  
 Comments         
15.  Smarter regulatory approach that  is  responsive to new discoveries whi le maintaining safety and ef f icacy standards wi l l  improve 
innovat ion dr ive? 
 Very Unl ikely  Unl ikely  L ikely     Very Likely   Don’t  Know  
 Comments         
16.  Regulatory in i t iat ives such as FDA's Cr i t ical  Path and EMA's Innovat ion Task force ( ITF) wi l l   have a s igni f icant impact in industry 's 
innovat ion dr ive? 
 Very Unl ikely  Unl ikely      L ikely     Very Likely    Don’t  Know  
 Comments        
SECTION E – Assessment of Transformation-Induced Quality Risks  
This section asks a number of questions about your experiences regarding Pharmaceutical Quality Risks present in an open innovation 
environment and their likelihood to cause regulatory compliance problems.  
 
Please answer quest ions 17 to 35 by placing a check/t ick in the box that  best represents your answer.  Opt ional ly use “Comments” f ie ld for 
addi t ional  informat ion.  
a) GxP Due Dil igence of External Partners and All iances -  Lack of  ef fect ive GxP due di l igence has the potent ial  to result  in:  
17.  Select ion of external  a l l iances /  partners with s igni f icant GxP compl iance problems? 
 Very Unl ikely  Unl ikely  L ikely     Very Likely   Don’t  Know  
 Comments         
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18.  Adverse GxP inspect ion outcomes dur ing pre-market evaluat ion? 
 Very Unl ikely  Unl ikely  L ikely     Very Likely   Don’t  Know  
 Comments         
19.  Adverse GxP inspect ion outcomes dur ing post-market survei l lance? 
 Very Unl ikely  Unl ikely      L ikely     Very Likely    Don’t  Know  
 Comments        
b)  Product Transfer - Lack of  ef fect ive product t ransfer pol icy and procedures has the potent ial  to resul t  in:  
20.  Poor process understanding? 
 Very Unl ikely  Unl ikely      L ikely     Very Likely    Don’t  Know  
 Comments        
21.  Signi f icant  problems with control  methods (release test ing and c leaning val idat ion)? 
 Very Unl ikely  Unl ikely      L ikely     Very Likely    Don’t  Know  
 Comments        
22.  Adverse GxP inspect ion outcomes dur ing pre-market evaluat ion? 
 Very Unl ikely  Unl ikely  L ikely     Very Likely   Don’t  Know  
 Comments         
23.  Adverse GxP inspect ion outcomes dur ing post-market survei l lance? 
 Very Unl ikely  Unl ikely      L ikely     Very Likely    Don’t  Know  
 Comments        
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c) Mult idiscipl inary Regulatory Approach - Lack of  mult id isc ipl inary qual i ty knowledge and ski l ls  has the potent ial  to resul t  in:  
24.  Inabi l i ty  to maintain qual i ty and compliance effect iveness across a range a regulatory s i tuat ions (e.g.  combinat ion products that may 
require regulatory knowledge of  diagnost ics,  drugs and devices)? 
 Very Unl ikely  Unl ikely  L ikely     Very Likely   Don’t  Know  
 Comments         
25.  Adverse GxP inspect ion outcomes dur ing pre-market evaluat ion? 
 Very Unl ikely  Unl ikely  L ikely     Very Likely   Don’t  Know  
 Comments         
26.  Adverse GxP inspect ion outcomes dur ing post-market survei l lance? 
 Very Unl ikely  Unl ikely      L ikely     Very Likely    Don’t  Know  
 Comments        
d)  Biological /Biotech Products  
27.  Are more complex and di f f icul t  to character ise than chemical ly synthesised products? 
 Yes  No      Don’t  Know  
 Comments       
Lack of robust processes for product contaminat ion, ster i l i ty and stabi l i ty control  has the potent ial  to result  in:  
28.  Adverse GxP inspect ion outcomes dur ing pre-market evaluat ion? 
 Very Unl ikely  Unl ikely  L ikely     Very Likely   Don’t  Know  
 Comments       
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29.  Adverse GxP inspect ion outcomes dur ing post-market survei l lance? 
 Very Unl ikely  Unl ikely      L ikely     Very Likely    Don’t  Know  
 Comments       
e) Data Securi ty and Integrity -  Lack of  robust  procedures for  outsourc ing and al l iance management has the potent ial  to resul t  in:  
30.  Data securi ty,  integri ty and pr ivacy issues dur ing product l i fecycle? 
 Very Unl ikely  Unl ikely      L ikely     Very Likely    Don’t  Know  
 Comments       
31.  Adverse GxP inspect ion outcomes dur ing pre-market evaluat ion? 
 Very Unl ikely  Unl ikely      L ikely     Very Likely    Don’t  Know  
 Comments       
32.  Adverse GxP inspect ion outcomes dur ing post-market survei l lance? 
 Very Unl ikely  Unl ikely      L ikely     Very Likely    Don’t  Know  
 Comments       
f )  Technology Validation - Lack of  val idat ion methods for pervasive technologies has the potent ial  to resul t  in:  
33.  Unrel iable product performance resul t ing in adverse events or customer complaints? 
 Very Unl ikely  Unl ikely      L ikely     Very Likely    Don’t  Know  
 Comments       
34.  Adverse GxP inspect ion outcomes dur ing pre-market evaluat ion? 
 Very Unl ikely  Unl ikely      L ikely     Very Likely    Don’t  Know  
 Comments       
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35.  Adverse GxP inspect ion outcomes dur ing post-market survei l lance? 
 Very Unl ikely  Unl ikely      L ikely     Very Likely    Don’t  Know  
 Comments       
 
Please ini tial  here        Please return the completed quest ionnaire (elect ronic vers ion or scanned copy) v ia e-mai l  to the pr inc ipal  
invest igator at  N.Shafiei@2009.l jmu.ac.uk   Thank you for taking t ime to complete this quest ionnaire.    
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LJMU Ethical Approval : 11/PBS/004              
SECTION B - Participant Details  Interview 
Date 
Interview 
Date 
Interview 
Date 
Interview 
Date 
Interview 
Date 
Interview 
Date 
This section of the questionnaire requires you to give some information about your 
expertise and type of organization you represent. It is important that we are able to 
categorise your opinion in relation to your business, regulatory and quality perspecti 
1-Sep-11 9-Sep-11 15-Sep-11 16-Sep-11 19-Sep-11 22-Sep-11 
Please complete the question 2 with the relevant information. For questions 3 to 6 
check/tick all that apply. 
AM-BP-SA-
UE-01 
IS-BP-SA-
UE-02 
AD-BP-SA-
US-03 
OI-BP-SA-
UE-04 
IR-BP-SA-
UE-05 
AN-BP-SA-
US-06 
1. Expert identification code:           
2. Organization name: 
Sanofi 
R&D 
Quality 
Sanofi R&D 
Quality 
Sanofi 
GQA Sanofi IQC 
Sanofi 
GQA Sanofi R&D 
3. Regulatory domain of expertise: 
US–FDA x x x x x x 
EU-EMA x x   x x   
Other  (please specify):   Japan, latAm   
Health 
Canada 
TGA, 
LatAm OECD 
4. Organization type: 
Big Pharma x x x x x x 
Small Pharma             
Consulting             
Small Pharma             
Contract 
Research/Manufacturing 
Organization
            
Other (please specify):             
5a. Experience in: 
Pharmaceuticals x x x x x x 
Biopharmaceuticals x     x x   
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5b. Years of Experience: 
5 to 10             
10 to 15             
15+ x x x x x x 
6. Quality domain of expertise: 
GLP       x   x 
GMP x   x x x x 
GCP   x         
GxP           x 
SECTION C – Pharma Transformation Triggers and Risks Please answer questions 7 to 9 by placing a check/tick in the relevant box/boxes that indicate your answer. 
If you also select “other” please specify your answer. 
7. Which of the following is a key driver for the 
current Pharmaceutical Transformation? 
Business Environment x x   x   x 
Regulatory Environment x x x x x x 
Open Innovation x   x   x x 
Other (please specify):   1 1   2   
8. Which of the following Open Innovation trends do 
you think is currently practiced in the  
pharmaceutical industry? 
Commercial Partnerships x x x x   x 
Increased In Licensing x x x x x   
Research Partnerships x x x x x x 
Research Information 
Sharing 
x         x 
Focus on Combination 
Products
x     x     
Focus on Biological 
Products
x x x x x x 
Focus on Pervasive 
Technologies  
  x   x x x 
Externalization of S/W 
Applications
1     x     
Other (please Specify): 1     1 1 2 
	 
    
230 
Appendix B3 Cont inued 
9. Lack of which of the following will pose a GxP 
Risk in an Open Innovation environment? 
Effective Due Diligence x x x x x x 
Effective Product Transfer x x x x x x 
Multidisciplinary Regulatory 
Knowledge
x x   x x x 
Effective Product 
Characterization 
x x x x x x 
Data Security and Integrity x x x x x x 
Technology Validation x x x x x x 
Other (please Specify)   1   3 3 1 
SECTION D – Open Innovation and Regulatory Compliance Please answer questions 10 to 17 by placing a check/tick in the box that best represents your answer. 
Optionally use “Comments” field to expand on your opinion.    
10. Open Innovation will have significant impact on 
external partner/alliance selection and  oversight? 
Very Unlikely             
Unlikely             
Likely   x         
Very Likely x   x x x x 
Don’t Know             
Comments: 1           
11. Open Innovation will have significant impact on 
legal framework for exchange of research  
information? 
Very Unlikely             
Unlikely             
Likely       x     
Very Likely x       x x 
Don’t Know   x x       
Comments: 1       1 1 
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12. Open Innovation will have significant impact on 
data management in the context of data security, 
integrity and privacy? 
Very Unlikely             
Unlikely             
Likely             
Very Likely x x x x x x 
Don’t Know             
Comments:             
13. Biological/Biotech products will become major 
part of the project and product portfolio? 
Very Unlikely             
Unlikely             
Likely       x     
Very Likely x x x   x x 
Don’t Know             
Comments:         1   
14. Prevalence of pervasive technologies will 
require multidisciplinary knowledge and skills to 
deal with convergent scientific disciplines (e.g. 
smart implantable drug delivery devices)? 
Very Unlikely             
Unlikely             
Likely           x 
Very Likely x x   x x   
Don’t Know     x       
Comments: 1     1   1 
15. Existing regulatory approaches are adversely 
impacting the innovation drive in the industry? 
Very Unlikely             
Unlikely x x         
Likely     x x   x 
Very Likely         x   
Don’t Know             
Comments: 1     1   1 
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16. Smarter regulatory approach that is responsive 
to new discoveries while maintaining safety and 
efficacy standards will improve innovation drive? 
Very Unlikely             
Unlikely         x   
Likely   x x       
Very Likely x     x   x 
Don’t Know             
Comments: 1       1   
17. Regulatory initiatives such as FDA's Critical 
Path and EMA's Innovation Task force (ITF) will  
have a significant impact in industry's innovation 
drive? 
Very Unlikely             
Unlikely       x x x 
Likely   x         
Very Likely             
Don’t Know x   x       
Comments:     1 1 1 1 
SECTION E – Assessment of Transformation-Induced Quality Risks 
This section asks a number of questions about your experiences regarding Pharmaceutical Quality Risks present in an open innovation environment and their likelihood to 
cause regulatory compliance problems. 
Please answer questions 18 to 36 by placing a check/tick in the box that best represents your answer. Optionally use “Comments” field for additional information. 
a) GxP Due Diligence of External Partners and Alliances - Lack of effective GxP 
due diligence has the potential to result in: 
      
1 
  
1 
18. Selection of external alliances / partners with 
significant GxP compliance problems? 
Very Unlikely             
Unlikely             
Likely       x   x 
Very Likely x x x   x   
Don’t Know             
Comments:       1   1 
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19. Adverse GxP inspection outcomes during pre-
market evaluation? 
Very Unlikely             
Unlikely             
Likely   x   x     
Very Likely x   x   x   
Don’t Know           x 
Comments: 1 2 1 1 1 1 
20. Adverse GxP inspection outcomes during post-
market surveillance? 
Very Unlikely             
Unlikely x           
Likely       x     
Very Likely   x     x   
Don’t Know     x     x 
Comments: 1   1       
b) Product Transfer - Lack of effective product transfer policy and procedures has the potential to 
result in: 
        1 
21. Poor process understanding? Very Unlikely             
Unlikely             
Likely       x     
Very Likely x x x   x x 
Don’t Know             
Comments:       1 1   
22. Significant problems with control methods 
(release testing and cleaning validation)? 
Very Unlikely             
Unlikely             
Likely   x   x   x 
Very Likely x   x   x   
Don’t Know             
Comments:           1 
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23. Adverse GxP inspection outcomes during pre-
market evaluation? 
Very Unlikely             
Unlikely             
Likely     x x x   
Very Likely x x         
Don’t Know           x 
Comments:       1   1 
24. Adverse GxP inspection outcomes during post-
market surveillance? 
Very Unlikely             
Unlikely             
Likely       x x   
Very Likely x x x       
Don’t Know           x 
Comments:             
c) Multidisciplinary Regulatory Approach - Lack of multidisciplinary quality knowledge and skills 
has the potential to result in: 
  1 1 1   
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25. Inability to maintain quality and compliance 
effectiveness across a range of regulatory 
situations (e.g. combination products that may 
require regulatory knowledge of diagnostics, drugs 
and devices)? 
Very Unlikely             
Unlikely             
Likely   x       x 
Very Likely x   x   x   
Don’t Know       x     
Comments: 1       1   
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26. Adverse GxP inspection outcomes during pre-
market evaluation? 
Very Unlikely             
Unlikely             
Likely           x 
Very Likely x x x   x   
Don’t Know       x     
Comments: 1 1       1 
27. Adverse GxP inspection outcomes during post-
market surveillance? 
Very Unlikely             
Unlikely             
Likely           x 
Very Likely x x x   x   
Don’t Know       x     
Comments: 1           
d) Biological/Biotech Products                
28. Are more complex and difficult to characterise 
than chemically synthesised products? 
Yes x x x x x x 
No             
Don’t Know             
Comments             
Lack of robust processes for product contamination, sterility and stability control has 
the potential to result in: 
  1 1 1 1   
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29. Adverse GxP inspection outcomes during pre-
market evaluation? 
Very Unlikely             
Unlikely             
Likely             
Very Likely x x x x x x 
Don’t Know             
Comments:             
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30. Adverse GxP inspection outcomes during post-
market surveillance? 
Very Unlikely             
Unlikely             
Likely             
Very Likely x x x x x x 
Don’t Know             
Comments:           1 
e) Data Security and Integrity - Lack of robust procedures for outsourcing and alliance 
management has the potential to result in: 
  1       
31. Data security, integrity and privacy  issues 
during product lifecycle? 
Very Unlikely             
Unlikely             
Likely   x     x x 
Very Likely x   x x     
Don’t Know             
Comments: 1   1   1 1 
32. Adverse GxP inspection outcomes during pre-
market evaluation? 
Very Unlikely             
Unlikely             
Likely   x   x x x 
Very Likely x   x       
Don’t Know             
Comments: 1   1 1 1   
33. Adverse GxP inspection outcomes during post-
market surveillance? 
Very Unlikely             
Unlikely           x 
Likely   x   x x   
Very Likely x   x       
Don’t Know             
Comments: 1       1 1 
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f) Technology Validation - Lack of validation methods for pervasive technologies has the potential 
to result in: 
1 1       
34. Unreliable product performance resulting in 
adverse events or customer complaints? 
Very Unlikely             
Unlikely             
Likely           x 
Very Likely x x   x x   
Don’t Know     x       
Comments:             
35. Adverse GxP inspection outcomes during pre-
market evaluation? 
Very Unlikely             
Unlikely         x   
Likely       x   x 
Very Likely x x         
Don’t Know     x       
Comments:       1     
36. Adverse GxP inspection outcomes during post-
market surveillance? 
Very Unlikely             
Unlikely           x 
Likely       x     
Very Likely x x     x   
Don’t Know     x       
Comments:       1 1 1 
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STUDY PROTOCOL 
A Survey of expert opinion on Pharmaceutical Quality Risks 
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File Management, Backup and Recovery (LJMU) 
	239 
Appendix B4 Continued 
 
1  BACKGROUND AND RATIONALE 
1.1 Pharmaceutical regulations and quality 
Historically the pharmaceutical industry is heavily regulated particularly in Europe Union (EU) and 
the United States (US) with the primary aim to protect and promote public health but also to 
respond to unexpected crisis. Since the pharmaceutical industry develops and manufacture 
products that affect patients’ quality of life, world governments have a keen interest in the industry 
and its products.   
 
The regulatory environment in the EU is driven by the need to ensure free movement of goods and 
protection of public health [Hartmann]. Regulatory procedures have been standardised and the 
European Medicines Agency (EMA) has been established to approve medical products for all EU 
countries (Tancer, 2002; Li Bassi, 2003).  
 
In contrast, the regulatory environment in the US has been shaped by series of reactive steps of 
legislation adaptation in response to public health crises [Borchers, Slater]. This led to the 
establishment of the Food, Drug Administration (FDA) in 1906, which was primarily charged to 
protect public health. Since its inception, it has gained additional responsibility to advance public 
health by helping to speed innovations that make medicines safer, more effective and affordable. 
Up to 1980s the focus of regulators was Centred on crisis management and public health 
protection - a basic mission that has remained consistent over the years [US Supreme Court].    
 
A review of the regulatory events indicates that since 1980s there has been a gradual change in 
regulatory direction towards a greater focus on public health promotion, international harmonization, 
innovation, and risk management. 
 
The regulatory harmonization is achieved through the International Conference on Harmonization 
(ICH). Launched 20 years ago, ICH brings together the drug regulatory authorities of Europe, 
Japan, and the United States, along with the pharmaceutical trade associations from these three 
regions, to discuss scientific and technical aspects of product registration. It is ICH’s mission to 
achieve greater harmonization in the interpretation and application of technical guidelines and 
requirements for product registration, thereby reducing duplication of testing and reporting carried 
out during the research and development of new medicines (ICH Anniversary, 2010). 
 
Innovation in this context relates to establishment of a robust regulatory science program aimed at 
strengthening advances in biomedical sciences. Regulatory science is critical to effectively 
translate cutting edge developments in science and technology into promising products and 
therapies for the patients who need them. Just as biomedical research has evolved over the past 
few decades, regulatory science must also evolve in important and powerful ways (FDA Priorities, 
2010; EMA Roadmap, 2010). 
 
Risk management is another key regulatory focus that intends to define a framework to improve 
regulator’s ability to adjust the level of regulatory scrutiny commensurate with public health risk, a 
major component of which concerns inspection of pharmaceutical company’s laboratory, clinical, 
manufacturing, and distribution practices.    
 
There is a key difference between the pharmaceutical and other industries regarding product 
quality, safety and data-integrity. In the pharmaceutical industry quality practices are mandated by 
law and require establishment of an independent internal Quality Unit whereas in most other 
industries quality is often a voluntary activity. Within the pharmaceutical context, the health 
authorities accomplish their regulatory scrutiny through review of new product applications and 
inspection of laboratory, clinical, manufacturing, and distribution practices. The regulators rely on 
the industry to do internal supervision through their Quality Unit. The role of the Pharmaceutical 
Quality (through the Quality Unit) is to establish and monitor internal standards to ensure product 
quality, patient safety and data integrity from the GxP8 perspective. The extent to which each 
pharmaceutical company meets GxP requirements has a direct impact on their ability to obtain 
approvals for their products and maintain the marketing authorization for those products.  
 
1.2 What is the problem? 
The change in regulatory direction stated above, is because the pharmaceutical industry in the last 
couple of decades has experienced a significant decline in productivity despite revolution in  
                                                 
8 GxP - Good Laboratory / Clinical / Manufacturing / Distribution Practices 
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biomedical sciences and increasing Research & Development (R&D) expenditure. According to 
FDA, the problem exists because the current medical product development path is becoming 
increasingly challenging, inefficient, and costly. FDA in its 2004 landmark publication 
“Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products” 
(FDA CPI, 2004) illustrated that between 1993 and 2003 the agency saw a significant drop in a 
number of new chemical and biologic applications submitted for approval. This, the agency claims 
is because rising costs of product development often force the innovators to focus their efforts on 
products with potentially high market return. This consequently poses a major public health 
concern since less resources is deployed on products targeted for important public health needs 
such as rare diseases, prevention indications, or individualised therapies.  This and other factors 
such as dramatic increase in number of non-domestic R&D and manufacturing facilities (due to 
globalization) and diversity and complexity of medical products and processes (due to advances in 
pharmaceutical sciences) also play a key role in regulatory bodies to make transformational 
changes in how they work with the industry to protect and promote public health. 
 
1.3 What are the regulators doing? 
Both the FDA and EMA have strategic initiatives to address the innovation problem. The FDA’s 
national strategy for transforming the way FDA-regulated medical products are developed, 
evaluated, and manufactured involves the Critical Path Initiative (CPI).  
 
In Europe the EMA initially started by establishing the Innovation Task Force (ITF) in 2001. EMA 
expanded this effort through the publication of its March 2007 report “Innovative Drug Development 
Approaches” with the aim of identifying scientific bottlenecks to the development of innovative 
medicines, both in the industry’s R&D and in the academic environment.  
 
Review of the outlined reports and related documents revealed the following common innovation 
enablers:  
 Better product safety toolkit and standards - show that product is adequately safe for each 
stage of development 
 Better product effectiveness toolkit and standards - show that product benefits people 
 Better product manufacturing toolkit and standards – show product manufacturability, that it 
can go from laboratory concept to a manufacturable product 
 Better product quality risk management toolkit and standards – show that the level of 
regulatory scrutiny can be adjusted commensurate with public health risk  
 
1.4 What is the industry doing? 
To address the innovation problem the industry has been going through significant transformational 
changes affecting the business model (R&D, manufacturing, etc.), regulatory compliance and 
technology. Open innovation (Chesbrough, 2006) is a key characteristic of the ongoing industry 
transformation. In the open innovation paradigm centralised and internally focused approach to 
innovation is becoming obsolete and the pharmaceutical companies are not only trying to create 
value internally but increasingly leveraging external sources of innovation (small biotech, 
universities, research partnerships, etc.). Industry transformation triggers are characterised by the 
literature review conducted as part of the current PhD effort titled “Science and Risk Based 
Pharmaceutical Quality”. The important point to note is that the transformation triggers in the 
context of open innovation paradigm pose considerable challenges to Pharmaceutical Quality 
which needs further research which is the main subject of this Study Protocol. 
The industry is also fully engaged with the ICH effort on establishing international quality guidelines 
as an enabling toolkit to help improve innovation, as detailed above.  
 
1.5 What is role of Pharmaceutical Quality? 
Achievement of the goals implied in the outlined common innovation enablers requires expertise 
throughout the medical product lifecycle, including contribution of the Pharmaceutical Quality 
(OECD, 1997; ICH E6, 1996; PIC/S, 2009). To harmonise practices for this contribution the 
regulatory agencies and industry started collaboration under the auspices of the ICH. This effort 
resulted in the following important quality guidelines that have been adopted internationally:  
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 Pharmaceutical Quality Risk Management – provides principles and examples of tools for 
quality risk management that can be applied to different aspects of pharmaceutical quality 
(ICH Q9, 2005) 
 Pharmaceutical Development  – describes the process for presenting the knowledge gained 
through the application of scientific approaches and quality risk management to the 
development of a product and its manufacturing process (ICH Q8, 2005) 
 Pharmaceutical Quality Systems - describes model for a pharmaceutical quality system that 
can be implemented throughout the different stages of a product lifecycle (ICH Q10, 2008) 
 
1.6 Literature Search: transformational triggers 
The regulatory and industry transformation has already been characterised via literature review and 
supported by archive analysis (Flynn, 1990) - i.e. validation of literature findings through existing 
empirical evidence. Review of 82 articles (1998 to 2009) yielded a total of fourteen transformation 
triggers of which the following four were determined to have the highest importance and were 
selected for further analysis (see highlighted rows in Table 1 below). The open innovation trends 
for each of the four transformation triggers were identified and the associated transformation-
induced quality risks were determined (Figure 1). 
Qualitative analysis of the literature identified the fourteen transformation triggers referenced below 
as the key drivers for the industry transformation. The four selected triggers are the most prevalent 
within the articles studied, have the strongest empirical evidence, and pose substantive challenge 
to regulatory science since they introduce innovative changes to the way medical products are 
discovered, developed, manufactured and registered. This is why they are selected for further 
analysis. 
 
Transformation Triggers 
Relative 
importance 
derived 
from 
literature 
Open 
Innovation 
Trends 
(prevalence of) 
Transformation-
induced Quality 
Risk areas 
Healthcare Management Focus – T1 6   
Fully Integrated Pharma Network – T2 3 
External 
Partnerships 
In-Licensing 
Effective Due-
Diligence 
Effective Product 
Transfer 
Personalised Medicine – T3 1 
Combination 
Products 
Biotech Products 
Multidisciplinary 
Reg. Knowledge 
Product 
Characterization 
Virtual R&D – T4 11   
Translational Research – T5 4 
Research 
Partnership 
Information 
Sharing 
Effective Due-
Diligence 
Data Security and 
Integrity 
Adaptive and In-life Trials – T6 12   
Global Harmonization – T7 9   
Science & Risk Based Regulations – T8 7   
 Live Licensing – T9 13   
 Enforcement – T10 14   
Biotechnology – T11 8   
Nanomedicine – T12 10   
Bioinformatics – T13 5   
 Pervasive/ Cloud Computing – F14 2 
Tiny Smart 
Implantable 
Devices 
Externalization 
of s/w Solutions 
Technology 
Validation 
Data Security and 
Integrity 
Table 1 - Transformation Triggers 
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Fully Integrated Pharma Network: refers to a business model where pharmaceutical companies 
would have a fully integrated global network that includes other pharmaceutical or biotech 
companies, universities, organizations, and even individuals in some cases.  
Personalised Medicine: is Centred on specific treatments and therapeutics best suited for an 
individual.  
Translation Research: describes a bi-directional sharing of knowledge and ideas by the scientific 
and clinical disciplines to develop diagnostics that reliably select the mechanisms leading to 
breakthrough therapeutics.  
Pervasive Computing: this is characterised as an environment saturated with computing and 
communication capability. Smart medication packaging, tiny wireless sensors implanted on the 
patient body to monitor various vital signs, and remote monitoring devices to determine how 
patients respond during clinical trials are just some examples.  
Cloud Computing: is a computing model consisting of services that are commoditised and 
delivered in a manner similar to traditional utilities such as water, electricity, gas, and telephony. In 
such a model, users access services based on their requirements without regard to where the 
services are hosted or how they are delivered.  
 
Transformation-induced quality risks for these four triggers are listed in Table 1. These quality risks 
can potentially result in major adverse regulatory compliance outcomes if not managed properly. In 
order to facilitate development of a pharmaceutical Quality Risk Model for the new environment the 
relationship between transformation-induced risks and the regulatory compliance outcomes must 
be characterised. This goal will be achieved through a survey which remainder of this document 
will describe. 
 
1.7 Importance to the Pharmaceutical Industry 
There is academic research in support of the common innovation enablers highlighted in section 
1.3 (NIH Research, 2009); EMA Research, 2010). The research is mainly concentrated on the 
safety and efficacy aspects. Although Pharmaceutical Quality is playing a key role however there is 
no academic research to support this fact. Furthermore there is no academic research exploring 
the Quality Risk Model needed to cope with the new environment. Review of the 38 most cited 
quality management articles published between 1989 and 2009 revealed only 2 articles that 
studied pharmaceutical industry. Neither of these articles focuses on the industry transformation. 
Therefore, there is a real need for research to characterise the regulatory evolution and industry 
transformation, identify the most important transformation triggers, determine the impact on 
Pharmaceutical Quality, and develop a Quality Risk Model for the new environment. 
 
2 SURVEY AIM 
The aim of this survey research is to determine the opinions of people who are experts in the field 
of pharmaceutical innovation regarding transformation-induced quality risks and its impact / 
influence on regulatory compliance.  
 
3 SURVEY DESIGN 
3.1 Design Overview 
The research study involves a questionnaire-based survey with participants who are experts in the 
field of Pharmaceutical Quality. The survey will be piloted to ensure the reliability and validity of the 
questionnaire and the robustness of the data analysis methods. The design approach and 
methodology used for data collection / analysis are described below for the piloting activity as well 
as the actual survey: 
 
 
Piloting the survey (mixed method – qualitative and quantitative) 
 Purpose is to i) assess validity and reliability of the questionnaire and ii) robustness of the 
data analysis method selected for the actual survey  
 Design approach will be based on cognitive interviewing using verbal probing technique 
 Data will be collected using the interview notebook 
 Collected data will be analyzed using qualitative description of the emerging themes, 
quantitative description of the classified observations, and quantitative analysis of the 
responses to the questionnaire  
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 Expected outcome is improved questionnaire and confirmation that the selected data 
analysis method for the actual survey is appropriate 
Conducting the survey (quantitative method) 
 Purpose is to solicit expert opinion on the relationship between the transformation induced 
quality risks (independent variables) and regulatory compliance (dependant variables) 
 Survey design is based on relational non-experimental fixed method (Robson, 2002) 
 Data will be collected using the questionnaire in appendix 3 
 Collected data will be analyzed using descriptive statistics 
 Expected outcome will be the frequency distribution for the independent variables and the 
description of the relationship between independent and dependant variables    
 
3.2 Questionnaire Design 
The questionnaire has been designed to measure expert opinion with questions being derived from 
the literature. It is important to note that the questions are compiled around four categories of 
pharmaceutical transformation triggers, open innovation, transformation-induced quality risks, and 
regulatory compliance outcomes in alignment with the literature review. This is demonstrated by 
comparing key topic in the questionnaire with topics highlighted in Figure 1.   
The questionnaire contains a number of close-ended questions based on Likert Scale with four 
options (Leal et al., 2007): 1. Very Unlikely 2. Unlikely 3. Likely 4. Very Likely including an option 
for Don’t Know. The rationale behind choosing a four-interval measurement scale is to avoid 
gravitation toward Centre and encourage the participants who are recognised experts in this field to 
take a clear stance.  The questions are categorised into four sections with an additional section 
focusing on participant instructions and definition of terms, these are listed below: 
Section A: Definitions and Instructions to the participants 
Section B: Participant Details 
Section C: Pharma Transformation Triggers & Risks 
Section D: Open Innovation and Regulatory Compliance 
Section E: Assessment of Transformation-Induced Quality Risks 
 
a) Piloting the Questionnaire 
The questionnaire will be piloted to determine its reliability and validity by interviewing participants 
recruited from the collaborator organization (sanofi-aventis – Table 2) using the cognitive 
interviewing method (Robson, 2002; Carmines, 1979, Wallis, 1999).   
 
Pilot interview  
participants 
Quality  
experience in  
Product type 
 knowledge 
Domain of 
regulatory 
knowledge 
EA-BP-SA-UE01 
Pharmaceutical 
Development 
Clinical Development 
Biologics 
US (FDA) 
EU (EMA) 
AM-BP-SA-UE02 Pharmaceutical Development 
Pharmaceutical 
Biologics 
US (FDA) 
EU (EMA) 
IS-BP-SA-UE03 Clinical Development Pharmaceutical US (FDA) EU (EMA) 
IA-BP-SA-US04 Pharmaceutical Development Biologics 
US (FDA) 
IA-BP-SA-EU05 Manufacturing Pharmaceutical EU (EMA) 
IR-BP-SA-UE06 Manufacturing Pharmaceutical Biologics 
US (FDA) 
EU (EMA) 
Table 2 – Questionnaire Piloting: Participant list and profile 
 
b) Cognitive Interviewing 
During piloting, the cognitive interviewing methodology will be applied using the verbal probing 
technique (Wallis, 1999). The focus of the verbal probing will be on the survey questions. A one-
hour interview will be set up with each of the participants during which the interviewer asks the  
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survey question, the participant answers, the interviewer then asks for other specific information 
relevant to the question, or to the specific answer given. In general, the interviewer "probes" further 
into the rationale and basis for the response. Key benefit is to improve the questions by exploring 
issues relating to participant comprehension and identify structural problems such as erroneous 
skip patterns and unclear layout during the interview process. 
The pilot interview notebook will be used to collect the observations. The notebook will contain the 
questions, participant’s response to the questions, and classification of any comments that the 
participant makes related to the question or the survey procedure. The participant comments are 
classified into the following categories (each category within the notebook will have an associated 
selection box for the interviewer to choose depending on the nature of the comment): 
 
Reliability related comments: 
 Survey procedure  
 Logical layout and flow of the questions 
 Clarification for better  understanding 
 Spelling or grammatical errors/suggestions 
 
Validity related comments: 
 Appropriateness of the measurement scale 
 Challenges to the usefulness/validity of the question 
 
This interview captures two types of data. Participant’s responses to survey questions and 
participants comments relating to the reliability and validity assessment.  The actual survey will not 
start until the piloting activity is completed and the ensuing improvements are implemented.  
 
c) Reliability and Validity Assessment 
i) Reliability of the data collection method:  
Pilot data relating to participant comments will be analyzed with the aim of improving the 
reproducibility of the survey questionnaire. As a comparative exercise the same data may be 
analyzed statistically using Cronbach’s alpha (Gliem, 1993). 
 
ii) Validity of the data collection method: 
The purpose of the validity assessment is to improve fitness of the questionnaire for its intended 
use. This involves assessment of validity with respect to questionnaire content, structure and 
participant sampling (external validity). The external validity is improved using the purposive 
sampling method, the construct validity is assessed and improved during cognitive interviewing, 
and content validity is derived from the literature.  
 
iii) Validity of the data analysis method:  
The participant response data captured during piloting activity will be analyzed to confirm the 
appropriateness of the selected data analysis method.  
 
iv) Qualitative description of the emerging themes: 
The data from the cognitive interviewing will be categorised into themes, which in turn will inform 
the actions needed to improve the questionnaire and the associated survey procedures.    
 
d) Questionnaire Anonymisation 
The questionnaires will be anonymised according to the following Pseudo-Code procedure:  
EE-SS-CC-RR-NN 
EE – Expert’s second letter of first name and second letter of last name 
SS – BP for Big Pharma / SP for Small Pharma / CO for Contract Organization / CN for Consulting 
organization / OT for Other 
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CC – First two letters of participant’s organization name 
RR – Regulatory Domain of Expertise; US for FDA / EU for EMA / UE for both 
NN – Participant ID. A sequential number assigned based on the order in which the questionnaires 
are sent to the participants. 
 
Example: AA-BP-SA-UE-05 -> Nader Shafiei_Big Pharma_Sanofi_US & EU_5th questionnaire sent 
 
A link file containing the participant details and the corresponding anonymised code will be stored 
in the dedicated LJMU network folder. 
 
3.3 Participants 
The participants of the study will be recognised experts in the field of Pharmaceutical Quality. They 
will have strategic view of the pharmaceutical quality in their respective organization, are typically 
the go-to person on matters of quality and regulatory compliance and often represent their 
companies in external academic or industry organizations. They should have multidisciplinary 
quality expertise with exposure9 to quality issues affecting the medicinal product lifecycle10, and 
experience in the pharmaceutical or biopharmaceutical industry as an employee or a service 
provider.  
 
Combination of representative (the primary sampling method) and snowball sampling offers the 
best guidance for participant selection (Robson, 2007). The sample will be taken from 
representative of the population, which is characterised by the organizations that make up the 
sampling frame (see next section).  Snowball sampling will be used as an aid to the representative 
sampling, which requires the principal investigator to use his contacts as informants to identify 
potential candidates from the sampling frame.  
 
a) Sampling Frame 
Sampling frame is the source of the eligible population from which the survey sample is drawn. 
Potential candidates for the study will be recruited from the following organizations.  These 
organizations are representative of the population since they provide a forum where 
Pharmaceutical Quality experts gather and formulate solutions to challenging regulatory problems 
and publish their work.  
 Drug Information Association 
 Quality Risk Management special interest group 
 European Federation of Pharmaceutical Industries Association (EFPIA)  
 Compliance working group 
 International Society for Pharmaceutical Engineers (ISPE) 
 Board of directors  
 International Conference on Harmonisation 
 Quality working group  
 Journal of Quality Assurance 
 Editorial board (co-editors with pharmaceutical background only) 
 Parenteral Drug Association 
 Quality Systems interest group 
 
The participant confirmation requires contact with the candidates, which will only commence after 
approval of this study protocol by the LJMU REC. 
 
b) Inclusion Criteria 
Candidates meeting the following criteria will be selected for the survey: 
 
                                                 
9 Exposure to quality issues affecting two or more elements of the medicinal product lifecycle 
10 Lifecycle:  laboratory > clinical > registration > manufacturing > distribution > surveillance 
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 Those who have quality and compliance knowledge in good laboratory, clinical, and/or 
manufacturing practice AND 
 Those who have experience with US (FDA) regulations and/or EU (EMA) regulation AND 
 Those who have current working knowledge of quality relevant to medicinal products based 
on pharmaceuticals and/or biologics      
 
c) Participant Withdrawal and Replacement 
 Participants can withdraw from the study at any time.  
 
3.4 Procedure 
The survey conduct has two key steps: i) participant awareness and informed consent ii) 
questionnaire completion. Potential candidates will be contacted by telephone to secure their 
verbal consent to participate in the survey. The telephone conversation will last up to 30 minutes 
and will focus on explaining the information leaflet, instructions on how to complete the 
questionnaire and addressing any process related questions that candidates may have. During the 
telephone conversation it will be explicitly stated that participation in the survey is voluntary and 
there is no obligation to contribute to research study. The telephone conversation stops at this point 
and if the candidate consents he/she will be considered as a “participant” in the study. Prior to the 
teleconference meeting an e-mail containing electronic copy of the information leaflet (see 
appendix, ref: NS-PhD_LJMU_PIL_01) and the questionnaire (see appendix, ref: NS-
PhD_LJMU_QAR_01) will be sent to the candidates. After the phone conversation an e-mail 
containing a brief statement referencing the summary of the phone conversation and that the 
candidate had verbally consented to take part in the survey will be sent to the participant. The 
LJMU e-mail ( N.Shafiei@2009.ljmu.ac.uk ) will be used for all e-mail communication. 
The participants will be asked to complete the questionnaire offline and return the completed 
electronic or scanned copy to the above e-mail address. The questionnaires will be checked for 
completeness upon receipt and the participant will be contacted to address any gaps. The study 
conduct is closed once all the completed questionnaires are received and any subsequent 
communication with the participant to address problems is concluded. 
 
4 SURVEY DATA 
The completed questionnaires (electronic or scanned version) and any associated e-mail 
correspondence will be stored on dedicated LJMU network folder which is password protected. All 
survey documentation will be retained for 5 years after completion of research in accordance with 
the LJMU regulations. Questionnaires will be anonymised to safeguard the identity of the 
participants, their organization and facilitate confidentiality (see below).  
 
The Questionnaire data will be transferred to a computer for further analysis. Combination of hard 
disk encryption and password protection will be used to minimise unauthorised access. The study 
data residing in the computer will be backed up to the LJMU secure network folder on a daily basis. 
After the study completion, any analysis results residing within the computer will be removed 
securely. 
 
5 ETHICAL CONSIDERATIONS 
5.1 Informed Consent 
Informed consent for survey participants will be performed in compliance with the LJMU procedure 
on “Obtaining Informed Consent for Research Participation”. The content of this study protocol 
incorporates the 11 key points stated in the LJMU procedure. 
Initially verbal consent of the participant will be secured during the awareness discussions (via 
telephone). Subsequently an e-mail containing a brief statement referencing the summary of the 
telephone conversation and that the candidate had verbally consented to take part in the survey 
will be sent to the participant. In addition a statement will be included in PIL and the questionnaire 
to clearly indicate its voluntary nature and the fact that returned completed questionnaire implies 
participant’s consent. 
 
5.2 Research Ethics Committee (REC) Review 
This Study Protocol will be submitted to LJMU REC for review. The survey research will NOT 
commence recruitment until this protocol is fully and unconditionally approved by the REC. 
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5.3 Data Dissemination 
The anonymised results will be used in the publication of a PhD thesis and in papers in a number 
of prestigious peer-reviewed scientific journals. 
 
6 SURVEY SCHEDULE 
 
Activity       Milestone 
Study Protocol Preparation    Jan - March 2011  
 
Submission to LJMU REC for review   April    2011 
 
LJMU REC approval     July    2011 
 
Questionnaire Design and Piloting   July - Aug   2011 
 
Industry Expert Survey     Aug – Dec   2011 
 Expert Recruitment    Aug 
 Expert Awareness     Sep 
 Questionnaire Dissemination   Sep 
 Return of Completed Questionnaires  Sep -  Dec 
 Follow-up non Respondents    Jan   2012 
 
Data Analysis      Jan - Feb  2012 
 
Study Cost: 
There is no monetary impact since all the survey material will created and exchanged 
electronically. Time and effort of the principal investigator (PhD student) and the participants 
(collaborator and industry experts – estimated at 2 hours per expert, which includes the 
teleconference and completion of the survey) is needed for successful completion of this survey. 
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INTERVIEWS 
 
Section/ 
Question  Sub-section / Sub-question Individual Participant Comments 
Section A Entire survey 
Quality Risk - should also include 
business decision to take a risk that 
may result in a regulatory finding 
(tolerable risk). Should refine the 
definition to include this. 
Section B Entire survey 
Questions in general are suggestive 
and could be rephrased to make them 
open 
Q6 GxP Consider Good Research Practices (GRP) 
Q7 Regulatory Environment FDA regulation is driving Pharma companies offshore 
Q7 Open Innovation The old model of in house R&D outlived its usefulness 
Q7 Other (please specify): 
Current blockbusters are running out of 
patent and this is partly responsible for 
industry transformation. Traditional 
science has reached its limits and 
another key driver is to find new 
innovative way of discovering drugs. 
Open innovation is more of an outcome 
of transformation and not the driver. 
Regulatory environment had not 
changed significantly and hence is not a 
key driver. 
Q7 Other (please specify): How about mergers and acquisitions 
Q8 Externalization of S/W Applications 
Clarify terminology of the software 
application to include GxP data and the 
service component. 
Q8 Externalization of S/W Applications 
Provide some examples: Data 
management, Product Technical 
Complaints, Pharmaco-vigilance. Also 
clarify if "Apps" also covered. (Apple, 
Smart Phone, etc.) 
Q8 Externalization of S/W Applications Not in the GMP arena (for GMP data) 
Q8 Externalization of S/W Applications Consider replacing "externalization" by outsourcing. 
Q8 Other (please Specify): Information and Knowledge Management 
Q8 Other (please Specify): 
Partnership and research information 
sharing and Biotech are the current hot 
topics. 
Q8 Other (please Specify): 
Develop an approach for managing 
quality in a new environment. The 
agencies are pushing us to develop a 
quality system similar to GMP which 
may not completely be appropriate for 
the OI environment. Do we need a new 
quality approach?  
Q9 Multidisciplinary Regulatory Knowledge This is related to combination products 
Q9 Multidisciplinary Regulatory Knowledge Because of sharing information across boundaries 
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Appendix B5 Cont inued 
Section/ 
Question Sub-section / Sub-question Individual Participant Comments 
Q9 Effective Product Characterization  
Product characterization means critical 
quality attributes and critical process 
parameters. 
Q9 Effective Product Characterization  
If you don't have full characterization it 
will impact product transfer 
Q9 Technology Validation 
Terminology ambiguous – consider 
selection of new technology 
Q9 Technology Validation 
define Technology validation as 
Equipment and Systems) 
Q9 Other (please Specify) 
Clear legal and quality agreements to 
support the open innovation 
environment 
Q9 Other (please Specify) 
Suggest keeping Data Security and 
Data Integrity as separate questions. 
Security is more involved with technical 
aspects and Integrity is important from 
data validity perspective 
Q9 Other (please Specify) 
How do we convert data to knowledge 
and be able to search and sort. E.g. 
how can we mine information from old 
products? 
Q9 Other (please Specify) 
Changing regulatory environment (e.g. 
EMA regulation on audit of entire API 
supply chain) 
Q9 Other (please Specify) 
Lack of IP protection in emerging 
regions (e.g. China, India, Brazil, etc) 
 
Q10 
Certain elements of the Open 
Innovation as indicated in question 7 will 
impact partnership and others may not 
such as pervasive technologies. 
 
Q11 
There is a risk associated with the OIL 
model in that partners normally 
associated with research realise their 
business potential and as such 
negotiate their worth accordingly. 
This is a new paradigm  - with the 
demise of the old in house R&D 
Q11 
In order to have protection from an IP 
perspective the legal framework must 
be clearly defined. Especially true from 
a GRP perspective. 
 
Q15 
Likely depending on the area; e.g.  
Sterile products or medical devices.  
We may not make improvements to 
products because it means opening the 
CMC dossier 
 
 
 
	251 
Appendix B5 Continued 
Section/ 
Question Individual Participant Comments Individual Participant Comments 
Q15 
It is my impression that the regulatory 
expectations will always be in place and 
are designed to protect the patient. 
Documentation and institutional 
knowledge data management are purely 
good scientific practices and not 
blockers of innovation. 
We are less likely to consider truly 
innovative technologies because of the 
regulatory risk. 
Q15 
The work gets done but perhaps not in 
the most effective and efficient way. 
There is a need for the agencies to take 
a pragmatic approach which they don't 
do easily (e.g. investigator flexibility). 
 
Q16 
The current regulatory structure is 
capable of innovation because of 
political pressures on the regulators 
from the legislators (US perspective 
only).  
The chances of smarter regulatory 
approaches keeping pace with 
innovation are highly unlikely simply 
because they are political and 
bureaucratic organizations.  
Q17 
In the current regulatory environment 
these are not effective programs. 
Example: the concept of QBD is not yet 
proven to be successful) 
Not familiar with these initiatives 
Q17 
Very few companies took advantage of 
PAT because the trust factor with the 
regulatory authorities 
Innovation is there regardless of what is 
happening in regulations. I am making 
the assumption that they are not making 
the innovation environment more 
negative.  
Section E 
This question ignores the fact that there 
may be remedial controls to control 
associated GxP Risks. 
a) Look more at the value of effective 
due diligence. Multidisciplinary GxP Due 
Diligence 
Section E 
b) I was thinking of transfer products to 
outside alliances not bringing products 
inside. The focus is Inbound but the 
question could be taken either way. 
c) Define multi-disciplinary more clearly 
Section E 
c) Ask the question in the context of 
why you need it. The use of “Lack of” 
xxx is suggestive. Consider changing 
the measurement scale also. 
c) Is this also across regulatory 
agencies (i.e. knowledge of US, EU, 
LatAm etc…)? 
Section E 
d – Lack of…) This is a no-brainer 
based on the composition. May be the 
question should be composed 
differently.  
D – Lack of…) The question is 
suggestive, rephrase. 
Section E d – Lack of…) very suggestive 
d – Lack of…) Suggestive, consider 
rephrasing. Avoid use of the word “lack 
of”. 
Section E 
e) Provide some product/patient related 
examples. Are we talking about the 
whole gambit (including the GCP areas) 
f) Same comment as e). Instead of 
focusing on “Lack of” may be have a 
grading scale. Lack of is “all or none” 
Section E 
f) A GMP, GLP, GCP example would 
help to answer this question. E.g. smart 
blister packs. This technology is too 
futuristic! 
 
Q18 
Additional question to ask would: Which 
of the following factors drive the 
selection process: Efficacy/Safety, 
Market Potential, GxP Compliance 
Scientists have enough knowledge to 
pick up on significant compliance 
issues. 
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Appendix B5 Continued 
Section/ 
Question Individual Participant Comments Individual Participant Comments 
Q19 Assuming we have products that are in both stages 
This assumes that there is no risk 
mitigation strategy from a point of initial 
contract to the Pre-Approval Inspection.  
Q19 
Clarify premarket. Are we talking about 
Pre Approval Inspection or early 
development? 
The inherit risk exists but the probability 
of it happening is lower because most of 
the companies would aim to have 
reasonable level of compliance to begin 
with. 
Q19 
Don’t understand the question clearly. 
Are you referring to agency inspection 
or internal. Is it pre IND? The response 
differs based on if the product is 
acquired pre IND or Pre NDA 
depending on Agency involvement (is 
key). After agency review of 
submissions. 
The problem is not the likelihood. Even 
if the likelihood is not that high you do 
not want to have this situation since it 
will be costly. May be to rephrase using 
different scale. Focus on inherent risk. 
One question on Risk and another on 
Likelihood. 
Q20 
By this point the registration dossier is 
submitted and most of the potential GxP 
issues have been resolved.  
Clarify if we are talking about a product 
that was procured prior or post PAI 
Q21 
Process understanding comes before 
the transfer. Assumes that you have 
good process understanding in the first 
place. 
Assuming that source site has a good 
process understanding in the first place 
Q22 Assumption that Due Diligence on lab methodology is already performed 
 
Q23 Depends on the robustness of the process 
Does it really matter to ask this question 
in the context of pre vs. post? If the 
question is consolidated the likelihood 
would be “Likely”.  
Q23 Product transfer is the first place that the agencies tend to gravitate to. 
 
Q24 None None 
Q25 From perspective of regulatory 
knowledge it is clear that individual 
responsibility can no longer be 
sustained and teams of experts in 
associated fields will be required to 
maintain quality and compliance 
effectiveness. 
Product with a delivery device. One part 
is regulated by the Drug side and other 
parts by the device side and of course 
there is a lot in between. 
Q26 Related to knowledge management and 
being able to provide expert advise in all 
the fields related to the product  
This is substantiated by increase on 
warning letters that highlight lack of 
regulatory knowledge at the clinical 
investigator site and sponsor level (e.g. 
Under device regulations the 
Investigator has direct reporting 
requirements to the FDA while under 
the drug regulations. He does not). 
Q26 No need to have pre and post. 
Consolidate into one question. If so the 
answer would be “Likely” based on the 
answer to 25. 
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Section/ 
Question Individual Participant Comments Individual Participant Comments 
Q27 Related to knowledge management and 
being able to provide expert advice in all 
the fields related to the product.  
 
Q28 This makes sense purely from a size of the molecule which dictates complexity 
 
Q29 None None 
Q30 Potential for very strong patient safety issue! 
 
Q31 Logically seems appropriate to select this response. 
Privacy should be linked to the patient 
not the product 
Q31 
The response is focused on GMP 
aspects: e.g. CMC data, stability data, 
etc. 
This could also include risks from 
legal/IP perspective (in addition to 
compliance). 
Q32 Potential problems in gaining approval 
If we start the alliance in the wrong 
footing with substandard procedures it 
is highly likely that this would result in 
compliance problems later on. 
Q32 
Regulators don’t always inspection this 
topic.  Consider an additional 
measurement scale (somewhat likely) 
Agencies are catching up and in due 
course this could be very likely 
(example – Quality technical 
agreements being the hot topic) 
Q33 Potential product recall, product withdrawal, etc 
Agencies are catching up and in due 
course this could be very likely 
(example - Quality technical 
agreements being the hot topic) 
Q33 
Assumption being that the legal and 
Intellectual Property issues would be 
addressed 
 
Q34 None None 
Q35 
Regulators don't always inspect this 
topic. Consider an additional 
measurement scale (somewhat likely) 
 
Q36 
This is where the regulators will see the 
adverse event 
Regulators don't always inspect this 
topic.  Consider an additional 
measurement scale (somewhat likely). 
The average inspector does not 
probably understand the technology. 
Not expert in this field of technology. 
Q36 
How about the expertise of the 
Regulatory Reviewers (e.g. CMC 
review)? 
By this time there should be enough 
checks and balances in place to ensure 
reliability. Most likely already been 
inspected and approved by the agency. 
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